<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href="http://www.blogger.com/styles/atom.css" type="text/css"?><feed xmlns='http://www.w3.org/2005/Atom' xmlns:openSearch='http://a9.com/-/spec/opensearchrss/1.0/' xmlns:blogger='http://schemas.google.com/blogger/2008' xmlns:georss='http://www.georss.org/georss' xmlns:gd="http://schemas.google.com/g/2005" xmlns:thr='http://purl.org/syndication/thread/1.0'><id>tag:blogger.com,1999:blog-7196398195634872986</id><updated>2026-03-01T15:02:50.580-05:00</updated><category term="Book Contents"/><category term="References"/><category term="diet"/><category term="Coronary Artery disease"/><category term="HDL"/><category term="Sleep"/><category term="deprivation"/><category term="heart attack"/><category term="magnesium"/><category term="niacin"/><category term="potassium"/><category term="studying"/><category term="sugar"/><title type='text'>The Pillars of Health:The Prelude</title><subtitle type='html'>The intent of this blog is to promote health of human beings by applying scientific principles. I am using my previous electronic publication: The Pillars of Health: The Prelude, as a launching pad for discussion and to promote the scientific principles I believe to be accurate at this time. I tried to keep the language I used understandable for the layman but there were areas, which were somewhat technical. I encourage questioning anything I say or claim. I will update the chapters as we go. </subtitle><link rel='http://schemas.google.com/g/2005#feed' type='application/atom+xml' href='http://thepillarsofhealth.blogspot.com/feeds/posts/default'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default?redirect=false'/><link rel='alternate' type='text/html' href='http://thepillarsofhealth.blogspot.com/'/><link rel='hub' href='http://pubsubhubbub.appspot.com/'/><link rel='next' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default?start-index=26&amp;max-results=25&amp;redirect=false'/><author><name>Dr Dhia Aldoori</name><uri>http://www.blogger.com/profile/12785445082984259058</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='23' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgIcbY6lOf-A2OAQZ3CCF-V44BF68CUZ1wYcXS06NXVQS-lTFiik3VkOYsT0dmfX2RcYB8yuWeKbUAP5w5AeDWHc1bdI-0eQEt4lr6yM4tplO9dgbQ9nT74rRU6KPLeXw/s149/Cropped+PA307202'/></author><generator version='7.00' uri='http://www.blogger.com'>Blogger</generator><openSearch:totalResults>43</openSearch:totalResults><openSearch:startIndex>1</openSearch:startIndex><openSearch:itemsPerPage>25</openSearch:itemsPerPage><entry><id>tag:blogger.com,1999:blog-7196398195634872986.post-6792812870042826555</id><published>2021-12-31T13:18:00.001-05:00</published><updated>2022-02-06T06:44:43.123-05:00</updated><title type='text'>About COVID-19 Booster Vaccinations</title><content type='html'>&lt;p align=&quot;center&quot; class=&quot;MsoNormal&quot; style=&quot;text-align: center;&quot;&gt;&lt;span style=&quot;font-size: 9pt; line-height: 107%;&quot;&gt;By Dr. Dhia Aldoori December 31, 2021&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot; style=&quot;margin-left: 0.2in; text-indent: -0.2in;&quot;&gt;To the question
posed by ‘Anonymous’, whether I “believe” in booster vaccinations for COVID-19
my current stance is I have reservations on their administration. There are some
people with special circumstances (older age, immune system compromised, absence
of antibody response to initial vaccination) that may benefit from the booster.
There also may be a slight temporary boost in immunity from having a booster
shot as well. That said, we should focus our resources on vaccinating those who
are not vaccinated in the world, and this will help overcome this virus (among
other things decreasing the probability of new variants of SARS-Cov-2 arising).&lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot; style=&quot;margin-left: 0.2in; text-indent: -0.2in;&quot;&gt;My opinions have
been expressed in words which I find hard to improve upon in the viewpoint
published in Lancet in October 2021 which I pretty much agree with on almost
everything they wrote &lt;!--[if supportFields]&gt;&lt;span style=&#39;mso-element:field-begin;
mso-field-lock:yes&#39;&gt;&lt;/span&gt;ADDIN CSL_CITATION
{&amp;quot;citationItems&amp;quot;:[{&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;itemData&amp;quot;:{&amp;quot;DOI&amp;quot;:&amp;quot;10.1016/S0140-6736(21)02046-8/ATTACHMENT/99B4689E-FA37-476A-B30E-8D1E3B4E33BC/MMC1.PDF&amp;quot;,&amp;quot;ISSN&amp;quot;:&amp;quot;1474547X&amp;quot;,&amp;quot;PMID&amp;quot;:&amp;quot;34534516&amp;quot;,&amp;quot;author&amp;quot;:[{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Krause&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Philip
R.&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Fleming&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Thomas
R.&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Peto&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Richard&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Longini&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Ira
M.&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Figueroa&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;J.
Peter&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Sterne&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Jonathan
A.C.&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Cravioto&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Alejandro&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Rees&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Helen&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Higgins&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Julian
P.T.&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Boutron&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Isabelle&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Pan&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Hongchao&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Gruber&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Marion
F.&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Arora&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Narendra&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Kazi&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Fatema&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Gaspar&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Rogerio&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Swaminathan&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Soumya&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Ryan&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Michael
J.&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Henao-Restrepo&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Ana
Maria&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;}],&amp;quot;container-title&amp;quot;:&amp;quot;The
Lancet&amp;quot;,&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;issue&amp;quot;:&amp;quot;10308&amp;quot;,&amp;quot;issued&amp;quot;:{&amp;quot;date-parts&amp;quot;:[[&amp;quot;2021&amp;quot;,&amp;quot;10&amp;quot;,&amp;quot;9&amp;quot;]]},&amp;quot;page&amp;quot;:&amp;quot;1377-1380&amp;quot;,&amp;quot;publisher&amp;quot;:&amp;quot;Elsevier
B.V.&amp;quot;,&amp;quot;title&amp;quot;:&amp;quot;Considerations in boosting COVID-19 vaccine
immune
responses&amp;quot;,&amp;quot;type&amp;quot;:&amp;quot;article-journal&amp;quot;,&amp;quot;volume&amp;quot;:&amp;quot;398&amp;quot;},&amp;quot;uris&amp;quot;:[&amp;quot;http://www.mendeley.com/documents/?uuid=694b0d00-ff7b-3171-bf7b-2cb237417817&amp;quot;]}],&amp;quot;mendeley&amp;quot;:{&amp;quot;formattedCitation&amp;quot;:&amp;quot;[1]&amp;quot;,&amp;quot;plainTextFormattedCitation&amp;quot;:&amp;quot;[1]&amp;quot;,&amp;quot;previouslyFormattedCitation&amp;quot;:&amp;quot;[1]&amp;quot;},&amp;quot;properties&amp;quot;:{&amp;quot;noteIndex&amp;quot;:0},&amp;quot;schema&amp;quot;:&amp;quot;https://github.com/citation-style-language/schema/raw/master/csl-citation.json&amp;quot;}&lt;span
style=&#39;mso-element:field-separator&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;span style=&quot;mso-no-proof: yes;&quot;&gt;[1]&lt;/span&gt;&lt;!--[if supportFields]&gt;&lt;span style=&#39;mso-element:field-end&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;.
What follows is from their writing and notations from me are in orange:&lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot; style=&quot;margin-left: 0.2in; text-indent: -0.2in;&quot;&gt;“A new wave of COVID-19
cases caused by the highly transmissible delta variant (&lt;span style=&quot;color: #ff9900;&quot;&gt;and now the omicron variant&lt;/span&gt;) is
exacerbating the worldwide public health crisis, and has led to consideration
of the potential need for, and optimal timing
of, booster doses for vaccinated populations.&lt;!--[if supportFields]&gt;&lt;span
style=&#39;mso-element:field-begin;mso-field-lock:yes&#39;&gt;&lt;/span&gt;ADDIN CSL_CITATION
{&amp;quot;citationItems&amp;quot;:[{&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;itemData&amp;quot;:{&amp;quot;DOI&amp;quot;:&amp;quot;10.1038/D41586-021-02158-6&amp;quot;,&amp;quot;ISSN&amp;quot;:&amp;quot;14764687&amp;quot;,&amp;quot;PMID&amp;quot;:&amp;quot;34354274&amp;quot;,&amp;quot;author&amp;quot;:[{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Callaway&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Ewen&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;}],&amp;quot;container-title&amp;quot;:&amp;quot;Nature&amp;quot;,&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;issue&amp;quot;:&amp;quot;7871&amp;quot;,&amp;quot;issued&amp;quot;:{&amp;quot;date-parts&amp;quot;:[[&amp;quot;2021&amp;quot;,&amp;quot;8&amp;quot;,&amp;quot;1&amp;quot;]]},&amp;quot;page&amp;quot;:&amp;quot;178-180&amp;quot;,&amp;quot;publisher&amp;quot;:&amp;quot;NLM
(Medline)&amp;quot;,&amp;quot;title&amp;quot;:&amp;quot;COVID vaccine boosters: the most
important questions&amp;quot;,&amp;quot;type&amp;quot;:&amp;quot;article-journal&amp;quot;,&amp;quot;volume&amp;quot;:&amp;quot;596&amp;quot;},&amp;quot;uris&amp;quot;:[&amp;quot;http://www.mendeley.com/documents/?uuid=03541ed8-36e4-302a-b926-b5ce87706f31&amp;quot;]}],&amp;quot;mendeley&amp;quot;:{&amp;quot;formattedCitation&amp;quot;:&amp;quot;[2]&amp;quot;,&amp;quot;plainTextFormattedCitation&amp;quot;:&amp;quot;[2]&amp;quot;,&amp;quot;previouslyFormattedCitation&amp;quot;:&amp;quot;[2]&amp;quot;},&amp;quot;properties&amp;quot;:{&amp;quot;noteIndex&amp;quot;:0},&amp;quot;schema&amp;quot;:&amp;quot;https://github.com/citation-style-language/schema/raw/master/csl-citation.json&amp;quot;}&lt;span
style=&#39;mso-element:field-separator&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;span style=&quot;mso-no-proof: yes;&quot;&gt;[2]&lt;/span&gt;&lt;!--[if supportFields]&gt;&lt;span style=&#39;mso-element:field-end&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;b&gt;
&lt;o:p&gt;&lt;/o:p&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot; style=&quot;margin-left: 0.2in; text-indent: -0.2in;&quot;&gt;Although the idea
of further reducing the number of COVID-19 cases by enhancing immunity in
vaccinated people is appealing, any decision to do so should be evidence-based
and consider the benefits and risks for individuals and society. COVID-19
vaccines continue to be effective against severe disease, including that caused
by the delta variant. Most of the &lt;span style=&quot;background-color: #ffa400;&quot;&gt;observational&lt;/span&gt; studies on which this conclusion is based are,
however, &lt;span style=&quot;background-color: #ffa400;&quot;&gt;preliminary&lt;/span&gt;&lt;span style=&quot;color: #ed7d31; mso-themecolor: accent2;&quot;&gt;,&lt;/span&gt; and difficult to
interpret precisely due to potential &lt;span style=&quot;background-color: #ffa400;&quot;&gt;confounding and selective reporting&lt;/span&gt;.&lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot; style=&quot;margin-left: 0.2in; text-indent: -0.2in;&quot;&gt;Even if boosting
were eventually shown to decrease the medium-term risk of serious disease,&lt;span style=&quot;mso-spacerun: yes;&quot;&gt;&amp;nbsp;&lt;/span&gt;current vaccine supplies could save more
lives if used in previously unvaccinated populations than if used as boosters
in vaccinated populations.&lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot; style=&quot;margin-left: 0.2in; text-indent: -0.2in;&quot;&gt;Boosting could be
appropriate for some individuals in whom the primary vaccination, defined here
as the original one-dose or two-dose series of each vaccine, might not have induced
adequate protection—e.g., recipients of vaccines with low efficacy or those who
are immunocompromised&lt;!--[if supportFields]&gt;&lt;span style=&#39;mso-element:field-begin;
mso-field-lock:yes&#39;&gt;&lt;/span&gt;ADDIN CSL_CITATION
{&amp;quot;citationItems&amp;quot;:[{&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;itemData&amp;quot;:{&amp;quot;DOI&amp;quot;:&amp;quot;10.1056/NEJMC2108861&amp;quot;,&amp;quot;ISSN&amp;quot;:&amp;quot;0028-4793&amp;quot;,&amp;quot;PMID&amp;quot;:&amp;quot;34161700&amp;quot;,&amp;quot;abstract&amp;quot;:&amp;quot;Three
Covid-19 Vaccine Doses in Transplant Recipients Solid-organ transplant
recipients receiving immunosuppressive therapy appear to have a poor response
to Covid-19 vaccination. A group of 101 co...&amp;quot;,&amp;quot;author&amp;quot;:[{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Kamar&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Nassim&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Abravanel&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Florence&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Marion&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Olivier&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Couat&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Chloé&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Izopet&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Jacques&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Bello&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Arnaud&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;Del&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;}],&amp;quot;container-title&amp;quot;:&amp;quot;New
England Journal of Medicine&amp;quot;,&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;issue&amp;quot;:&amp;quot;7&amp;quot;,&amp;quot;issued&amp;quot;:{&amp;quot;date-parts&amp;quot;:[[&amp;quot;2021&amp;quot;,&amp;quot;8&amp;quot;,&amp;quot;12&amp;quot;]]},&amp;quot;page&amp;quot;:&amp;quot;661-662&amp;quot;,&amp;quot;publisher&amp;quot;:&amp;quot;Massachusetts
Medical Society&amp;quot;,&amp;quot;title&amp;quot;:&amp;quot;Three Doses of an mRNA Covid-19
Vaccine in Solid-Organ Transplant
Recipients&amp;quot;,&amp;quot;type&amp;quot;:&amp;quot;article-journal&amp;quot;,&amp;quot;volume&amp;quot;:&amp;quot;385&amp;quot;},&amp;quot;uris&amp;quot;:[&amp;quot;http://www.mendeley.com/documents/?uuid=392c9208-6efd-3db1-90e9-2dc92b4bd1fe&amp;quot;]}],&amp;quot;mendeley&amp;quot;:{&amp;quot;formattedCitation&amp;quot;:&amp;quot;[3]&amp;quot;,&amp;quot;plainTextFormattedCitation&amp;quot;:&amp;quot;[3]&amp;quot;,&amp;quot;previouslyFormattedCitation&amp;quot;:&amp;quot;[3]&amp;quot;},&amp;quot;properties&amp;quot;:{&amp;quot;noteIndex&amp;quot;:0},&amp;quot;schema&amp;quot;:&amp;quot;https://github.com/citation-style-language/schema/raw/master/csl-citation.json&amp;quot;}&lt;span
style=&#39;mso-element:field-separator&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;span style=&quot;mso-no-proof: yes;&quot;&gt;[3]&lt;/span&gt;&lt;!--[if supportFields]&gt;&lt;span style=&#39;mso-element:field-end&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;.&lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot; style=&quot;margin-left: 0.2in; text-indent: -0.2in;&quot;&gt;Although the
benefits of primary COVID-19 vaccination clearly outweigh the risks, there
could be risks if boosters are widely introduced too soon, or too frequently,
especially with vaccines that can have immune-mediated side-effects (such as
myocarditis, which is more common after the second dose of some mRNA vaccines,&lt;!--[if supportFields]&gt;&lt;span
style=&#39;mso-element:field-begin;mso-field-lock:yes&#39;&gt;&lt;/span&gt;ADDIN CSL_CITATION
{&amp;quot;citationItems&amp;quot;:[{&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;itemData&amp;quot;:{&amp;quot;DOI&amp;quot;:&amp;quot;10.15585/MMWR.MM7027E2&amp;quot;,&amp;quot;ISSN&amp;quot;:&amp;quot;0149-21951545-861X&amp;quot;,&amp;quot;PMID&amp;quot;:&amp;quot;34237049&amp;quot;,&amp;quot;abstract&amp;quot;:&amp;quot;In
December 2020, the Food and Drug Administration (FDA) issued Emergency Use
Authorizations (EUAs) for the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine and
the Moderna COVID-19 (mRNA-1273) vaccine,† and the Advisory Committee on
Immunization Practices (ACIP) issued interim recommendations for their use in
persons aged ≥16 years and ≥18 years, respectively.§ In May 2021, FDA expanded
the EUA for the Pfizer-BioNTech COVID-19 vaccine to include adolescents aged
12-15 years; ACIP recommends that all persons aged ≥12 years receive a COVID-19
vaccine. Both Pfizer-BioNTech and Moderna vaccines are mRNA vaccines encoding
the stabilized prefusion spike glycoprotein of SARS-CoV-2, the virus that
causes COVID-19. Both mRNA vaccines were authorized and recommended as a 2-dose
schedule, with second doses administered 21 days (Pfizer-BioNTech) or 28 days
(Moderna) after the first dose. After reports of myocarditis and pericarditis
in mRNA vaccine recipients,¶ which predominantly occurred in young males after
the second dose, an ACIP meeting was rapidly convened to review reported cases
of myocarditis and pericarditis and discuss the benefits and risks of mRNA
COVID-19 vaccination in the United States. Myocarditis is an inflammation of
the heart muscle; if it is accompanied by pericarditis, an inflammation of the
thin tissue surrounding the heart (the pericardium), it is referred to as
myopericarditis. Hereafter, myocarditis is used to refer to myocarditis,
pericarditis, or myopericarditis. On June 23, 2021, after reviewing available
evidence including that for risks of myocarditis, ACIP determined that the
benefits of using mRNA COVID-19 vaccines under the FDA&#39;s EUA clearly outweigh
the risks in all populations, including adolescents and young adults. The EUA
has been modified to include information on myocarditis after receipt of mRNA
COVID-19 vaccines. The EUA fact sheets should be provided before vaccination;
in addition, CDC has developed patient and provider education materials about
the possibility of myocarditis and symptoms of concern, to ensure prompt
recognition and management of
myocarditis.&amp;quot;,&amp;quot;author&amp;quot;:[{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Gargano&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Julia
W.&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Wallace&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Megan&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Hadler&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Stephen
C.&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Langley&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Gayle&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Su&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;John
R.&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Oster&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Matthew
E.&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Broder&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Karen
R.&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Gee&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Julianne&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Weintraub&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Eric&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Shimabukuro&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Tom&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Scobie&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Heather
M.&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Moulia&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Danielle&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Markowitz&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Lauri
E.&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Wharton&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Melinda&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;V.&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;McNally&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Veronica&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Romero&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;José
R.&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Talbot&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;H.
Keipp&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Lee&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Grace
M.&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Daley&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Matthew
F.&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Oliver&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Sara
E.&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;}],&amp;quot;container-title&amp;quot;:&amp;quot;MMWR.
Morbidity and Mortality Weekly Report&amp;quot;,&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;issue&amp;quot;:&amp;quot;27&amp;quot;,&amp;quot;issued&amp;quot;:{&amp;quot;date-parts&amp;quot;:[[&amp;quot;2021&amp;quot;,&amp;quot;7&amp;quot;,&amp;quot;9&amp;quot;]]},&amp;quot;page&amp;quot;:&amp;quot;977-982&amp;quot;,&amp;quot;publisher&amp;quot;:&amp;quot;Centers
for Disease Control MMWR Office&amp;quot;,&amp;quot;title&amp;quot;:&amp;quot;Use of mRNA
COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update
from the Advisory Committee on Immunization Practices — United States, June
2021&amp;quot;,&amp;quot;type&amp;quot;:&amp;quot;article-journal&amp;quot;,&amp;quot;volume&amp;quot;:&amp;quot;70&amp;quot;},&amp;quot;uris&amp;quot;:[&amp;quot;http://www.mendeley.com/documents/?uuid=838555f4-7eee-3934-a353-2ca71348772e&amp;quot;]}],&amp;quot;mendeley&amp;quot;:{&amp;quot;formattedCitation&amp;quot;:&amp;quot;[4]&amp;quot;,&amp;quot;plainTextFormattedCitation&amp;quot;:&amp;quot;[4]&amp;quot;,&amp;quot;previouslyFormattedCitation&amp;quot;:&amp;quot;[4]&amp;quot;},&amp;quot;properties&amp;quot;:{&amp;quot;noteIndex&amp;quot;:0},&amp;quot;schema&amp;quot;:&amp;quot;https://github.com/citation-style-language/schema/raw/master/csl-citation.json&amp;quot;}&lt;span
style=&#39;mso-element:field-separator&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;span style=&quot;mso-no-proof: yes;&quot;&gt;[4]&lt;/span&gt;&lt;!--[if supportFields]&gt;&lt;span style=&#39;mso-element:field-end&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;
or Guillain-Barre syndrome, which has been associated with &lt;br /&gt;
&lt;span style=&quot;mso-spacerun: yes;&quot;&gt;&amp;nbsp;&lt;/span&gt;adenovirus-vectored COVID-19 vaccines&lt;!--[if supportFields]&gt;&lt;span
style=&#39;mso-element:field-begin;mso-field-lock:yes&#39;&gt;&lt;/span&gt;ADDIN CSL_CITATION
{&amp;quot;citationItems&amp;quot;:[{&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;itemData&amp;quot;:{&amp;quot;URL&amp;quot;:&amp;quot;https://www.who.int/news/item/26-07-2021-statement-of-the-who-gacvs-covid-19-subcommittee-on-gbs&amp;quot;,&amp;quot;accessed&amp;quot;:{&amp;quot;date-parts&amp;quot;:[[&amp;quot;2021&amp;quot;,&amp;quot;12&amp;quot;,&amp;quot;31&amp;quot;]]},&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;issued&amp;quot;:{&amp;quot;date-parts&amp;quot;:[[&amp;quot;0&amp;quot;]]},&amp;quot;title&amp;quot;:&amp;quot;Statement
of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19
subcommittee on reports of Guillain-Barré Syndrome (GBS) following adenovirus
vector COVID-19
vaccines&amp;quot;,&amp;quot;type&amp;quot;:&amp;quot;webpage&amp;quot;},&amp;quot;uris&amp;quot;:[&amp;quot;http://www.mendeley.com/documents/?uuid=5b54aae5-74ba-31e8-81b1-6540b07d70d9&amp;quot;]}],&amp;quot;mendeley&amp;quot;:{&amp;quot;formattedCitation&amp;quot;:&amp;quot;[5]&amp;quot;,&amp;quot;plainTextFormattedCitation&amp;quot;:&amp;quot;[5]&amp;quot;,&amp;quot;previouslyFormattedCitation&amp;quot;:&amp;quot;[5]&amp;quot;},&amp;quot;properties&amp;quot;:{&amp;quot;noteIndex&amp;quot;:0},&amp;quot;schema&amp;quot;:&amp;quot;https://github.com/citation-style-language/schema/raw/master/csl-citation.json&amp;quot;}&lt;span
style=&#39;mso-element:field-separator&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;span style=&quot;mso-no-proof: yes;&quot;&gt;[5]&lt;/span&gt;&lt;!--[if supportFields]&gt;&lt;span style=&#39;mso-element:field-end&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;).&lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot; style=&quot;margin-left: 0.2in; text-indent: -0.2in;&quot;&gt;Current evidence
does not, therefore, appear to show a need for boosting in the general
population, in which efficacy against severe disease remains high. Even if
humoral immunity appears to wane, &lt;span style=&quot;background-color: #ffa400;&quot;&gt;reductions in neutralising antibody titre do not necessarily predict
reductions in vaccine efficacy over time, and reductions in vaccine efficacy
against mild disease do not necessarily predict reductions in the (typically
higher) efficacy against severe disease&lt;/span&gt;. This effect could be because &lt;span style=&quot;background-color: #ffa400;&quot;&gt;protection
against severe disease is mediated not only by antibody responses, which might
be relatively short lived for some vaccines, but also by memory responses and
cell-mediated immunity, which are generally longer lived&lt;/span&gt;.&lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot; style=&quot;margin-left: 0.2in; text-indent: -0.2in;&quot;&gt;Of interest,
reported effectiveness against severe disease in Israel was lower among people&lt;span style=&quot;mso-spacerun: yes;&quot;&gt;&amp;nbsp;&lt;/span&gt;vaccinated either in January or April
than in those vaccinated in February or March,&lt;span style=&quot;color: red;&quot;&gt; &lt;/span&gt;exemplifying
the difficulty of interpreting such data. A recent report on the experience in
Israel during the first 3 weeks of August 2021, just after booster doses were
approved and began to be deployed widely, has suggested efficacy of a third
dose (relative to two doses). &lt;span style=&quot;background-color: #ffa400;&quot;&gt;Mean follow-up was, however, only about 7 person-days&lt;/span&gt; (less than
expected based on the apparent study design); perhaps more importantly, a very
short-term protective effect would not necessarily imply worthwhile long-term
benefit.&lt;!--[if supportFields]&gt;&lt;span style=&#39;mso-element:field-begin;mso-field-lock:
yes&#39;&gt;&lt;/span&gt;ADDIN CSL_CITATION
{&amp;quot;citationItems&amp;quot;:[{&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;itemData&amp;quot;:{&amp;quot;DOI&amp;quot;:&amp;quot;10.1056/NEJMOA2114255&amp;quot;,&amp;quot;ISSN&amp;quot;:&amp;quot;1533-4406&amp;quot;,&amp;quot;PMID&amp;quot;:&amp;quot;34525275&amp;quot;,&amp;quot;abstract&amp;quot;:&amp;quot;BACKGROUND
On July 30, 2021, the administration of a third (booster) dose of the BNT162b2
messenger RNA vaccine (Pfizer-BioNTech) was approved in Israel for persons who
were 60 years of age or older and who had received a second dose of vaccine at
least 5 months earlier. Data are needed regarding the effect of the booster
dose on the rate of confirmed coronavirus 2019 disease (Covid-19) and the rate
of severe illness. METHODS We extracted data for the period from July 30
through August 31, 2021, from the Israeli Ministry of Health database regarding
1,137,804 persons who were 60 years of age or older and had been fully
vaccinated (i.e., had received two doses of BNT162b2) at least 5 months
earlier. In the primary analysis, we compared the rate of confirmed Covid-19
and the rate of severe illness between those who had received a booster
injection at least 12 days earlier (booster group) and those who had not
received a booster injection (nonbooster group). In a secondary analysis, we
evaluated the rate of infection 4 to 6 days after the booster dose as compared
with the rate at least 12 days after the booster. In all the analyses, we used
Poisson regression after adjusting for possible confounding factors. RESULTS At
least 12 days after the booster dose, the rate of confirmed infection was lower
in the booster group than in the nonbooster group by a factor of 11.3 (95%
confidence interval [CI], 10.4 to 12.3); the rate of severe illness was lower
by a factor of 19.5 (95% CI, 12.9 to 29.5). In a secondary analysis, the rate
of confirmed infection at least 12 days after vaccination was lower than the
rate after 4 to 6 days by a factor of 5.4 (95% CI, 4.8 to 6.1). CONCLUSIONS In
this study involving participants who were 60 years of age or older and had
received two doses of the BNT162b2 vaccine at least 5 months earlier, we found
that the rates of confirmed Covid-19 and severe illness were substantially
lower among those who received a booster (third) dose of the BNT162b2
vaccine.&amp;quot;,&amp;quot;author&amp;quot;:[{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Bar-On&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Yinon
M.&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Goldberg&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Yair&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Mandel&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Micha&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Bodenheimer&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Omri&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Freedman&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Laurence&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Kalkstein&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Nir&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Mizrahi&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Barak&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Alroy-Preis&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Sharon&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Ash&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Nachman&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Milo&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Ron&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Huppert&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Amit&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;}],&amp;quot;container-title&amp;quot;:&amp;quot;The
New England journal of
medicine&amp;quot;,&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;issue&amp;quot;:&amp;quot;15&amp;quot;,&amp;quot;issued&amp;quot;:{&amp;quot;date-parts&amp;quot;:[[&amp;quot;2021&amp;quot;,&amp;quot;10&amp;quot;,&amp;quot;7&amp;quot;]]},&amp;quot;page&amp;quot;:&amp;quot;1393-1400&amp;quot;,&amp;quot;publisher&amp;quot;:&amp;quot;N
Engl J Med&amp;quot;,&amp;quot;title&amp;quot;:&amp;quot;Protection of BNT162b2 Vaccine Booster
against Covid-19 in Israel&amp;quot;,&amp;quot;type&amp;quot;:&amp;quot;article-journal&amp;quot;,&amp;quot;volume&amp;quot;:&amp;quot;385&amp;quot;},&amp;quot;uris&amp;quot;:[&amp;quot;http://www.mendeley.com/documents/?uuid=f2cd16ca-2d1c-379e-a4d0-c532ecf99a4e&amp;quot;]}],&amp;quot;mendeley&amp;quot;:{&amp;quot;formattedCitation&amp;quot;:&amp;quot;[6]&amp;quot;,&amp;quot;plainTextFormattedCitation&amp;quot;:&amp;quot;[6]&amp;quot;,&amp;quot;previouslyFormattedCitation&amp;quot;:&amp;quot;[6]&amp;quot;},&amp;quot;properties&amp;quot;:{&amp;quot;noteIndex&amp;quot;:0},&amp;quot;schema&amp;quot;:&amp;quot;https://github.com/citation-style-language/schema/raw/master/csl-citation.json&amp;quot;}&lt;span
style=&#39;mso-element:field-separator&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;span style=&quot;mso-no-proof: yes;&quot;&gt;[6]&lt;/span&gt;&lt;!--[if supportFields]&gt;&lt;span style=&#39;mso-element:field-end&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot; style=&quot;margin-left: 0.2in; text-indent: -0.2in;&quot;&gt;…even in
populations with fairly high vaccination rates the unvaccinated are still the
major drivers of transmission and are themselves at the highest risk of serious
disease.&lt;!--[if supportFields]&gt;&lt;span style=&#39;mso-element:field-begin;mso-field-lock:
yes&#39;&gt;&lt;/span&gt;ADDIN CSL_CITATION
{&amp;quot;citationItems&amp;quot;:[{&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;itemData&amp;quot;:{&amp;quot;DOI&amp;quot;:&amp;quot;10.15585/MMWR.MM7034E5&amp;quot;,&amp;quot;ISSN&amp;quot;:&amp;quot;1545-861X&amp;quot;,&amp;quot;PMID&amp;quot;:&amp;quot;34437525&amp;quot;,&amp;quot;abstract&amp;quot;:&amp;quot;What
is already known about this topic? Although COVID-19 vaccines are highly
effective, some fully vaccinated persons will be infected with SARS-CoV-2. What
is added by this report? During May 1—July 25, 2021, among 43,127 SARS-CoV-2
infections in residents of Los Angeles County, California, 10,895 (25.3%) were
in fully vaccinated persons, 1,431 (3.3%) were in partially vaccinated persons,
and 30,801 (71.4%) were in unvaccinated persons. On July 25, infection and
hospitalization rates among unvaccinated persons were 4.9 and 29.2 times,
respectively, those in fully vaccinated persons. In July, when the Delta
variant was predominant, cycle threshold values were similar for unvaccinated,
partially vaccinated, and vaccinated persons. What are the implications for
public health practice? Efforts to enhance COVID-19 vaccination coverage, in
coordination with other prevention strategies, are critical to preventing
COVID-19-related hospitalizations and
deaths.&amp;quot;,&amp;quot;author&amp;quot;:[{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Griffin&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Jennifer
B.&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Haddix&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Meredith&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Danza&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Phoebe&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Fisher&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Rebecca&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Koo&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Tae
Hee&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Traub&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Elizabeth&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Gounder&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Prabhu&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Jarashow&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Claire&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Balter&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Sharon&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;}],&amp;quot;container-title&amp;quot;:&amp;quot;MMWR.
Morbidity and mortality weekly
report&amp;quot;,&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;issue&amp;quot;:&amp;quot;34&amp;quot;,&amp;quot;issued&amp;quot;:{&amp;quot;date-parts&amp;quot;:[[&amp;quot;2021&amp;quot;]]},&amp;quot;page&amp;quot;:&amp;quot;1170-1176&amp;quot;,&amp;quot;publisher&amp;quot;:&amp;quot;MMWR
Morb Mortal Wkly Rep&amp;quot;,&amp;quot;title&amp;quot;:&amp;quot;SARS-CoV-2 Infections and
Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status - Los
Angeles County, California, May 1-July 25,
2021&amp;quot;,&amp;quot;type&amp;quot;:&amp;quot;article-journal&amp;quot;,&amp;quot;volume&amp;quot;:&amp;quot;70&amp;quot;},&amp;quot;uris&amp;quot;:[&amp;quot;http://www.mendeley.com/documents/?uuid=7b95614f-4695-3389-877c-2235763dc3fa&amp;quot;]}],&amp;quot;mendeley&amp;quot;:{&amp;quot;formattedCitation&amp;quot;:&amp;quot;[7]&amp;quot;,&amp;quot;plainTextFormattedCitation&amp;quot;:&amp;quot;[7]&amp;quot;},&amp;quot;properties&amp;quot;:{&amp;quot;noteIndex&amp;quot;:0},&amp;quot;schema&amp;quot;:&amp;quot;https://github.com/citation-style-language/schema/raw/master/csl-citation.json&amp;quot;}&lt;span
style=&#39;mso-element:field-separator&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;span style=&quot;mso-no-proof: yes;&quot;&gt;[7]&lt;/span&gt;&lt;!--[if supportFields]&gt;&lt;span style=&#39;mso-element:field-end&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot; style=&quot;margin-left: 0.2in; text-indent: -0.2in;&quot;&gt;If boosters
(whether expressing original or variant antigens) are ultimately to be used,
there will be a need to identify specific circumstances in which the direct and
indirect benefits of doing so are, on balance, clearly beneficial. any
decisions about the need for boosting or timing of boosting should be based on
careful analyses of adequately controlled clinical or epidemiological data, or
both, indicating a persistent and meaningful reduction in severe disease, with
a benefit–risk evaluation that considers the number of severe cases that
boosting would be expected to prevent, along with evidence about whether a
specific boosting regimen is likely to be safe and effective against currently
circulating variants.&lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot; style=&quot;margin-left: 0.2in; text-indent: -0.2in;&quot;&gt;The vaccines that
are currently available are (&lt;span style=&quot;color: #ed7d31; mso-themecolor: accent2;&quot;&gt;relatively&lt;/span&gt;)
safe, effective, and save lives. The limited supply of these vaccines will save
the most lives if made available to people who are at appreciable risk of
serious disease and have not yet received any vaccine. Even if some gain can
ultimately be obtained from boosting, it will not outweigh&lt;span style=&quot;mso-spacerun: yes;&quot;&gt;&amp;nbsp; &lt;/span&gt;the benefits of providing initial protection
to the unvaccinated.&quot;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot;&gt;&lt;u&gt;Bibliography&lt;/u&gt;:&lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-left: 32pt; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none; text-indent: -32pt;&quot;&gt;&lt;!--[if supportFields]&gt;&lt;span
style=&#39;mso-element:field-begin;mso-field-lock:yes&#39;&gt;&lt;/span&gt;ADDIN Mendeley
Bibliography CSL_BIBLIOGRAPHY &lt;span style=&#39;mso-element:field-separator&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;span style=&quot;mso-ascii-font-family: Calibri; mso-bidi-font-family: Calibri; mso-bidi-font-size: 12.0pt; mso-hansi-font-family: Calibri; mso-no-proof: yes;&quot;&gt;[1]&lt;span style=&quot;mso-tab-count: 1;&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/span&gt;P. R. Krause &lt;i&gt;et al.&lt;/i&gt;, “Considerations
in boosting COVID-19 vaccine immune responses,” &lt;i&gt;Lancet&lt;/i&gt;, vol. 398, no.
10308, pp. 1377–1380, Oct. 2021, doi:
10.1016/S0140-6736(21)02046-8/ATTACHMENT/99B4689E-FA37-476A-B30E-8D1E3B4E33BC/MMC1.PDF.&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-left: 32pt; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none; text-indent: -32pt;&quot;&gt;&lt;span style=&quot;mso-ascii-font-family: Calibri; mso-bidi-font-family: Calibri; mso-bidi-font-size: 12.0pt; mso-hansi-font-family: Calibri; mso-no-proof: yes;&quot;&gt;[2]&lt;span style=&quot;mso-tab-count: 1;&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/span&gt;E. Callaway, “COVID vaccine boosters:
the most important questions,” &lt;i&gt;Nature&lt;/i&gt;, vol. 596, no. 7871, pp. 178–180,
Aug. 2021, doi: 10.1038/D41586-021-02158-6.&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-left: 32pt; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none; text-indent: -32pt;&quot;&gt;&lt;span style=&quot;mso-ascii-font-family: Calibri; mso-bidi-font-family: Calibri; mso-bidi-font-size: 12.0pt; mso-hansi-font-family: Calibri; mso-no-proof: yes;&quot;&gt;[3]&lt;span style=&quot;mso-tab-count: 1;&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/span&gt;N. Kamar, F. Abravanel, O. Marion, C.
Couat, J. Izopet, and A. Del Bello, “Three Doses of an mRNA Covid-19 Vaccine in
Solid-Organ Transplant Recipients,” &lt;i&gt;N. Engl. J. Med.&lt;/i&gt;, vol. 385, no. 7,
pp. 661–662, Aug. 2021, doi: 10.1056/NEJMC2108861.&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-left: 32pt; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none; text-indent: -32pt;&quot;&gt;&lt;span style=&quot;mso-ascii-font-family: Calibri; mso-bidi-font-family: Calibri; mso-bidi-font-size: 12.0pt; mso-hansi-font-family: Calibri; mso-no-proof: yes;&quot;&gt;[4]&lt;span style=&quot;mso-tab-count: 1;&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/span&gt;J. W. Gargano &lt;i&gt;et al.&lt;/i&gt;, “Use of
mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients:
Update from the Advisory Committee on Immunization Practices — United States,
June 2021,” &lt;i&gt;MMWR. Morb. Mortal. Wkly. Rep.&lt;/i&gt;, vol. 70, no. 27, pp. 977–982,
Jul. 2021, doi: 10.15585/MMWR.MM7027E2.&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-left: 32pt; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none; text-indent: -32pt;&quot;&gt;&lt;span style=&quot;mso-ascii-font-family: Calibri; mso-bidi-font-family: Calibri; mso-bidi-font-size: 12.0pt; mso-hansi-font-family: Calibri; mso-no-proof: yes;&quot;&gt;[5]&lt;span style=&quot;mso-tab-count: 1;&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/span&gt;“Statement of the WHO Global Advisory
Committee on Vaccine Safety (GACVS) COVID-19 subcommittee on reports of
Guillain-Barré Syndrome (GBS) following adenovirus vector COVID-19 vaccines.”
[Online]. Available:
https://www.who.int/news/item/26-07-2021-statement-of-the-who-gacvs-covid-19-subcommittee-on-gbs.
[Accessed: 31-Dec-2021].&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-left: 32pt; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none; text-indent: -32pt;&quot;&gt;&lt;span style=&quot;mso-ascii-font-family: Calibri; mso-bidi-font-family: Calibri; mso-bidi-font-size: 12.0pt; mso-hansi-font-family: Calibri; mso-no-proof: yes;&quot;&gt;[6]&lt;span style=&quot;mso-tab-count: 1;&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/span&gt;Y. M. Bar-On &lt;i&gt;et al.&lt;/i&gt;, “Protection
of BNT162b2 Vaccine Booster against Covid-19 in Israel,” &lt;i&gt;N. Engl. J. Med.&lt;/i&gt;,
vol. 385, no. 15, pp. 1393–1400, Oct. 2021, doi: 10.1056/NEJMOA2114255.&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-left: 32pt; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none; text-indent: -32pt;&quot;&gt;&lt;span style=&quot;mso-ascii-font-family: Calibri; mso-bidi-font-family: Calibri; mso-bidi-font-size: 12.0pt; mso-hansi-font-family: Calibri; mso-no-proof: yes;&quot;&gt;[7]&lt;span style=&quot;mso-tab-count: 1;&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/span&gt;J. B. Griffin &lt;i&gt;et al.&lt;/i&gt;, “SARS-CoV-2
Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination
Status - Los Angeles County, California, May 1-July 25, 2021,” &lt;i&gt;MMWR. Morb.
Mortal. Wkly. Rep.&lt;/i&gt;, vol. 70, no. 34, pp. 1170–1176, 2021, doi:
10.15585/MMWR.MM7034E5.&lt;/span&gt;&lt;span style=&quot;mso-ascii-font-family: Calibri; mso-bidi-font-family: Calibri; mso-hansi-font-family: Calibri; mso-no-proof: yes;&quot;&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot;&gt;&lt;!--[if supportFields]&gt;&lt;span style=&#39;mso-element:field-end&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/p&gt;</content><link rel='replies' type='application/atom+xml' href='http://thepillarsofhealth.blogspot.com/feeds/6792812870042826555/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://thepillarsofhealth.blogspot.com/2021/12/about-covid-19-booster-vaccinations.html#comment-form' title='4 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/6792812870042826555'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/6792812870042826555'/><link rel='alternate' type='text/html' href='http://thepillarsofhealth.blogspot.com/2021/12/about-covid-19-booster-vaccinations.html' title='About COVID-19 Booster Vaccinations'/><author><name>Dr Dhia Aldoori</name><uri>http://www.blogger.com/profile/12785445082984259058</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='23' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgIcbY6lOf-A2OAQZ3CCF-V44BF68CUZ1wYcXS06NXVQS-lTFiik3VkOYsT0dmfX2RcYB8yuWeKbUAP5w5AeDWHc1bdI-0eQEt4lr6yM4tplO9dgbQ9nT74rRU6KPLeXw/s149/Cropped+PA307202'/></author><thr:total>4</thr:total></entry><entry><id>tag:blogger.com,1999:blog-7196398195634872986.post-2919331923583583890</id><published>2021-11-22T11:19:00.000-05:00</published><updated>2021-11-22T11:19:22.919-05:00</updated><title type='text'> Ivermectin and Covid-19 </title><content type='html'>&lt;blockquote style=&quot;border: none; margin: 0 0 0 40px; padding: 0px;&quot;&gt;&lt;blockquote style=&quot;border: none; margin: 0 0 0 40px; padding: 0px;&quot;&gt;&lt;blockquote style=&quot;border: none; margin: 0 0 0 40px; padding: 0px;&quot;&gt;&lt;blockquote style=&quot;border: none; margin: 0 0 0 40px; padding: 0px;&quot;&gt;&lt;blockquote style=&quot;border: none; margin: 0 0 0 40px; padding: 0px;&quot;&gt;&lt;blockquote style=&quot;border: none; margin: 0 0 0 40px; padding: 0px;&quot;&gt;&lt;p style=&quot;text-align: left;&quot;&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; color: windowtext; font-family: &amp;quot;Segoe UI&amp;quot;, &amp;quot;Segoe UI Web&amp;quot;, Arial, Verdana, sans-serif; font-size: 10pt; font-variant-ligatures: none; line-height: 18.3458px; margin: 0px; padding: 0px; text-align: center; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;By&amp;nbsp;&lt;/span&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;D&lt;/span&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;hia Aldoori November 22, 2021&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;EOP BCX0 SCXW31925924&quot; data-ccp-props=&quot;{&amp;quot;201341983&amp;quot;:0,&amp;quot;335551550&amp;quot;:2,&amp;quot;335551620&amp;quot;:2,&amp;quot;335559739&amp;quot;:160,&amp;quot;335559740&amp;quot;:259}&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; color: windowtext; font-family: &amp;quot;Segoe UI&amp;quot;, &amp;quot;Segoe UI Web&amp;quot;, Arial, Verdana, sans-serif; font-size: 10pt; line-height: 18.3458px; margin: 0px; padding: 0px; text-align: center; user-select: text;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/p&gt;&lt;/blockquote&gt;&lt;/blockquote&gt;&lt;/blockquote&gt;&lt;/blockquote&gt;&lt;/blockquote&gt;&lt;/blockquote&gt;&lt;div class=&quot;OutlineElement Ltr BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; background-color: white; clear: both; cursor: text; direction: ltr; font-family: &amp;quot;Segoe UI&amp;quot;, &amp;quot;Segoe UI Web&amp;quot;, Arial, Verdana, sans-serif; font-size: 12px; margin: 0px; overflow: visible; padding: 0px; position: relative; user-select: text;&quot;&gt;&lt;p class=&quot;Paragraph BCX0 SCXW31925924&quot; paraeid=&quot;{de417c68-a50f-43d2-9d1c-76daf0dd365a}{136}&quot; paraid=&quot;1980905199&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; background-color: transparent; color: windowtext; font-kerning: none; margin: 0px; overflow-wrap: break-word; padding: 0px; user-select: text; vertical-align: baseline;&quot;&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 19.425px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;I have updated my knowledge and stance on ivermectin&lt;/span&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;&amp;nbsp;use in humans for treating the SARS-CoV-2 viral infection&lt;/span&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;&amp;nbsp;to where I consider it to have&amp;nbsp;&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun Underlined BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 19.425px; margin: 0px; padding: 0px; text-decoration-line: underline; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;potential&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 19.425px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;&amp;nbsp;benefit in treating severe cases of&amp;nbsp;&lt;/span&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;COVID&amp;nbsp;&lt;/span&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;19. I may endorse&amp;nbsp;&lt;/span&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;(not yet though)&amp;nbsp;&lt;/span&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;its regular use in severe cases after randomized controlled trials are carried out on it.&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;FieldRange BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; background-color: #e1e3e6; margin: 0px; padding: 0px; user-select: text;&quot;&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 19.425px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;[1]–[6]&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun EmptyTextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 19.425px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;/span&gt;&lt;span class=&quot;FieldRange BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; background-color: #e1e3e6; margin: 0px; padding: 0px; user-select: text;&quot;&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 19.425px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;[7],[8]&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun EmptyTextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 19.425px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;/span&gt;&lt;span class=&quot;EOP BCX0 SCXW31925924&quot; data-ccp-props=&quot;{&amp;quot;201341983&amp;quot;:0,&amp;quot;335559739&amp;quot;:160,&amp;quot;335559740&amp;quot;:259}&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; line-height: 19.425px; margin: 0px; padding: 0px; user-select: text;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div class=&quot;OutlineElement Ltr BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; background-color: white; clear: both; cursor: text; direction: ltr; font-family: &amp;quot;Segoe UI&amp;quot;, &amp;quot;Segoe UI Web&amp;quot;, Arial, Verdana, sans-serif; font-size: 12px; margin: 0px; overflow: visible; padding: 0px; position: relative; user-select: text;&quot;&gt;&lt;p class=&quot;Paragraph BCX0 SCXW31925924&quot; paraeid=&quot;{de417c68-a50f-43d2-9d1c-76daf0dd365a}{170}&quot; paraid=&quot;584334553&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; background-color: transparent; color: windowtext; font-kerning: none; margin: 0px; overflow-wrap: break-word; padding: 0px; user-select: text; vertical-align: baseline;&quot;&gt;&lt;span class=&quot;TextRun Underlined BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 19.425px; margin: 0px; padding: 0px; text-decoration-line: underline; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class=&quot;Paragraph BCX0 SCXW31925924&quot; paraeid=&quot;{de417c68-a50f-43d2-9d1c-76daf0dd365a}{170}&quot; paraid=&quot;584334553&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; background-color: transparent; color: windowtext; font-kerning: none; margin: 0px; overflow-wrap: break-word; padding: 0px; user-select: text; vertical-align: baseline;&quot;&gt;&lt;span class=&quot;TextRun Underlined BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 19.425px; margin: 0px; padding: 0px; text-decoration-line: underline; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;Bibliography&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 19.425px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;:&lt;/span&gt;&lt;span class=&quot;EOP BCX0 SCXW31925924&quot; data-ccp-props=&quot;{&amp;quot;201341983&amp;quot;:0,&amp;quot;335559739&amp;quot;:160,&amp;quot;335559740&amp;quot;:259}&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; line-height: 19.425px; margin: 0px; padding: 0px; user-select: text;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div class=&quot;OutlineElement Ltr BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; background-color: white; clear: both; cursor: text; direction: ltr; font-family: &amp;quot;Segoe UI&amp;quot;, &amp;quot;Segoe UI Web&amp;quot;, Arial, Verdana, sans-serif; font-size: 12px; margin: 0px; overflow: visible; padding: 0px; position: relative; user-select: text;&quot;&gt;&lt;p class=&quot;Paragraph BCX0 SCXW31925924&quot; paraeid=&quot;{de417c68-a50f-43d2-9d1c-76daf0dd365a}{174}&quot; paraid=&quot;1387305615&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; background-color: transparent; color: windowtext; font-kerning: none; margin: 0px 0px 0px 42px; overflow-wrap: break-word; padding: 0px; text-indent: -42px; user-select: text; vertical-align: baseline;&quot;&gt;&lt;span class=&quot;TextRun EmptyTextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;/span&gt;&lt;span class=&quot;FieldRange BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; background-color: #e1e3e6; margin: 0px; padding: 0px; user-select: text;&quot;&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;[1]&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TabRun IPSelectionBlob BlobObject DragDrop BCX0 SCXW31925924&quot; face=&quot;Calibri, sans-serif&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; display: inline-block; font-size: 11pt; margin: 0px; padding: 0px; position: relative; text-indent: 0px; user-select: text; white-space: nowrap; width: 0px;&quot;&gt;&lt;span class=&quot;TabChar BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; display: inline-block; margin: 0px; padding: 0px; user-select: text; white-space: pre;&quot;&gt;	&lt;/span&gt;&lt;span aria-hidden=&quot;true&quot; class=&quot;TabLeaderChars BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; display: inline-block; left: 0px; margin: 0px; padding: 0px; position: absolute; top: 0px; user-select: none; white-space: pre;&quot;&gt;&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;S. Ahmed&amp;nbsp;&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-style: italic; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;et al.&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;, “A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness,”&amp;nbsp;&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-style: italic; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;Int. J. Infect. Dis.&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;, vol. 103, no. 0, pp. 214–216, Feb. 2021, doi: 10.1016/j.ijid.2020.11.191.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun EmptyTextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;/span&gt;&lt;span class=&quot;EOP BCX0 SCXW31925924&quot; data-ccp-props=&quot;{&amp;quot;201341983&amp;quot;:0,&amp;quot;335559685&amp;quot;:640,&amp;quot;335559739&amp;quot;:160,&amp;quot;335559740&amp;quot;:240,&amp;quot;335559991&amp;quot;:640}&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div class=&quot;OutlineElement Ltr BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; background-color: white; clear: both; cursor: text; direction: ltr; font-family: &amp;quot;Segoe UI&amp;quot;, &amp;quot;Segoe UI Web&amp;quot;, Arial, Verdana, sans-serif; font-size: 12px; margin: 0px; overflow: visible; padding: 0px; position: relative; user-select: text;&quot;&gt;&lt;p class=&quot;Paragraph BCX0 SCXW31925924&quot; paraeid=&quot;{de417c68-a50f-43d2-9d1c-76daf0dd365a}{197}&quot; paraid=&quot;1546015747&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; background-color: transparent; color: windowtext; font-kerning: none; margin: 0px 0px 0px 42px; overflow-wrap: break-word; padding: 0px; text-indent: -42px; user-select: text; vertical-align: baseline;&quot;&gt;&lt;span class=&quot;TextRun EmptyTextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;/span&gt;&lt;span class=&quot;FieldRange BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; background-color: #e1e3e6; margin: 0px; padding: 0px; user-select: text;&quot;&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;[2]&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TabRun IPSelectionBlob BlobObject DragDrop BCX0 SCXW31925924&quot; face=&quot;Calibri, sans-serif&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; display: inline-block; font-size: 11pt; margin: 0px; padding: 0px; position: relative; text-indent: 0px; user-select: text; white-space: nowrap; width: 0px;&quot;&gt;&lt;span class=&quot;TabChar BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; display: inline-block; margin: 0px; padding: 0px; user-select: text; white-space: pre;&quot;&gt;	&lt;/span&gt;&lt;span aria-hidden=&quot;true&quot; class=&quot;TabLeaderChars BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; display: inline-block; left: 0px; margin: 0px; padding: 0px; position: absolute; top: 0px; user-select: none; white-space: pre;&quot;&gt;&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;N. Okumuş&amp;nbsp;&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-style: italic; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;et al.&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;, “Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients,”&amp;nbsp;&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-style: italic; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;BMC Infect. Dis.&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;, vol. 21, no. 1, 2021, doi: 10.1186/s12879-021-06104-9.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun EmptyTextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;/span&gt;&lt;span class=&quot;EOP BCX0 SCXW31925924&quot; data-ccp-props=&quot;{&amp;quot;201341983&amp;quot;:0,&amp;quot;335559685&amp;quot;:640,&amp;quot;335559739&amp;quot;:160,&amp;quot;335559740&amp;quot;:240,&amp;quot;335559991&amp;quot;:640}&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div class=&quot;OutlineElement Ltr BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; background-color: white; clear: both; cursor: text; direction: ltr; font-family: &amp;quot;Segoe UI&amp;quot;, &amp;quot;Segoe UI Web&amp;quot;, Arial, Verdana, sans-serif; font-size: 12px; margin: 0px; overflow: visible; padding: 0px; position: relative; user-select: text;&quot;&gt;&lt;p class=&quot;Paragraph BCX0 SCXW31925924&quot; paraeid=&quot;{de417c68-a50f-43d2-9d1c-76daf0dd365a}{217}&quot; paraid=&quot;1165090506&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; background-color: transparent; color: windowtext; font-kerning: none; margin: 0px 0px 0px 42px; overflow-wrap: break-word; padding: 0px; text-indent: -42px; user-select: text; vertical-align: baseline;&quot;&gt;&lt;span class=&quot;TextRun EmptyTextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;/span&gt;&lt;span class=&quot;FieldRange BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; background-color: #e1e3e6; margin: 0px; padding: 0px; user-select: text;&quot;&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;[3]&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TabRun IPSelectionBlob BlobObject DragDrop BCX0 SCXW31925924&quot; face=&quot;Calibri, sans-serif&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; display: inline-block; font-size: 11pt; margin: 0px; padding: 0px; position: relative; text-indent: 0px; user-select: text; white-space: nowrap; width: 0px;&quot;&gt;&lt;span class=&quot;TabChar BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; display: inline-block; margin: 0px; padding: 0px; user-select: text; white-space: pre;&quot;&gt;	&lt;/span&gt;&lt;span aria-hidden=&quot;true&quot; class=&quot;TabLeaderChars BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; display: inline-block; left: 0px; margin: 0px; padding: 0px; position: absolute; top: 0px; user-select: none; white-space: pre;&quot;&gt;&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;S. Lehrer and P. H. Rheinstein, “Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2,”&amp;nbsp;&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-style: italic; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;In Vivo (Brooklyn).&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;, vol. 34, no. 5, 2020, doi: 10.21873/invivo.12134.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun EmptyTextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;/span&gt;&lt;span class=&quot;EOP BCX0 SCXW31925924&quot; data-ccp-props=&quot;{&amp;quot;201341983&amp;quot;:0,&amp;quot;335559685&amp;quot;:640,&amp;quot;335559739&amp;quot;:160,&amp;quot;335559740&amp;quot;:240,&amp;quot;335559991&amp;quot;:640}&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div class=&quot;OutlineElement Ltr BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; background-color: white; clear: both; cursor: text; direction: ltr; font-family: &amp;quot;Segoe UI&amp;quot;, &amp;quot;Segoe UI Web&amp;quot;, Arial, Verdana, sans-serif; font-size: 12px; margin: 0px; overflow: visible; padding: 0px; position: relative; user-select: text;&quot;&gt;&lt;p class=&quot;Paragraph BCX0 SCXW31925924&quot; paraeid=&quot;{de417c68-a50f-43d2-9d1c-76daf0dd365a}{233}&quot; paraid=&quot;1014813749&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; background-color: transparent; color: windowtext; font-kerning: none; margin: 0px 0px 0px 42px; overflow-wrap: break-word; padding: 0px; text-indent: -42px; user-select: text; vertical-align: baseline;&quot;&gt;&lt;span class=&quot;TextRun EmptyTextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;/span&gt;&lt;span class=&quot;FieldRange BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; background-color: #e1e3e6; margin: 0px; padding: 0px; user-select: text;&quot;&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;[4]&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TabRun IPSelectionBlob BlobObject DragDrop BCX0 SCXW31925924&quot; face=&quot;Calibri, sans-serif&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; display: inline-block; font-size: 11pt; margin: 0px; padding: 0px; position: relative; text-indent: 0px; user-select: text; white-space: nowrap; width: 0px;&quot;&gt;&lt;span class=&quot;TabChar BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; display: inline-block; margin: 0px; padding: 0px; user-select: text; white-space: pre;&quot;&gt;	&lt;/span&gt;&lt;span aria-hidden=&quot;true&quot; class=&quot;TabLeaderChars BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; display: inline-block; left: 0px; margin: 0px; padding: 0px; position: absolute; top: 0px; user-select: none; white-space: pre;&quot;&gt;&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;J. C. Rajter, M. S. Sherman, N. Fatteh, F. Vogel, J. Sacks, and J.-J. Rajter, “Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019,”&amp;nbsp;&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-style: italic; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;Chest&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;, vol. 159, no. 1, pp. 85–92, Jan. 2021, doi: 10.1016/j.chest.2020.10.009.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun EmptyTextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;/span&gt;&lt;span class=&quot;EOP BCX0 SCXW31925924&quot; data-ccp-props=&quot;{&amp;quot;201341983&amp;quot;:0,&amp;quot;335559685&amp;quot;:640,&amp;quot;335559739&amp;quot;:160,&amp;quot;335559740&amp;quot;:240,&amp;quot;335559991&amp;quot;:640}&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div class=&quot;OutlineElement Ltr BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; background-color: white; clear: both; cursor: text; direction: ltr; font-family: &amp;quot;Segoe UI&amp;quot;, &amp;quot;Segoe UI Web&amp;quot;, Arial, Verdana, sans-serif; font-size: 12px; margin: 0px; overflow: visible; padding: 0px; position: relative; user-select: text;&quot;&gt;&lt;p class=&quot;Paragraph BCX0 SCXW31925924&quot; paraeid=&quot;{de417c68-a50f-43d2-9d1c-76daf0dd365a}{249}&quot; paraid=&quot;468046724&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; background-color: transparent; color: windowtext; font-kerning: none; margin: 0px 0px 0px 42px; overflow-wrap: break-word; padding: 0px; text-indent: -42px; user-select: text; vertical-align: baseline;&quot;&gt;&lt;span class=&quot;TextRun EmptyTextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;/span&gt;&lt;span class=&quot;FieldRange BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; background-color: #e1e3e6; margin: 0px; padding: 0px; user-select: text;&quot;&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;[5]&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TabRun IPSelectionBlob BlobObject DragDrop BCX0 SCXW31925924&quot; face=&quot;Calibri, sans-serif&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; display: inline-block; font-size: 11pt; margin: 0px; padding: 0px; position: relative; text-indent: 0px; user-select: text; white-space: nowrap; width: 0px;&quot;&gt;&lt;span class=&quot;TabChar BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; display: inline-block; margin: 0px; padding: 0px; user-select: text; white-space: pre;&quot;&gt;	&lt;/span&gt;&lt;span aria-hidden=&quot;true&quot; class=&quot;TabLeaderChars BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; display: inline-block; left: 0px; margin: 0px; padding: 0px; position: absolute; top: 0px; user-select: none; white-space: pre;&quot;&gt;&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;F. Heidary and R. Gharebaghi, “Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen,”&amp;nbsp;&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-style: italic; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;Journal of Antibiotics&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;, vol. 73, no. 9. 2020, doi: 10.1038/s41429-020-0336-z.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun EmptyTextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;/span&gt;&lt;span class=&quot;EOP BCX0 SCXW31925924&quot; data-ccp-props=&quot;{&amp;quot;201341983&amp;quot;:0,&amp;quot;335559685&amp;quot;:640,&amp;quot;335559739&amp;quot;:160,&amp;quot;335559740&amp;quot;:240,&amp;quot;335559991&amp;quot;:640}&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div class=&quot;OutlineElement Ltr BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; background-color: white; clear: both; cursor: text; direction: ltr; font-family: &amp;quot;Segoe UI&amp;quot;, &amp;quot;Segoe UI Web&amp;quot;, Arial, Verdana, sans-serif; font-size: 12px; margin: 0px; overflow: visible; padding: 0px; position: relative; user-select: text;&quot;&gt;&lt;p class=&quot;Paragraph BCX0 SCXW31925924&quot; paraeid=&quot;{e7e927cd-d1cf-48e4-815b-3944e384a4b8}{10}&quot; paraid=&quot;1525691842&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; background-color: transparent; color: windowtext; font-kerning: none; margin: 0px 0px 0px 42px; overflow-wrap: break-word; padding: 0px; text-indent: -42px; user-select: text; vertical-align: baseline;&quot;&gt;&lt;span class=&quot;TextRun EmptyTextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;/span&gt;&lt;span class=&quot;FieldRange BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; background-color: #e1e3e6; margin: 0px; padding: 0px; user-select: text;&quot;&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;[6]&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TabRun IPSelectionBlob BlobObject DragDrop BCX0 SCXW31925924&quot; face=&quot;Calibri, sans-serif&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; display: inline-block; font-size: 11pt; margin: 0px; padding: 0px; position: relative; text-indent: 0px; user-select: text; white-space: nowrap; width: 0px;&quot;&gt;&lt;span class=&quot;TabChar BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; display: inline-block; margin: 0px; padding: 0px; user-select: text; white-space: pre;&quot;&gt;	&lt;/span&gt;&lt;span aria-hidden=&quot;true&quot; class=&quot;TabLeaderChars BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; display: inline-block; left: 0px; margin: 0px; padding: 0px; position: absolute; top: 0px; user-select: none; white-space: pre;&quot;&gt;&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;L. Caly, J. D. Druce, M. G. Catton, D. A. Jans, and K. M. Wagstaff, “The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro,”&amp;nbsp;&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-style: italic; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;Antiviral Res.&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;, vol. 178, 2020, doi: 10.1016/j.antiviral.2020.104787.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun EmptyTextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;/span&gt;&lt;span class=&quot;EOP BCX0 SCXW31925924&quot; data-ccp-props=&quot;{&amp;quot;201341983&amp;quot;:0,&amp;quot;335559685&amp;quot;:640,&amp;quot;335559739&amp;quot;:160,&amp;quot;335559740&amp;quot;:240,&amp;quot;335559991&amp;quot;:640}&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div class=&quot;OutlineElement Ltr BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; background-color: white; clear: both; cursor: text; direction: ltr; font-family: &amp;quot;Segoe UI&amp;quot;, &amp;quot;Segoe UI Web&amp;quot;, Arial, Verdana, sans-serif; font-size: 12px; margin: 0px; overflow: visible; padding: 0px; position: relative; user-select: text;&quot;&gt;&lt;p class=&quot;Paragraph BCX0 SCXW31925924&quot; paraeid=&quot;{e7e927cd-d1cf-48e4-815b-3944e384a4b8}{26}&quot; paraid=&quot;1280001604&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; background-color: transparent; color: windowtext; font-kerning: none; margin: 0px 0px 0px 42px; overflow-wrap: break-word; padding: 0px; text-indent: -42px; user-select: text; vertical-align: baseline;&quot;&gt;&lt;span class=&quot;TextRun EmptyTextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;/span&gt;&lt;span class=&quot;FieldRange BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; background-color: #e1e3e6; margin: 0px; padding: 0px; user-select: text;&quot;&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;[7]&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TabRun IPSelectionBlob BlobObject DragDrop BCX0 SCXW31925924&quot; face=&quot;Calibri, sans-serif&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; display: inline-block; font-size: 11pt; margin: 0px; padding: 0px; position: relative; text-indent: 0px; user-select: text; white-space: nowrap; width: 0px;&quot;&gt;&lt;span class=&quot;TabChar BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; display: inline-block; margin: 0px; padding: 0px; user-select: text; white-space: pre;&quot;&gt;	&lt;/span&gt;&lt;span aria-hidden=&quot;true&quot; class=&quot;TabLeaderChars BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; display: inline-block; left: 0px; margin: 0px; padding: 0px; position: absolute; top: 0px; user-select: none; white-space: pre;&quot;&gt;&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;G. Momekov and D. Momekova, “Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens,”&amp;nbsp;&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-style: italic; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;Biotechnol. Biotechnol. Equip.&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;, vol. 34, no. 1, pp. 469–474, Jan. 2020, doi: 10.1080/13102818.2020.1775118.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun EmptyTextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;/span&gt;&lt;span class=&quot;EOP BCX0 SCXW31925924&quot; data-ccp-props=&quot;{&amp;quot;201341983&amp;quot;:0,&amp;quot;335559685&amp;quot;:640,&amp;quot;335559739&amp;quot;:160,&amp;quot;335559740&amp;quot;:240,&amp;quot;335559991&amp;quot;:640}&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div class=&quot;OutlineElement Ltr BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; background-color: white; clear: both; cursor: text; direction: ltr; font-family: &amp;quot;Segoe UI&amp;quot;, &amp;quot;Segoe UI Web&amp;quot;, Arial, Verdana, sans-serif; font-size: 12px; margin: 0px; overflow: visible; padding: 0px; position: relative; user-select: text;&quot;&gt;&lt;p class=&quot;Paragraph BCX0 SCXW31925924&quot; paraeid=&quot;{e7e927cd-d1cf-48e4-815b-3944e384a4b8}{42}&quot; paraid=&quot;2127790855&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; background-color: transparent; color: windowtext; font-kerning: none; margin: 0px 0px 0px 42px; overflow-wrap: break-word; padding: 0px; text-indent: -42px; user-select: text; vertical-align: baseline;&quot;&gt;&lt;span class=&quot;TextRun EmptyTextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;/span&gt;&lt;span class=&quot;FieldRange BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; background-color: #e1e3e6; margin: 0px; padding: 0px; user-select: text;&quot;&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;[8]&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TabRun IPSelectionBlob BlobObject DragDrop BCX0 SCXW31925924&quot; face=&quot;Calibri, sans-serif&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; display: inline-block; font-size: 11pt; margin: 0px; padding: 0px; position: relative; text-indent: 0px; user-select: text; white-space: nowrap; width: 0px;&quot;&gt;&lt;span class=&quot;TabChar BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; display: inline-block; margin: 0px; padding: 0px; user-select: text; white-space: pre;&quot;&gt;	&lt;/span&gt;&lt;span aria-hidden=&quot;true&quot; class=&quot;TabLeaderChars BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; display: inline-block; left: 0px; margin: 0px; padding: 0px; position: absolute; top: 0px; user-select: none; white-space: pre;&quot;&gt;&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;“Ivermectin | COVID-19 Treatment Guidelines.” [Online]. Available: https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ivermectin/. [Accessed: 22-Nov-2021].&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TextRun EmptyTextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;/span&gt;&lt;span class=&quot;EOP BCX0 SCXW31925924&quot; data-ccp-props=&quot;{&amp;quot;201341983&amp;quot;:0,&amp;quot;335559685&amp;quot;:640,&amp;quot;335559739&amp;quot;:160,&amp;quot;335559740&amp;quot;:240,&amp;quot;335559991&amp;quot;:640}&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; line-height: 18px; margin: 0px; padding: 0px; user-select: text;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div class=&quot;OutlineElement Ltr BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; background-color: white; clear: both; cursor: text; direction: ltr; font-family: &amp;quot;Segoe UI&amp;quot;, &amp;quot;Segoe UI Web&amp;quot;, Arial, Verdana, sans-serif; font-size: 12px; margin: 0px; overflow: visible; padding: 0px; position: relative; user-select: text;&quot;&gt;&lt;p class=&quot;Paragraph BCX0 SCXW31925924&quot; paraeid=&quot;{e7e927cd-d1cf-48e4-815b-3944e384a4b8}{54}&quot; paraid=&quot;1190670521&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; background-color: transparent; color: windowtext; font-kerning: none; margin: 0px; overflow-wrap: break-word; padding: 0px; user-select: text; vertical-align: baseline;&quot;&gt;&lt;span class=&quot;TextRun BCX0 SCXW31925924&quot; data-contrast=&quot;auto&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; lang=&quot;EN-US&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; font-variant-ligatures: none; line-height: 19.425px; margin: 0px; padding: 0px; user-select: text;&quot; xml:lang=&quot;EN-US&quot;&gt;&lt;span class=&quot;NormalTextRun BCX0 SCXW31925924&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; margin: 0px; padding: 0px; user-select: text;&quot;&gt;&lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;EOP BCX0 SCXW31925924&quot; data-ccp-props=&quot;{&amp;quot;201341983&amp;quot;:0,&amp;quot;335559739&amp;quot;:160,&amp;quot;335559740&amp;quot;:259}&quot; face=&quot;Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif&quot; style=&quot;-webkit-tap-highlight-color: transparent; -webkit-user-drag: none; font-size: 11pt; line-height: 19.425px; margin: 0px; padding: 0px; user-select: text;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://thepillarsofhealth.blogspot.com/feeds/2919331923583583890/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://thepillarsofhealth.blogspot.com/2021/11/ivermectin-and-covid-19.html#comment-form' title='3 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/2919331923583583890'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/2919331923583583890'/><link rel='alternate' type='text/html' href='http://thepillarsofhealth.blogspot.com/2021/11/ivermectin-and-covid-19.html' title=' Ivermectin and Covid-19 '/><author><name>Dr Dhia Aldoori</name><uri>http://www.blogger.com/profile/12785445082984259058</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='23' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgIcbY6lOf-A2OAQZ3CCF-V44BF68CUZ1wYcXS06NXVQS-lTFiik3VkOYsT0dmfX2RcYB8yuWeKbUAP5w5AeDWHc1bdI-0eQEt4lr6yM4tplO9dgbQ9nT74rRU6KPLeXw/s149/Cropped+PA307202'/></author><thr:total>3</thr:total></entry><entry><id>tag:blogger.com,1999:blog-7196398195634872986.post-1519244712244276260</id><published>2021-04-17T08:17:00.002-04:00</published><updated>2021-05-02T06:37:30.084-04:00</updated><title type='text'>Notes about Vaccinating With the Covid-19 Janssen/Biotech Vaccine Given the Recent CVST Pause</title><content type='html'>&lt;p&gt;&amp;nbsp;&lt;span style=&quot;text-align: center;&quot;&gt;By Dr. Dhia Aldoori April
16, 2021&lt;/span&gt;&lt;/p&gt;&lt;p align=&quot;center&quot; class=&quot;MsoNormal&quot; style=&quot;text-align: center;&quot;&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot;&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;As of today I am aware of 6 patients with the diagnosis of
&lt;a href=&quot;https://en.wikipedia.org/wiki/Cerebral_venous_sinus_thrombosis&quot; target=&quot;_blank&quot;&gt;cerebral venous sinus thrombosis&lt;/a&gt; (CVST) who have received the Johnson &amp;amp;
Johnson (Janssen/Biotech Vaccine) within three weeks of manifestations
emanating from CVST.&lt;sup&gt;1&lt;/sup&gt; One sadly passed away, one
currently in hospital and all are female.&lt;/p&gt;&lt;p class=&quot;MsoNormal&quot;&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot;&gt;&lt;span style=&quot;mso-spacerun: yes;&quot;&gt;&amp;nbsp;&lt;/span&gt;Pending further
analysis of the safety of administering this vaccination, a ‘pause’ has been
advised by the CDC (Centers for Disease Control) and Food and Drug Administration
(FDA). A pause doesn’t mean stopping this vaccine and a caregiver may discuss
administration of it with her/his patient and go ahead and advise its receipt.&lt;!--[if supportFields]&gt;&lt;span
style=&#39;mso-element:field-begin;mso-field-lock:yes&#39;&gt;&lt;/span&gt;ADDIN CSL_CITATION
{&amp;quot;citationItems&amp;quot;:[{&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;itemData&amp;quot;:{&amp;quot;URL&amp;quot;:&amp;quot;https://www.youtube.com/watch?v=_ELXnGYgsJY&amp;quot;,&amp;quot;accessed&amp;quot;:{&amp;quot;date-parts&amp;quot;:[[&amp;quot;2021&amp;quot;,&amp;quot;4&amp;quot;,&amp;quot;16&amp;quot;]]},&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;issued&amp;quot;:{&amp;quot;date-parts&amp;quot;:[[&amp;quot;0&amp;quot;]]},&amp;quot;title&amp;quot;:&amp;quot;Joint
Media Call: FDA &amp;amp; CDC to Discuss Janssen COVID-19 Vaccine - 4/13/2021 -
YouTube&amp;quot;,&amp;quot;type&amp;quot;:&amp;quot;webpage&amp;quot;},&amp;quot;uris&amp;quot;:[&amp;quot;http://www.mendeley.com/documents/?uuid=1c6333b4-c333-3bc7-8cc4-ad61a5f0c145&amp;quot;]}],&amp;quot;mendeley&amp;quot;:{&amp;quot;formattedCitation&amp;quot;:&amp;quot;&amp;lt;sup&amp;gt;1&amp;lt;/sup&amp;gt;&amp;quot;,&amp;quot;plainTextFormattedCitation&amp;quot;:&amp;quot;1&amp;quot;,&amp;quot;previouslyFormattedCitation&amp;quot;:&amp;quot;&amp;lt;sup&amp;gt;1&amp;lt;/sup&amp;gt;&amp;quot;},&amp;quot;properties&amp;quot;:{&amp;quot;noteIndex&amp;quot;:0},&amp;quot;schema&amp;quot;:&amp;quot;https://github.com/citation-style-language/schema/raw/master/csl-citation.json&amp;quot;}&lt;span
style=&#39;mso-element:field-separator&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;sup&gt;&lt;span style=&quot;mso-no-proof: yes;&quot;&gt;1&lt;/span&gt;&lt;/sup&gt;&lt;!--[if supportFields]&gt;&lt;span
style=&#39;mso-element:field-end&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot;&gt;A limited literature search revealed there has been the
association of cerebral venous sinus thrombosis (CVST) with prior medical
conditions. Examples are thrombophilias (blood platelet abnormalities),
inflammatory bowel disease, transient situations (e.g., pregnancy, dehydration,
and infection), some medications (e.g., oral contraceptives), substance abuse,
and unpredictable events (e.g., head trauma).&lt;!--[if supportFields]&gt;&lt;span
style=&#39;mso-element:field-begin;mso-field-lock:yes&#39;&gt;&lt;/span&gt;ADDIN CSL_CITATION
{&amp;quot;citationItems&amp;quot;:[{&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;itemData&amp;quot;:{&amp;quot;DOI&amp;quot;:&amp;quot;10.1161/STR.0b013e31820a8364&amp;quot;,&amp;quot;ISSN&amp;quot;:&amp;quot;00392499&amp;quot;,&amp;quot;PMID&amp;quot;:&amp;quot;21293023&amp;quot;,&amp;quot;abstract&amp;quot;:&amp;quot;Background-
The purpose of this statement is to provide an overview of cerebral venous
sinus thrombosis and to provide recommendations for its diagnosis, management,
and treatment. The intended audience is physicians and other healthcare
providers who are responsible for the diagnosis and management of patients with
cerebral venous sinus thrombosis. Methods and Results- Members of the panel
were appointed by the American Heart Association Stroke Council&#39;s Scientific
Statement Oversight Committee and represent different areas of expertise. The
panel reviewed the relevant literature with an emphasis on reports published
since 1966 and used the American Heart Association levels-of-evidence grading
algorithm to rate the evidence and to make recommendations. After approval of
the statement by the panel, it underwent peer review and approval by the
American Heart Association Science Advisory and Coordinating Committee.
Conclusions- Evidence-based recommendations are provided for the diagnosis,
management, and prevention of recurrence of cerebral venous thrombosis.
Recommendations on the evaluation and management of cerebral venous thrombosis
during pregnancy and in the pediatric population are provided. Considerations
for the management of clinical complications (seizures, hydrocephalus,
intracranial hypertension, and neurological deterioration) are also summarized.
An algorithm for diagnosis and management of patients with cerebral venous
sinus thrombosis is described. © 2011 American Heart Association. All rights
reserved.&amp;quot;,&amp;quot;author&amp;quot;:[{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Saposnik&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Gustavo&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Barinagarrementeria&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Fernando&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Brown&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Robert
D.&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Bushnell&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Cheryl
D.&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Cucchiara&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Brett&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Cushman&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Mary&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Deveber&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Gabrielle&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Ferro&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Jose
M.&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Tsai&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Fong
Y.&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;}],&amp;quot;container-title&amp;quot;:&amp;quot;Stroke&amp;quot;,&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;issue&amp;quot;:&amp;quot;4&amp;quot;,&amp;quot;issued&amp;quot;:{&amp;quot;date-parts&amp;quot;:[[&amp;quot;2011&amp;quot;,&amp;quot;4&amp;quot;,&amp;quot;1&amp;quot;]]},&amp;quot;page&amp;quot;:&amp;quot;1158-1192&amp;quot;,&amp;quot;publisher&amp;quot;:&amp;quot;CRC
Press&amp;quot;,&amp;quot;title&amp;quot;:&amp;quot;Diagnosis and management of cerebral venous
thrombosis: A statement for healthcare professionals from the American Heart
Association/American Stroke Association&amp;quot;,&amp;quot;type&amp;quot;:&amp;quot;article-journal&amp;quot;,&amp;quot;volume&amp;quot;:&amp;quot;42&amp;quot;},&amp;quot;uris&amp;quot;:[&amp;quot;http://www.mendeley.com/documents/?uuid=a492706c-cee2-3268-bf31-94f6639425f7&amp;quot;]}],&amp;quot;mendeley&amp;quot;:{&amp;quot;formattedCitation&amp;quot;:&amp;quot;&amp;lt;sup&amp;gt;2&amp;lt;/sup&amp;gt;&amp;quot;,&amp;quot;plainTextFormattedCitation&amp;quot;:&amp;quot;2&amp;quot;},&amp;quot;properties&amp;quot;:{&amp;quot;noteIndex&amp;quot;:0},&amp;quot;schema&amp;quot;:&amp;quot;https://github.com/citation-style-language/schema/raw/master/csl-citation.json&amp;quot;}&lt;span
style=&#39;mso-element:field-separator&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;sup&gt;&lt;span style=&quot;mso-no-proof: yes;&quot;&gt;2&lt;/span&gt;&lt;/sup&gt;&lt;!--[if supportFields]&gt;&lt;span
style=&#39;mso-element:field-end&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot;&gt;Considering above and pending clarification of the situation
I would say you should avoid getting the Janssen Biotech, Inc. (a
pharmaceutical company of Johnson &amp;amp; Johnson) vaccine if you have any of the
above conditions mentioned in paragraph 3 above. &lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot;&gt;Furthermore I would not critique those who do &lt;u&gt;not&lt;/u&gt;
have a possible predisposing condition and wish to avoid this vaccine until the
dust is settled. Bear in mind this is a vaccine that is not fully vetted study/safety
wise (like the Pfizer and Moderna vaccines), and hence being administered by
virtue of the Emergency Use Authorization (EUA) pathway.&lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot;&gt;&lt;u&gt;Bibliography&lt;o:p&gt;&lt;/o:p&gt;&lt;/u&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-left: 32pt; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none; text-indent: -32pt;&quot;&gt;&lt;!--[if supportFields]&gt;&lt;span
style=&#39;mso-element:field-begin;mso-field-lock:yes&#39;&gt;&lt;/span&gt;ADDIN Mendeley
Bibliography CSL_BIBLIOGRAPHY &lt;span style=&#39;mso-element:field-separator&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;span style=&quot;mso-ascii-font-family: Calibri; mso-bidi-font-family: Calibri; mso-bidi-font-size: 12.0pt; mso-hansi-font-family: Calibri; mso-no-proof: yes;&quot;&gt;1. &lt;span style=&quot;mso-tab-count: 1;&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/span&gt;Joint Media Call: FDA &amp;amp; CDC to
Discuss Janssen COVID-19 Vaccine - 4/13/2021 - YouTube. Accessed April 16,
2021. https://www.youtube.com/watch?v=_ELXnGYgsJY&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-left: 32pt; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none; text-indent: -32pt;&quot;&gt;&lt;span style=&quot;mso-ascii-font-family: Calibri; mso-bidi-font-family: Calibri; mso-bidi-font-size: 12.0pt; mso-hansi-font-family: Calibri; mso-no-proof: yes;&quot;&gt;2. &lt;span style=&quot;mso-tab-count: 1;&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/span&gt;Saposnik G, Barinagarrementeria F,
Brown RD, et al. Diagnosis and management of cerebral venous thrombosis: A
statement for healthcare professionals from the American Heart
Association/American Stroke Association. &lt;i&gt;Stroke&lt;/i&gt;. 2011;42(4):1158-1192.
doi:10.1161/STR.0b013e31820a8364&lt;/span&gt;&lt;span style=&quot;mso-ascii-font-family: Calibri; mso-bidi-font-family: Calibri; mso-hansi-font-family: Calibri; mso-no-proof: yes;&quot;&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot;&gt;&lt;!--[if supportFields]&gt;&lt;span style=&#39;mso-element:field-end&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/p&gt;</content><link rel='replies' type='application/atom+xml' href='http://thepillarsofhealth.blogspot.com/feeds/1519244712244276260/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://thepillarsofhealth.blogspot.com/2021/04/notes-about-vaccinating-with-covid-19.html#comment-form' title='1 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/1519244712244276260'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/1519244712244276260'/><link rel='alternate' type='text/html' href='http://thepillarsofhealth.blogspot.com/2021/04/notes-about-vaccinating-with-covid-19.html' title='Notes about Vaccinating With the Covid-19 Janssen/Biotech Vaccine Given the Recent CVST Pause'/><author><name>Dr Dhia Aldoori</name><uri>http://www.blogger.com/profile/12785445082984259058</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='23' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgIcbY6lOf-A2OAQZ3CCF-V44BF68CUZ1wYcXS06NXVQS-lTFiik3VkOYsT0dmfX2RcYB8yuWeKbUAP5w5AeDWHc1bdI-0eQEt4lr6yM4tplO9dgbQ9nT74rRU6KPLeXw/s149/Cropped+PA307202'/></author><thr:total>1</thr:total></entry><entry><id>tag:blogger.com,1999:blog-7196398195634872986.post-2800461294037064251</id><published>2021-03-31T15:22:00.003-04:00</published><updated>2021-04-03T10:07:25.291-04:00</updated><title type='text'>Notes about Vaccinating against COVID-19 (Pfizer/BioNtech, Moderna and Janssen/Biotech vaccines)</title><content type='html'>&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p align=&quot;center&quot; class=&quot;MsoNormal&quot; style=&quot;text-align: center;&quot;&gt;&lt;br /&gt;&lt;/p&gt;

&lt;p align=&quot;center&quot; class=&quot;MsoNormal&quot; style=&quot;line-height: 107%; margin-bottom: 8.0pt; margin-left: 0in; margin-right: 0in; margin-top: 0in; margin: 0in 0in 8pt; text-align: center;&quot;&gt;&lt;span face=&quot;&amp;quot;Calibri&amp;quot;,sans-serif&quot; style=&quot;mso-ascii-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin;&quot;&gt;&lt;span style=&quot;font-size: x-small;&quot;&gt;By Dr. Dhia
Aldoori March/2021&lt;/span&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p align=&quot;center&quot; class=&quot;MsoNormal&quot; style=&quot;text-align: center;&quot;&gt;&lt;span style=&quot;font-size: 9pt; line-height: 150%; mso-ascii-font-family: Arial; mso-bidi-font-family: Arial; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-font-family: Arial;&quot;&gt;(&lt;i&gt;&lt;span style=&quot;color: #ed7d31; mso-themecolor: accent2;&quot;&gt;Orange
font text targets other caregivers or indicates that &lt;span style=&quot;mso-spacerun: yes;&quot;&gt;&amp;nbsp;&lt;/span&gt;that text is my conclusion.&lt;/span&gt;&lt;/i&gt;)&lt;/span&gt;&lt;span style=&quot;font-size: 14pt; line-height: 150%;&quot;&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot;&gt;When the vaccines looked like they were going to hit the
stage somewhere in December 2020, I started looking for the data related to its
testing. I was looking at efficacy, safety, how many people were vaccinated,
how many controls (individuals given sham vaccinations to compare) were
employed, mechanism of action, etc. &lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot;&gt;The numbers we were hearing were the stellar efficacy of 95%
and 94.5% for the Pfizer/BioNtek and Moderna vaccines, respectively. &lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot;&gt;Starting with ingredients: &lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot; style=&quot;margin-left: 0.5in;&quot;&gt;The Pfizer-BioNTech COVID-19
Vaccine includes the following ingredients: mRNA (messenger ribonucleic acid),
lipids ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), 2
[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide,
1,2-Distearoyl-sn-glycero-3- phosphocholine, and cholesterol), potassium
chloride, monobasic potassium phosphate, sodium chloride, dibasic sodium
phosphate dihydrate, and sucrose.&lt;!--[if supportFields]&gt;&lt;span style=&#39;mso-element:
field-begin;mso-field-lock:yes&#39;&gt;&lt;/span&gt;ADDIN CSL_CITATION
{&amp;quot;citationItems&amp;quot;:[{&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;itemData&amp;quot;:{&amp;quot;URL&amp;quot;:&amp;quot;https://www.fda.gov/media/144414/download&amp;quot;,&amp;quot;accessed&amp;quot;:{&amp;quot;date-parts&amp;quot;:[[&amp;quot;2021&amp;quot;,&amp;quot;3&amp;quot;,&amp;quot;29&amp;quot;]]},&amp;quot;author&amp;quot;:[{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Pfizer&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;}],&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;issued&amp;quot;:{&amp;quot;date-parts&amp;quot;:[[&amp;quot;0&amp;quot;]]},&amp;quot;title&amp;quot;:&amp;quot;PFIZER-BIONTECH
COVID-19
VACCINE&amp;quot;,&amp;quot;type&amp;quot;:&amp;quot;webpage&amp;quot;},&amp;quot;uris&amp;quot;:[&amp;quot;http://www.mendeley.com/documents/?uuid=634ac318-047f-3c30-a3b9-b1502fb1ea58&amp;quot;]}],&amp;quot;mendeley&amp;quot;:{&amp;quot;formattedCitation&amp;quot;:&amp;quot;[1]&amp;quot;,&amp;quot;plainTextFormattedCitation&amp;quot;:&amp;quot;[1]&amp;quot;,&amp;quot;previouslyFormattedCitation&amp;quot;:&amp;quot;[1]&amp;quot;},&amp;quot;properties&amp;quot;:{&amp;quot;noteIndex&amp;quot;:0},&amp;quot;schema&amp;quot;:&amp;quot;https://github.com/citation-style-language/schema/raw/master/csl-citation.json&amp;quot;}&lt;span
style=&#39;mso-element:field-separator&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;span style=&quot;mso-no-proof: yes;&quot;&gt;[1]&lt;/span&gt;&lt;!--[if supportFields]&gt;&lt;span style=&#39;mso-element:field-end&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot; style=&quot;margin-left: 0.5in;&quot;&gt;The Moderna COVID-19 Vaccine
contains the following ingredients: messenger ribonucleic acid (mRNA), lipids
(SM-102, polyethylene glycol [PEG] 2000 dimyristoyl glycerol [DMG],
cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC]),
tromethamine, tromethamine hydrochloride, acetic acid, sodium acetate, and
sucrose.&lt;!--[if supportFields]&gt;&lt;span style=&#39;mso-element:field-begin;mso-field-lock:
yes&#39;&gt;&lt;/span&gt;ADDIN CSL_CITATION
{&amp;quot;citationItems&amp;quot;:[{&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;itemData&amp;quot;:{&amp;quot;author&amp;quot;:[{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Moderna
TX&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Inc&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;}],&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;issued&amp;quot;:{&amp;quot;date-parts&amp;quot;:[[&amp;quot;0&amp;quot;]]},&amp;quot;title&amp;quot;:&amp;quot;FACT
SHEET FOR RECIPIENTS AND CAREGIVERS EMERGENCY USE AUTHORIZATION (EUA)
OF&amp;quot;,&amp;quot;type&amp;quot;:&amp;quot;report&amp;quot;},&amp;quot;uris&amp;quot;:[&amp;quot;http://www.mendeley.com/documents/?uuid=a4f93a2c-ceb3-3d96-aa18-ba1bc4311d13&amp;quot;]}],&amp;quot;mendeley&amp;quot;:{&amp;quot;formattedCitation&amp;quot;:&amp;quot;[2]&amp;quot;,&amp;quot;plainTextFormattedCitation&amp;quot;:&amp;quot;[2]&amp;quot;},&amp;quot;properties&amp;quot;:{&amp;quot;noteIndex&amp;quot;:0},&amp;quot;schema&amp;quot;:&amp;quot;https://github.com/citation-style-language/schema/raw/master/csl-citation.json&amp;quot;}&lt;span
style=&#39;mso-element:field-separator&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;span style=&quot;mso-no-proof: yes;&quot;&gt;[2]&lt;/span&gt;&lt;!--[if supportFields]&gt;&lt;span style=&#39;mso-element:field-end&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot;&gt;Both Pfizer/BioNtech and Moderna vaccines do NOT contain
live virus and therefore can NOT cause infection in recipients. They also do
NOT interact with our own DNA in any way, but rather use mRNA (messenger
ribonucleic acid). &lt;span style=&quot;color: #ed7d31; mso-themecolor: accent2;&quot;&gt;How it
works: the ‘instructions’ (mRNA) enter immune cells, who ‘listen’ to the
instructions and make the spike protein piece. After the protein piece is made,
the cell breaks down the instructions and gets rid of them. Next, the cell
displays the protein (spike) piece on its surface which trigger an immune
response with cytokines and ultimate antibody production which can defend
against severe disease caused by SARS-CoV-2.&lt;/span&gt; (&lt;span style=&quot;color: #ed7d31; mso-themecolor: accent2;&quot;&gt;I do not know yet to what extent it prevents against
actual infection – science pending&lt;/span&gt;).&lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot;&gt;The next thing here I want to look at is, what do they mean
by ‘efficacy’?&lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot;&gt;The Moderna vaccine phase 3 trial had 30,351 participants.
The primary efficacy end point relied on manifestation of symptoms suggestive
of COVID-19 with a positive SARS-CoV-2 by RT-PCR. In those aged 65 and older
the efficacy was 100% (meaning no symptoms), and in ages 18 to under 65 the
efficacy was 93.4% with an overall participant average efficacy of &lt;u&gt;&lt;b&gt;94.5%&lt;/b&gt;&lt;/u&gt;. None vaccinated
had severe illness or were admitted to a hospital.&lt;span class=&quot;MsoFootnoteReference&quot;&gt; &lt;/span&gt;&lt;!--[if supportFields]&gt;&lt;span
class=MsoFootnoteReference&gt;&lt;span style=&#39;mso-element:field-begin;mso-field-lock:
yes&#39;&gt;&lt;/span&gt;&lt;/span&gt;ADDIN CSL_CITATION
{&amp;quot;citationItems&amp;quot;:[{&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;itemData&amp;quot;:{&amp;quot;author&amp;quot;:[{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;FDA&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;},{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Cber&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;}],&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;issued&amp;quot;:{&amp;quot;date-parts&amp;quot;:[[&amp;quot;2020&amp;quot;]]},&amp;quot;title&amp;quot;:&amp;quot;Vaccines
and Related Biological Products Advisory Committee December 17, 2020 Meeting
Briefing Document -
FDA&amp;quot;,&amp;quot;type&amp;quot;:&amp;quot;report&amp;quot;},&amp;quot;uris&amp;quot;:[&amp;quot;http://www.mendeley.com/documents/?uuid=acfca8ee-b41f-3b64-a96b-95601760c3db&amp;quot;]}],&amp;quot;mendeley&amp;quot;:{&amp;quot;formattedCitation&amp;quot;:&amp;quot;[3]&amp;quot;,&amp;quot;plainTextFormattedCitation&amp;quot;:&amp;quot;[3]&amp;quot;,&amp;quot;previouslyFormattedCitation&amp;quot;:&amp;quot;[2]&amp;quot;},&amp;quot;properties&amp;quot;:{&amp;quot;noteIndex&amp;quot;:0},&amp;quot;schema&amp;quot;:&amp;quot;https://github.com/citation-style-language/schema/raw/master/csl-citation.json&amp;quot;}&lt;span
class=MsoFootnoteReference&gt;&lt;span style=&#39;mso-element:field-separator&#39;&gt;&lt;/span&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;span style=&quot;mso-bidi-font-weight: bold; mso-no-proof: yes;&quot;&gt;[3]&lt;/span&gt;&lt;!--[if supportFields]&gt;&lt;span
class=MsoFootnoteReference&gt;&lt;span style=&#39;mso-element:field-end&#39;&gt;&lt;/span&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot;&gt;The Pfizer/BioNtech vaccine phase 3 trial had 44,000+
participants. Here also the primary efficacy end point relied on manifestation
of symptoms suggestive of COVID-19 with a positive SARS-CoV-2 by RT-PCR or in
some cases a local nucleic acid amplification test (NAAT) result. There was 1 severe
COVID-19 occurrence from 14 days after Dose 2 out of 18,175 vaccinated. In the
placebo group of 18,261 there were 3 severe cases.&lt;!--[if supportFields]&gt;&lt;span
style=&#39;mso-element:field-begin;mso-field-lock:yes&#39;&gt;&lt;/span&gt;ADDIN CSL_CITATION
{&amp;quot;citationItems&amp;quot;:[{&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;itemData&amp;quot;:{&amp;quot;author&amp;quot;:[{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Pfizer&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;}],&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;issued&amp;quot;:{&amp;quot;date-parts&amp;quot;:[[&amp;quot;2020&amp;quot;]]},&amp;quot;title&amp;quot;:&amp;quot;Vaccines
and Related Biological Products Advisory Committee December 10, 2020 Meeting
Briefing Document- Sponsor&amp;quot;,&amp;quot;type&amp;quot;:&amp;quot;report&amp;quot;},&amp;quot;uris&amp;quot;:[&amp;quot;http://www.mendeley.com/documents/?uuid=6e6ba5c2-dfca-3c13-a4c9-f8adbe2cb310&amp;quot;]}],&amp;quot;mendeley&amp;quot;:{&amp;quot;formattedCitation&amp;quot;:&amp;quot;[4]&amp;quot;,&amp;quot;plainTextFormattedCitation&amp;quot;:&amp;quot;[4]&amp;quot;,&amp;quot;previouslyFormattedCitation&amp;quot;:&amp;quot;[3]&amp;quot;},&amp;quot;properties&amp;quot;:{&amp;quot;noteIndex&amp;quot;:0},&amp;quot;schema&amp;quot;:&amp;quot;https://github.com/citation-style-language/schema/raw/master/csl-citation.json&amp;quot;}&lt;span
style=&#39;mso-element:field-separator&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;span style=&quot;mso-no-proof: yes;&quot;&gt;[4]&lt;/span&gt;&lt;!--[if supportFields]&gt;&lt;span style=&#39;mso-element:field-end&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;
(&lt;span style=&quot;color: #ed7d31; mso-themecolor: accent2;&quot;&gt;I thought there would be
more in the placebo group.&lt;/span&gt;)&amp;nbsp;The other efficacy endpoint I looked at was based on the first COVID-19 occurrence based on CDC defined symptoms from 7 days after dose 2.&amp;nbsp; See table 22 in reference [4].&amp;nbsp; The number of vaccinated participants was 19,965 and the placebo group was 20,172.&amp;nbsp; The number of cases in the vaccinated group was 9, and the number of cases in the placebo group was 172 ending with a vaccine efficacy of &lt;u&gt;&lt;b&gt;94.7%&lt;/b&gt;&lt;/u&gt;.&amp;nbsp;(&lt;span style=&quot;color: #ffa400;&quot;&gt;I am assuming the different numbers of vaccinated and placebo seen, results from the different times at which data was extracted for analysis, or because of their status regarding whether or not they were infected previously. I could not tell which.&lt;/span&gt;)&lt;/p&gt;&lt;p class=&quot;MsoNormal&quot;&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot;&gt;Given that both methods relied on reporting symptoms, I surmise
an unknown number of participants must have gotten COVID-19 without being detected,
as they were symptom free subjectively. (&lt;span style=&quot;color: #ed7d31; mso-themecolor: accent2;&quot;&gt;I wish all the participants would have had periodic, e.g. weekly testing
for the virus, which would have given us more accurate numbers overall.&lt;/span&gt;)
&lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot;&gt;The safety issues: (&lt;span style=&quot;color: #ed7d31; mso-themecolor: accent2;&quot;&gt;I have relied on the CDC - Centers for Disease Control - which I do trust
at this time for safety information.&lt;/span&gt;) COVID-19 vaccines appear
relatively safe to date (March 28, 2021) after millions of people in the United
States have received COVID-19 vaccines, and these vaccines will continue to undergo
safety monitoring. Some people have no side effects. Others have reported
common side effects after COVID-19 vaccination like swelling, redness and pain
at injection site, fever, headache, tiredness, muscle pain, chills, and nausea.
A small number of people have had a severe allergic reaction (called
“anaphylaxis”) after vaccination, but this is extremely &lt;u&gt;rare&lt;/u&gt;.&lt;!--[if supportFields]&gt;&lt;span
style=&#39;mso-element:field-begin;mso-field-lock:yes&#39;&gt;&lt;/span&gt;ADDIN CSL_CITATION
{&amp;quot;citationItems&amp;quot;:[{&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;itemData&amp;quot;:{&amp;quot;URL&amp;quot;:&amp;quot;https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/safety-of-vaccines.html&amp;quot;,&amp;quot;accessed&amp;quot;:{&amp;quot;date-parts&amp;quot;:[[&amp;quot;2021&amp;quot;,&amp;quot;3&amp;quot;,&amp;quot;28&amp;quot;]]},&amp;quot;author&amp;quot;:[{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;CDC&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;}],&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;issued&amp;quot;:{&amp;quot;date-parts&amp;quot;:[[&amp;quot;0&amp;quot;]]},&amp;quot;title&amp;quot;:&amp;quot;Safety
of COVID-19 Vaccines |
CDC&amp;quot;,&amp;quot;type&amp;quot;:&amp;quot;webpage&amp;quot;},&amp;quot;uris&amp;quot;:[&amp;quot;http://www.mendeley.com/documents/?uuid=76dd7112-a30e-39d8-b010-b6e3320ccf74&amp;quot;]}],&amp;quot;mendeley&amp;quot;:{&amp;quot;formattedCitation&amp;quot;:&amp;quot;[5]&amp;quot;,&amp;quot;plainTextFormattedCitation&amp;quot;:&amp;quot;[5]&amp;quot;,&amp;quot;previouslyFormattedCitation&amp;quot;:&amp;quot;[4]&amp;quot;},&amp;quot;properties&amp;quot;:{&amp;quot;noteIndex&amp;quot;:0},&amp;quot;schema&amp;quot;:&amp;quot;https://github.com/citation-style-language/schema/raw/master/csl-citation.json&amp;quot;}&lt;span
style=&#39;mso-element:field-separator&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;span style=&quot;mso-no-proof: yes;&quot;&gt;[5]&lt;/span&gt;&lt;!--[if supportFields]&gt;&lt;span style=&#39;mso-element:field-end&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;
That said, the word ‘rare’ takes on a different meaning when you know that the
actual reports of death through March 22, 2021 have been 2,216. That’s a very
unfortunate loss of life representing 0.0018% of 126 million doses of COVID-19
vaccines administered in the United States from December 14, 2020.&lt;!--[if supportFields]&gt;&lt;span
style=&#39;mso-element:field-begin;mso-field-lock:yes&#39;&gt;&lt;/span&gt;ADDIN CSL_CITATION
{&amp;quot;citationItems&amp;quot;:[{&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;itemData&amp;quot;:{&amp;quot;URL&amp;quot;:&amp;quot;https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html&amp;quot;,&amp;quot;accessed&amp;quot;:{&amp;quot;date-parts&amp;quot;:[[&amp;quot;2021&amp;quot;,&amp;quot;3&amp;quot;,&amp;quot;28&amp;quot;]]},&amp;quot;author&amp;quot;:[{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;CDC&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;}],&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;issued&amp;quot;:{&amp;quot;date-parts&amp;quot;:[[&amp;quot;0&amp;quot;]]},&amp;quot;title&amp;quot;:&amp;quot;Selected
Adverse Events Reported after COVID-19 Vaccination |
CDC&amp;quot;,&amp;quot;type&amp;quot;:&amp;quot;webpage&amp;quot;},&amp;quot;uris&amp;quot;:[&amp;quot;http://www.mendeley.com/documents/?uuid=1ba7604e-da7c-389e-b0b1-5649b1bdcc26&amp;quot;]}],&amp;quot;mendeley&amp;quot;:{&amp;quot;formattedCitation&amp;quot;:&amp;quot;[6]&amp;quot;,&amp;quot;plainTextFormattedCitation&amp;quot;:&amp;quot;[6]&amp;quot;,&amp;quot;previouslyFormattedCitation&amp;quot;:&amp;quot;[5]&amp;quot;},&amp;quot;properties&amp;quot;:{&amp;quot;noteIndex&amp;quot;:0},&amp;quot;schema&amp;quot;:&amp;quot;https://github.com/citation-style-language/schema/raw/master/csl-citation.json&amp;quot;}&lt;span
style=&#39;mso-element:field-separator&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;span style=&quot;mso-no-proof: yes;&quot;&gt;[6]&lt;/span&gt;&lt;!--[if supportFields]&gt;&lt;span style=&#39;mso-element:field-end&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;
So I recommend getting the vaccine in a venue that has the capacity to deal
with a possible severe allergic reaction. Also stay for 15–30 minutes after
your injection for observation, which becomes even more important if you are an
allergy prone person. &lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot;&gt;The third vaccine I would like to talk about is the vaccine from
Janssen Biotech, Inc. (a pharmaceutical company of Johnson &amp;amp; Johnson). The
related Emergency Use Authorization (EUA) application is dated February 26,
2021 and since has been granted by the Food and Drug Administration (FDA).&lt;span style=&quot;mso-spacerun: yes;&quot;&gt;&amp;nbsp; &lt;/span&gt;This vaccine is administered in 1 shot with
similar side effects to the two dose vaccines (Pfizer/BioNtech, Moderna). &lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot;&gt;The Janssen COVID-19 Vaccine includes the following
ingredients: recombinant, &lt;a href=&quot;https://www.fda.gov/media/146305/download&quot; title=&quot;can NOT cause infections&quot;&gt;replication-incompetent&lt;/a&gt; (i.e. can NOT
cause infections) adenovirus type 26 expressing the SARS-CoV-2 spike protein,
citric acid monohydrate, trisodium citrate dihydrate, ethanol,
2-hydroxypropyl-β-cyclodextrin (HBCD), polysorbate-80, sodium chloride.&lt;!--[if supportFields]&gt;&lt;span
style=&#39;mso-element:field-begin;mso-field-lock:yes&#39;&gt;&lt;/span&gt;ADDIN CSL_CITATION
{&amp;quot;citationItems&amp;quot;:[{&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;itemData&amp;quot;:{&amp;quot;author&amp;quot;:[{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;Administration&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;Drug&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;}],&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;issued&amp;quot;:{&amp;quot;date-parts&amp;quot;:[[&amp;quot;0&amp;quot;]]},&amp;quot;title&amp;quot;:&amp;quot;FACT
SHEET FOR RECIPIENTS AND CAREGIVERS EMERGENCY USE AUTHORIZATION (EUA) OF&amp;quot;,&amp;quot;type&amp;quot;:&amp;quot;report&amp;quot;},&amp;quot;uris&amp;quot;:[&amp;quot;http://www.mendeley.com/documents/?uuid=825759c3-b9e5-3f52-b65f-cb390e5e18f6&amp;quot;]}],&amp;quot;mendeley&amp;quot;:{&amp;quot;formattedCitation&amp;quot;:&amp;quot;[7]&amp;quot;,&amp;quot;plainTextFormattedCitation&amp;quot;:&amp;quot;[7]&amp;quot;,&amp;quot;previouslyFormattedCitation&amp;quot;:&amp;quot;[6]&amp;quot;},&amp;quot;properties&amp;quot;:{&amp;quot;noteIndex&amp;quot;:0},&amp;quot;schema&amp;quot;:&amp;quot;https://github.com/citation-style-language/schema/raw/master/csl-citation.json&amp;quot;}&lt;span
style=&#39;mso-element:field-separator&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;span style=&quot;mso-no-proof: yes;&quot;&gt;[7]&lt;/span&gt;&lt;!--[if supportFields]&gt;&lt;span style=&#39;mso-element:field-end&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot;&gt;&lt;span style=&quot;color: #ed7d31; mso-themecolor: accent2;&quot;&gt;How it
works: after administration of Ad26.COV2.S, binding of the Ad26 vector to
cellular receptors is mediated by fibers on the Ad26 capsid. After transduction
of the cell, episomal vector DNA drives cellular production of the transgene
encoded S protein. The S protein is then expressed on the cell membrane where
it is sensed by the host immune system, resulting in humoral and cellular
immune responses directed against the SARS-CoV-2 S protein.&lt;/span&gt;&lt;!--[if supportFields]&gt;&lt;span
style=&#39;mso-element:field-begin;mso-field-lock:yes&#39;&gt;&lt;/span&gt;ADDIN CSL_CITATION
{&amp;quot;citationItems&amp;quot;:[{&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;itemData&amp;quot;:{&amp;quot;author&amp;quot;:[{&amp;quot;dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;family&amp;quot;:&amp;quot;JANSSEN
BIOTECH&amp;quot;,&amp;quot;given&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;non-dropping-particle&amp;quot;:&amp;quot;&amp;quot;,&amp;quot;parse-names&amp;quot;:false,&amp;quot;suffix&amp;quot;:&amp;quot;&amp;quot;}],&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;issued&amp;quot;:{&amp;quot;date-parts&amp;quot;:[[&amp;quot;2021&amp;quot;]]},&amp;quot;number-of-pages&amp;quot;:&amp;quot;1-119&amp;quot;,&amp;quot;title&amp;quot;:&amp;quot;Vaccines
and Related Biological Products Advisory Committee February 26, 2021 Meeting
Briefing Document-
Sponsor&amp;quot;,&amp;quot;type&amp;quot;:&amp;quot;report&amp;quot;},&amp;quot;uris&amp;quot;:[&amp;quot;http://www.mendeley.com/documents/?uuid=f5a0450b-89be-3340-92b8-72ddcdfc456c&amp;quot;]}],&amp;quot;mendeley&amp;quot;:{&amp;quot;formattedCitation&amp;quot;:&amp;quot;[8]&amp;quot;,&amp;quot;plainTextFormattedCitation&amp;quot;:&amp;quot;[8]&amp;quot;,&amp;quot;previouslyFormattedCitation&amp;quot;:&amp;quot;[7]&amp;quot;},&amp;quot;properties&amp;quot;:{&amp;quot;noteIndex&amp;quot;:0},&amp;quot;schema&amp;quot;:&amp;quot;https://github.com/citation-style-language/schema/raw/master/csl-citation.json&amp;quot;}&lt;span
style=&#39;mso-element:field-separator&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;span style=&quot;mso-no-proof: yes;&quot;&gt;[8]&lt;/span&gt;&lt;!--[if supportFields]&gt;&lt;span style=&#39;mso-element:field-end&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot;&gt;The J&amp;amp;J/Janssen vaccine was &lt;b&gt;&lt;u&gt;66.3%&lt;/u&gt;&lt;/b&gt; effective in clinical
trials (efficacy) at preventing laboratory-confirmed COVID-19 illness in people
who had no evidence of prior infection 2 weeks after receiving the vaccine. The
vaccine had high efficacy at preventing hospitalization and death in people who
did get sick. &lt;u&gt;No&lt;/u&gt; one who got COVID-19 at least 4 weeks after receiving
the J&amp;amp;J/Janssen vaccine had to be hospitalized.&lt;!--[if supportFields]&gt;&lt;span
style=&#39;mso-element:field-begin;mso-field-lock:yes&#39;&gt;&lt;/span&gt;ADDIN CSL_CITATION
{&amp;quot;citationItems&amp;quot;:[{&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;itemData&amp;quot;:{&amp;quot;URL&amp;quot;:&amp;quot;https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/janssen.html&amp;quot;,&amp;quot;accessed&amp;quot;:{&amp;quot;date-parts&amp;quot;:[[&amp;quot;2021&amp;quot;,&amp;quot;3&amp;quot;,&amp;quot;29&amp;quot;]]},&amp;quot;id&amp;quot;:&amp;quot;ITEM-1&amp;quot;,&amp;quot;issued&amp;quot;:{&amp;quot;date-parts&amp;quot;:[[&amp;quot;0&amp;quot;]]},&amp;quot;title&amp;quot;:&amp;quot;Information
About Johnson &amp;amp; Johnson’s Janssen COVID-19 Vaccine |
CDC&amp;quot;,&amp;quot;type&amp;quot;:&amp;quot;webpage&amp;quot;},&amp;quot;uris&amp;quot;:[&amp;quot;http://www.mendeley.com/documents/?uuid=f4565536-31d8-3aa5-974a-8e1b90e10896&amp;quot;]}],&amp;quot;mendeley&amp;quot;:{&amp;quot;formattedCitation&amp;quot;:&amp;quot;[9]&amp;quot;,&amp;quot;plainTextFormattedCitation&amp;quot;:&amp;quot;[9]&amp;quot;,&amp;quot;previouslyFormattedCitation&amp;quot;:&amp;quot;[8]&amp;quot;},&amp;quot;properties&amp;quot;:{&amp;quot;noteIndex&amp;quot;:0},&amp;quot;schema&amp;quot;:&amp;quot;https://github.com/citation-style-language/schema/raw/master/csl-citation.json&amp;quot;}&lt;span
style=&#39;mso-element:field-separator&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;span style=&quot;mso-no-proof: yes;&quot;&gt;[9]&lt;/span&gt;&lt;!--[if supportFields]&gt;&lt;span style=&#39;mso-element:field-end&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;&lt;p class=&quot;MsoNormal&quot;&gt;&lt;span style=&quot;color: #e69138; mso-no-proof: yes;&quot;&gt;The efficacy numbers will change as more people are vaccinated.&lt;/span&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot;&gt;So, what is the actual benefit from these vaccines? They help
prevent serious illness and death from SARS-CoV-2. Also, of vital import is it will
help end the pandemic by increasing herd immunity (&lt;span style=&quot;color: #ed7d31; mso-themecolor: accent2;&quot;&gt;assuming enough individuals get it&lt;/span&gt;) and by
virtue of lessening manifestations of COVID-19 which spread the virus such as
coughing and resultant aerosolization of virus particles. &lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot;&gt;To get or not to get: GET. The risk/benefit ratio is very
convincing to me in favor of getting one of the&amp;nbsp; vaccines above. I personally received my first Moderna
shot December 29, 2020 and the second one January 26, 2021. (The second shot
laid me out in bed the next day with significant achiness, headache, and chills
– &lt;span style=&quot;color: #ed7d31; mso-themecolor: accent2;&quot;&gt;so allegedly my immune
system is still intact &lt;/span&gt;&lt;span style=&quot;color: #ed7d31; font-family: Wingdings; mso-ascii-font-family: Arial; mso-ascii-theme-font: minor-bidi; mso-char-type: symbol; mso-hansi-font-family: Arial; mso-hansi-theme-font: minor-bidi; mso-symbol-font-family: Wingdings; mso-themecolor: accent2;&quot;&gt;&lt;span style=&quot;mso-char-type: symbol; mso-symbol-font-family: Wingdings;&quot;&gt;J&lt;/span&gt;&lt;/span&gt;.)&lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;

&lt;div style=&quot;border-bottom: solid windowtext 1.5pt; border: none; margin-left: 0.1in; margin-right: 0.1in; mso-element: para-border-div; padding: 0in 0in 1pt;&quot;&gt;

&lt;p class=&quot;MsoNormal&quot; style=&quot;border: none; margin-bottom: 6.0pt; margin-left: 0in; margin-right: 0in; margin-top: 0in; margin: 0in 0in 6pt; mso-border-bottom-alt: solid windowtext 1.5pt; mso-padding-alt: 0in 0in 1.0pt 0in; padding: 0in;&quot;&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/p&gt;

&lt;/div&gt;

&lt;p class=&quot;MsoNormal&quot;&gt;&lt;u&gt;Bibliography&lt;o:p&gt;&lt;/o:p&gt;&lt;/u&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot; style=&quot;margin-left: 32pt; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none; text-indent: -32pt;&quot;&gt;&lt;!--[if supportFields]&gt;&lt;u&gt;&lt;span
style=&#39;mso-element:field-begin;mso-field-lock:yes&#39;&gt;&lt;/span&gt;ADDIN Mendeley
Bibliography CSL_BIBLIOGRAPHY &lt;span style=&#39;mso-element:field-separator&#39;&gt;&lt;/span&gt;&lt;/u&gt;&lt;![endif]--&gt;&lt;span style=&quot;line-height: 150%; mso-ascii-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-hansi-font-family: Arial; mso-no-proof: yes;&quot;&gt;[1]&lt;span style=&quot;mso-tab-count: 1;&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/span&gt;Pfizer, “PFIZER-BIONTECH COVID-19
VACCINE.” https://www.fda.gov/media/144414/download (accessed Mar. 29, 2021).&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot; style=&quot;margin-left: 32pt; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none; text-indent: -32pt;&quot;&gt;&lt;span style=&quot;line-height: 150%; mso-ascii-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-hansi-font-family: Arial; mso-no-proof: yes;&quot;&gt;[2]&lt;span style=&quot;mso-tab-count: 1;&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/span&gt;Moderna TX and Inc, “FACT SHEET FOR RECIPIENTS AND CAREGIVERS
EMERGENCY USE AUTHORIZATION (EUA) OF.” Accessed: Mar. 29, 2021. [Online].
Available: www.modernatx.com/covid19vaccine-eua.&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot; style=&quot;margin-left: 32pt; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none; text-indent: -32pt;&quot;&gt;&lt;span style=&quot;line-height: 150%; mso-ascii-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-hansi-font-family: Arial; mso-no-proof: yes;&quot;&gt;[3]&lt;span style=&quot;mso-tab-count: 1;&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/span&gt;FDA and Cber, “Vaccines and Related Biological Products
Advisory Committee December 17, 2020 Meeting Briefing Document - FDA,” 2020.&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot; style=&quot;margin-left: 32pt; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none; text-indent: -32pt;&quot;&gt;&lt;span style=&quot;line-height: 150%; mso-ascii-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-hansi-font-family: Arial; mso-no-proof: yes;&quot;&gt;[4]&lt;span style=&quot;mso-tab-count: 1;&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/span&gt;Pfizer, “Vaccines and Related Biological Products Advisory
Committee December 10, 2020 Meeting Briefing Document- Sponsor,” 2020.&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot; style=&quot;margin-left: 32pt; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none; text-indent: -32pt;&quot;&gt;&lt;span style=&quot;line-height: 150%; mso-ascii-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-hansi-font-family: Arial; mso-no-proof: yes;&quot;&gt;[5]&lt;span style=&quot;mso-tab-count: 1;&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/span&gt;CDC, “Safety of COVID-19 Vaccines | CDC.”
https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/safety-of-vaccines.html
(accessed Mar. 28, 2021).&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot; style=&quot;margin-left: 32pt; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none; text-indent: -32pt;&quot;&gt;&lt;span style=&quot;line-height: 150%; mso-ascii-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-hansi-font-family: Arial; mso-no-proof: yes;&quot;&gt;[6]&lt;span style=&quot;mso-tab-count: 1;&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/span&gt;CDC, “Selected Adverse Events Reported after COVID-19
Vaccination | CDC.”
https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html
(accessed Mar. 28, 2021).&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot; style=&quot;margin-left: 32pt; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none; text-indent: -32pt;&quot;&gt;&lt;span style=&quot;line-height: 150%; mso-ascii-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-hansi-font-family: Arial; mso-no-proof: yes;&quot;&gt;[7]&lt;span style=&quot;mso-tab-count: 1;&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/span&gt;D. Administration, “FACT SHEET FOR RECIPIENTS AND CAREGIVERS
EMERGENCY USE AUTHORIZATION (EUA) OF.” Accessed: Mar. 29, 2021. [Online].
Available: www.janssencovid19vaccine.com.&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot; style=&quot;margin-left: 32pt; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none; text-indent: -32pt;&quot;&gt;&lt;span style=&quot;line-height: 150%; mso-ascii-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-hansi-font-family: Arial; mso-no-proof: yes;&quot;&gt;[8]&lt;span style=&quot;mso-tab-count: 1;&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/span&gt;JANSSEN BIOTECH, “Vaccines and Related Biological Products
Advisory Committee February 26, 2021 Meeting Briefing Document- Sponsor,” 2021.
Accessed: Mar. 29, 2021. [Online]. Available:
https://www.fda.gov/media/146219/download.&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot; style=&quot;margin-left: 32pt; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none; text-indent: -32pt;&quot;&gt;&lt;span style=&quot;line-height: 150%; mso-ascii-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-hansi-font-family: Arial; mso-no-proof: yes;&quot;&gt;[9]&lt;span style=&quot;mso-tab-count: 1;&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/span&gt;“Information About Johnson &amp;amp; Johnson’s Janssen COVID-19
Vaccine | CDC.”
https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/janssen.html
(accessed Mar. 29, 2021).&lt;/span&gt;&lt;span style=&quot;mso-ascii-font-family: Arial; mso-bidi-font-family: Arial; mso-hansi-font-family: Arial; mso-no-proof: yes;&quot;&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p class=&quot;MsoNormal&quot;&gt;&lt;!--[if supportFields]&gt;&lt;u&gt;&lt;span style=&#39;mso-element:field-end&#39;&gt;&lt;/span&gt;&lt;/u&gt;&lt;![endif]--&gt;&lt;u&gt;&lt;o:p&gt;&lt;span style=&quot;text-decoration: none;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/o:p&gt;&lt;/u&gt;&lt;/p&gt;</content><link rel='replies' type='application/atom+xml' href='http://thepillarsofhealth.blogspot.com/feeds/2800461294037064251/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://thepillarsofhealth.blogspot.com/2021/03/notes-about-vaccinating-against-covid.html#comment-form' title='2 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/2800461294037064251'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/2800461294037064251'/><link rel='alternate' type='text/html' href='http://thepillarsofhealth.blogspot.com/2021/03/notes-about-vaccinating-against-covid.html' title='Notes about Vaccinating against COVID-19 (Pfizer/BioNtech, Moderna and Janssen/Biotech vaccines)'/><author><name>Dr Dhia Aldoori</name><uri>http://www.blogger.com/profile/12785445082984259058</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='23' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgIcbY6lOf-A2OAQZ3CCF-V44BF68CUZ1wYcXS06NXVQS-lTFiik3VkOYsT0dmfX2RcYB8yuWeKbUAP5w5AeDWHc1bdI-0eQEt4lr6yM4tplO9dgbQ9nT74rRU6KPLeXw/s149/Cropped+PA307202'/></author><thr:total>2</thr:total></entry><entry><id>tag:blogger.com,1999:blog-7196398195634872986.post-939288933010469740</id><published>2020-06-12T15:33:00.000-04:00</published><updated>2020-06-12T15:37:06.164-04:00</updated><title type='text'>COVID-19: The Jury is OUT again on Hydroxychloroquine</title><content type='html'>&lt;h4&gt;
The jury is out again on hydroxychloroquine (HCQ) and chloroquine (CQ)&amp;nbsp;as a result of refusal of&amp;nbsp;Surgisphere Corporation
 (the analyzing agency of the database
elements presented in the paper) to divulge the full dataset, client
contracts, and the full ISO audit report to peer review for analysis. The claim was that such transfer would violate client
agreements and confidentiality requirements.&lt;br /&gt;This retraction is appropriate in my view as the full scientific evaluation wasn&#39;t completed.&lt;br /&gt;In spite of the retraction, the information and data didn&#39;t appear flawed to me and therefore I would hesitate in endorsing use of HCQ and CQ pending further elucidation of this quandary.&amp;nbsp;&lt;/h4&gt;
&lt;div&gt;
Frustrating stuff.&lt;/div&gt;
&lt;div&gt;
D. Aldoori&lt;/div&gt;
&lt;div&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div&gt;
[Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis.&amp;nbsp;&lt;a href=&quot;https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(20)31324-6.pdf&quot; target=&quot;_blank&quot;&gt;Lancet&lt;/a&gt;]&lt;br /&gt;
[&lt;a href=&quot;https://app.diagrams.net/?lightbox=1&amp;amp;highlight=0000ff&amp;amp;edit=_blank&amp;amp;layers=1&amp;amp;nav=1&amp;amp;title=Dealing%20with%20COVID-19.drawio#Uhttps%3A%2F%2Fdrive.google.com%2Fuc%3Fid%3D1AcW9g6mD5iuCcVfZehFbvQcQVzyepwMh%26export%3Ddownload&quot; target=&quot;_blank&quot;&gt;COVID-19 Running Notes&lt;/a&gt;]&lt;/div&gt;
</content><link rel='replies' type='application/atom+xml' href='http://thepillarsofhealth.blogspot.com/feeds/939288933010469740/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://thepillarsofhealth.blogspot.com/2020/06/covid-19-jury-is-out-again-on.html#comment-form' title='2 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/939288933010469740'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/939288933010469740'/><link rel='alternate' type='text/html' href='http://thepillarsofhealth.blogspot.com/2020/06/covid-19-jury-is-out-again-on.html' title='COVID-19: The Jury is OUT again on Hydroxychloroquine'/><author><name>Dr Dhia Aldoori</name><uri>http://www.blogger.com/profile/12785445082984259058</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='23' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgIcbY6lOf-A2OAQZ3CCF-V44BF68CUZ1wYcXS06NXVQS-lTFiik3VkOYsT0dmfX2RcYB8yuWeKbUAP5w5AeDWHc1bdI-0eQEt4lr6yM4tplO9dgbQ9nT74rRU6KPLeXw/s149/Cropped+PA307202'/></author><thr:total>2</thr:total></entry><entry><id>tag:blogger.com,1999:blog-7196398195634872986.post-5907043090446427504</id><published>2020-05-23T18:40:00.000-04:00</published><updated>2020-05-24T08:06:31.860-04:00</updated><title type='text'>COVID-19: The Jury is Back on Hydroxychloroquine</title><content type='html'>&lt;br /&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
At this time, I recommend &lt;u&gt;against&lt;/u&gt; using chloroquine
or hydroxychloroquine to prevent or treat COVID-19 infection. This
recommendation is mostly based on the study published in the Lancet online, May
22, 2020.&lt;o:p&gt;&lt;/o:p&gt;[1]&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
Included in this study were 96,032 hospitalized patients
from 671 hospitals who were diagnosed with COVID-19 between Dec 20, 2019, and
April 14, 2020 and met the inclusion criteria for said study. It was convincingly
a large multinational real-world analysis. &lt;o:p&gt;&lt;/o:p&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
The authors (who I agree with), did not observe any benefit
of hydroxychloroquine or chloroquine (when used alone or in combination with a
macrolide) on in-hospital outcomes, when initiated early after diagnosis of
COVID-19. Each of the drug regimens of chloroquine or hydroxychloroquine alone
or in combination with a macrolide was associated with an &lt;u&gt;increased hazard&lt;/u&gt; for
clinically significant occurrence of ventricular arrhythmias and &lt;u&gt;increased risk
of in-hospital death&lt;/u&gt; with COVID-19.&lt;!--[if supportFields]&gt;&lt;span
style=&#39;mso-element:field-begin;mso-field-lock:yes&#39;&gt;&lt;/span&gt;ADDIN CSL_CITATION
{&quot;citationItems&quot;:[{&quot;id&quot;:&quot;ITEM-1&quot;,&quot;itemData&quot;:{&quot;DOI&quot;:&quot;https://doi.org/10.1016/S0140-6736(20)31180-6&quot;,&quot;abstract&quot;:&quot;Background
Hydroxychloroquine or chloroquine, often in combination with a
second-generation macrolide, are being widely used for treatment of COVID-19,
despite no conclusive evidence of their benefit. Although generally safe when
used for approved indications such as autoimmune disease or malaria, the safety
and benefit of these treatment regimens are poorly evaluated in
COVID-19.&quot;,&quot;author&quot;:[{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Mehra&quot;,&quot;given&quot;:&quot;Mandeep
R&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Desai&quot;,&quot;given&quot;:&quot;Sapan
S&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Ruschitzka&quot;,&quot;given&quot;:&quot;Frank&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;},{&quot;dropping-particle&quot;:&quot;&quot;,&quot;family&quot;:&quot;Patel&quot;,&quot;given&quot;:&quot;Amit
N&quot;,&quot;non-dropping-particle&quot;:&quot;&quot;,&quot;parse-names&quot;:false,&quot;suffix&quot;:&quot;&quot;}],&quot;container-title&quot;:&quot;The
Lancet&quot;,&quot;id&quot;:&quot;ITEM-1&quot;,&quot;issue&quot;:&quot;0&quot;,&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2020&quot;]]},&quot;note&quot;:&quot;Published:May
22, 2020\n&gt;&gt;&gt;Twice as likely to survive if on
ACE&quot;,&quot;title&quot;:&quot;Hydroxychloroquine or chloroquine with or
without a macrolide for treatment of COVID-19: a multinational registry
analysis&quot;,&quot;type&quot;:&quot;article-journal&quot;,&quot;volume&quot;:&quot;0&quot;},&quot;uris&quot;:[&quot;http://www.mendeley.com/documents/?uuid=9838e63c-97f9-38f7-8304-59a28bd32323&quot;]}],&quot;mendeley&quot;:{&quot;formattedCitation&quot;:&quot;[1]&quot;,&quot;plainTextFormattedCitation&quot;:&quot;[1]&quot;,&quot;previouslyFormattedCitation&quot;:&quot;[1]&quot;},&quot;properties&quot;:{&quot;noteIndex&quot;:0},&quot;schema&quot;:&quot;https://github.com/citation-style-language/schema/raw/master/csl-citation.json&quot;}&lt;span
style=&#39;mso-element:field-separator&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;span style=&quot;mso-no-proof: yes;&quot;&gt;[1]&lt;/span&gt;&lt;!--[if supportFields]&gt;&lt;span style=&#39;mso-element:field-end&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;margin-left: 32.0pt; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none; text-indent: -32.0pt;&quot;&gt;
&lt;!--[if supportFields]&gt;&lt;span
style=&#39;mso-element:field-begin;mso-field-lock:yes&#39;&gt;&lt;/span&gt;ADDIN Mendeley
Bibliography CSL_BIBLIOGRAPHY &lt;span style=&#39;mso-element:field-separator&#39;&gt;&lt;/span&gt;&lt;![endif]--&gt;&lt;span style=&quot;line-height: 150%; mso-ascii-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-hansi-font-family: Arial; mso-no-proof: yes;&quot;&gt;[1]&lt;span style=&quot;mso-tab-count: 1;&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/span&gt;M. R. Mehra, S. S. Desai, F. Ruschitzka,
and A. N. Patel, “Hydroxychloroquine or chloroquine with or without a macrolide
for treatment of COVID-19: a multinational registry analysis,” &lt;i&gt;Lancet&lt;/i&gt;,
vol. 0, no. 0, 2020. &lt;a href=&quot;https://doi.org/10.1016/S0140-6736(20)31180-6&quot; target=&quot;_blank&quot;&gt;Link to study&lt;/a&gt;.&lt;/span&gt;&lt;/div&gt;
</content><link rel='replies' type='application/atom+xml' href='http://thepillarsofhealth.blogspot.com/feeds/5907043090446427504/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://thepillarsofhealth.blogspot.com/2020/05/covid-19-jury-is-out-on.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/5907043090446427504'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/5907043090446427504'/><link rel='alternate' type='text/html' href='http://thepillarsofhealth.blogspot.com/2020/05/covid-19-jury-is-out-on.html' title='COVID-19: The Jury is Back on Hydroxychloroquine'/><author><name>Dr Dhia Aldoori</name><uri>http://www.blogger.com/profile/12785445082984259058</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='23' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgIcbY6lOf-A2OAQZ3CCF-V44BF68CUZ1wYcXS06NXVQS-lTFiik3VkOYsT0dmfX2RcYB8yuWeKbUAP5w5AeDWHc1bdI-0eQEt4lr6yM4tplO9dgbQ9nT74rRU6KPLeXw/s149/Cropped+PA307202'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-7196398195634872986.post-1873285416688136461</id><published>2020-04-24T16:24:00.000-04:00</published><updated>2020-04-24T16:24:49.608-04:00</updated><title type='text'>Can the Surgical N95 Respirator Mask Halt the SARS-CoV-2 Virus?</title><content type='html'>&lt;br /&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;margin-bottom: 10.0pt;&quot;&gt;
&lt;b&gt;&lt;span style=&quot;font-size: 12.0pt;&quot;&gt;How
does the &lt;/span&gt;&lt;a href=&quot;https://www.cdc.gov/niosh/npptl/topics/respirators/disp_part/respsource3healthcare.html#e&quot;&gt;&lt;span style=&quot;font-size: 12.0pt;&quot;&gt;surgical N95 respirator mask by 3M&lt;/span&gt;&lt;/a&gt;&lt;/b&gt;&lt;b&gt;&lt;span style=&quot;font-size: 12.0pt;&quot;&gt; stop the SARS-CoV-2 virus from accessing the airway
passages of the wearer?&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/b&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;margin-bottom: 10.0pt;&quot;&gt;
&lt;span style=&quot;font-size: 12.0pt;&quot;&gt;Coronavirus
virions are spherical with diameters of approximately &lt;/span&gt;&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4369385/&quot;&gt;&lt;span style=&quot;font-size: 12.0pt;&quot;&gt;125 nm&lt;/span&gt;&lt;/a&gt;&lt;span style=&quot;font-size: 12.0pt;&quot;&gt;. Where
an ‘nm’, indicates a nanometer which is a billionth of a meter. &lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;margin-bottom: 10.0pt;&quot;&gt;
&lt;span style=&quot;font-size: 12.0pt;&quot;&gt;The
indicated mask is documented to have a &lt;/span&gt;&lt;a href=&quot;https://multimedia.3m.com/mws/media/995608O/1860-1860s-user-instructions.pdf&quot;&gt;&lt;span style=&quot;font-size: 12.0pt;&quot;&gt;filter efficiency&lt;/span&gt;&lt;/a&gt;&lt;span style=&quot;font-size: 12.0pt;&quot;&gt; level of at least 95% against particulate aerosols free of oil and was
tested against a 0.3 micron (0.0000003 meter) particle (mass median aerodynamic
diameter). Where a micron is one millionth of a meter.&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;margin-bottom: 10.0pt;&quot;&gt;
&lt;span style=&quot;font-size: 12.0pt;&quot;&gt;Given
above facts where the virion (0.000000125 meter) is 2.4 times &lt;u&gt;smaller&lt;/u&gt;
than the mask’s preventive ‘entry’ capacity of 0.0000003 meter, one may wonder is
it not going to go through?&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;margin-bottom: 10.0pt;&quot;&gt;
&lt;span style=&quot;font-size: 12.0pt;&quot;&gt;Answer:
viruses do not fly through the air all by themselves, rather they are carried in
the aerosol particles expelled from the infected with or carrier person of the
virus. This originates from the coughing or sneezing process. And since aerosols
seem to average at &lt;a href=&quot;https://www.biorxiv.org/content/10.1101/2020.03.08.982637v1.full&quot;&gt;1.25 microns&lt;/a&gt;
(0.00000125 meter), which is larger than the 0.3 micron above, therefore the virus
conveying aerosol should be stopped by the mask. &lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;margin-bottom: 10.0pt;&quot;&gt;
&lt;span style=&quot;font-size: 12.0pt;&quot;&gt;Notably
here, the aerosols with its virions lodge in the outside of the mask and
therefore the wearer should avoid touching the outward surface of the mask.&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/div&gt;
&lt;br /&gt;</content><link rel='replies' type='application/atom+xml' href='http://thepillarsofhealth.blogspot.com/feeds/1873285416688136461/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://thepillarsofhealth.blogspot.com/2020/04/can-surgical-n95-respirator-mask-halt.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/1873285416688136461'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/1873285416688136461'/><link rel='alternate' type='text/html' href='http://thepillarsofhealth.blogspot.com/2020/04/can-surgical-n95-respirator-mask-halt.html' title='Can the Surgical N95 Respirator Mask Halt the SARS-CoV-2 Virus?'/><author><name>Dr Dhia Aldoori</name><uri>http://www.blogger.com/profile/12785445082984259058</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='23' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgIcbY6lOf-A2OAQZ3CCF-V44BF68CUZ1wYcXS06NXVQS-lTFiik3VkOYsT0dmfX2RcYB8yuWeKbUAP5w5AeDWHc1bdI-0eQEt4lr6yM4tplO9dgbQ9nT74rRU6KPLeXw/s149/Cropped+PA307202'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-7196398195634872986.post-7493823289753176336</id><published>2020-04-09T18:17:00.000-04:00</published><updated>2020-04-09T18:17:57.214-04:00</updated><title type='text'>COVID-19: Should I wear a protective mask? Masks for general public?</title><content type='html'>&lt;div class=&quot;MsoNormal&quot;&gt;
&lt;u&gt;Question (TK)&lt;/u&gt;: Hi there, what are your thoughts on the general public buying masks online to wear when shopping or going outside? I know there is a shortage of masks in hospitals, but it seems like there’s a surplus online, so I assume hospitals aren’t buying the ones I am finding. An example:&lt;o:p&gt;&lt;/o:p&gt;&lt;/div&gt;
&lt;a href=&quot;https://www.amazon.com/Disposable-Hypoallergenic-Breathability-Comfort-Great-Allergies/dp/B078718WVB/ref=mp_s_a_1_3?dchild=1&amp;amp;keywords=surgical+masks&amp;amp;qid=1585777028&amp;amp;sr=8-3&quot; target=&quot;_blank&quot;&gt;Amazon Link&lt;/a&gt;&lt;br /&gt;
&lt;div&gt;
&lt;br /&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;mso-margin-bottom-alt: auto; mso-margin-top-alt: auto;&quot;&gt;
&lt;u&gt;Answer (&lt;/u&gt;Dhia Aldoori): I
think it is a good idea for all to wear masks in public at this time, particularly when
you are going to be in a place which may force too close person proximity, and
always if you are sick with the possibility &amp;nbsp;people may come near you
(especially &amp;nbsp;important in a closed environment).&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;mso-margin-bottom-alt: auto; mso-margin-top-alt: auto;&quot;&gt;
&lt;o:p&gt;&lt;/o:p&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;mso-margin-bottom-alt: auto; mso-margin-top-alt: auto;&quot;&gt;
That
said, let us (health professionals) have first dibs on the really useful kind,
the NIOSH N95 version by 3M which I couldn’t find on Amazon.&amp;nbsp;&amp;nbsp;&lt;o:p&gt;&lt;/o:p&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;mso-margin-bottom-alt: auto; mso-margin-top-alt: auto;&quot;&gt;
The
ones in the link are apparently abundant and will help prevent aerosol
projection from a cougher and sneezer, and prevent a person from unconsciously
hand-face touching. It won’t protect against incoming viruses. The other kind
does, and isn’t currently very available to many caregivers.&lt;/div&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;div style=&quot;text-align: center;&quot;&gt;
&lt;a href=&quot;https://app.diagrams.net/?lightbox=1&amp;amp;highlight=0000ff&amp;amp;edit=_blank&amp;amp;layers=1&amp;amp;nav=1&amp;amp;title=Dealing%20with%20COVID-19.drawio#Uhttps%3A%2F%2Fdrive.google.com%2Fuc%3Fid%3D1AcW9g6mD5iuCcVfZehFbvQcQVzyepwMh%26export%3Ddownload&quot; target=&quot;_blank&quot;&gt;Running Notes COVID-19&lt;/a&gt;&lt;/div&gt;
&lt;/div&gt;
</content><link rel='replies' type='application/atom+xml' href='http://thepillarsofhealth.blogspot.com/feeds/7493823289753176336/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://thepillarsofhealth.blogspot.com/2020/04/should-i-wear-protective-mask-masks-for.html#comment-form' title='1 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/7493823289753176336'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/7493823289753176336'/><link rel='alternate' type='text/html' href='http://thepillarsofhealth.blogspot.com/2020/04/should-i-wear-protective-mask-masks-for.html' title='COVID-19: Should I wear a protective mask? Masks for general public?'/><author><name>Dr Dhia Aldoori</name><uri>http://www.blogger.com/profile/12785445082984259058</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='23' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgIcbY6lOf-A2OAQZ3CCF-V44BF68CUZ1wYcXS06NXVQS-lTFiik3VkOYsT0dmfX2RcYB8yuWeKbUAP5w5AeDWHc1bdI-0eQEt4lr6yM4tplO9dgbQ9nT74rRU6KPLeXw/s149/Cropped+PA307202'/></author><thr:total>1</thr:total></entry><entry><id>tag:blogger.com,1999:blog-7196398195634872986.post-14794482539333018</id><published>2020-04-09T09:48:00.000-04:00</published><updated>2020-04-09T18:17:02.701-04:00</updated><title type='text'>COVID-19: Using Anti-inflammatory Medications</title><content type='html'>At this time I am of the opinion that avoidance of NSAIDs for flu like symptoms is the way to go [non steroidal anti-inflammatory drugs are like ibuprofen (Advil, Motrin), naproxen (Aleve), diclofenac (Voltaren), meloxicam (Mobic), etc.]. Of course, that is if you even feel inclined to band-aid your symptoms. Barring an allergy or medical condition where it is contraindicated, I would go with acetaminophen (Tylenol). &lt;a href=&quot;https://www.bmj.com/content/368/bmj.m1086.full&quot; target=&quot;_blank&quot;&gt;Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists.&lt;/a&gt;&lt;br /&gt;
The theory behind this is that NSAIDs may hinder the natural inflammation cascade of events otherwise needed to fight against viral infections. That said, even acetaminophen, has an antipyretic action which I am not sure I want to impede during this process. I change my stance if there is excessive fever making the patient uncomfortable or symptomatic (e.g. delirious).&lt;br /&gt;
I am more a fan of rest, hydrate, good nutrition (beef barley soup rocks) and stay warm. After you do the preceding, hydrate some more. 🙂</content><link rel='replies' type='application/atom+xml' href='http://thepillarsofhealth.blogspot.com/feeds/14794482539333018/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://thepillarsofhealth.blogspot.com/2020/04/covid-19-using-anti-inflammatory.html#comment-form' title='1 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/14794482539333018'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/14794482539333018'/><link rel='alternate' type='text/html' href='http://thepillarsofhealth.blogspot.com/2020/04/covid-19-using-anti-inflammatory.html' title='COVID-19: Using Anti-inflammatory Medications'/><author><name>Dr Dhia Aldoori</name><uri>http://www.blogger.com/profile/12785445082984259058</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='23' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgIcbY6lOf-A2OAQZ3CCF-V44BF68CUZ1wYcXS06NXVQS-lTFiik3VkOYsT0dmfX2RcYB8yuWeKbUAP5w5AeDWHc1bdI-0eQEt4lr6yM4tplO9dgbQ9nT74rRU6KPLeXw/s149/Cropped+PA307202'/></author><thr:total>1</thr:total></entry><entry><id>tag:blogger.com,1999:blog-7196398195634872986.post-8077354755604387750</id><published>2020-03-24T09:45:00.000-04:00</published><updated>2020-05-24T08:17:40.220-04:00</updated><title type='text'>COVID-19: Running Notes (quick link above or click on my picture above)</title><content type='html'>&lt;h1 style=&quot;background-color: #f8f9fa; font-family: helvetica; text-align: left;&quot;&gt;
&lt;span style=&quot;font-size: small;&quot;&gt;Clicking on the quick link above or the link below within this post will take you to the diagram.&lt;/span&gt;&lt;/h1&gt;
&lt;div&gt;
&lt;div class=&quot;separator&quot; style=&quot;clear: left; float: left; margin-bottom: 1em; margin-right: 1em; text-align: center;&quot;&gt;
&lt;a href=&quot;https://app.diagrams.net/?lightbox=1&amp;amp;highlight=0000ff&amp;amp;edit=_blank&amp;amp;layers=1&amp;amp;nav=1&amp;amp;title=Dealing%20with%20COVID-19.drawio#Uhttps%3A%2F%2Fdrive.google.com%2Fuc%3Fid%3D1AcW9g6mD5iuCcVfZehFbvQcQVzyepwMh%26export%3Ddownload&quot; target=&quot;_blank&quot;&gt;&lt;img border=&quot;0&quot; data-original-height=&quot;867&quot; data-original-width=&quot;1028&quot; height=&quot;167&quot; src=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhRNvE6_1ErTVY-Ug93rKmArImbY9ZcpIS2ycXLimK2YficQK3H3kcc1i0dhz_kphjgVCizqt9e0cHfcRaTZYkxDHnARYKEXutx9eauK73_r0JZqeiVyjP47D7_stQ2y-Hxa85JpY9-B2dB/s200/SARS-CoV-2+Image.jpg&quot; width=&quot;200&quot; /&gt;&lt;/a&gt;&lt;/div&gt;
See &quot;Black Box Warning&quot; update for 4/3/20.&lt;br /&gt;
&lt;span style=&quot;color: red; font-size: large;&quot;&gt;&lt;a href=&quot;https://app.diagrams.net/?lightbox=1&amp;amp;highlight=0000ff&amp;amp;edit=_blank&amp;amp;layers=1&amp;amp;nav=1&amp;amp;title=Dealing%20with%20COVID-19.drawio#Uhttps%3A%2F%2Fdrive.google.com%2Fuc%3Fid%3D1AcW9g6mD5iuCcVfZehFbvQcQVzyepwMh%26export%3Ddownload&quot; target=&quot;_blank&quot;&gt;My COVID-19 Running Notes @ Diagrams.net&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;
&lt;div&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div&gt;
Depending on feedback I will answer questions within the updated diagram.&amp;nbsp;&lt;/div&gt;
</content><link rel='replies' type='application/atom+xml' href='http://thepillarsofhealth.blogspot.com/feeds/8077354755604387750/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://thepillarsofhealth.blogspot.com/2020/03/covid-19-running-notes.html#comment-form' title='9 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/8077354755604387750'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/8077354755604387750'/><link rel='alternate' type='text/html' href='http://thepillarsofhealth.blogspot.com/2020/03/covid-19-running-notes.html' title='COVID-19: Running Notes (quick link above or click on my picture above)'/><author><name>Dr Dhia Aldoori</name><uri>http://www.blogger.com/profile/12785445082984259058</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='23' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgIcbY6lOf-A2OAQZ3CCF-V44BF68CUZ1wYcXS06NXVQS-lTFiik3VkOYsT0dmfX2RcYB8yuWeKbUAP5w5AeDWHc1bdI-0eQEt4lr6yM4tplO9dgbQ9nT74rRU6KPLeXw/s149/Cropped+PA307202'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhRNvE6_1ErTVY-Ug93rKmArImbY9ZcpIS2ycXLimK2YficQK3H3kcc1i0dhz_kphjgVCizqt9e0cHfcRaTZYkxDHnARYKEXutx9eauK73_r0JZqeiVyjP47D7_stQ2y-Hxa85JpY9-B2dB/s72-c/SARS-CoV-2+Image.jpg" height="72" width="72"/><thr:total>9</thr:total></entry><entry><id>tag:blogger.com,1999:blog-7196398195634872986.post-935789421107848907</id><published>2017-08-13T09:42:00.000-04:00</published><updated>2017-08-13T09:42:57.939-04:00</updated><title type='text'>Nightshade Vegetable Allergies</title><content type='html'>&lt;div style=&quot;border-width: 100%; direction: ltr;&quot;&gt;
&lt;div style=&quot;direction: ltr; margin-left: 0in; margin-top: 0in;&quot;&gt;
&lt;div style=&quot;direction: ltr; margin-left: 0in; margin-top: 0in;&quot;&gt;
&lt;ul style=&quot;direction: ltr; margin-bottom: 0in; margin-left: .277in; margin-top: 0in; unicode-bidi: embed;&quot;&gt;&lt;div style=&quot;font-family: Calibri; margin: 0in; text-align: justify; text-indent: -0.1666in;&quot;&gt;
In response to:&lt;/div&gt;
&lt;div style=&quot;font-family: Calibri, sans-serif; text-align: justify;&quot;&gt;
[&lt;a href=&quot;https://www.blogger.com/profile/08307492789715859190&quot;&gt;Bess Rhoades&lt;/a&gt; has left a new comment on your post &quot;&lt;a href=&quot;http://thepillarsofhealth.blogspot.com/2012/04/why-im-fan-of-copper.html&quot;&gt;Why I&#39;m a Fan of Copper&lt;/a&gt;&quot;:&amp;nbsp;&lt;/div&gt;
&lt;div style=&quot;text-align: justify;&quot;&gt;
&lt;span style=&quot;font-family: &amp;quot;calibri&amp;quot; , sans-serif;&quot;&gt; &lt;/span&gt;&lt;/div&gt;
&lt;span style=&quot;font-family: &amp;quot;calibri&amp;quot; , sans-serif;&quot;&gt;&lt;div style=&quot;text-align: justify;&quot;&gt;
Dr. A- I do not know how to enter a question on this blog, so this is the best I could do. Could you please address what you believe about nightshade vegetable allergies- and their possible role in inflammatory process and perhaps even arthrities in certain individuals. I thought this was far fetched until I began reading. This article in particular caught my interest:&amp;nbsp;&lt;/div&gt;
&lt;/span&gt; &lt;div style=&quot;font-family: Calibri, sans-serif; text-align: justify;&quot;&gt;
&lt;a href=&quot;https://www.westonaprice.org/health-topics/food-features/nightshades/&quot;&gt;https://www.westonaprice.org/health-topics/food-features/nightshades/&lt;/a&gt;&lt;/div&gt;
&lt;span style=&quot;font-family: &amp;quot;calibri&amp;quot; , sans-serif;&quot;&gt;&lt;div style=&quot;text-align: justify;&quot;&gt;
Thank you]&amp;nbsp;&lt;/div&gt;
&lt;/span&gt;&lt;div style=&quot;font-family: Calibri; margin: 0in; text-align: justify; text-indent: -0.1666in;&quot;&gt;
&lt;/div&gt;
&lt;div style=&quot;font-family: Calibri; margin: 0in; text-align: justify; text-indent: -0.1666in;&quot;&gt;
Looking at your reference.&lt;/div&gt;
&lt;div style=&quot;font-family: Calibri; margin: 0in; text-align: justify;&quot;&gt;
Paragraph 1:  Claiming sensitivity to these plants without delineating a causal  pathophysiology is always concerning to me and makes the content lack  credibility.&lt;/div&gt;
&lt;div style=&quot;font-family: Calibri; margin: 0in; text-align: justify;&quot;&gt;
Paragraph 3: If you  have as claimed a sensitivity to a certain food, I don’t think it would be  harmful to avoid them for a month or two, and monitor the improvement or lack  thereof. I doubt with pretty good logic and science that nightshade plants  &quot;cause&quot; heartburn. They may exacerbate symptoms but don’t cause  relaxation of the lower esophageal sphincter, as far as I know at this time.  (One of these days I will write up the causes of alluded to relaxation). &lt;/div&gt;
&lt;div style=&quot;font-family: Calibri; margin: 0in; text-align: justify;&quot;&gt;
Paragraph 5:  Potatoes causing dropsy. Anytime a human relies on a high carbohydrate low  protein diet in tandem with a&amp;nbsp;  deficiency of other important nutrients, expect there to be  body swelling.&lt;/div&gt;
&lt;div style=&quot;font-family: Calibri; margin: 0in; text-align: justify;&quot;&gt;
&lt;/div&gt;
&lt;div style=&quot;font-family: Calibri; margin: 0in; text-align: justify;&quot;&gt;
I stopped reading  after paragraph 6 as the author&#39;s arguments and evidence presentation were  excessively weak and lacking in logic and definite pathophysiological cause,  not to mention heavily infused with loose associations being put forth as  evidence. Also the author, although listing references, didn’t associate them  with the facts being quoted and therefore very difficult to verify his  studies/articles/references. &lt;/div&gt;
&lt;div style=&quot;font-family: Calibri; margin: 0in; text-align: justify;&quot;&gt;
&lt;/div&gt;
&lt;div style=&quot;font-family: Calibri; margin: 0in; text-align: justify;&quot;&gt;
Notes: Tomatoes  have evidence of being anticancer.&lt;/div&gt;
&lt;div style=&quot;font-family: Calibri; margin: 0in; text-align: justify;&quot;&gt;
&lt;/div&gt;
&lt;div style=&quot;font-family: Calibri; margin: 0in; text-align: justify;&quot;&gt;
In summary I would  say that it&#39;s possible some people may have increased sensitivities to certain  foods, but I would hesitate to say that &#39;nightshade&#39; plants are dangerous as a  group.&lt;/div&gt;
&lt;div style=&quot;font-family: Calibri; margin: 0in; text-align: justify;&quot;&gt;
DA&lt;/div&gt;
&lt;/ul&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
</content><link rel='replies' type='application/atom+xml' href='http://thepillarsofhealth.blogspot.com/feeds/935789421107848907/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://thepillarsofhealth.blogspot.com/2017/08/nightshade-vegetable-allergies.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/935789421107848907'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/935789421107848907'/><link rel='alternate' type='text/html' href='http://thepillarsofhealth.blogspot.com/2017/08/nightshade-vegetable-allergies.html' title='Nightshade Vegetable Allergies'/><author><name>Dr Dhia Aldoori</name><uri>http://www.blogger.com/profile/12785445082984259058</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='23' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgIcbY6lOf-A2OAQZ3CCF-V44BF68CUZ1wYcXS06NXVQS-lTFiik3VkOYsT0dmfX2RcYB8yuWeKbUAP5w5AeDWHc1bdI-0eQEt4lr6yM4tplO9dgbQ9nT74rRU6KPLeXw/s149/Cropped+PA307202'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-7196398195634872986.post-4472799994944409208</id><published>2015-11-13T19:33:00.000-05:00</published><updated>2015-11-13T19:33:12.185-05:00</updated><title type='text'>Mucuna Pruriens in Anxiety/Depression</title><content type='html'>&lt;div&gt;
&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;;&quot;&gt;&lt;span style=&quot;font-size: 16px;&quot;&gt;&lt;u&gt;Question&lt;/u&gt;:&amp;nbsp;&lt;/span&gt;&lt;/span&gt;&lt;cite class=&quot;user&quot; style=&quot;color: #333333; font-family: &#39;Trebuchet MS&#39;, Verdana, Arial, sans-serif; font-size: 12.61px; font-style: normal; font-weight: bold; line-height: 18.915px;&quot;&gt;Anonymous&lt;/cite&gt;&lt;span class=&quot;icon user&quot; style=&quot;color: #333333; font-family: &#39;Trebuchet MS&#39;, Verdana, Arial, sans-serif; font-size: 12.61px; font-weight: bold; line-height: 18.915px;&quot;&gt;&lt;/span&gt;&lt;span class=&quot;datetime secondary-text&quot; style=&quot;color: #333333; font-family: &#39;Trebuchet MS&#39;, Verdana, Arial, sans-serif; font-size: 12.61px; line-height: 18.915px; margin-left: 6px;&quot;&gt;&lt;a href=&quot;http://thepillarsofhealth.blogspot.com/2013/06/how-to-decide-on-how-much-5-htp-5.html?showComment=1447443951378#c5239578510145827144&quot; rel=&quot;nofollow&quot; style=&quot;color: purple;&quot;&gt;November 13, 2015 at 2:45 PM&lt;/a&gt;&lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;;&quot;&gt;&lt;span style=&quot;font-size: 16px;&quot;&gt;&lt;span style=&quot;background-color: #eeeecc; color: #333333; font-family: &#39;Trebuchet MS&#39;, Verdana, Arial, sans-serif; font-size: 12.61px; line-height: 18.915px; text-align: justify;&quot;&gt;What are your thoughts on the herbal supplement, mucuna pruriens, for anxiety/depression?&lt;/span&gt;&amp;nbsp;&lt;/span&gt;&lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;;&quot;&gt;&lt;span style=&quot;font-size: 16px;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;
&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;;&quot;&gt;&lt;span style=&quot;font-size: 16px;&quot;&gt;&lt;u&gt;Answer&lt;/u&gt;: I have personally not been aware of this herb,&amp;nbsp;Mucuna pruriens, till your question. After a quick research I found the following:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
&lt;span style=&quot;background-color: white; font-family: arial; font-size: 16px;&quot;&gt;&lt;br /&gt;&lt;/span&gt;
&lt;span style=&quot;background-color: white; font-family: arial; font-size: 16px;&quot;&gt;The major phenolic constituent of M. pruriens beans was found to be L-dopa (5%), along with 5-indole compounds, two of which were identified as tryptamine and 5-hydroxytryptamine.&lt;/span&gt;&lt;br /&gt;
&lt;div style=&quot;background-color: #cccccc; font-style: normal; font-variant: normal; font-weight: normal;&quot;&gt;
&lt;div style=&quot;overflow: hidden; text-align: left;&quot;&gt;
&lt;div style=&quot;background-color: white; box-shadow: rgba(0, 0, 0, 0.298039) 0.4em 0.4em 0.5em; overflow: hidden;&quot;&gt;
&lt;div style=&quot;word-wrap: break-word;&quot;&gt;
&lt;div style=&quot;background-color: white; overflow: hidden; word-wrap: break-word;&quot;&gt;
&lt;div style=&quot;background-color: white; border-bottom-left-radius: 0px; border-bottom-right-radius: 0px; border-top-left-radius: 0px; border-top-right-radius: 0px; font-style: normal; font-variant: normal; font-weight: normal; overflow: hidden; word-wrap: break-word;&quot;&gt;
&lt;div style=&quot;clear: both;&quot;&gt;
&lt;div style=&quot;margin: 0.6923em 0px;&quot;&gt;
&lt;div&gt;
&lt;span style=&quot;font-size: 16px;&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;;&quot;&gt;The thought is that L-dopa being a precursor of dopamine, thence the different pharmacological effects. (Anti-diabetic, anti-inflammatory, neuroprotective, and anti-oxidant properties).&amp;nbsp;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
&lt;div&gt;
&lt;span style=&quot;font-size: 16px;&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;;&quot;&gt;I would think that the benefit of this herb would be via &lt;u&gt;1&lt;/u&gt;- the increased production of adrenaline (from the precursor L-dopa), outside the brain, &lt;u&gt;2&lt;/u&gt;- the provision of a significant amount of precursors (&lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;;&quot;&gt;&lt;span style=&quot;font-size: 16px;&quot;&gt;tryptamine and 5-hydroxytryptamine&lt;/span&gt;&lt;/span&gt;),&amp;nbsp;&lt;span style=&quot;font-size: 16px;&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;;&quot;&gt;for serotonin peripherally and centrally, and &lt;u&gt;3&lt;/u&gt;- provision of L-dopa to the brain (as it crosses the blood brain barrier), which is a precursor for dopamine centrally. The increased production of adrenalin physiologically, in addition to increased production of serotonin and dopamine centrally should have a positive impact on depression.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
&lt;div&gt;
&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;;&quot;&gt;&lt;span style=&quot;font-size: 16px;&quot;&gt;In India, the seeds of&amp;nbsp;&lt;i&gt;M. pruriens&lt;/i&gt;&amp;nbsp;have traditionally been used as a nervine tonic, and as an aphrodisiac for male virility.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
&lt;div&gt;
&lt;span style=&quot;font-size: 16px;&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;;&quot;&gt;It looks promising logically for anxiety but more so for depression, but I&#39;m afraid I can&#39;t endorse its use at this time as I am not familiar with its dosing, its safety profile, purity of preparation, and studies where it has been used for anxiety or depression.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
&lt;div&gt;
&lt;span style=&quot;font-size: 16px;&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;arial&amp;quot;;&quot;&gt;[Ref.- &lt;span style=&quot;-webkit-text-stroke-width: 0px; background-color: white; color: #303030; display: inline !important; float: none; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px;&quot;&gt;Lampariello LR, Cortelazzo A, Guerranti R, Sticozzi C, Valacchi G. The Magic Velvet Bean of&amp;nbsp;&lt;/span&gt;&lt;i style=&quot;-webkit-text-stroke-width: 0px; background-color: white; color: #303030; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px;&quot;&gt;Mucuna pruriens&lt;/i&gt;&lt;span style=&quot;-webkit-text-stroke-width: 0px; background-color: white; color: #303030; display: inline !important; float: none; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px;&quot;&gt;.&amp;nbsp;&lt;/span&gt;&lt;i style=&quot;-webkit-text-stroke-width: 0px; background-color: white; color: #303030; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px;&quot;&gt;Journal of Traditional and Complementary Medicine&lt;/i&gt;&lt;span style=&quot;-webkit-text-stroke-width: 0px; background-color: white; color: #303030; display: inline !important; float: none; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px;&quot;&gt;. 2012;2(4):331-339.]&lt;/span&gt;&amp;nbsp;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
</content><link rel='replies' type='application/atom+xml' href='http://thepillarsofhealth.blogspot.com/feeds/4472799994944409208/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://thepillarsofhealth.blogspot.com/2015/11/mucuna-pruriens-in-anxietydepression.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/4472799994944409208'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/4472799994944409208'/><link rel='alternate' type='text/html' href='http://thepillarsofhealth.blogspot.com/2015/11/mucuna-pruriens-in-anxietydepression.html' title='Mucuna Pruriens in Anxiety/Depression'/><author><name>Dr Dhia Aldoori</name><uri>http://www.blogger.com/profile/12785445082984259058</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='23' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgIcbY6lOf-A2OAQZ3CCF-V44BF68CUZ1wYcXS06NXVQS-lTFiik3VkOYsT0dmfX2RcYB8yuWeKbUAP5w5AeDWHc1bdI-0eQEt4lr6yM4tplO9dgbQ9nT74rRU6KPLeXw/s149/Cropped+PA307202'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-7196398195634872986.post-3384435028365266579</id><published>2013-06-07T21:13:00.000-04:00</published><updated>2017-01-15T20:28:46.202-05:00</updated><title type='text'>How to Decide On How Much 5-HTP (5-Hydroxytryptophan) and L-Tyrosine to Take In Mild Depression? (Edited: 1/15/17)</title><content type='html'>&lt;!--[if gte mso 9]&gt;&lt;xml&gt;
 &lt;w:WordDocument&gt;
  &lt;w:View&gt;Normal&lt;/w:View&gt;
  &lt;w:Zoom&gt;0&lt;/w:Zoom&gt;
  &lt;w:TrackMoves/&gt;
  &lt;w:TrackFormatting/&gt;
  &lt;w:PunctuationKerning/&gt;
  &lt;w:ValidateAgainstSchemas/&gt;
  &lt;w:SaveIfXMLInvalid&gt;false&lt;/w:SaveIfXMLInvalid&gt;
  &lt;w:IgnoreMixedContent&gt;false&lt;/w:IgnoreMixedContent&gt;
  &lt;w:AlwaysShowPlaceholderText&gt;false&lt;/w:AlwaysShowPlaceholderText&gt;
  &lt;w:DoNotPromoteQF/&gt;
  &lt;w:LidThemeOther&gt;EN-US&lt;/w:LidThemeOther&gt;
  &lt;w:LidThemeAsian&gt;X-NONE&lt;/w:LidThemeAsian&gt;
  &lt;w:LidThemeComplexScript&gt;AR-SA&lt;/w:LidThemeComplexScript&gt;
  &lt;w:Compatibility&gt;
   &lt;w:BreakWrappedTables/&gt;
   &lt;w:SnapToGridInCell/&gt;
   &lt;w:WrapTextWithPunct/&gt;
   &lt;w:UseAsianBreakRules/&gt;
   &lt;w:DontGrowAutofit/&gt;
   &lt;w:SplitPgBreakAndParaMark/&gt;
   &lt;w:DontVertAlignCellWithSp/&gt;
   &lt;w:DontBreakConstrainedForcedTables/&gt;
   &lt;w:DontVertAlignInTxbx/&gt;
   &lt;w:Word11KerningPairs/&gt;
   &lt;w:CachedColBalance/&gt;
  &lt;/w:Compatibility&gt;
  &lt;w:BrowserLevel&gt;MicrosoftInternetExplorer4&lt;/w:BrowserLevel&gt;
  &lt;m:mathPr&gt;
   &lt;m:mathFont m:val=&quot;Cambria Math&quot;/&gt;
   &lt;m:brkBin m:val=&quot;before&quot;/&gt;
   &lt;m:brkBinSub m:val=&quot;--&quot;/&gt;
   &lt;m:smallFrac m:val=&quot;off&quot;/&gt;
   &lt;m:dispDef/&gt;
   &lt;m:lMargin m:val=&quot;0&quot;/&gt;
   &lt;m:rMargin m:val=&quot;0&quot;/&gt;
   &lt;m:defJc m:val=&quot;centerGroup&quot;/&gt;
   &lt;m:wrapIndent m:val=&quot;1440&quot;/&gt;
   &lt;m:intLim m:val=&quot;subSup&quot;/&gt;
   &lt;m:naryLim m:val=&quot;undOvr&quot;/&gt;
  &lt;/m:mathPr&gt;&lt;/w:WordDocument&gt;
&lt;/xml&gt;&lt;![endif]--&gt;&lt;br /&gt;
&lt;!--[if gte mso 9]&gt;&lt;xml&gt;
 &lt;w:LatentStyles DefLockedState=&quot;false&quot; DefUnhideWhenUsed=&quot;true&quot;
  DefSemiHidden=&quot;true&quot; DefQFormat=&quot;false&quot; DefPriority=&quot;99&quot;
  LatentStyleCount=&quot;267&quot;&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;0&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Normal&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;heading 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 7&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 8&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 9&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 7&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 8&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 9&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;35&quot; QFormat=&quot;true&quot; Name=&quot;caption&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;10&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Title&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;1&quot; Name=&quot;Default Paragraph Font&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;11&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Subtitle&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;22&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Strong&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;20&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Emphasis&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;59&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Table Grid&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; UnhideWhenUsed=&quot;false&quot; Name=&quot;Placeholder Text&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;1&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;No Spacing&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; UnhideWhenUsed=&quot;false&quot; Name=&quot;Revision&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;34&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;List Paragraph&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;29&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Quote&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;30&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Intense Quote&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;19&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Subtle Emphasis&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;21&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Intense Emphasis&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;31&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Subtle Reference&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;32&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Intense Reference&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;33&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Book Title&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;37&quot; Name=&quot;Bibliography&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; QFormat=&quot;true&quot; Name=&quot;TOC Heading&quot;/&gt;
 &lt;/w:LatentStyles&gt;
&lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 10]&gt;
&lt;style&gt;
 /* Style Definitions */
 table.MsoNormalTable
 {mso-style-name:&quot;Table Normal&quot;;
 mso-tstyle-rowband-size:0;
 mso-tstyle-colband-size:0;
 mso-style-noshow:yes;
 mso-style-priority:99;
 mso-style-qformat:yes;
 mso-style-parent:&quot;&quot;;
 mso-padding-alt:0in 5.4pt 0in 5.4pt;
 mso-para-margin-top:0in;
 mso-para-margin-right:0in;
 mso-para-margin-bottom:10.0pt;
 mso-para-margin-left:0in;
 line-height:115%;
 mso-pagination:widow-orphan;
 font-size:11.0pt;
 font-family:&quot;Calibri&quot;,&quot;sans-serif&quot;;
 mso-ascii-font-family:Calibri;
 mso-ascii-theme-font:minor-latin;
 mso-fareast-font-family:&quot;Times New Roman&quot;;
 mso-fareast-theme-font:minor-fareast;
 mso-hansi-font-family:Calibri;
 mso-hansi-theme-font:minor-latin;}
&lt;/style&gt;
&lt;![endif]--&gt;

&lt;br /&gt;
&lt;div align=&quot;center&quot; class=&quot;MsoNormal&quot; style=&quot;text-align: center;&quot;&gt;
&lt;span style=&quot;font-size: small;&quot;&gt;&lt;span style=&quot;line-height: 115%;&quot;&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
&lt;span style=&quot;font-size: small;&quot;&gt;The question posed: “&lt;i&gt;I am taking 5-HTP and L-Tyrosine
supplements for mild depression and have been doing some research. I have read
that a 10:1 ration (L-tyrosine to 5-HTP) is recommended so that no
neurotransmitter is depleted. What are your thoughts? How about a 5:1 ratio? I
know everyone is different but how would you recommend starting out and
adjusting dosage?&lt;/i&gt;”&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
&lt;span style=&quot;font-size: small;&quot;&gt;My answer: (run the following by your doctor first before applying)&amp;nbsp;&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
&lt;span style=&quot;font-size: small;&quot;&gt;I don’t agree with tying these two building blocks together
in a ratio as posed because of the following: each one is involved in the production
of different neurotransmitters, and everyone has a different magnitude of symptoms
of depression which is commensurate with the neurotransmitter that is
deficient. Therefore the symptoms and the response thereby to ingesting these
precursors can be your guide on how much to take in the beginning and thereafter
tailor accordingly. &lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
&lt;span style=&quot;font-size: small;&quot;&gt;If the exhibited symptoms include headache, poor sleep,
inexplicable body pains, and/or memory issues then the anticipated deficiency is
more in line with serotonin deficiency. Hence I would think 5-HTP is going to
be needed for sure. I would start with a dose of 50 mg nightly after the evening
meal and escalate a week later to 100 mg nightly and hold there for at least one
month to see if the symptoms described here improve. It takes time to build up the
amino acid pools in the body. This is assuming the 5-HTP is good quality and
pure. If nausea arises,&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;color: #cc0000;&quot;&gt;or if you become jittery, sweaty or get a rapid heart rate 30-60 minutes after (Edited: 1/15/17)&lt;/span&gt;&lt;span style=&quot;color: #e69138;&quot;&gt;&amp;nbsp;&lt;/span&gt;intake of the 5-HTP in spite of taking it after a regular sized
meal then you may be taking too much.&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
&lt;span style=&quot;font-size: small;&quot;&gt;If the exhibited symptoms include sugar and starch craving, fatigue,
preponderance of gloom, poor stamina, feeling cold more than normal people
around you then the anticipated deficiency would be more in the adrenaline, and
noradrenaline (neurotransmitter) arena. In this setting the tyrosine will be
essential to production of the forementioned, as it is the precursor to both. As such I would
go with a starting dose of 100 mg daily with a meal. This may be upped 100 mg
every three days to a maximum of 1000 mg daily depending on side effects and
therapeutic response. Once you get improvement then I would hold at that dose
for 6 to 9 months then start weaning off over the following 3 months. I started
low on the tyrosine as some patients may be deficient in this amino acid and on
taking it in a large dose may result in hypotension, and or dizziness secondary
to a higher production of adrenaline in a more than used to fashion. The body should
be able to adjust to this over the following weeks, and if not I would do the escalation
even more slowly.&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
&lt;span style=&quot;font-size: small;&quot;&gt;Note: to produce neurotransmitters from precursors like you
are targeting, there must be available certain vitamins which are part of certain
enzymes and co-enzymes necessary for this production. Specifically I will
mention vitamin C for production of serotonin and noradrenaline. Also copper and
iron for production of noradrenaline. The amount I recommend is vitamin C 250
mg daily, copper 2 mg daily and iron 8-15 mg daily,&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;color: #cc0000;&quot;&gt;or even better getting the equivalents in food (tomatoes, peanuts, red meat) (Edited: 1/15/17)&lt;/span&gt;. The last two may be found in
many multivitamin preparations. I would also recommend taking the multivitamin
after the main meal of the day to enhance their absorption and decrease the possibility
of nausea.&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
&lt;span style=&quot;font-size: small;&quot;&gt;Note: do not take above supplements with anti-depressants. &lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
</content><link rel='replies' type='application/atom+xml' href='http://thepillarsofhealth.blogspot.com/feeds/3384435028365266579/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://thepillarsofhealth.blogspot.com/2013/06/how-to-decide-on-how-much-5-htp-5.html#comment-form' title='7 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/3384435028365266579'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/3384435028365266579'/><link rel='alternate' type='text/html' href='http://thepillarsofhealth.blogspot.com/2013/06/how-to-decide-on-how-much-5-htp-5.html' title='How to Decide On How Much 5-HTP (5-Hydroxytryptophan) and L-Tyrosine to Take In Mild Depression? (Edited: 1/15/17)'/><author><name>Dr Dhia Aldoori</name><uri>http://www.blogger.com/profile/12785445082984259058</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='23' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgIcbY6lOf-A2OAQZ3CCF-V44BF68CUZ1wYcXS06NXVQS-lTFiik3VkOYsT0dmfX2RcYB8yuWeKbUAP5w5AeDWHc1bdI-0eQEt4lr6yM4tplO9dgbQ9nT74rRU6KPLeXw/s149/Cropped+PA307202'/></author><thr:total>7</thr:total></entry><entry><id>tag:blogger.com,1999:blog-7196398195634872986.post-5069090905127847177</id><published>2012-12-20T11:18:00.000-05:00</published><updated>2012-12-20T11:28:43.168-05:00</updated><title type='text'>A DIET FOR FIBROMYALGIA? FOODS ACCEPTABLE FOR FIBROMYALGIA AT THE RESTAURANT.</title><content type='html'>&lt;!--[if gte mso 9]&gt;&lt;xml&gt;
 &lt;w:WordDocument&gt;
  &lt;w:View&gt;Normal&lt;/w:View&gt;
  &lt;w:Zoom&gt;0&lt;/w:Zoom&gt;
  &lt;w:TrackMoves/&gt;
  &lt;w:TrackFormatting/&gt;
  &lt;w:PunctuationKerning/&gt;
  &lt;w:ValidateAgainstSchemas/&gt;
  &lt;w:SaveIfXMLInvalid&gt;false&lt;/w:SaveIfXMLInvalid&gt;
  &lt;w:IgnoreMixedContent&gt;false&lt;/w:IgnoreMixedContent&gt;
  &lt;w:AlwaysShowPlaceholderText&gt;false&lt;/w:AlwaysShowPlaceholderText&gt;
  &lt;w:DoNotPromoteQF/&gt;
  &lt;w:LidThemeOther&gt;EN-US&lt;/w:LidThemeOther&gt;
  &lt;w:LidThemeAsian&gt;X-NONE&lt;/w:LidThemeAsian&gt;
  &lt;w:LidThemeComplexScript&gt;AR-SA&lt;/w:LidThemeComplexScript&gt;
  &lt;w:Compatibility&gt;
   &lt;w:BreakWrappedTables/&gt;
   &lt;w:SnapToGridInCell/&gt;
   &lt;w:WrapTextWithPunct/&gt;
   &lt;w:UseAsianBreakRules/&gt;
   &lt;w:DontGrowAutofit/&gt;
   &lt;w:SplitPgBreakAndParaMark/&gt;
   &lt;w:DontVertAlignCellWithSp/&gt;
   &lt;w:DontBreakConstrainedForcedTables/&gt;
   &lt;w:DontVertAlignInTxbx/&gt;
   &lt;w:Word11KerningPairs/&gt;
   &lt;w:CachedColBalance/&gt;
  &lt;/w:Compatibility&gt;
  &lt;m:mathPr&gt;
   &lt;m:mathFont m:val=&quot;Cambria Math&quot;/&gt;
   &lt;m:brkBin m:val=&quot;before&quot;/&gt;
   &lt;m:brkBinSub m:val=&quot;&amp;#45;-&quot;/&gt;
   &lt;m:smallFrac m:val=&quot;off&quot;/&gt;
   &lt;m:dispDef/&gt;
   &lt;m:lMargin m:val=&quot;0&quot;/&gt;
   &lt;m:rMargin m:val=&quot;0&quot;/&gt;
   &lt;m:defJc m:val=&quot;centerGroup&quot;/&gt;
   &lt;m:wrapIndent m:val=&quot;1440&quot;/&gt;
   &lt;m:intLim m:val=&quot;subSup&quot;/&gt;
   &lt;m:naryLim m:val=&quot;undOvr&quot;/&gt;
  &lt;/m:mathPr&gt;&lt;/w:WordDocument&gt;
&lt;/xml&gt;&lt;![endif]--&gt;

&lt;br /&gt;Regarding the diet for Fibromyalgia, with a couple of
exceptions, it is basically the one found here:&lt;span style=&quot;mso-spacerun: yes;&quot;&gt;&amp;nbsp;
&lt;/span&gt;&lt;a href=&quot;http://thepillarsofhealth.blogspot.com/2008/04/appendix-diet.html&quot;&gt;http://thepillarsofhealth.blogspot.com/2008/04/appendix-diet.html&lt;/a&gt;
&lt;br /&gt;

&lt;br /&gt;For Fibromyalgia I prefer that the patient not have any
products containing white flour, because of its refinement and the ease with
which it is absorbed into the blood stream as glucose, which will elicit an
insulin response which will inhibit adrenalin output, which we don’t want. &lt;br /&gt;

&lt;br /&gt;A practical principle here is to avoid high glycemic index
foods. A nice list is here: &lt;a href=&quot;http://www.health.harvard.edu/newsweek/Glycemic_index_and_glycemic_load_for_100_foods.htm&quot;&gt;http://www.health.harvard.edu/newsweek/Glycemic_index_and_glycemic_load_for_100_foods.htm&lt;/a&gt;
&lt;br /&gt;

&lt;br /&gt;Another point is that there should be emphasis on protein intake
(fish, chicken, turkey, eggs, cheese, etc.), as there is the need to keep the
amino acid pool satisfactorily stocked with the building blocks for energy
hormones, and neurotransmitters. &lt;span style=&quot;mso-spacerun: yes;&quot;&gt;&amp;nbsp;&lt;/span&gt;In
addition amino acids can act as a source for slow production of glucose (which shouldn’t
initiate an insulin secretion response – I have not verified this factoid).
This production of glucose takes place in the liver in a process called
gluconeogenesis. &lt;br /&gt;

&lt;br /&gt;Acceptable restaurants foods for Fibromyalgia:&lt;br /&gt;

&lt;br /&gt;&lt;span style=&quot;font-family: Symbol; mso-bidi-font-family: Symbol; mso-fareast-font-family: Symbol;&quot;&gt;&lt;span style=&quot;mso-list: Ignore;&quot;&gt;·&lt;span style=&quot;font: 7.0pt &amp;quot;Times New Roman&amp;quot;;&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span dir=&quot;LTR&quot;&gt;&lt;/span&gt;Chicken paprikash without
the dumplings or noodles. More sour cream or yoghurt and vegetables.&lt;br /&gt;

&lt;br /&gt;&lt;span style=&quot;font-family: Symbol; mso-bidi-font-family: Symbol; mso-fareast-font-family: Symbol;&quot;&gt;&lt;span style=&quot;mso-list: Ignore;&quot;&gt;·&lt;span style=&quot;font: 7.0pt &amp;quot;Times New Roman&amp;quot;;&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span dir=&quot;LTR&quot;&gt;&lt;/span&gt;Salads topped with chicken,
or steak.&lt;br /&gt;

&lt;br /&gt;&lt;span style=&quot;font-family: Symbol; mso-bidi-font-family: Symbol; mso-fareast-font-family: Symbol;&quot;&gt;&lt;span style=&quot;mso-list: Ignore;&quot;&gt;·&lt;span style=&quot;font: 7.0pt &amp;quot;Times New Roman&amp;quot;;&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span dir=&quot;LTR&quot;&gt;&lt;/span&gt;Steak and eggs. For
breakfast. Hold on the white bread.&lt;br /&gt;

&lt;br /&gt;Basically apply: no refined sugars and no white starches.&lt;br /&gt;

&lt;br /&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;
 &lt;w:LatentStyles DefLockedState=&quot;false&quot; DefUnhideWhenUsed=&quot;true&quot;
  DefSemiHidden=&quot;true&quot; DefQFormat=&quot;false&quot; DefPriority=&quot;99&quot;
  LatentStyleCount=&quot;267&quot;&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;0&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Normal&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;heading 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 7&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 8&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 9&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 7&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 8&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 9&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;35&quot; QFormat=&quot;true&quot; Name=&quot;caption&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;10&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Title&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;1&quot; Name=&quot;Default Paragraph Font&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;11&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Subtitle&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;22&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Strong&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;20&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Emphasis&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;59&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Table Grid&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; UnhideWhenUsed=&quot;false&quot; Name=&quot;Placeholder Text&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;1&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;No Spacing&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; UnhideWhenUsed=&quot;false&quot; Name=&quot;Revision&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;34&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;List Paragraph&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;29&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Quote&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;30&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Intense Quote&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;19&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Subtle Emphasis&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;21&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Intense Emphasis&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;31&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Subtle Reference&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;32&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Intense Reference&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;33&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Book Title&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;37&quot; Name=&quot;Bibliography&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; QFormat=&quot;true&quot; Name=&quot;TOC Heading&quot;/&gt;
 &lt;/w:LatentStyles&gt;
&lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 10]&gt;
&lt;style&gt;
 /* Style Definitions */
 table.MsoNormalTable
 {mso-style-name:&quot;Table Normal&quot;;
 mso-tstyle-rowband-size:0;
 mso-tstyle-colband-size:0;
 mso-style-noshow:yes;
 mso-style-priority:99;
 mso-style-qformat:yes;
 mso-style-parent:&quot;&quot;;
 mso-padding-alt:0in 5.4pt 0in 5.4pt;
 mso-para-margin-top:0in;
 mso-para-margin-right:0in;
 mso-para-margin-bottom:10.0pt;
 mso-para-margin-left:0in;
 line-height:115%;
 mso-pagination:widow-orphan;
 font-size:11.0pt;
 font-family:&quot;Calibri&quot;,&quot;sans-serif&quot;;
 mso-ascii-font-family:Calibri;
 mso-ascii-theme-font:minor-latin;
 mso-hansi-font-family:Calibri;
 mso-hansi-theme-font:minor-latin;
 mso-bidi-font-family:Arial;
 mso-bidi-theme-font:minor-bidi;}
&lt;/style&gt;
&lt;![endif]--&gt;</content><link rel='replies' type='application/atom+xml' href='http://thepillarsofhealth.blogspot.com/feeds/5069090905127847177/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://thepillarsofhealth.blogspot.com/2012/12/a-diet-for-fibromyalgia-foods.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/5069090905127847177'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/5069090905127847177'/><link rel='alternate' type='text/html' href='http://thepillarsofhealth.blogspot.com/2012/12/a-diet-for-fibromyalgia-foods.html' title='A DIET FOR FIBROMYALGIA? FOODS ACCEPTABLE FOR FIBROMYALGIA AT THE RESTAURANT.'/><author><name>Dr Dhia Aldoori</name><uri>http://www.blogger.com/profile/12785445082984259058</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='23' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgIcbY6lOf-A2OAQZ3CCF-V44BF68CUZ1wYcXS06NXVQS-lTFiik3VkOYsT0dmfX2RcYB8yuWeKbUAP5w5AeDWHc1bdI-0eQEt4lr6yM4tplO9dgbQ9nT74rRU6KPLeXw/s149/Cropped+PA307202'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-7196398195634872986.post-7039064745570354092</id><published>2012-11-29T17:26:00.001-05:00</published><updated>2020-03-03T09:22:22.922-05:00</updated><title type='text'>Smoking and Depression</title><content type='html'>&lt;!--[if gte mso 9]&gt;&lt;xml&gt;
 &lt;w:WordDocument&gt;
  &lt;w:View&gt;Normal&lt;/w:View&gt;
  &lt;w:Zoom&gt;0&lt;/w:Zoom&gt;
  &lt;w:TrackMoves/&gt;
  &lt;w:TrackFormatting/&gt;
  &lt;w:PunctuationKerning/&gt;
  &lt;w:ValidateAgainstSchemas/&gt;
  &lt;w:SaveIfXMLInvalid&gt;false&lt;/w:SaveIfXMLInvalid&gt;
  &lt;w:IgnoreMixedContent&gt;false&lt;/w:IgnoreMixedContent&gt;
  &lt;w:AlwaysShowPlaceholderText&gt;false&lt;/w:AlwaysShowPlaceholderText&gt;
  &lt;w:DoNotPromoteQF/&gt;
  &lt;w:LidThemeOther&gt;EN-US&lt;/w:LidThemeOther&gt;
  &lt;w:LidThemeAsian&gt;X-NONE&lt;/w:LidThemeAsian&gt;
  &lt;w:LidThemeComplexScript&gt;AR-SA&lt;/w:LidThemeComplexScript&gt;
  &lt;w:Compatibility&gt;
   &lt;w:BreakWrappedTables/&gt;
   &lt;w:SnapToGridInCell/&gt;
   &lt;w:WrapTextWithPunct/&gt;
   &lt;w:UseAsianBreakRules/&gt;
   &lt;w:DontGrowAutofit/&gt;
   &lt;w:SplitPgBreakAndParaMark/&gt;
   &lt;w:DontVertAlignCellWithSp/&gt;
   &lt;w:DontBreakConstrainedForcedTables/&gt;
   &lt;w:DontVertAlignInTxbx/&gt;
   &lt;w:Word11KerningPairs/&gt;
   &lt;w:CachedColBalance/&gt;
  &lt;/w:Compatibility&gt;
  &lt;w:BrowserLevel&gt;MicrosoftInternetExplorer4&lt;/w:BrowserLevel&gt;
  &lt;m:mathPr&gt;
   &lt;m:mathFont m:val=&quot;Cambria Math&quot;/&gt;
   &lt;m:brkBin m:val=&quot;before&quot;/&gt;
   &lt;m:brkBinSub m:val=&quot;--&quot;/&gt;
   &lt;m:smallFrac m:val=&quot;off&quot;/&gt;
   &lt;m:dispDef/&gt;
   &lt;m:lMargin m:val=&quot;0&quot;/&gt;
   &lt;m:rMargin m:val=&quot;0&quot;/&gt;
   &lt;m:defJc m:val=&quot;centerGroup&quot;/&gt;
   &lt;m:wrapIndent m:val=&quot;1440&quot;/&gt;
   &lt;m:intLim m:val=&quot;subSup&quot;/&gt;
   &lt;m:naryLim m:val=&quot;undOvr&quot;/&gt;
  &lt;/m:mathPr&gt;&lt;/w:WordDocument&gt;
&lt;/xml&gt;&lt;![endif]--&gt;&lt;br /&gt;
&lt;!--[if gte mso 9]&gt;&lt;xml&gt;
 &lt;w:LatentStyles DefLockedState=&quot;false&quot; DefUnhideWhenUsed=&quot;true&quot;
  DefSemiHidden=&quot;true&quot; DefQFormat=&quot;false&quot; DefPriority=&quot;99&quot;
  LatentStyleCount=&quot;267&quot;&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;0&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Normal&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;heading 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 7&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 8&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 9&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 7&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 8&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 9&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;35&quot; QFormat=&quot;true&quot; Name=&quot;caption&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;10&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Title&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;1&quot; Name=&quot;Default Paragraph Font&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;11&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Subtitle&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;22&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Strong&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;20&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Emphasis&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;59&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Table Grid&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; UnhideWhenUsed=&quot;false&quot; Name=&quot;Placeholder Text&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;1&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;No Spacing&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; UnhideWhenUsed=&quot;false&quot; Name=&quot;Revision&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;34&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;List Paragraph&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;29&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Quote&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;30&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Intense Quote&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;19&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Subtle Emphasis&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;21&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Intense Emphasis&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;31&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Subtle Reference&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;32&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Intense Reference&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;33&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Book Title&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;37&quot; Name=&quot;Bibliography&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; QFormat=&quot;true&quot; Name=&quot;TOC Heading&quot;/&gt;
 &lt;/w:LatentStyles&gt;
&lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 10]&gt;
&lt;style&gt;
 /* Style Definitions */
 table.MsoNormalTable
 {mso-style-name:&quot;Table Normal&quot;;
 mso-tstyle-rowband-size:0;
 mso-tstyle-colband-size:0;
 mso-style-noshow:yes;
 mso-style-priority:99;
 mso-style-qformat:yes;
 mso-style-parent:&quot;&quot;;
 mso-padding-alt:0in 5.4pt 0in 5.4pt;
 mso-para-margin-top:0in;
 mso-para-margin-right:0in;
 mso-para-margin-bottom:10.0pt;
 mso-para-margin-left:0in;
 line-height:115%;
 mso-pagination:widow-orphan;
 font-size:11.0pt;
 font-family:&quot;Calibri&quot;,&quot;sans-serif&quot;;
 mso-ascii-font-family:Calibri;
 mso-ascii-theme-font:minor-latin;
 mso-hansi-font-family:Calibri;
 mso-hansi-theme-font:minor-latin;
 mso-bidi-font-family:Arial;
 mso-bidi-theme-font:minor-bidi;}
&lt;/style&gt;
&lt;![endif]--&gt;

&lt;br /&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
&lt;b&gt;First, let us try and understand what cigarettes do as
relates to depression.&lt;/b&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
According to the American Heart Association, nicotine
addiction (I prefer calling it tobacco addiction because it is not only
nicotine that is addictive in the tobacco), has historically been one of the
hardest addictions to break, while the pharmacological and behavioral
characteristics that determine tobacco addiction are similar to those
determining addiction to heroin and cocaine. &lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
Is there anything mystical about how cigarettes are
addictive? No. It is all very organic, and physical. The tobacco contains two
categories of chemicals that establish addiction in addition to the conditioned
reflex aspect (Pavlovian), which also fortifies the addiction. This last part
is more related to the whole process of the activity itself of the cigarette
touching the lips, the action of inhalation, the smell of the cigarette,
holding the cigarette, etc. As nicotine enters the body, it is distributed
quickly through the bloodstream and crosses the blood–brain barrier reaching
the brain within 10–20 seconds after inhalation. The elimination half-life of
nicotine in the body is around two hours.&lt;a href=&quot;http://www.blogger.com/blogger.g?blogID=7196398195634872986#_edn1&quot; name=&quot;_ednref1&quot; style=&quot;mso-endnote-id: edn1;&quot; title=&quot;&quot;&gt;&lt;sup&gt;&lt;span style=&quot;mso-special-character: footnote;&quot;&gt;&lt;sup&gt;&lt;span style=&quot;font-family: &amp;quot;calibri&amp;quot; , &amp;quot;sans-serif&amp;quot;; font-size: 11.0pt; line-height: 115%;&quot;&gt;[i]&lt;/span&gt;&lt;/sup&gt;&lt;/span&gt;&lt;/sup&gt;&lt;/a&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
Tobacco smoke contains, in addition to nicotine (the first
category I alluded to above), the monoamine oxidase inhibitors harman and
norharman (the second category I alluded to above). These second category compounds
significantly decrease MAO activity in smokers. This was evidenced by positron
emission tomography imaging that showed smokers have a much lower activity of
peripheral and brain MAO-A (30%) and -B (40%) isozymes compared to non-smokers.&lt;a href=&quot;http://www.blogger.com/blogger.g?blogID=7196398195634872986#_edn2&quot; name=&quot;_ednref2&quot; style=&quot;mso-endnote-id: edn2;&quot; title=&quot;&quot;&gt;&lt;sup&gt;&lt;span style=&quot;mso-special-character: footnote;&quot;&gt;&lt;sup&gt;&lt;span style=&quot;font-family: &amp;quot;calibri&amp;quot; , &amp;quot;sans-serif&amp;quot;; font-size: 11.0pt; line-height: 115%;&quot;&gt;[ii]&lt;/span&gt;&lt;/sup&gt;&lt;/span&gt;&lt;/sup&gt;&lt;/a&gt;,&lt;a href=&quot;http://www.blogger.com/blogger.g?blogID=7196398195634872986#_edn3&quot; name=&quot;_ednref3&quot; style=&quot;mso-endnote-id: edn3;&quot; title=&quot;&quot;&gt;&lt;sup&gt;&lt;span style=&quot;mso-special-character: footnote;&quot;&gt;&lt;sup&gt;&lt;span style=&quot;font-family: &amp;quot;calibri&amp;quot; , &amp;quot;sans-serif&amp;quot;; font-size: 11.0pt; line-height: 115%;&quot;&gt;[iii]&lt;/span&gt;&lt;/sup&gt;&lt;/span&gt;&lt;/sup&gt;&lt;/a&gt; MAO
enzymes break down monoaminergic neurotransmitters such as dopamine,
norepinephrine, and serotonin. It is thought that the powerful interaction
between the MAOIs and the nicotine is responsible for most of the addictive
properties of tobacco smoking.&lt;a href=&quot;http://www.blogger.com/blogger.g?blogID=7196398195634872986#_edn4&quot; name=&quot;_ednref4&quot; style=&quot;mso-endnote-id: edn4;&quot; title=&quot;&quot;&gt;&lt;sup&gt;&lt;span style=&quot;mso-special-character: footnote;&quot;&gt;&lt;sup&gt;&lt;span style=&quot;font-family: &amp;quot;calibri&amp;quot; , &amp;quot;sans-serif&amp;quot;; font-size: 11.0pt; line-height: 115%;&quot;&gt;[iv]&lt;/span&gt;&lt;/sup&gt;&lt;/span&gt;&lt;/sup&gt;&lt;/a&gt; Therefore
when the activity of MAO enzymes is impeded these neurotransmitters are higher
in quantity (enhancing brain function artificially), but the flip side of this
is when the tobacco is gone the MAO enzymes increase and hence decrease those
neurotransmitters (at least temporarily. This translates into the withdrawal
syndrome from tobacco in addition to worsening of any depression state present.
The magnitude and duration of these phenomena will vary with how long and how
much the person has been using tobacco, and how healthy the individual is. In
other words a less healthy person will take longer to renovate their brain
neurotransmitter production compared to a healthier person.&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
As such a treatment strategy for you: target increasing the
neurotransmitters in the brain by all means possible which are safe if supervised:&lt;/div&gt;
&lt;br /&gt;
&lt;ol&gt;
&lt;li&gt;Decrease MAO enzymes
activity by taking a MAO enzyme inhibitor drug. An example of this kind of drug
is phenelzine (Nardil). &lt;span style=&quot;color: orange;&quot;&gt;[As a last resort only]&lt;/span&gt;.&lt;/li&gt;
&lt;li&gt;Provide the building blocks
for the neurotransmitters:&lt;span style=&quot;mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;&quot;&gt;&lt;span style=&quot;mso-list: Ignore;&quot;&gt; i.&lt;span style=&quot;font: 7.0pt &amp;quot;Times New Roman&amp;quot;;&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;Protein is the major
component of almost all major currently recognized neurotransmitters. &lt;span style=&quot;mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;&quot;&gt;&lt;span style=&quot;mso-list: Ignore;&quot;&gt;ii.&lt;span style=&quot;font: 7.0pt &amp;quot;Times New Roman&amp;quot;;&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;Vitamin C is essential for
the manufacture of certain neurotransmitters. &lt;span style=&quot;mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;&quot;&gt;&lt;span style=&quot;mso-list: Ignore;&quot;&gt;iii.&lt;span style=&quot;font: 7.0pt &amp;quot;Times New Roman&amp;quot;;&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;All the B-complexes play a
significant role in the production of neurotransmitters and are of paramount
significance for their function. &lt;span style=&quot;mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;&quot;&gt;&lt;span style=&quot;mso-list: Ignore;&quot;&gt;iv.&lt;span style=&quot;font: 7.0pt &amp;quot;Times New Roman&amp;quot;;&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;Good hydration. How this
works is multifactorial and I won&#39;t go into here in biochemical/physiological
detail. That being said, intake sufficient fluid to maintain urine color a very
light light yellow. If you are sweating in your exercise routine then replace
your losses with a fluid containing sodium chloride (salt), potassium and some
magnesium. The last isn&#39;t as important as the first two, so if not present in
the purchased fluid then no worries. &lt;/li&gt;
&lt;li&gt;Stimulate the production of
adrenaline peripherally to stimulate neurotransmission and neurotransmitters in
the brain. This is done by regular exercise targeting sweating 10 minutes per
session in the beginning and later increasing that according to what your body
tells you. Do one day per week (minimum), per decade of your age. If you are 28
years old then minimum three days exercise per week. If you are 44 years old,
then five days per week, and so on. &lt;/li&gt;
&lt;li&gt;&lt;span style=&quot;mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;&quot;&gt;&lt;span style=&quot;mso-list: Ignore;&quot;&gt;&lt;span style=&quot;font: 7.0pt &amp;quot;Times New Roman&amp;quot;;&quot;&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;Avoid food substances that
inhibit adrenaline production. Any food that leads to secretion of insulin in
high quantities causes inhibition of adrenaline secretion. This would be all
foods that are assimilated and absorbed rapidly into the blood stream as
glucose (a simple sugar). Examples are all refined sugars and all white refined
starch products. (Candy, candybars, pastries, pasta, lasagna, pizza, mashed potatoes,
rice, etc.)&lt;/li&gt;
&lt;li&gt;Provide an environment to
your body which enhances production and conservation of these
neurotransmitters. In other words, sufficient regular sleep. To the tune of 8
hours per 24 hours. Preferably in one block. &lt;/li&gt;
&lt;li&gt;Stop smoking, start 7 mg
patch nicotine (while awake) for two weeks, start the MAO enzyme inhibitor, all
in addition to above. &lt;/li&gt;
&lt;li&gt;You must be off
escitalopram for 10 days prior to starting MAO enzyme inhibitor. (They
interact).&lt;/li&gt;
&lt;/ol&gt;
&lt;br /&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
Comments:&lt;/div&gt;
&lt;ol&gt;
&lt;li&gt;Overcoming the conditioned
     reflexes will take time. Think months to a year. So the craving triggered
     by memory will take a while to go away.&lt;/li&gt;
&lt;li&gt;The physical organic
     aspect of the addiction goes away quicker.&lt;/li&gt;
&lt;li&gt;Taking MAO enzyme
     inhibitors as an antidepressant medication is serious business and must be
     supervised &lt;u&gt;closely&lt;/u&gt; by the prescribing physician. Avoid over the counter
     medications unless cleared by physician who is aware you are on a MAO
     enzyme inhibitor.&lt;/li&gt;
&lt;li&gt;Tobacco smoke will enhance
     the activity of the escitalopram in an ongoing fashion. (answering your
     question above.&lt;/li&gt;
&lt;li&gt;The nicotine content of
     popular American-brand cigarettes has slowly increased over the years, and
     one study found that there was an average increase of 1.6% per year
     between the years of 1998 and 2005. This was found for all major market
     categories of cigarettes.&lt;a href=&quot;http://www.blogger.com/blogger.g?blogID=7196398195634872986#_edn5&quot; name=&quot;_ednref5&quot; style=&quot;mso-endnote-id: edn5;&quot; title=&quot;&quot;&gt;&lt;sup&gt;&lt;span style=&quot;mso-special-character: footnote;&quot;&gt;&lt;sup&gt;&lt;span style=&quot;font-family: &amp;quot;calibri&amp;quot; , &amp;quot;sans-serif&amp;quot;; font-size: 11.0pt; line-height: 115%;&quot;&gt;[v]&lt;/span&gt;&lt;/sup&gt;&lt;/span&gt;&lt;/sup&gt;&lt;/a&gt;
     So the sooner you quit the better.&lt;/li&gt;
&lt;/ol&gt;
&lt;ol start=&quot;1&quot; style=&quot;margin-top: 0in;&quot; type=&quot;A&quot;&gt;





&lt;/ol&gt;
&lt;div style=&quot;mso-element: endnote-list;&quot;&gt;
References:&lt;br /&gt;
&lt;hr align=&quot;left&quot; size=&quot;1&quot; width=&quot;33%&quot; /&gt;
&lt;div id=&quot;edn1&quot; style=&quot;mso-element: endnote;&quot;&gt;
&lt;div class=&quot;MsoEndnoteText&quot;&gt;
&lt;a href=&quot;http://www.blogger.com/blogger.g?blogID=7196398195634872986#_ednref1&quot; name=&quot;_edn1&quot; style=&quot;mso-endnote-id: edn1;&quot; title=&quot;&quot;&gt;&lt;span class=&quot;MsoEndnoteReference&quot;&gt;&lt;span style=&quot;mso-special-character: footnote;&quot;&gt;&lt;span class=&quot;MsoEndnoteReference&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;calibri&amp;quot; , &amp;quot;sans-serif&amp;quot;; font-size: 10.0pt; line-height: 115%;&quot;&gt;[i]&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt; &lt;a href=&quot;http://en.wikipedia.org/wiki/Nicotine&quot;&gt;http://en.wikipedia.org/wiki/Nicotine&lt;/a&gt;&lt;/div&gt;
&lt;div class=&quot;MsoEndnoteText&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div id=&quot;edn2&quot; style=&quot;mso-element: endnote;&quot;&gt;
&lt;div class=&quot;MsoEndnoteText&quot;&gt;
&lt;a href=&quot;http://www.blogger.com/blogger.g?blogID=7196398195634872986#_ednref2&quot; name=&quot;_edn2&quot; style=&quot;mso-endnote-id: edn2;&quot; title=&quot;&quot;&gt;&lt;span class=&quot;MsoEndnoteReference&quot;&gt;&lt;span style=&quot;mso-special-character: footnote;&quot;&gt;&lt;span class=&quot;MsoEndnoteReference&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;calibri&amp;quot; , &amp;quot;sans-serif&amp;quot;; font-size: 10.0pt; line-height: 115%;&quot;&gt;[ii]&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt; Herraiz
T, Chaparro C (2005). &quot;Human monoamine oxidase is inhibited by tobacco
smoke: beta-carboline alkaloids act as potent and reversible inhibitors&quot;.
Biochem. Biophys. Res. Commun. 326 (2): 378–86.&lt;/div&gt;
&lt;/div&gt;
&lt;div id=&quot;edn3&quot; style=&quot;mso-element: endnote;&quot;&gt;
&lt;div class=&quot;MsoEndnoteText&quot;&gt;
&lt;a href=&quot;http://www.blogger.com/blogger.g?blogID=7196398195634872986#_ednref3&quot; name=&quot;_edn3&quot; style=&quot;mso-endnote-id: edn3;&quot; title=&quot;&quot;&gt;&lt;span class=&quot;MsoEndnoteReference&quot;&gt;&lt;span style=&quot;mso-special-character: footnote;&quot;&gt;&lt;span class=&quot;MsoEndnoteReference&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;calibri&amp;quot; , &amp;quot;sans-serif&amp;quot;; font-size: 10.0pt; line-height: 115%;&quot;&gt;[iii]&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt; Fowler
JS, Volkow ND, Wang GJ, et al. (1998). &quot;Neuropharmacological actions of
cigarette smoke: brain monoamine oxidase B (MAO B) inhibition&quot;. J Addict
Dis 17 (1): 23–34.&lt;/div&gt;
&lt;/div&gt;
&lt;div id=&quot;edn4&quot; style=&quot;mso-element: endnote;&quot;&gt;
&lt;div class=&quot;MsoEndnoteText&quot;&gt;
&lt;a href=&quot;http://www.blogger.com/blogger.g?blogID=7196398195634872986#_ednref4&quot; name=&quot;_edn4&quot; style=&quot;mso-endnote-id: edn4;&quot; title=&quot;&quot;&gt;&lt;span class=&quot;MsoEndnoteReference&quot;&gt;&lt;span style=&quot;mso-special-character: footnote;&quot;&gt;&lt;span class=&quot;MsoEndnoteReference&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;calibri&amp;quot; , &amp;quot;sans-serif&amp;quot;; font-size: 10.0pt; line-height: 115%;&quot;&gt;[iv]&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt; Villégier
AS, Blanc G, Glowinski J, Tassin JP (September 2003). &quot;Transient
behavioral sensitization to nicotine becomes long-lasting with monoamine
oxidases inhibitors&quot;. Pharmacol. Biochem. Behav. 76 (2): 267–74.&lt;/div&gt;
&lt;/div&gt;
&lt;div id=&quot;edn5&quot; style=&quot;mso-element: endnote;&quot;&gt;
&lt;div class=&quot;MsoEndnoteText&quot;&gt;
&lt;a href=&quot;http://www.blogger.com/blogger.g?blogID=7196398195634872986#_ednref5&quot; name=&quot;_edn5&quot; style=&quot;mso-endnote-id: edn5;&quot; title=&quot;&quot;&gt;&lt;span class=&quot;MsoEndnoteReference&quot;&gt;&lt;span style=&quot;mso-special-character: footnote;&quot;&gt;&lt;span class=&quot;MsoEndnoteReference&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;calibri&amp;quot; , &amp;quot;sans-serif&amp;quot;; font-size: 10.0pt; line-height: 115%;&quot;&gt;[v]&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt; Connolly,
G. N; Alpert, H. R; Wayne, G. F; Koh, H (2007). &quot;Trends in nicotine yield
in smoke and its relationship with design characteristics among popular US
cigarette brands, 1997–2005&quot;. Tobacco Control 16 (5): e5.
doi:10.1136/tc.2006.019695. PMC 2598548. PMID 17897974.&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
</content><link rel='replies' type='application/atom+xml' href='http://thepillarsofhealth.blogspot.com/feeds/7039064745570354092/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://thepillarsofhealth.blogspot.com/2012/11/smoking-and-depression.html#comment-form' title='2 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/7039064745570354092'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/7039064745570354092'/><link rel='alternate' type='text/html' href='http://thepillarsofhealth.blogspot.com/2012/11/smoking-and-depression.html' title='Smoking and Depression'/><author><name>Dr Dhia Aldoori</name><uri>http://www.blogger.com/profile/12785445082984259058</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='23' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgIcbY6lOf-A2OAQZ3CCF-V44BF68CUZ1wYcXS06NXVQS-lTFiik3VkOYsT0dmfX2RcYB8yuWeKbUAP5w5AeDWHc1bdI-0eQEt4lr6yM4tplO9dgbQ9nT74rRU6KPLeXw/s149/Cropped+PA307202'/></author><thr:total>2</thr:total></entry><entry><id>tag:blogger.com,1999:blog-7196398195634872986.post-1960889719702503094</id><published>2012-10-07T20:44:00.000-04:00</published><updated>2012-10-07T20:45:29.548-04:00</updated><title type='text'>Is it safe to take 200-300mg of 5-HTP a day for Depression? Is Rhodiola Rosea useful for depression?</title><content type='html'>&lt;br /&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
&lt;span style=&quot;mso-fareast-font-family: &amp;quot;Times New Roman&amp;quot;;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
&lt;span style=&quot;mso-fareast-font-family: &amp;quot;Times New Roman&amp;quot;;&quot;&gt;Depending
on the actual bioavailability provided by different 5-HTP preparations I would
say a good pure preparation of 100 mg daily should be a sufficient amount in
this situation. Taking too much could end up in a serotonergic reaction
(agitation, consciousness impairment, tachycardia, hallucinations, etc.)&lt;a href=&quot;http://www.blogger.com/blogger.g?blogID=7196398195634872986#_edn1&quot; name=&quot;_ednref1&quot; style=&quot;mso-endnote-id: edn1;&quot; title=&quot;&quot;&gt;&lt;span class=&quot;MsoEndnoteReference&quot;&gt;&lt;span style=&quot;mso-special-character: footnote;&quot;&gt;&lt;span class=&quot;MsoEndnoteReference&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12.0pt; mso-ansi-language: EN-US; mso-bidi-language: AR-SA; mso-fareast-font-family: &amp;quot;Times New Roman&amp;quot;; mso-fareast-language: EN-US;&quot;&gt;[1]&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;. Therefore
with a reliable preparation, as seen with ‘PureEncapsulations’ I would stick to
100 mg daily only. &lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
&lt;span style=&quot;mso-fareast-font-family: &amp;quot;Times New Roman&amp;quot;;&quot;&gt;&lt;span style=&quot;color: #e69138;&quot;&gt;Rhodiola
Rosea&lt;/span&gt;: In Russia and Scandinavia, it has been used for centuries to cope with
the cold Siberian climate and stressful life.&lt;a href=&quot;http://www.blogger.com/blogger.g?blogID=7196398195634872986#_edn2&quot; name=&quot;_ednref2&quot; style=&quot;mso-endnote-id: edn2;&quot; title=&quot;&quot;&gt;&lt;span class=&quot;MsoEndnoteReference&quot;&gt;&lt;span style=&quot;mso-special-character: footnote;&quot;&gt;&lt;span class=&quot;MsoEndnoteReference&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12.0pt; mso-ansi-language: EN-US; mso-bidi-language: AR-SA; mso-fareast-font-family: &amp;quot;Times New Roman&amp;quot;; mso-fareast-language: EN-US;&quot;&gt;[2]&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;
The theory is that is has a positive impact on serotonin, dopamine and acts as
a monoamine oxidase inhibitor. This would affect depression in a positive way.&lt;a href=&quot;http://www.blogger.com/blogger.g?blogID=7196398195634872986#_edn3&quot; name=&quot;_ednref3&quot; style=&quot;mso-endnote-id: edn3;&quot; title=&quot;&quot;&gt;&lt;span class=&quot;MsoEndnoteReference&quot;&gt;&lt;span style=&quot;mso-special-character: footnote;&quot;&gt;&lt;span class=&quot;MsoEndnoteReference&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 12.0pt; mso-ansi-language: EN-US; mso-bidi-language: AR-SA; mso-fareast-font-family: &amp;quot;Times New Roman&amp;quot;; mso-fareast-language: EN-US;&quot;&gt;[3]&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt; In
light of what it can do and the lack of studies, and lack of standardization I would
only use it with a high degree of caution and under direct supervision of your physician
lest you trigger a sertonergic reaction as described above. I have never used
this substance before but after reading about it, it does look interesting. &lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
&lt;span style=&quot;mso-fareast-font-family: &amp;quot;Times New Roman&amp;quot;;&quot;&gt;For
depression: Are there any &lt;span style=&quot;color: #e69138;&quot;&gt;other herbs, amino acids, or vitamins you would recommend&lt;/span&gt;?
I also like Copper 2-3 mg once daily with a meal (which can be in a multivitamin).
Be cautious with other amino acids though as they can have some pretty
significant effects and side effects. Sometimes I will also use St. Johns Wort at 300 to 900 mg daily in divided doses. This last is a weak serotonin reuptake inhibitor. &lt;/span&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/div&gt;
&lt;div style=&quot;mso-element: endnote-list;&quot;&gt;
&lt;br clear=&quot;all&quot; /&gt;
&lt;hr align=&quot;left&quot; size=&quot;1&quot; width=&quot;33%&quot; /&gt;
&lt;div id=&quot;edn1&quot; style=&quot;mso-element: endnote;&quot;&gt;
&lt;div class=&quot;MsoEndnoteText&quot;&gt;
&lt;a href=&quot;http://www.blogger.com/blogger.g?blogID=7196398195634872986#_ednref1&quot; name=&quot;_edn1&quot; style=&quot;mso-endnote-id: edn1;&quot; title=&quot;&quot;&gt;&lt;span class=&quot;MsoEndnoteReference&quot;&gt;&lt;span style=&quot;mso-special-character: footnote;&quot;&gt;&lt;span class=&quot;MsoEndnoteReference&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 10.0pt; mso-ansi-language: EN-US; mso-bidi-language: AR-SA; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-fareast-theme-font: minor-latin;&quot;&gt;[1]&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt; &lt;a href=&quot;http://www.nlm.nih.gov/medlineplus/ency/article/007272.htm&quot;&gt;http://www.nlm.nih.gov/medlineplus/ency/article/007272.htm&lt;/a&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div id=&quot;edn2&quot; style=&quot;mso-element: endnote;&quot;&gt;
&lt;div class=&quot;MsoEndnoteText&quot;&gt;
&lt;a href=&quot;http://www.blogger.com/blogger.g?blogID=7196398195634872986#_ednref2&quot; name=&quot;_edn2&quot; style=&quot;mso-endnote-id: edn2;&quot; title=&quot;&quot;&gt;&lt;span class=&quot;MsoEndnoteReference&quot;&gt;&lt;span style=&quot;mso-special-character: footnote;&quot;&gt;&lt;span class=&quot;MsoEndnoteReference&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 10.0pt; mso-ansi-language: EN-US; mso-bidi-language: AR-SA; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-fareast-theme-font: minor-latin;&quot;&gt;[2]&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt; &lt;a href=&quot;http://en.wikipedia.org/wiki/Rhodiola_rosea&quot;&gt;http://en.wikipedia.org/wiki/Rhodiola_rosea&lt;/a&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div id=&quot;edn3&quot; style=&quot;mso-element: endnote;&quot;&gt;
&lt;div class=&quot;MsoEndnoteText&quot;&gt;
&lt;a href=&quot;http://www.blogger.com/blogger.g?blogID=7196398195634872986#_ednref3&quot; name=&quot;_edn3&quot; style=&quot;mso-endnote-id: edn3;&quot; title=&quot;&quot;&gt;&lt;span class=&quot;MsoEndnoteReference&quot;&gt;&lt;span style=&quot;mso-special-character: footnote;&quot;&gt;&lt;span class=&quot;MsoEndnoteReference&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;; font-size: 10.0pt; mso-ansi-language: EN-US; mso-bidi-language: AR-SA; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-fareast-theme-font: minor-latin;&quot;&gt;[3]&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt; Monoamine
oxidase inhibition by Rhodiola rosea L. roots. [J Ethnopharmacol. 2009] -
PubMed - NCBI . &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pubmed/19168123.%20Accessed%2010/7/2012%202012&quot;&gt;http://www.ncbi.nlm.nih.gov/pubmed/19168123.
Accessed 10/7/2012 2012&lt;/a&gt;. &lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;br /&gt;</content><link rel='replies' type='application/atom+xml' href='http://thepillarsofhealth.blogspot.com/feeds/1960889719702503094/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://thepillarsofhealth.blogspot.com/2012/10/is-it-safe-to-take-200-300mg-of-5-htp.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/1960889719702503094'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/1960889719702503094'/><link rel='alternate' type='text/html' href='http://thepillarsofhealth.blogspot.com/2012/10/is-it-safe-to-take-200-300mg-of-5-htp.html' title='Is it safe to take 200-300mg of 5-HTP a day for Depression? Is Rhodiola Rosea useful for depression?'/><author><name>Dr Dhia Aldoori</name><uri>http://www.blogger.com/profile/12785445082984259058</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='23' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgIcbY6lOf-A2OAQZ3CCF-V44BF68CUZ1wYcXS06NXVQS-lTFiik3VkOYsT0dmfX2RcYB8yuWeKbUAP5w5AeDWHc1bdI-0eQEt4lr6yM4tplO9dgbQ9nT74rRU6KPLeXw/s149/Cropped+PA307202'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-7196398195634872986.post-927810448367325231</id><published>2012-05-27T16:20:00.000-04:00</published><updated>2012-05-27T16:20:59.246-04:00</updated><title type='text'>How to Raise GABA (Gamma-amino-butyric acid) in the Brain by Natural Means</title><content type='html'>&lt;br /&gt;
&lt;div align=&quot;center&quot; class=&quot;MsoNormal&quot; style=&quot;text-align: center;&quot;&gt;
&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
&lt;span style=&quot;color: #f79646; font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;[Answering M.F.’s questions: You recently stressed that I need to
increase the levels of GABA in my body to help with my persistent anxiety. Are
there natural ways to do this through specific foods or even drinks, such as
loose leaf tea (due to its precursor l-theanine)?]&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-bottom: 6.0pt;&quot;&gt;
&lt;span style=&quot;color: #f79646; font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;Background:
&lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;As a general rule, in promoting health I like
to stay as close as possible to letting and assisting the body in building its
own enzymes, hormones, different substances via its own machinery because of my
fear of disrupting the body’s magnificent equilibrium. This fear encompasses
different issues of feedback mechanisms, rate limiting steps, dependency
issues, etc. &lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-bottom: 6.0pt;&quot;&gt;
&lt;span style=&quot;color: #f79646; font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;Without further
ado:&lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt; GABA (Gamma-amino-butyric acid) functions in
brain tissue as an inhibitory neurotransmitter by altering transmembrane
potential differences. Throughout the adult brain, where scientists have mostly
studied the roles of glutamate and GABA, it has been established that both
amino acids function primarily as signals transmitted between cells. Most of
the cells transmitting either glutamate or GABA signals are neurons. After
release, GABA diffuses a very short distance and binds to receptor proteins on
the surface of the target neuron, which are specialized for sensing either GABA
or glutamate via either glutamatergic or GABA receptors. GABA subsequently will
be taken up, or transported out by carrier proteins. The uptake process
requires energy and involves co-transport of &lt;span id=&quot;bits_marker_local20120527070953&quot;&gt;GABA, which is neutral at physiological
pH, together with two sodium ions and one chloride ion.&lt;/span&gt;[3],[5] The
result of GABA stimulation of GABA receptors specifically serves to retard the
stimulatory effects of glutamate throughout the brain. &lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-bottom: 6.0pt;&quot;&gt;
&lt;span style=&quot;color: #f79646; font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;Why&lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt; &lt;span style=&quot;color: #f79646;&quot;&gt;is it important for anxiety?&lt;/span&gt; All &lt;a href=&quot;http://en.wikipedia.org/wiki/Anxiogenic&quot;&gt;anxiogenic&lt;/a&gt; agents act on the
GABA-A receptor/chloride ion channel complex, implicating this neurotransmitter
system in the pathogenesis of anxiety and panic attacks.[7] As such increasing GABA
availability, and or increasing the efficiency/effect of, or sensitivity of GABA
receptors should help alleviate the feelings of anxiety.&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-bottom: 6.0pt;&quot;&gt;
&lt;span style=&quot;color: #f79646; font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;How to
promote its availability:&lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt; GABA (Gamma-amino-butyric
acid) can be formed from glutamic acid in the presence of pyridoxal
phosphate[1]&amp;nbsp; (as a cofactor for glutamic
acid decarboxylase – GAD).[2]&lt;/span&gt; &lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;The pyridoxal phosphate
arises from vitamin B6 (pyridoxine). Therefore availability of B6 is necessary.
Don&#39;t overdo. Too much B6 has neurotoxic effects. 10 mg per day is easily
sufficient. Other factors that may promote healthy GABA metabolism would be
physiological levels of sodium and chloride (salt), in an ample fluid medium.
Practical translation: sufficient salt and water intake. Lyte-Hydrate well.&lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-bottom: 6.0pt;&quot;&gt;
&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;&lt;a href=&quot;http://en.wikipedia.org/wiki/Valerian_%28herb%29#Biochemical_composition&quot;&gt;Valerian&lt;/a&gt;
raises GAD (glutamic acid decarboxylase) activity[4] which may raise GABA
(Gamma-amino-butyric acid) in the neuronal tissues which should have a calming
effect. The extract also contains GABA[8] which may have a direct impact on GABA
receptors.&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-bottom: 6.0pt;&quot;&gt;
&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;Make sure the building block of GABA is
available (glutamic acid): All meats, poultry, fish, eggs, dairy products, and
kombu are excellent sources of glutamic acid. Some protein-rich plant foods
also serve as sources.[1]&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-bottom: 6.0pt;&quot;&gt;
&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;To my knowledge only certain pharmaceuticals
(such as phenobarbitone) function as a GABA receptor modulator which enhances the
target function of said receptors.&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-bottom: 6.0pt;&quot;&gt;
&lt;span style=&quot;color: #f79646; font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;Theanine:&lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt; is an amino acid present in green tea which appears
to have stimulatory effects and inhibitory effects on glutamic acid. For calming
one would desire the inhibitory effect. How it works seems unclear to date
(5-28-12). As such I would think it would be okay to use although in this case
it is functioning more as a pharmaceutical agent and not as a building block. Theanine
is similar in molecular structure to glutamic acid and hence could be ‘pressuring’
glutamic acid and causing it to be more available for transforming into GABA. Here
I am theorizing. Then again it could be occupying glutamatergic receptors without
causing the usual excitatory activity which glutamic acid usually results in. Here
I am theorizing again. &lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;&lt;u&gt;References&lt;/u&gt;:&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in;&quot;&gt;
&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;[1] Rodwell VW. Chapter 30. Conversion of Amino
Acids to Specialized Products. In: Bender DA, Botham KM, Weil PA, Kennelly PJ,
Murray RK, Rodwell VW, eds. Harper&#39;s Illustrated Biochemistry. 29th ed. New
York: McGraw-Hill; 2011. &lt;a href=&quot;http://0-www.accessmedicine.com.library.ccf.org/&quot;&gt;http://0-www.accessmedicine.com.library.ccf.org&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in;&quot;&gt;
&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;[2] &lt;a href=&quot;http://en.wikipedia.org/wiki/Glutamate_decarboxylase&quot;&gt;http://en.wikipedia.org/wiki/Glutamate_decarboxylase&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in;&quot;&gt;
&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;[3] GABA as a Neurotransmitter and Neurogenic
Signal - eLS - Barker - Wiley Online Library . &lt;a href=&quot;http://0-onlinelibrary.wiley.com.library.ccf.org/doi/10.1038/npg.els.0000121/full.%20Accessed%205/13/2012%202012&quot;&gt;http://0-onlinelibrary.wiley.com.library.ccf.org/doi/10.1038/npg.els.0000121/full.
Accessed 5/13/2012 2012&lt;/a&gt;.&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in;&quot;&gt;
&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;[4] R Awad, D Levac, P Cybulska, Z Merali, VL
Trudeau, JT Arnason (2007) Effects of traditionally used anxiolytic botanicals
on enzymes of the gamma-aminobutyric acid (GABA) system Can J Physiol Pharmacol
85: 933-942. Doi:10.1139/Y07-083.&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in;&quot;&gt;
&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;[5] Nicotinic Acetylcholine Receptors - eLS -
Lindstrom - Wiley Online Library . &lt;a href=&quot;http://0-onlinelibrary.wiley.com.library.ccf.org/doi/10.1002/9780470015902.a0000245.pub2/full.%20Accessed%205/20/2012%202012&quot;&gt;http://0-onlinelibrary.wiley.com.library.ccf.org/doi/10.1002/9780470015902.a0000245.pub2/full.
Accessed 5/20/2012 2012&lt;/a&gt;. &lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in;&quot;&gt;
&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;[6] Russek, S. J. 2006. γ-Aminobutyric Acid
(GABA) Receptors. eLS. &lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in;&quot;&gt;
&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;[7] Reus VI. Chapter 391. Mental Disorders. In:
Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, eds.
Harrison&#39;s Principles of Internal Medicine. 18th ed. New York: McGraw-Hill;
2012. http://0-www.accessmedicine.com.library.ccf.org/content.aspx?aID=9112222.
Accessed May 27, 2012.&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in;&quot;&gt;
&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;[8] &lt;a href=&quot;http://en.wikipedia.org/wiki/Valerian_%28herb%29#Biochemical_composition&quot;&gt;http://en.wikipedia.org/wiki/Valerian_%28herb%29#Biochemical_composition&lt;/a&gt; &lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in;&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in;&quot;&gt;
&lt;br /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://thepillarsofhealth.blogspot.com/feeds/927810448367325231/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://thepillarsofhealth.blogspot.com/2012/05/how-to-raise-gaba-gamma-amino-butyric.html#comment-form' title='3 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/927810448367325231'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/927810448367325231'/><link rel='alternate' type='text/html' href='http://thepillarsofhealth.blogspot.com/2012/05/how-to-raise-gaba-gamma-amino-butyric.html' title='How to Raise GABA (Gamma-amino-butyric acid) in the Brain by Natural Means'/><author><name>Dr Dhia Aldoori</name><uri>http://www.blogger.com/profile/12785445082984259058</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='23' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgIcbY6lOf-A2OAQZ3CCF-V44BF68CUZ1wYcXS06NXVQS-lTFiik3VkOYsT0dmfX2RcYB8yuWeKbUAP5w5AeDWHc1bdI-0eQEt4lr6yM4tplO9dgbQ9nT74rRU6KPLeXw/s149/Cropped+PA307202'/></author><thr:total>3</thr:total></entry><entry><id>tag:blogger.com,1999:blog-7196398195634872986.post-9108749036742414709</id><published>2012-04-29T14:51:00.001-04:00</published><updated>2012-04-30T15:44:42.165-04:00</updated><title type='text'>Why I&#39;m a Fan of Copper</title><content type='html'>&lt;br /&gt;
&lt;div align=&quot;center&quot; class=&quot;MsoNormal&quot; style=&quot;text-align: center;&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;color: #0b5394;&quot;&gt;
&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;[Answering M.F.’s questions: What is the importance of taking
copper? Should everyone be taking 2mg of this supplement daily, separate from a
multivitamin? Or does this apply only to a specific group of individuals? Also,
is there an advantage to taking either the citrate or glycinate form in terms
of absorption?]&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;color: #0b5394;&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-bottom: 0.0001pt;&quot;&gt;
&lt;span style=&quot;color: #0b5394; font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;What is
the importance of taking copper? &lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;Copper is an integral part of numerous enzyme
systems, including amine oxidases, ferroxidase (ceruloplasmin), cytochrome-&lt;i&gt;c&lt;/i&gt; oxidase, superoxide dismutase, and dopamine hydroxylase.
Copper is also a component of ferroprotein, a transport protein involved in the
basolateral transfer of iron during absorption from the intestine. As such,
copper plays a role in iron metabolism (important for blood formation), melanin
synthesis (important for skin color), energy production, neurotransmitter
synthesis, and nervous system function; the synthesis and cross-linking of
elastin and collagen; and the scavenging of superoxide radicals.&lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;[1]&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-bottom: 0.0001pt;&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-bottom: 0.0001pt;&quot;&gt;
&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;From my viewpoint, the most important aspects
are for the insurance of presence of sufficient quantities of copper for the cross
linking of elastin and collagen and the dopamine hydroxylase. &lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-bottom: 0.0001pt;&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-bottom: 0.0001pt;&quot;&gt;
&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;The cross linking of elastin and collagen is of
immediate importance in the health of bones, joints, tendons, skin and hair
among other things. Of paramount importance though is the dopamine hydroxylase.
This is because this enzyme is necessary for the hydroxylation of dopamine to
noradrenalin which is the precursor to adrenalin.[2] I consider adrenalin to
be of supreme importance for health when generated physiologically naturally. Of
note here is that vitamin C (ascorbic acid) is a cofactor for the hydroxylation
of dopamine to noradrenalin. &lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-bottom: 0.0001pt;&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-bottom: 0.0001pt;&quot;&gt;
&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;Don&#39;t take more than the recommended 2-3 mg
daily, as at higher levels toxicity may ensue. (More isn&#39;t better). 10 mg
intake can be dangerous.[1] See table:&lt;/span&gt;&lt;br /&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;table align=&quot;center&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; class=&quot;tr-caption-container&quot; style=&quot;margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;tbody&gt;
&lt;tr&gt;&lt;td style=&quot;text-align: center;&quot;&gt;&lt;a href=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEid6jw8VjC3tlN3HLXOfcc2P9Lm-8O2ehU0bQtwlramirOBOerHErRXGvVIcv7W7FUgXu6MAcoOdjPRBkwjhaYuIHqYgMdvmtBY33suYYJeWyXzl6jrDzLza5dxKy43XPBfUJ5xEkDwgHLC/s1600/Picture1.jpg&quot; imageanchor=&quot;1&quot; style=&quot;margin-left: auto; margin-right: auto;&quot;&gt;&lt;img border=&quot;0&quot; height=&quot;356&quot; src=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEid6jw8VjC3tlN3HLXOfcc2P9Lm-8O2ehU0bQtwlramirOBOerHErRXGvVIcv7W7FUgXu6MAcoOdjPRBkwjhaYuIHqYgMdvmtBY33suYYJeWyXzl6jrDzLza5dxKy43XPBfUJ5xEkDwgHLC/s400/Picture1.jpg&quot; width=&quot;400&quot; /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;tr-caption&quot; style=&quot;text-align: center;&quot;&gt;&lt;div align=&quot;center&quot; class=&quot;MsoCaption&quot; style=&quot;text-align: center;&quot;&gt;
Deficiencies and Toxicities of Metals - from
Harrison&#39;s Online via AccessMedicine&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;&lt;/span&gt;&lt;/div&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
&lt;div class=&quot;separator&quot; style=&quot;clear: both; text-align: center;&quot;&gt;
&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-bottom: 0.0001pt;&quot;&gt;
&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;/div&gt;
&lt;div align=&quot;center&quot; class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-bottom: 0.0001pt; page-break-after: avoid; text-align: center;&quot;&gt;
&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-bottom: 0.0001pt;&quot;&gt;
&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-bottom: 0.0001pt;&quot;&gt;
&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;It has been seen that copper did have a positive
impact on HDL (the cardioprotective cholesterol) and did lower oxidized LDL
values. This last is the type that tends to form the clogging cholesterol within
the walls of blood vessels (specifically arteries). The study showing this was somewhat
short for my taste and wasn’t consistent in its results but the logical tie-in
to the heart protective factors is solid.[3] This study used the glycinate
form of copper.&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-bottom: 0.0001pt;&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-bottom: 0.0001pt;&quot;&gt;
&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;Another study shows that patients suffering from
diabetes mellitus have lower levels of copper in their serum compared to
control patients.[4] Again the tie-in here is logical. &lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-bottom: 0.0001pt;&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: normal; margin-bottom: 0.0001pt;&quot;&gt;
&lt;span style=&quot;color: #f79646; font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;&lt;span style=&quot;color: #0b5394;&quot;&gt;Should everyone be taking 2mg of this supplement daily, separate from
a multivitamin?&lt;/span&gt; &lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;Individuals
whose nutrition is deficient or low in copper intake should take a separate
supplement. Dietary sources&lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt; of copper include shellfish, liver, nuts,
legumes, bran, and organ meats. For myself I prefer not to take a chance on not
getting enough of this essential mineral and hence take it anyway separate from
the copper from other sources. By taking it separately as a 2 mg pill/capsule in addition to a usual 2 mg in the multivitamin tablet then we cap at 4 mg per day plus nutritional
sources. We stay well below the 10 mg/day toxic level.&lt;/span&gt;&lt;br /&gt;
&lt;br /&gt;
&lt;div style=&quot;text-align: left;&quot;&gt;
&lt;span style=&quot;color: #0b5394; font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;Is there an advantage to taking either the citrate or glycinate form
in terms of absorption? &lt;/span&gt;&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;It would appear that, at least in animals the glycinate
form will provide superior bioavailability of the nutrient, compared to the citrate.
That being said I personally take the citrate form as I also take a multivitamin
tablet three times weekly, in addition to regular food intake.[5]&lt;/span&gt;&lt;/div&gt;
&lt;div style=&quot;text-align: left;&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div style=&quot;text-align: left;&quot;&gt;
&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;&lt;u&gt;References&lt;/u&gt;:&lt;/span&gt;&lt;/div&gt;
&lt;div style=&quot;text-align: left;&quot;&gt;
&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;[1] SP Russell RM (2012) Chapter 74. Vitamin
and Trace Mineral Deficiency and Excess. In: Longo DL, Fauci AS, Kasper DL,
Hauser SL, Jameson JL, Loscalzo J, eds. (ed), Harrison&#39;s Principles of Internal
Medicine. 18th ed. edn., McGraw-Hill, New York, pp &lt;a href=&quot;http://0-www.accessmedicine.com.library.ccf.org/content.aspx?aID=9099706.&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: black; text-decoration: none;&quot;&gt;http://0-www.accessmedicine.com.library.ccf.org/content.aspx?aID=9099706.&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;
&lt;div style=&quot;text-align: left;&quot;&gt;
&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;[2] Molina PE. Chapter 6.
Adrenal Gland. In: Molina PE, ed. Endocrine Physiology. 3rd ed. New York:
McGraw-Hill; 2010.
http://0-www.accessmedicine.com.library.ccf.org/content.aspx?aID=6169718.
Accessed April 29, 2012.&lt;/span&gt;&lt;/div&gt;
&lt;div style=&quot;text-align: left;&quot;&gt;
&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;[3] RA Disilvestro, EL
Joseph, W Zhang, AE Raimo, YM Kim (2012) A randomized trial of copper
supplementation effects on blood copper enzyme activities and parameters
related to cardiovascular health Metabolism Doi:10.1016/j.metabol.2012.02.002.&lt;/span&gt;&lt;/div&gt;
&lt;div style=&quot;text-align: left;&quot;&gt;
&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;[4] M Basaki, M Saeb, S
Nazifi, HA Shamsaei (2012) Zinc, Copper, Iron, and Chromium Concentrations in
Young Patients with Type 2 Diabetes Mellitus Biol Trace Elem Res
Doi:10.1007/s12011-012-9360-6.&lt;/span&gt;&lt;/div&gt;
&lt;div style=&quot;text-align: left;&quot;&gt;
&lt;span style=&quot;font-family: &amp;quot;Times New Roman&amp;quot;,&amp;quot;serif&amp;quot;;&quot;&gt;[5] Ammerman CB, Baker DH. Bioavailability
of Nutrients for Animals: Amino Acids, Minerals, Vitamins. Chapter 7. Copper Bioavailability.
Pp. 127-156. &lt;a href=&quot;http://books.google.com/books?hl=en&amp;amp;lr=&amp;amp;id=iWszTfQOpYAC&amp;amp;oi=fnd&amp;amp;pg=PA127&amp;amp;dq=copper+glycinate+or+copper+citrate&amp;amp;ots=Yc0qj5F9Ib&amp;amp;sig=tDS7-StZxxfOMD4QCvFnPQtSwZw#v=onepage&amp;amp;q&amp;amp;f=false&quot;&gt;Link&lt;/a&gt;.
&lt;/span&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
&lt;br /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://thepillarsofhealth.blogspot.com/feeds/9108749036742414709/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://thepillarsofhealth.blogspot.com/2012/04/why-im-fan-of-copper.html#comment-form' title='8 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/9108749036742414709'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/9108749036742414709'/><link rel='alternate' type='text/html' href='http://thepillarsofhealth.blogspot.com/2012/04/why-im-fan-of-copper.html' title='Why I&#39;m a Fan of Copper'/><author><name>Dr Dhia Aldoori</name><uri>http://www.blogger.com/profile/12785445082984259058</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='23' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgIcbY6lOf-A2OAQZ3CCF-V44BF68CUZ1wYcXS06NXVQS-lTFiik3VkOYsT0dmfX2RcYB8yuWeKbUAP5w5AeDWHc1bdI-0eQEt4lr6yM4tplO9dgbQ9nT74rRU6KPLeXw/s149/Cropped+PA307202'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEid6jw8VjC3tlN3HLXOfcc2P9Lm-8O2ehU0bQtwlramirOBOerHErRXGvVIcv7W7FUgXu6MAcoOdjPRBkwjhaYuIHqYgMdvmtBY33suYYJeWyXzl6jrDzLza5dxKy43XPBfUJ5xEkDwgHLC/s72-c/Picture1.jpg" height="72" width="72"/><thr:total>8</thr:total></entry><entry><id>tag:blogger.com,1999:blog-7196398195634872986.post-5844323430055760864</id><published>2012-01-02T21:31:00.000-05:00</published><updated>2012-01-02T21:31:20.059-05:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Book Contents"/><title type='text'>Chapter 10: Depression</title><content type='html'>&lt;span style=&quot;font-family: arial; font-style: italic;&quot;&gt;Opinion: It is time to relegate Freudian theories to the museum and to realize that emotions, feelings, mood and thinking are results of organic processes in the body and brain interacting with the environment. Healthy organic processes can handle bad memories.&lt;/span&gt;&lt;br /&gt;
&lt;br /&gt;
We have repeatedly heard that depression is due to an imbalance of chemicals in the brain without specification of those chemicals and why they even became imbalanced. I will outline to you what I think is amiss and how to prevent and alleviate the condition of depression.&lt;br /&gt;
By not following The Pillars described in previous chapters, we run the risk of not having certain chemicals in our brains in sufficient amounts to function correctly. Specifically these chemical deficiencies are those, which are responsible for thinking, memory, feeling happy, libido, good sleeping and just overall energy. To name the main players I will mention serotonin, endorphins, TRH, GABA, adrenaline and thyroxin. Cortisol is also a player but I think that in depression it gets produced in a chaotic excess pattern more than that it is in a deficient state. So depression can ensue by not having good nutrition (vitamins included), not having enough physical activity, not sleeping regularly and not avoiding harmful substances, or a combination in varying degrees of some or all of the above.&lt;br /&gt;
Stress is another player that I would like to talk a little about. If a person is healthy and gets exposed to severe acute emotional stress then their reserves of the chemicals mentioned above will be drawn upon and they will be able to withstand the onslaught and not develop depression. But, if the stress is long enough, the reserves will be depleted and the depression syndrome will develop. On the other hand an unhealthy person can develop depression even without emotional stresses.&lt;br /&gt;
Another factor is that people who have abused their bodies with harmful substances which shut down the body’s own “machinery” for producing the chemicals above, will be much more likely to develop depression. An example of this is people who have been addicted to narcotics will have deconditioned endorphin-producing tissue. This will of course predispose them to depression but the degree of predisposition will vary with how much and how long they were addicted. Alcohol will hurt the body in a similar way. In general my advice for curing the common form of depression is to apply The Pillars Of Health judiciously and use antidepressant medicines temporarily as a helping tool. Once reasonable improvement has occurred then the antidepressants may be weaned off.&lt;br /&gt;
Supplements of 5-HTP, and tyrosine are beneficial in this context and will assist above curing process and assist the onboard antidepressant by supplying the building blocks for serotonin in the instance of 5-HTP, and adrenaline and noradrenaline in the instance of tyrosine. This must be done under your doctor’s supervision.&lt;br /&gt;
&lt;br /&gt;
&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;w:WordDocument&gt;   &lt;w:View&gt;Normal&lt;/w:View&gt;   &lt;w:Zoom&gt;0&lt;/w:Zoom&gt;   &lt;w:TrackMoves/&gt;   &lt;w:TrackFormatting/&gt;   &lt;w:PunctuationKerning/&gt;   &lt;w:ValidateAgainstSchemas/&gt;   &lt;w:SaveIfXMLInvalid&gt;false&lt;/w:SaveIfXMLInvalid&gt;   &lt;w:IgnoreMixedContent&gt;false&lt;/w:IgnoreMixedContent&gt;   &lt;w:AlwaysShowPlaceholderText&gt;false&lt;/w:AlwaysShowPlaceholderText&gt;   &lt;w:DoNotPromoteQF/&gt;   &lt;w:LidThemeOther&gt;EN-US&lt;/w:LidThemeOther&gt;   &lt;w:LidThemeAsian&gt;X-NONE&lt;/w:LidThemeAsian&gt;   &lt;w:LidThemeComplexScript&gt;AR-SA&lt;/w:LidThemeComplexScript&gt;   &lt;w:Compatibility&gt;    &lt;w:BreakWrappedTables/&gt;    &lt;w:SnapToGridInCell/&gt;    &lt;w:WrapTextWithPunct/&gt;    &lt;w:UseAsianBreakRules/&gt;    &lt;w:DontGrowAutofit/&gt;    &lt;w:SplitPgBreakAndParaMark/&gt;    &lt;w:DontVertAlignCellWithSp/&gt;    &lt;w:DontBreakConstrainedForcedTables/&gt;    &lt;w:DontVertAlignInTxbx/&gt;    &lt;w:Word11KerningPairs/&gt;    &lt;w:CachedColBalance/&gt;   &lt;/w:Compatibility&gt;   &lt;w:BrowserLevel&gt;MicrosoftInternetExplorer4&lt;/w:BrowserLevel&gt;   &lt;m:mathPr&gt;    &lt;m:mathFont m:val=&quot;Cambria Math&quot;/&gt;    &lt;m:brkBin m:val=&quot;before&quot;/&gt;    &lt;m:brkBinSub m:val=&quot;&amp;#45;-&quot;/&gt;    &lt;m:smallFrac m:val=&quot;off&quot;/&gt;    &lt;m:dispDef/&gt;    &lt;m:lMargin m:val=&quot;0&quot;/&gt;    &lt;m:rMargin m:val=&quot;0&quot;/&gt;    &lt;m:defJc m:val=&quot;centerGroup&quot;/&gt;    &lt;m:wrapIndent m:val=&quot;1440&quot;/&gt;    &lt;m:intLim m:val=&quot;subSup&quot;/&gt;    &lt;m:naryLim m:val=&quot;undOvr&quot;/&gt;   &lt;/m:mathPr&gt;&lt;/w:WordDocument&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;w:LatentStyles DefLockedState=&quot;false&quot; DefUnhideWhenUsed=&quot;true&quot;
  DefSemiHidden=&quot;true&quot; DefQFormat=&quot;false&quot; DefPriority=&quot;99&quot;
  LatentStyleCount=&quot;267&quot;&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;0&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Normal&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;heading 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 7&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 8&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 9&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 7&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 8&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 9&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;35&quot; QFormat=&quot;true&quot; Name=&quot;caption&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;10&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Title&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;1&quot; Name=&quot;Default Paragraph Font&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;11&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Subtitle&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;22&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Strong&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;20&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Emphasis&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;59&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Table Grid&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; UnhideWhenUsed=&quot;false&quot; Name=&quot;Placeholder Text&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;1&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;No Spacing&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; UnhideWhenUsed=&quot;false&quot; Name=&quot;Revision&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;34&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;List Paragraph&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;29&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Quote&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;30&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Intense Quote&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;19&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Subtle Emphasis&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;21&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Intense Emphasis&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;31&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Subtle Reference&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;32&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Intense Reference&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;33&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Book Title&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;37&quot; Name=&quot;Bibliography&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; QFormat=&quot;true&quot; Name=&quot;TOC Heading&quot;/&gt;  &lt;/w:LatentStyles&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 10]&gt; &lt;style&gt;
 /* Style Definitions */
 table.MsoNormalTable
 {mso-style-name:&quot;Table Normal&quot;;
 mso-tstyle-rowband-size:0;
 mso-tstyle-colband-size:0;
 mso-style-noshow:yes;
 mso-style-priority:99;
 mso-style-qformat:yes;
 mso-style-parent:&quot;&quot;;
 mso-padding-alt:0in 5.4pt 0in 5.4pt;
 mso-para-margin-top:0in;
 mso-para-margin-right:0in;
 mso-para-margin-bottom:10.0pt;
 mso-para-margin-left:0in;
 line-height:115%;
 mso-pagination:widow-orphan;
 font-size:11.0pt;
 font-family:&quot;Calibri&quot;,&quot;sans-serif&quot;;
 mso-ascii-font-family:Calibri;
 mso-ascii-theme-font:minor-latin;
 mso-fareast-font-family:&quot;Times New Roman&quot;;
 mso-fareast-theme-font:minor-fareast;
 mso-hansi-font-family:Calibri;
 mso-hansi-theme-font:minor-latin;
 mso-bidi-font-family:Arial;
 mso-bidi-theme-font:minor-bidi;}
&lt;/style&gt; &lt;![endif]--&gt;  &lt;br /&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;color: #b45f06;&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;Does light or sunlight play a role in depression?&lt;/span&gt;&lt;/div&gt;&lt;span style=&quot;color: #b45f06; font-size: small;&quot;&gt;  &lt;/span&gt;&lt;div class=&quot;MsoNormal&quot; style=&quot;color: #b45f06;&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;Light, especially sunlight definitely plays a role and this becomes most evident in the condition of seasonal affective disorder (SAD). The importance of light as a corrective treatment in SAD, with results superior to placebo has been established.[1]&lt;/span&gt;&lt;/div&gt;&lt;span style=&quot;color: #b45f06; font-size: small;&quot;&gt;  &lt;/span&gt;&lt;div class=&quot;MsoNormal&quot; style=&quot;color: #b45f06;&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;What appears to happen in SAD, is production of the neurotransmitter serotonin is disrupted. It has been seen that the turnover (production and metabolism) of serotonin by the brain was lowest in winter, and more significantly the rate of production of serotonin by the brain was directly related to the prevailing duration of bright sunlight. The production rose rapidly with increased light intensity.[2] In a situation of lower production of brain serotonin then we can anticipate the presence of depressive symptoms of tiredness, dejectedness, appetite changes (possibly anorexia or maybe increased desire for carbohydrates) and so on. &lt;/span&gt;&lt;/div&gt;&lt;span style=&quot;color: #b45f06; font-size: small;&quot;&gt;  &lt;/span&gt;&lt;div class=&quot;MsoNormal&quot; style=&quot;color: #b45f06;&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;I don&#39;t believe vitamin D plays a major role in SAD, although I would anticipate it may have a minor one, by virtue of its importance in calcium and phosphate absorption. It has been seen to have a positive impact on depression.[3] This stance should not be interpreted as belittling the role of vitamin D in health as I am a big proponent of its supplementation into our diets.&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;MsoNormal&quot; style=&quot;color: #b45f06;&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;[Rev.1/2/2012]&lt;/span&gt;&lt;span style=&quot;font-size: small;&quot;&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style=&quot;border-bottom: solid windowtext 1.5pt; border: none; mso-element: para-border-div; padding: 0in 0in 1.0pt 0in;&quot;&gt;  &lt;div class=&quot;MsoNormal&quot; style=&quot;border: none; mso-border-bottom-alt: solid windowtext 1.5pt; mso-padding-alt: 0in 0in 1.0pt 0in; padding: 0in;&quot;&gt;&lt;br /&gt;
&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;MsoNormal&quot;&gt;References:&lt;/div&gt;&lt;div class=&quot;MsoNormal&quot;&gt;[1] B Byrne, GC Brainard (2008) Seasonal Affective Disorder and Light Therapy Sleep Medicine Clinics 3: 307 - 315. Doi:10.1016/j.jsmc.2008.01.012.&lt;/div&gt;&lt;div class=&quot;MsoNormal&quot;&gt;[2] G Lambert, C Reid, D Kaye, G Jennings, M Esler (2002) Effect of sunlight and season on serotonin turnover in the brain The Lancet 360: 1840 - 1842. Doi:10.1016/S0140-6736(02)11737-5. &lt;/div&gt;&lt;div class=&quot;MsoNormal&quot;&gt;[3] Women&#39;s mental health: depression and anxiety. Nursing Clinics of North America - Volume 44, Issue 3 (September 2009)&lt;/div&gt;&lt;div class=&quot;MsoNormal&quot;&gt;&lt;br /&gt;
&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://thepillarsofhealth.blogspot.com/feeds/5844323430055760864/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://thepillarsofhealth.blogspot.com/2008/04/chapter-10-depression.html#comment-form' title='3 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/5844323430055760864'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/5844323430055760864'/><link rel='alternate' type='text/html' href='http://thepillarsofhealth.blogspot.com/2008/04/chapter-10-depression.html' title='Chapter 10: Depression'/><author><name>Dr Dhia Aldoori</name><uri>http://www.blogger.com/profile/12785445082984259058</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='23' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgIcbY6lOf-A2OAQZ3CCF-V44BF68CUZ1wYcXS06NXVQS-lTFiik3VkOYsT0dmfX2RcYB8yuWeKbUAP5w5AeDWHc1bdI-0eQEt4lr6yM4tplO9dgbQ9nT74rRU6KPLeXw/s149/Cropped+PA307202'/></author><thr:total>3</thr:total></entry><entry><id>tag:blogger.com,1999:blog-7196398195634872986.post-5263272591361994735</id><published>2011-12-22T09:17:00.052-05:00</published><updated>2016-05-17T11:36:31.875-04:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Coronary Artery disease"/><category scheme="http://www.blogger.com/atom/ns#" term="HDL"/><category scheme="http://www.blogger.com/atom/ns#" term="heart attack"/><category scheme="http://www.blogger.com/atom/ns#" term="niacin"/><title type='text'>How to Raise Your Cardioprotective HDL [Rev. 12-22-11, 04-18-12, 05-17-16]</title><content type='html'>&lt;span style=&quot;font-size: 8pt; line-height: 150%;&quot;&gt;&lt;/span&gt;  &lt;br /&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: 150%; text-align: justify;&quot;&gt;
&lt;div style=&quot;color: #990000;&quot;&gt;
&lt;i&gt;&lt;span style=&quot;font-size: xx-small;&quot;&gt;Note: Revisions or additions are in red&amp;nbsp;&lt;/span&gt;&lt;/i&gt;&lt;span style=&quot;color: #990000; font-size: small;&quot;&gt; &lt;/span&gt;&lt;i&gt;&lt;span style=&quot;font-size: xx-small;&quot;&gt;font.&lt;/span&gt;&lt;/i&gt;&lt;/div&gt;
&lt;span style=&quot;font-size: small;&quot;&gt;What is HDL?&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: 150%; text-align: justify;&quot;&gt;
&lt;span style=&quot;font-family: &amp;quot;times new roman&amp;quot; , &amp;quot;serif&amp;quot;; font-size: small;&quot;&gt;HDL stands for high density lipoprotein and its importance in being a key player in preventing atherosclerosis (artery clogging) is more and more evident&lt;/span&gt;&lt;span style=&quot;font-size: small;&quot;&gt;.[1],&lt;/span&gt;&lt;span style=&quot;color: #990000; font-size: small;&quot;&gt;[16]&lt;/span&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;span style=&quot;color: #990000;&quot;&gt; &lt;/span&gt;It has even been seen that when LDL, (the ‘bad&#39; &lt;span style=&quot;color: #990000;&quot;&gt;or &#39;lousy&#39;&lt;/span&gt; cholesterol), is very low, it is the HDL which is the deciding parameter on whether or not heart attacks (and other events) occur.[2] I, for one, am very insistent with my patients in raising this factor. &lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: 150%; text-align: justify;&quot;&gt;
&lt;span style=&quot;font-size: small;&quot;&gt;How does it work?&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: 150%; text-align: justify;&quot;&gt;
&lt;span style=&quot;font-size: small;&quot;&gt;HDL promotes the mobilization and clearance of excess cholesterol via the series of reactions collectively termed ‘‘reverse cholesterol transport.’’[3] This is where cholesterol in the wall of the artery (and elsewhere) is removed before it is incorporated into the wall (or elsewhere) &lt;u&gt;pathologically&lt;/u&gt; and irreversibly &lt;span style=&quot;color: #990000;&quot;&gt;(it is a normal/natural constituent of cell structures and substances)&lt;/span&gt;. Another mechanism cited is that HDL possesses many antioxidant capabilities, and thereby pre-empting the oxidation reactions inherent in development of atherosclerosis.[3] Another mechanism is HDL stimulates endothelial nitric oxide production and thence increases vasodilatation (opening up of blood vessels) and heart muscle blood flow. HDL also significantly impacts the capacity of inflammatory white blood cells to enter and take up residence in the sub-endothelial spaces of arteries.[4][5] This last factor is a probable player in removal of cholesterol molecules by engulfing them and removing them to safer dispositions. &lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: 150%; text-align: justify;&quot;&gt;
&lt;span style=&quot;font-size: small;&quot;&gt;My personal conviction is that the first phenomenon of reverse cholesterol transport is the most important one. There are other described mechanisms outlined in the figure which I won&#39;t go into.[6]&lt;/span&gt;&lt;br /&gt;
&lt;table align=&quot;center&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; class=&quot;tr-caption-container&quot; style=&quot;margin-left: auto; margin-right: auto; text-align: center;&quot;&gt;&lt;tbody&gt;
&lt;tr&gt;&lt;td style=&quot;text-align: center;&quot;&gt;&lt;a href=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgs4P4QTlqT1UCgbhbl2LZ9OL2QHN9U5F651JI6rB__u_g9N61OfaVtPPEsxzTmVRjn-tePXIW0ti_e9dLBeDpNLDZwdJ1Nvv16s8WZLFOMwn4jEVf_GwnAa0auTDHe_6p4dPFYUJPxu8Se/s1600/HDL+anti-atherogenic+action.JPG&quot; imageanchor=&quot;1&quot; style=&quot;margin-left: auto; margin-right: auto;&quot;&gt;&lt;img border=&quot;0&quot; height=&quot;400&quot; src=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgs4P4QTlqT1UCgbhbl2LZ9OL2QHN9U5F651JI6rB__u_g9N61OfaVtPPEsxzTmVRjn-tePXIW0ti_e9dLBeDpNLDZwdJ1Nvv16s8WZLFOMwn4jEVf_GwnAa0auTDHe_6p4dPFYUJPxu8Se/s400/HDL+anti-atherogenic+action.JPG&quot; width=&quot;388&quot; /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;tr-caption&quot; style=&quot;text-align: center;&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;times new roman&amp;quot; , &amp;quot;serif&amp;quot;; font-size: 12.0pt;&quot;&gt;&lt;span style=&quot;color: red;&quot;&gt;Conceptually from Figure 1 in
reference [6]&lt;/span&gt;&lt;/span&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
&lt;span style=&quot;font-size: small;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: 150%; text-align: justify;&quot;&gt;
&lt;span style=&quot;font-size: small;&quot;&gt;The actual steps to take for increasing HDL are as follows:&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;line-height: 150%; text-align: justify;&quot;&gt;
&lt;span style=&quot;font-size: small;&quot;&gt;&lt;br /&gt;
&lt;/span&gt;&lt;/div&gt;
&lt;ul style=&quot;margin-top: 0in;&quot; type=&quot;disc&quot;&gt;
&lt;li class=&quot;MsoNormal&quot; style=&quot;line-height: 150%; text-align: justify;&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;Increase healthy oils intake - olive oil, fish oil, &lt;span style=&quot;color: #990000;&quot;&gt;coconut oil, &lt;/span&gt;butter and animal fats. Concerning the last two it applies to      organic products and not those which come from animals enhanced by bovine      growth hormones and whose products will contain supernatural levels of IGF      (such as present in the USA). This last may be the factor which increases      heart related events occurring in those consuming relatively high levels      of animal fats in some people in the USA.[7] I say this because there      is solid evidence that fat intake of animal origin is associated with      lower cardiac mortality compared to the USA as in the French population[8] and the Eskimos[9]. Their food products are      organic predominately. I &lt;/span&gt;&lt;span style=&quot;color: #990000; font-size: small;&quot;&gt;(personally),&lt;/span&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;span style=&quot;color: #990000;&quot;&gt; &lt;/span&gt;target a 45% calorie quota for fats and      oils of an overall calorie intake, and I emphasize the organic or natural      status of said&amp;nbsp; fats. &lt;/span&gt;&lt;span style=&quot;color: #990000; font-size: small;&quot;&gt;4&lt;/span&gt;&lt;span style=&quot;color: #990000; font-size: small;&quot;&gt;5%  is mid-way between the French and Eskimos.[8],[9] Here I would like to  add that I use calories as a practical measure only, as the scientific  basis of their translation into body energy is very shaky at this point in time (6-17-12, 5-17-16).&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;font-size: small;&quot;&gt; &lt;/span&gt;&lt;/li&gt;
&lt;li class=&quot;MsoNormal&quot; style=&quot;line-height: 150%; text-align: justify;&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;Increase low glycemic index foods – in other words      avoid sugars (sucrose and high fructose corn syrup), and foods containing      starch. This may also be described as a low-carbohydrate diet, with a      relatively high consumption of fat and protein.[10] &lt;/span&gt;&lt;/li&gt;
&lt;li class=&quot;MsoNormal&quot; style=&quot;line-height: 150%; text-align: justify;&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;span style=&quot;color: #990000;&quot;&gt;Fatty tissue &lt;/span&gt;weight loss if needed by controlling overall calorie      intake as follows: if the person is at a healthy body mass index (BMI)      then intake should be equal to calorie expenditure. If the BMI is high      resulting from high body fat then intake should be less than expenditure.      If the BMI is low then one should increase overall calorie intake. &lt;/span&gt;&lt;/li&gt;
&lt;li class=&quot;MsoNormal&quot; style=&quot;line-height: 150%; text-align: justify;&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;Engage in more aerobic exercise regularly, &lt;span style=&quot;color: #990000;&quot;&gt;daily&lt;/span&gt;.&lt;/span&gt;&lt;span style=&quot;color: #990000; font-size: small;&quot;&gt;[16]&lt;sup&gt; &lt;/sup&gt;&lt;/span&gt;&lt;/li&gt;
&lt;li class=&quot;MsoNormal&quot; style=&quot;line-height: 150%; text-align: justify;&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;Tobacco and smoking cessation if applicable.[11],&lt;/span&gt;&lt;span style=&quot;color: #990000; font-size: small;&quot;&gt;[16]&lt;/span&gt;&lt;/li&gt;
&lt;li class=&quot;MsoNormal&quot; style=&quot;line-height: 150%; text-align: justify;&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;Ensure intake of good quality protein (preferably      animal origin that hasn’t been treated with bovine growth hormone – BST).      Target a minimum of 1 gram per kilo body weight per day. This is because      protein is a building block for HDL. As mentioned previously HDL stands      for high density lipo&lt;b&gt;protein&lt;/b&gt;. &lt;/span&gt;&lt;/li&gt;
&lt;li class=&quot;MsoNormal&quot; style=&quot;line-height: 150%; text-align: justify;&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;With your physician’s consent and instruction – take niacin      500 – 2000 mg in the morning depending on how low your HDL is. This is also      known as nicotinic acid. Be ready for the &lt;b&gt;flushing&lt;/b&gt; and &lt;b&gt;itching&lt;/b&gt;.      This will occur 5 – 30 minutes after ingestion and happens in most people.      Lasts around 10 – 45 minutes. Use the &lt;b&gt;immediate&lt;/b&gt; release form. It is      worth the flush. This medicine (which is also a vitamin) has been shown to      decrease heart attack incidence. [6],[12],[13],[14],[15]&lt;/span&gt;&lt;/li&gt;
&lt;li class=&quot;MsoNormal&quot; style=&quot;line-height: 150%; text-align: justify;&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;Take vitamin C (ascorbic acid) as a supplement orally      to the tune of 250 mg daily.[11],&lt;/span&gt;&lt;span class=&quot;TF&quot; style=&quot;color: #990000; font-size: small;&quot;&gt;[17]&lt;/span&gt;&lt;/li&gt;
&lt;li class=&quot;MsoNormal&quot; style=&quot;line-height: 150%; text-align: justify;&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;Other agents are available that may raise HDL such as      statins &lt;/span&gt;&lt;span style=&quot;color: #990000;&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;(unusually)&lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;span style=&quot;color: #990000;&quot;&gt;, &lt;/span&gt;fibrates and more novel agents in the pipe line[3]. &lt;/span&gt;&lt;span style=&quot;color: #990000; font-size: small;&quot;&gt;That being said I am not too enthusiastic about all cholesterol ester transport protein inhibitors (CETP-I).&lt;/span&gt;&lt;span class=&quot;TF&quot; style=&quot;color: #990000; font-size: small;&quot;&gt;[18] My lack of enthusiasm here is because of their mechanism of action. They work by essentially preventing HDL from reaching its end-point target environment, and as such will increase the level in the blood, but won&#39;t remove LDL. Bad idea. It astounds me how much money is being/was spent on developing such a non-nonsensical drug.&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;color: orange;&quot;&gt;&lt;/span&gt;&lt;/li&gt;
&lt;li class=&quot;MsoNormal&quot; style=&quot;line-height: 150%; text-align: justify;&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;Of all current options,      nicotinic acid is not only the most potent agent for raising HDL-C but is      also effective in reducing key atherogenic lipid components including      triglyceride-rich lipoproteins (mainly very low-density lipoproteins      [VLDL] and VLDL remnants), LDL-C, and lipoprotein(a). The European      Consensus Panel recommends that the minimum target for HDL-C should be 40      mg/dL (1.03 mmol/L).[6] I prefer a target of 60      mg/dL or higher.&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;span style=&quot;font-size: small;&quot;&gt;&lt;u&gt;References&lt;/u&gt;:&lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;font-size: small;&quot;&gt;[1] P Natarajan, KK Ray, CP Cannon (2010) High-density lipoprotein and coronary heart disease: current and future therapies. J Am Coll Cardiol 55: 1283-1299. Doi:10.1016/j.jacc.2010.01.008. &lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;font-size: small;&quot;&gt;[2] P Barter, AM Gotto, JC LaRosa, J Maroni, M Szarek, SM Grundy et alHDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events. N Engl J Med 357: 1301-1310. &lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;font-size: small;&quot;&gt;[3] PT Peter (2009) Novel Therapies for Increasing Serum Levels of HDL. Endocrinology and metabolism clinics of North America 38: 151-170. &lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;font-size: small;&quot;&gt;[4] X Li (2000) Protective effect of high density lipoprotein on endothelium-dependent vasodilatation. Int J Cardiol 73: 231 &lt;last_page&gt; 236. Doi:10.1016/S0167-5273(00)00221-7. &lt;/last_page&gt;&lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;font-size: small;&quot;&gt;[5] B Levkau, S Hermann, G Theilmeier, M van der Giet, J Chun, O Schober et al (2004) High-Density Lipoprotein Stimulates Myocardial Perfusion In Vivo. Circulation 110: 3355-3359. Doi:10.1161/01.CIR.0000147827.43912.AE. &lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;font-size: small;&quot;&gt;[6] MJ Chapman, G Assmann, JC Fruchart, J Shepherd, C Sirtori, European Consensus Panel on HDL-C (2004) Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 20: 1253-1268. Doi:10.1185/030079904125004402. &lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;font-size: small;&quot;&gt;[7] TT Fung, RM van Dam, SE Hankinson, M Stampfer, WC Willett, FB Hu Low-Carbohydrate Diets and All-Cause and Cause-Specific Mortality. Annals of Internal Medicine 153: 289-298. Doi:10.1059/0003-4819-153-5-201009070-00003. &lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;font-size: small;&quot;&gt;[8] MH Criqui, BL Ringel (1994) Does diet or alcohol explain the French paradox? Lancet 344: 1719-1723. &lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;font-size: small;&quot;&gt;[9] H Bang, J Dyerberg, N Hjøorne (1976) The composition of food consumed by Greenland Eskimos. Acta Med Scand 200: 69-73. &lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;font-size: small;&quot;&gt;[10] GD Foster, HR Wyatt, JO Hill, AP Makris, DL Rosenbaum, C Brill et al (2010) Weight and Metabolic Outcomes After 2 Years on a Low-Carbohydrate Versus Low-Fat Diet. Annals of Internal Medicine 153: 147-157. Doi:10.1059/0003-4819-153-3-201008030-00005. &lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;font-size: small;&quot;&gt;[11] J Hallfrisch, VN Singh, DC Muller, H Baldwin, ME Bannon, R Andres (1994) High plasma vitamin C associated with high plasma HDL- and HDL2 cholesterol. Am J Clin Nutr 60: 100-105. &lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;font-size: small;&quot;&gt;[12] PL Canner, KG Berge, NK Wenger, J Stamler, L Friedman, RJ Prineas et al (1986) Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. Journal of the American College of Cardiology 8: 1245-1255. &lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;font-size: small;&quot;&gt;[13] K. G. Berge1 Contact Information,P.L.Canner2 and Coronary Drug Project Research Group, (1) Mayo Clinic, 55905 Rochester, Minnesota,USA, (2) Maryland Medical Research Institute, Baltimore, Maryland,USA (1991) Coronary drug project: Experience with niacin. European Journal of Clinical Pharmacology: S49-S51; S49. &lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;font-size: small;&quot;&gt;[14] JB Segal, J Eng, LJ Tamariz, EB Bass (2007) Review of the Evidence on Diagnosis of Deep Venous Thrombosis and Pulmonary Embolism. Ann Fam Med 5: 63-73. Doi:10.1370/afm.648. &lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;font-size: small;&quot;&gt;[15] Clofibrate and niacin in coronary heart disease. (1975) JAMA 231: 360-381.&lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;font-size: small; line-height: 1;&quot;&gt;&lt;span style=&quot;color: orange;&quot;&gt;&lt;span style=&quot;color: #990000;&quot;&gt;[16]&lt;/span&gt; &lt;/span&gt;&lt;/span&gt;&lt;span class=&quot;TF&quot; style=&quot;font-size: small; line-height: 1;&quot;&gt;Anonymous Association of  High-Density Lipoprotein Cholesterol With Incident Cardiovascular Events  in Women, by Low-Density Lipoprotein Cholesterol and Apolipoprotein  B100 Levels . &lt;a href=&quot;http://annals.org/content/155/11/742.abstract&quot; target=&quot;_blank&quot;&gt;http://annals.org/content/155/11/742.abstract&lt;/a&gt;. Accessed 12/22/2011 2011.&amp;nbsp;&lt;/span&gt;&lt;span class=&quot;TF&quot; style=&quot;font-size: small;&quot;&gt;&lt;/span&gt;&lt;br /&gt;
&lt;div style=&quot;line-height: 1;&quot;&gt;
&lt;span class=&quot;TF&quot; style=&quot;font-size: small;&quot;&gt;&lt;span style=&quot;color: orange;&quot;&gt;&lt;span style=&quot;color: #990000;&quot;&gt;[17]&lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;color: #990000;&quot;&gt; &lt;/span&gt;&lt;/span&gt;Jacques, PF.  “Ascorbic acid, HDL, and total plasma cholesterol in the elderly.” &lt;cite&gt;Journal Of The American College Of Nutrition&lt;/cite&gt;, v.&amp;nbsp;6 issue&amp;nbsp;2, 1987, p. 169-174.&lt;br /&gt;
&lt;div style=&quot;line-height: 1;&quot;&gt;
&lt;span style=&quot;color: orange;&quot;&gt;&lt;span style=&quot;color: #990000;&quot;&gt;[18]&lt;/span&gt; &lt;/span&gt;&lt;span class=&quot;TF&quot;&gt;J Poss, M Bohm, U Laufs (2010) HDL and CETP in atherogenesis. Dtsch Med Wochenschr 135: 188-192. Doi:10.1055/s-0030-1247862. &lt;/span&gt;&lt;/div&gt;
&lt;br /&gt;
&lt;span class=&quot;TF&quot; style=&quot;font-size: small;&quot;&gt; &lt;/span&gt;&lt;/div&gt;
</content><link rel='replies' type='application/atom+xml' href='http://thepillarsofhealth.blogspot.com/feeds/5263272591361994735/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://thepillarsofhealth.blogspot.com/2010/09/how-to-raise-your-cardioprotective-hdl.html#comment-form' title='10 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/5263272591361994735'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/5263272591361994735'/><link rel='alternate' type='text/html' href='http://thepillarsofhealth.blogspot.com/2010/09/how-to-raise-your-cardioprotective-hdl.html' title='How to Raise Your Cardioprotective HDL [Rev. 12-22-11, 04-18-12, 05-17-16]'/><author><name>Dr Dhia Aldoori</name><uri>http://www.blogger.com/profile/12785445082984259058</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='23' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgIcbY6lOf-A2OAQZ3CCF-V44BF68CUZ1wYcXS06NXVQS-lTFiik3VkOYsT0dmfX2RcYB8yuWeKbUAP5w5AeDWHc1bdI-0eQEt4lr6yM4tplO9dgbQ9nT74rRU6KPLeXw/s149/Cropped+PA307202'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgs4P4QTlqT1UCgbhbl2LZ9OL2QHN9U5F651JI6rB__u_g9N61OfaVtPPEsxzTmVRjn-tePXIW0ti_e9dLBeDpNLDZwdJ1Nvv16s8WZLFOMwn4jEVf_GwnAa0auTDHe_6p4dPFYUJPxu8Se/s72-c/HDL+anti-atherogenic+action.JPG" height="72" width="72"/><thr:total>10</thr:total></entry><entry><id>tag:blogger.com,1999:blog-7196398195634872986.post-3909126186826200520</id><published>2011-11-24T19:25:00.000-05:00</published><updated>2011-11-24T19:25:48.744-05:00</updated><title type='text'>If You Eat Too Late At Night Does Your Body Repair Stop</title><content type='html'>&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;w:WordDocument&gt;   &lt;w:View&gt;Normal&lt;/w:View&gt;   &lt;w:Zoom&gt;0&lt;/w:Zoom&gt;   &lt;w:TrackMoves/&gt;   &lt;w:TrackFormatting/&gt;   &lt;w:PunctuationKerning/&gt;   &lt;w:ValidateAgainstSchemas/&gt;   &lt;w:SaveIfXMLInvalid&gt;false&lt;/w:SaveIfXMLInvalid&gt;   &lt;w:IgnoreMixedContent&gt;false&lt;/w:IgnoreMixedContent&gt;   &lt;w:AlwaysShowPlaceholderText&gt;false&lt;/w:AlwaysShowPlaceholderText&gt;   &lt;w:DoNotPromoteQF/&gt;   &lt;w:LidThemeOther&gt;EN-US&lt;/w:LidThemeOther&gt;   &lt;w:LidThemeAsian&gt;X-NONE&lt;/w:LidThemeAsian&gt;   &lt;w:LidThemeComplexScript&gt;AR-SA&lt;/w:LidThemeComplexScript&gt;   &lt;w:Compatibility&gt;    &lt;w:BreakWrappedTables/&gt;    &lt;w:SnapToGridInCell/&gt;    &lt;w:WrapTextWithPunct/&gt;    &lt;w:UseAsianBreakRules/&gt;    &lt;w:DontGrowAutofit/&gt;    &lt;w:SplitPgBreakAndParaMark/&gt;    &lt;w:DontVertAlignCellWithSp/&gt;    &lt;w:DontBreakConstrainedForcedTables/&gt;    &lt;w:DontVertAlignInTxbx/&gt;    &lt;w:Word11KerningPairs/&gt;    &lt;w:CachedColBalance/&gt;   &lt;/w:Compatibility&gt;   &lt;m:mathPr&gt;    &lt;m:mathFont m:val=&quot;Cambria Math&quot;/&gt;    &lt;m:brkBin m:val=&quot;before&quot;/&gt;    &lt;m:brkBinSub m:val=&quot;&amp;#45;-&quot;/&gt;    &lt;m:smallFrac m:val=&quot;off&quot;/&gt;    &lt;m:dispDef/&gt;    &lt;m:lMargin m:val=&quot;0&quot;/&gt;    &lt;m:rMargin m:val=&quot;0&quot;/&gt;    &lt;m:defJc m:val=&quot;centerGroup&quot;/&gt;    &lt;m:wrapIndent m:val=&quot;1440&quot;/&gt;    &lt;m:intLim m:val=&quot;subSup&quot;/&gt;    &lt;m:naryLim m:val=&quot;undOvr&quot;/&gt;   &lt;/m:mathPr&gt;&lt;/w:WordDocument&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;w:LatentStyles DefLockedState=&quot;false&quot; DefUnhideWhenUsed=&quot;true&quot;
  DefSemiHidden=&quot;true&quot; DefQFormat=&quot;false&quot; DefPriority=&quot;99&quot;
  LatentStyleCount=&quot;267&quot;&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;0&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Normal&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;heading 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 7&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 8&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 9&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 7&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 8&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 9&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;35&quot; QFormat=&quot;true&quot; Name=&quot;caption&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;10&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Title&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;1&quot; Name=&quot;Default Paragraph Font&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;11&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Subtitle&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;22&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Strong&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;20&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Emphasis&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;59&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Table Grid&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; UnhideWhenUsed=&quot;false&quot; Name=&quot;Placeholder Text&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;1&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;No Spacing&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; UnhideWhenUsed=&quot;false&quot; Name=&quot;Revision&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;34&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;List Paragraph&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;29&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Quote&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;30&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Intense Quote&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;19&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Subtle Emphasis&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;21&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Intense Emphasis&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;31&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Subtle Reference&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;32&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Intense Reference&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;33&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Book Title&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;37&quot; Name=&quot;Bibliography&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; QFormat=&quot;true&quot; Name=&quot;TOC Heading&quot;/&gt;  &lt;/w:LatentStyles&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 10]&gt; &lt;style&gt;
 /* Style Definitions */
 table.MsoNormalTable
 {mso-style-name:&quot;Table Normal&quot;;
 mso-tstyle-rowband-size:0;
 mso-tstyle-colband-size:0;
 mso-style-noshow:yes;
 mso-style-priority:99;
 mso-style-qformat:yes;
 mso-style-parent:&quot;&quot;;
 mso-padding-alt:0in 5.4pt 0in 5.4pt;
 mso-para-margin-top:0in;
 mso-para-margin-right:0in;
 mso-para-margin-bottom:10.0pt;
 mso-para-margin-left:0in;
 line-height:115%;
 mso-pagination:widow-orphan;
 font-size:11.0pt;
 font-family:&quot;Calibri&quot;,&quot;sans-serif&quot;;
 mso-ascii-font-family:Calibri;
 mso-ascii-theme-font:minor-latin;
 mso-fareast-font-family:&quot;Times New Roman&quot;;
 mso-fareast-theme-font:minor-fareast;
 mso-hansi-font-family:Calibri;
 mso-hansi-theme-font:minor-latin;
 mso-bidi-font-family:Arial;
 mso-bidi-theme-font:minor-bidi;}
&lt;/style&gt; &lt;![endif]--&gt;  &lt;br /&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;Arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10.0pt;&quot;&gt;My friend at &lt;a href=&quot;http://anti-aginggames.com/&quot; target=&quot;_blank&quot;&gt;Anti-Aging Games&lt;/a&gt;, Elizabeth Amini had a another question for me:&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;MsoNormal&quot;&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div class=&quot;MsoNormal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;Arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10.0pt;&quot;&gt;Is it true that your body repairs one organ at a time every hour at night and if you eat late, your body chooses to focus on digestion instead of repairs during that time period and whatever organ is supposed to be repaired isn&#39;t during that time? &amp;nbsp;It seems suspicious that the body works on an arbitrary time slot that humans sliced up the day by. &amp;nbsp;I&#39;ve heard it from both Eastern and Western doctors.&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;MsoNormal&quot;&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div class=&quot;MsoNormal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;Arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10.0pt;&quot;&gt;Answer to first part of question: &lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;MsoNormal&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;Arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10.0pt;&quot;&gt;The body in all its tissues (and its organ units) is in continual repair, night and day. The extent of repair and who is getting the most attention will vary with the extent of damage, exhaustion or use of that specific tissue or organ. All of the processes of repair will depend on the signals emanating from the tissues (organs) signaling the need. This will be in the form of chemicals (such as lactic acid or substance P for example), or neurologic signals. Other factors are the availability of the building blocks (such as amino acids), assisting substances (such as vitamin C), energy hormones (such as growth hormone), building hormones (again such as growth hormone), fuel for energy (fatty acids) and appropriate surrounding temperature. A major factor is whether or not that tissue is being involved in full scale repair or not is if said tissue is in use or not. When the tissue is active then the amount of repair is less and vice versa.&lt;/span&gt;&lt;/div&gt;&lt;div style=&quot;border-bottom: solid windowtext 1.5pt; border: none; mso-element: para-border-div; padding: 0in 0in 1.0pt 0in;&quot;&gt;  &lt;div class=&quot;MsoNormal&quot; style=&quot;border: none; mso-border-bottom-alt: solid windowtext 1.5pt; mso-padding-alt: 0in 0in 1.0pt 0in; padding: 0in;&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;Arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10.0pt;&quot;&gt;Since most tissues and organs are less active when a person is sleeping, then a large part of repair of all tissues will occur during the person’s sleep cycle. In addition, there is escalation of growth hormone secretion when the eyes are closed (especially in adults), which is a major player in repair. Therefore, sleep truly is ‘renovation time’.&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;MsoNormal&quot; style=&quot;border: none; mso-border-bottom-alt: solid windowtext 1.5pt; mso-padding-alt: 0in 0in 1.0pt 0in; padding: 0in;&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;Arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10.0pt;&quot;&gt;The premise that the ‘body repairs one organ at a time every hour at night’, to me is without scientific basis and I don&#39;t think that any one organ has a specific hour to be repaired in. It is a continuous process. &lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;MsoNormal&quot; style=&quot;border: none; mso-border-bottom-alt: solid windowtext 1.5pt; mso-padding-alt: 0in 0in 1.0pt 0in; padding: 0in;&quot;&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div class=&quot;MsoNormal&quot; style=&quot;border: none; mso-border-bottom-alt: solid windowtext 1.5pt; mso-padding-alt: 0in 0in 1.0pt 0in; padding: 0in;&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;Arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10.0pt;&quot;&gt;Answer to second part of question:&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;MsoNormal&quot; style=&quot;border: none; mso-border-bottom-alt: solid windowtext 1.5pt; mso-padding-alt: 0in 0in 1.0pt 0in; padding: 0in;&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;Arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10pt;&quot;&gt;By eating late the repair of the gastrointestinal tract is probably delayed because of it being busy with digestion and absorption. Some of the energy resources required for the digestion and absorption which would otherwise be dedicated to repair or replenishment may be diverted away from the repair arena. This would especially be true if the meal size is large. To what extent this occurs isn&#39;t known to me, but I seriously doubt that it is as absolute as described in the question. As such it is my conviction that it is healthier to have frequent small meals instead of large ones to have a continuous low drain on energy resources needed for repair, while at the same time having a continuous influx of building blocks and energy resources. This concept, along with exercise, is capitalized upon (knowingly or otherwise), by Bill Phillips, in his strategy for getting healthy in his book, Body-for-LIFE: 12 Weeks to Mental and Physical Strength (1999). &lt;/span&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;w:WordDocument&gt;   &lt;w:View&gt;Normal&lt;/w:View&gt;   &lt;w:Zoom&gt;0&lt;/w:Zoom&gt;   &lt;w:TrackMoves/&gt;   &lt;w:TrackFormatting/&gt;   &lt;w:PunctuationKerning/&gt;   &lt;w:ValidateAgainstSchemas/&gt;   &lt;w:SaveIfXMLInvalid&gt;false&lt;/w:SaveIfXMLInvalid&gt;   &lt;w:IgnoreMixedContent&gt;false&lt;/w:IgnoreMixedContent&gt;   &lt;w:AlwaysShowPlaceholderText&gt;false&lt;/w:AlwaysShowPlaceholderText&gt;   &lt;w:DoNotPromoteQF/&gt;   &lt;w:LidThemeOther&gt;EN-US&lt;/w:LidThemeOther&gt;   &lt;w:LidThemeAsian&gt;X-NONE&lt;/w:LidThemeAsian&gt;   &lt;w:LidThemeComplexScript&gt;AR-SA&lt;/w:LidThemeComplexScript&gt;   &lt;w:Compatibility&gt;    &lt;w:BreakWrappedTables/&gt;    &lt;w:SnapToGridInCell/&gt;    &lt;w:WrapTextWithPunct/&gt;    &lt;w:UseAsianBreakRules/&gt;    &lt;w:DontGrowAutofit/&gt;    &lt;w:SplitPgBreakAndParaMark/&gt;    &lt;w:DontVertAlignCellWithSp/&gt;    &lt;w:DontBreakConstrainedForcedTables/&gt;    &lt;w:DontVertAlignInTxbx/&gt;    &lt;w:Word11KerningPairs/&gt;    &lt;w:CachedColBalance/&gt;   &lt;/w:Compatibility&gt;   &lt;m:mathPr&gt;    &lt;m:mathFont m:val=&quot;Cambria Math&quot;/&gt;    &lt;m:brkBin m:val=&quot;before&quot;/&gt;    &lt;m:brkBinSub m:val=&quot;&amp;#45;-&quot;/&gt;    &lt;m:smallFrac m:val=&quot;off&quot;/&gt;    &lt;m:dispDef/&gt;    &lt;m:lMargin m:val=&quot;0&quot;/&gt;    &lt;m:rMargin m:val=&quot;0&quot;/&gt;    &lt;m:defJc m:val=&quot;centerGroup&quot;/&gt;    &lt;m:wrapIndent m:val=&quot;1440&quot;/&gt;    &lt;m:intLim m:val=&quot;subSup&quot;/&gt;    &lt;m:naryLim m:val=&quot;undOvr&quot;/&gt;   &lt;/m:mathPr&gt;&lt;/w:WordDocument&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;w:LatentStyles DefLockedState=&quot;false&quot; DefUnhideWhenUsed=&quot;true&quot;
  DefSemiHidden=&quot;true&quot; DefQFormat=&quot;false&quot; DefPriority=&quot;99&quot;
  LatentStyleCount=&quot;267&quot;&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;0&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Normal&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;heading 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 7&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 8&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 9&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 7&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 8&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 9&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;35&quot; QFormat=&quot;true&quot; Name=&quot;caption&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;10&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Title&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;1&quot; Name=&quot;Default Paragraph Font&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;11&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Subtitle&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;22&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Strong&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;20&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Emphasis&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;59&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Table Grid&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; UnhideWhenUsed=&quot;false&quot; Name=&quot;Placeholder Text&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;1&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;No Spacing&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; UnhideWhenUsed=&quot;false&quot; Name=&quot;Revision&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;34&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;List Paragraph&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;29&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Quote&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;30&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Intense Quote&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;19&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Subtle Emphasis&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;21&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Intense Emphasis&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;31&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Subtle Reference&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;32&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Intense Reference&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;33&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Book Title&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;37&quot; Name=&quot;Bibliography&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; QFormat=&quot;true&quot; Name=&quot;TOC Heading&quot;/&gt;  &lt;/w:LatentStyles&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 10]&gt; &lt;style&gt;
 /* Style Definitions */
 table.MsoNormalTable
 {mso-style-name:&quot;Table Normal&quot;;
 mso-tstyle-rowband-size:0;
 mso-tstyle-colband-size:0;
 mso-style-noshow:yes;
 mso-style-priority:99;
 mso-style-qformat:yes;
 mso-style-parent:&quot;&quot;;
 mso-padding-alt:0in 5.4pt 0in 5.4pt;
 mso-para-margin-top:0in;
 mso-para-margin-right:0in;
 mso-para-margin-bottom:10.0pt;
 mso-para-margin-left:0in;
 line-height:115%;
 mso-pagination:widow-orphan;
 font-size:11.0pt;
 font-family:&quot;Calibri&quot;,&quot;sans-serif&quot;;
 mso-ascii-font-family:Calibri;
 mso-ascii-theme-font:minor-latin;
 mso-fareast-font-family:&quot;Times New Roman&quot;;
 mso-fareast-theme-font:minor-fareast;
 mso-hansi-font-family:Calibri;
 mso-hansi-theme-font:minor-latin;
 mso-bidi-font-family:Arial;
 mso-bidi-theme-font:minor-bidi;}
&lt;/style&gt; &lt;![endif]--&gt;&lt;span style=&quot;font-family: &amp;quot;Arial&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 10.0pt; mso-ansi-language: EN-US; mso-bidi-language: AR-SA; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-fareast-theme-font: minor-latin;&quot;&gt;So I would say it is okay to eat late as long as the meal size is small.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://thepillarsofhealth.blogspot.com/feeds/3909126186826200520/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://thepillarsofhealth.blogspot.com/2011/11/if-you-eat-too-late-at-night-does-your.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/3909126186826200520'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/3909126186826200520'/><link rel='alternate' type='text/html' href='http://thepillarsofhealth.blogspot.com/2011/11/if-you-eat-too-late-at-night-does-your.html' title='If You Eat Too Late At Night Does Your Body Repair Stop'/><author><name>Dr Dhia Aldoori</name><uri>http://www.blogger.com/profile/12785445082984259058</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='23' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgIcbY6lOf-A2OAQZ3CCF-V44BF68CUZ1wYcXS06NXVQS-lTFiik3VkOYsT0dmfX2RcYB8yuWeKbUAP5w5AeDWHc1bdI-0eQEt4lr6yM4tplO9dgbQ9nT74rRU6KPLeXw/s149/Cropped+PA307202'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-7196398195634872986.post-2426633809070927895</id><published>2011-11-06T16:37:00.001-05:00</published><updated>2011-11-24T13:16:04.086-05:00</updated><title type='text'>Does Alkalinizing The Body Through Ingesting Food and Fluids That ‘Alkalinize’ The Body Have a Positive Impact on Health?</title><content type='html'>&lt;div style=&quot;text-align: justify;&quot;&gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
My friend at &lt;a href=&quot;http://anti-aginggames.com/&quot;&gt;Anti-Aging Games&lt;/a&gt;, Elizabeth Amini (Founder &amp;amp; CEO, Anti-Aging Games, LLC) had a question for me:&lt;br /&gt;
&lt;br /&gt;
Does alkalinizing the body through ingesting food and fluids that ‘alkalinize’ the body have a positive impact on health? &lt;br /&gt;
&lt;br /&gt;
Answer:&lt;br /&gt;
&lt;br /&gt;
I doubt it very much. The body’s pH (acidity/alkalinity index), and here referring to blood and tissue fluids, is tightly regulated by among other organ systems, the lungs and kidneys. These two systems do that in a very magnificent synchronized fashion maintaining this tight range through multiple redundant backup tactics. &lt;br /&gt;
The pH of blood should be 7.35 to 7.45 which is truly on the alkaline side, but this shouldn’t translate into drinking or eating alkaline is better for us. I believe this is trying to fine-tune things artificially too much to the exclusion of highly important nutrients such as healthy proteins.&lt;br /&gt;
Also in-taking a consistently alkaline fluid or solid would put a burden on the kidneys to counter balance excess alkalinity. It would also trend our breathing to be slower so as to retain more carbon dioxide, especially if the kidneys aren&#39;t getting sufficient water (whose pH by the way is 7.0).&lt;br /&gt;
In conclusion I would say: eat healthy protein sufficiently (not less than 70 grams per day for a healthy adult), eat healthy fats (hormone free, and non-synthetic) sufficiently to the tune of 40-45% of the conventionally measured calorie intake, unlimited vegetables (preferably not genetically modified and also grown in fertile ground that hasn’t been exhausted of its minerals), and use fruits as a dessert. No refined sugars at all and keep refined carbohydrates (pasta, lasagna, breads, etc.) below 100 grams per day. Drink enough refined-sugar-free fluids to ensure a urine color that is very light yellow with a daily minimum of 3 urinary bladder full micturitions (urinations).&lt;br /&gt;
&lt;br /&gt;
The websites you had referred to are too unscientific in their presumptions.&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://thepillarsofhealth.blogspot.com/feeds/2426633809070927895/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://thepillarsofhealth.blogspot.com/2011/11/does-alkalinizing-body-through.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/2426633809070927895'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/2426633809070927895'/><link rel='alternate' type='text/html' href='http://thepillarsofhealth.blogspot.com/2011/11/does-alkalinizing-body-through.html' title='Does Alkalinizing The Body Through Ingesting Food and Fluids That ‘Alkalinize’ The Body Have a Positive Impact on Health?'/><author><name>Dr Dhia Aldoori</name><uri>http://www.blogger.com/profile/12785445082984259058</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='23' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgIcbY6lOf-A2OAQZ3CCF-V44BF68CUZ1wYcXS06NXVQS-lTFiik3VkOYsT0dmfX2RcYB8yuWeKbUAP5w5AeDWHc1bdI-0eQEt4lr6yM4tplO9dgbQ9nT74rRU6KPLeXw/s149/Cropped+PA307202'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-7196398195634872986.post-36412489317949919</id><published>2011-11-06T15:06:00.000-05:00</published><updated>2011-11-06T15:06:25.629-05:00</updated><title type='text'>How much fat to eat to absorb vitamin D and how many total calories per day to lose weight. (To Anonymous)</title><content type='html'>&lt;span id=&quot;internal-source-marker_0.41588019753344607&quot; style=&quot;background-color: transparent; color: black; font-family: Times New Roman; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline;&quot;&gt;In  reply to your lovely questions I think it necessary to understand the  premise of calorie (calorie=Kilocalorie) content of food: food calorie  content is usually assessed by totaling the calories of the individual  nutrients of a given food. For example the calorie production of protein  is assessed to be 4 calories per gram, and that of fat as 9 calories  per gram, and carbohydrates 4 calories per gram.[&lt;/span&gt;&lt;a href=&quot;http://en.wikipedia.org/wiki/Food_energy&quot;&gt;&lt;span style=&quot;background-color: transparent; color: #000099; font-family: Times New Roman; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: underline; vertical-align: baseline;&quot;&gt;Food Energy [1]&lt;/span&gt;&lt;/a&gt;&lt;span style=&quot;background-color: transparent; color: black; font-family: Times New Roman; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline;&quot;&gt;] These estimates for the individual food nutrients are done by direct calorimetry as follows:&amp;nbsp;&lt;/span&gt;&lt;br /&gt;
&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; class=&quot;tr-caption-container&quot; style=&quot;float: left; text-align: left;&quot;&gt;&lt;tbody&gt;
&lt;tr&gt;&lt;td style=&quot;text-align: center;&quot;&gt;&lt;img alt=&quot;&quot; height=&quot;165&quot; src=&quot;data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAecAAADKCAIAAAAQKh9fAAAgAElEQVR4nOy951dbV942/PwnBmfypq6ZeLKSOLnj2M6Kg22aC8YmGIzBmGaNDMHWA5YBWUh00REgehESvffeu+gdREeiq/ez3w8bHY4pMvh2ZpJnuBYf0NEpW+ecfe29f+X6/R9whjOc4Qxn+Ovg//ynG3CGM5zhDGc4Bc5Y+wxnOMMZ/ko4Y+0znOEMZ/gr4Yy1z3CGM5zhr4Qz1j7DGc5whr8Szlj7DGc4wxn+Sjhj7TOc4Qxn+CvhjLXPcIYznOGvhDPWPsMZznCGvxLOWPsMZzjDGf5KOGPt00Gt0Wg0yH+6FX9qqDUIgvz33qI/5xui1mg0Go2OHVRq9TsfmlqjeY8Hq1Kr/wvfBwRBVGr1H3TyU7A2b0u4sLaN3SKTK6cW+Aql6kO36iB2RdLhmVWl6g+5C3KFsmt4vr5nenR27Z07u9PyyYyK97jK2NxaffekSq2r55wc/G1RReuYQCR7j2NVag13ZXNoepUzscSZWBqYWl3fFn2QVgEAJFKFKT62vHX0tAdu7Igm5/lHPmIEAVPzvJX13Q/RwD8cT32zwjMbAAAqlbq0ecSFyrYlZTlRmI290zqOQhCwzN8ZmVlDH8ri233tfwk7nwx6dvNx3ypVKjN3Rl4tR/dJXKjs4LTa0176sVd6XG7LaY/690OjQRp6p4anVz7I2Sbn+Ub4uMl5/gc52wGcgrXJ8ZVuwXnYLQOTywbO0bNLGx+6VQfh5Ms8f8uv4vRc8E60cmbNCcm/OIQ/Imb8bB/hRGEt8nZ07H/dJdryVfJ7XIgQUfjVfT+RVP6eDX0blW1j+kZv+ieW3uPYhbXtK3ZhJs/jrV6lWHgkPyCkljQNf5BWAQAEIqmeoU9KUedpD/w9JO/8rYDA5OrDX+XWcvRN/axepXyoMe8PxXdWgfiAHADA1q74ZVhhZnl3K2f2TXzZhQd+xU1Dxx0lliruusX/6hRtTUyz8Eh+4JEal9f6AVt1wcL/Ja3guG8VStW5m16RWY26T3LJJsTBl3naS39l7ucRUXzaoz4gVtZ3J+f5715JqDX/tPB3Dcp7x37HYHFte3phHf3YO7Zw3tSvd2zh/c6mG6dgbVJcxYGfxJlY+jew9hJv2whHN3CJevgq5cOeuW9s8RvLgIDU2vVtoUKpWlzb9k+u7hvVdaPvuDHsSJnvca0tgWSZr2s8OBWkcuX86tb7LT4muDwDx6iekXmZXCmVK8VS+QdcxEik8o+MvDPKuk91FIIgDr6sey+SrtqHL/HfmlNL5coHhCQTt4RHXulyxR++qvvf44p9OOTHA9YE99CC/7GhqY8xnuyKpCb42ML6QfShfNgf++Nj2uvokuO+VShVn932jc15x4zYwDEKDkinwvfWIV70stMe9QGRWNB+wmYv83e2BJL3u0o0qwk7LnImlvQMfQYml9/vbLpxCtb2ZVT+HpKP3TIwuXzDOQbL2tsCSV33ZF4tp21gDuWC6YX1hdUtdJ9l/g5vU4h+5G0KVjcEOq5Lz27GBWT3jMxfsQubx5xHrlCNz/EQBPSPL5W1jG1rb/fQ1Ep+/UBF2xh/S3jMKQEAQCpXXrUPf3FoAgKNkiKJvJUzm1fLKW8dxT7Iw6zNXdksbR7JrxsYwqytRFL55DwfQZD2wbmq9nGFUi0Uy5b5O2rMbHFtQ1DRNpZfP3hgUdY/vpRbw6nrnpLIlcc1Xq5Qza9uybQde255Y1sgUSjVVR3jpc0jun/45Dz/hnPMxBzvyG/5W4Kq9vG82oGukfkD5kjepqCibSyvdqDn0MA2Mc/PreG0D3K3BZJPTEgoa+8IpVXt47m1nHEuT8dkB0EQezKTkddqT2aGZTZgvyppHrEgJKWVdFm9SsES2ejsWkH9YGnzCNZyIpUrO4a4+XUDpc0j6ztvmX327mrXpFimgFuWeTsLq/tWiPVt0dTCulqjAQAsrm3zt4RCsay0ebR/bBHdZ2qBX9gwVNw0vLC2hT35Mn+3oGGotmtSplBec4xwp73VTSCi2U2fmJJkxzzTXZH0lmtcbefEkd9yJpby6wfKWkaXDg38uyJpffdkXi2nhTN7wFa5yNvOrx+s756SyZWX7WjEyGMnvAdYWyCWNffP5NVyKtrGdkVSdLdfHSNf0PLVGqS2a7KoYWjhkA2Hu7JV3DRc2DA0g+EELGvL5MqGnqncWk7f+NJxAxiESq1p5czl1nA6h7lyzO8SS+VNvdN5tZzGvhmJ9lECAKYW+BKZQiiWlzaPVLbvNRsBYGZx3Z2Wf8ctvmtofmBi76K7Illj73RuDaeqfVwo2V/+rq7vbu6IAAAaBJnk8hVK1fq2qKhxqK57Unz8KlmDaCbnebiAXPOXid3D84OTywiCDEws6Rl6T8zzFnjbeXUDnUPcA6O4RoN0DnHzajn13VMSqeK4kx+J01lIPCKKsFtmljaMcPSZxb11wfjc2i3XODsS04nCMnuRZOOdtrEjAgC8iip+5JUO91Go1PcJiY6+WfCjWqO57ZaQXHzsglqt0TwgJLEqewEAl2xCYzC2ucl5/t/NKKEZ9bbeGdberO7heQBANLvZzD3BicJ6SmGbusbpMFWPza6du+ld331EP9nYEdmTmY7UbCcK6yEx/ZZb3LT2Nx5g7fy6gV8do5z9sp0orF+do6iJVZCXWzmzFx4ERLGaHnqmPCRmrG+LothNV5+GoyNZ79jiPXeGs1+OE4VliItNLGyH2xPy2+64MRwprKcUdkHD4HGN7xqe/+wOZXJ+j3nNCYlPSJnkuAonv5x7L5JM8LHc1a3jjp2c5xs+i5k6yuLWOcw1wtEdyCwnCsvkeRwuIEekfadbObM3nKOeUrKdKCyT5/FuIXli7atWWD942Y721JdtS8rCBeR8fpcKn9fahuAJifmEzHbyy3EPzT/MOCgQBLH1zsiu7suq6LtsR5Mp9qntPiGRll5f0Tp6n5CEsnZKcaepa5wzNduJmmOEo8N1qEAsc6ayn5LZThSWNTHDGE8fnV2F+ycXddxyjXOksJ5SsnNr+uHG5wG59wmJ6IVo6XVX7MLgA8L5Z5u/TPBLqrYkZqCr+5zqflPXOGcq28U/xxAX09g7Bbf3ji0YOEY99sl0oGTj/LMvPg4nRh/Bj24heYbPYo7zy0HWruuaPLBdrlCR4spvuyU4UVh2JOY1x8hijDlramHdzI1hS8pyorDuEVKsiKm8zb0JUNfI/DXHSFufrKdkNi4g51trGjn+WH8MlrXXNgQ23hmOVLYThfWbZ+o994Qlrc3QGE+/9XuST2y5i3/uQ2Lqt5YBbQOz6EkqWkdN8XEu/jnOftkGzpGl2nairC2SyN1D8m28MxwpbGcqa3hm9bj2iCRyt5A8sxfJjhSWBSE5ktUIR9Ml3s5vHkk23kwnCuu+R8p9QiL6nv9sH/GSVuAZXuTin2OMj7d6lbIjlAIAEvLarjnRv7UMeOrLfkErkMgUy+u71sQ0Z79cR98sc0LKA0ISb2vvphk4RpHiygAAUrnyolWgT2ypOy3f2S/HwIXuRGFhBwksNBokJrv5qkPMRetgRwrbM7JIrdEMT6/oG3r/Tst3prKd/LJ/fEwLSq1FiVsiU3hGllh5pTtRWLY+WY+80rd2xcfdjcM4BWuHZTR8axVyn5B8n5AI/4yfM360oUG3iUgiv2wXRowugQ3b2BGZ4OhesWUAgIbeqUt2tOX1HQDABJd33oj0g02wWCIHAEzN87+28B+aOtYDMDy9esU+FL43Iel15i8T1FpX+DiXp2fs+9gnc2V9V6VSqzVIafPwN5aB6OSLzKiw8c44zu1d0jR81T58+Sgr9vqOCO2Tag1iTkjyS6qCH7Gs3Te++NkdcmnLCPzImVj6+rfAyrZRAEBT37S+qf/vtPz1bZFSqYaN+adFACSFzV3xj49paaXd6Hku2dK4y5tyhcoIR+8c4sLt28cv1lr6Z/WM3oxpWckET//awr9jiAsAEIrlPztE6DDPTS+u/+oQlVc3MDS1zJlYGphchtMN3qbg698Cwpl7xs2V9d0rT8KjWU0AgNUNwQULf9Sdtbi2fdk2lJHXBgDgrmx+cY+aUtwJAFAoVRHMBn0TSnZ1HwAgpbjTmpgGDxFL5VLZsUsHyNrJhR0isfxn+zB0yjnO5Rk4RvG3RIX1g/cJiZC1G3unLjzwn9KOo6GZ9fcJiQqlCs464VIJQRBrYqoXvRQAIJTITfBxLf0zB+7qExLzhnMU2gYyo/LCA3/4gBzIzHM3vfPqBuQKpUyuAgD0jy9esPBHHQkpJZ0m+DipXClXqi7bhRHCC+H2woahv93yfY1hbYlM2T44F5xaY+AcjT7Zw4CsTc9uGZ5e4Uws9Y8vbu6KAQDhzMZvLAOX1vbeUkZ+20+2oasbuwAAiUzxs0PEC1oBnChsCyS33eJhS8QyBXaGm1vL+ZuJL+V4LzqWtXlbgiat41ShVJniY6NYTfDjLbe4CxbBDd1TAACVWo0LyLEmpsL+OLO08fVvgfU9e6NOcePQNYdwyERoSxp7p03wsfAOK5QqofhYX7pfUtX31iFwzrcjlHYMzSlVapVaY+oa70RhwSWFQCyzJqa5UNnwkG8sAw2co+FIwNsUXjD3p6XXw6+isprsSUyNNrRpibfdwpnVPh3FdefoxIK9OdNF62BCRCHc/rGpz31CIpyuTS2sf2pKytRp9wtKqcX5Z6Oj8tDUir4xGeefs7YhAACUNY/8zZiEEp1fYpUhjo6uIayJadSESh0nP4BTsHZoRsMPj0OfkrPQPwuPlEs2IdD60TYwe9U+HLtcza3lfP+IJhTLxFLFN5YBubX9AICsyt7H3hm/OESUNo8AADLKuh8QkpTHh8h4xZS5UPcm5sPTKxcwFD8+t6Zn6IO+KAAA16C830Pyd4QS3qZwWyDJru7XM3pznPklq7L3unP0xo6uIU6mUKo1GgffLBN8HNyCZW1aer01MRW7//OA3EfeGQCA5r5pPUOfEcxsgpJQ+Z1VIPSnVbaNXXOMnFna4G8J+VvC1fXd80ZecbmtCAJM8LGekUU6+BqibWDu3E3v8bm9lcSNZzFOFBb67VNyliEu5rhjZ5c2frKl3fdIcfJlOpBZzhTW2BwPAFDcNGzgHI1dCcZkN19zjFRrNAX1A0a4WOzqPjSj3sAlGkGQ3BqOyfM4dG0uVyhRu3Z5y8gPj0JbObPgXYCsHZfTAgB4HV2C01oh/RKr8IE5AICc6n5IzQAA75hSB9+sHaGUtynY2hVXto3qGftiHUEyuVKt0fwekv+LQwQAQK5Q3XFjvKQVbAneetaOviwTfCz60S+x6lvLvWHV1jvDEBeN3Tk4tdbqVcq2QMLfEm5si9oG5vSNfUdn16YW1q88CZ9b3kT3vGIXirVvdg5yv30YGMFsOGBUOQCBWHbLNc7keYILlW1PzrInMdsH59QazW+EpGgtaQIAxDLFT7a05KIOAEDPyMKVJ+FYM0Vx09DFRyFCiWxwcvmqffgib/+rH2yCT2vXlsoVao3GwiP5N489f5KBY9Qzv/3XrKV/5rIdDRotEwra77ol8DeF8P6MzKzqGb2p7hgHGNYeml75xjIwr46jOxBQoVSbv0xk5Lcd2D7O5V2xC8Ounht7p795GARnjRcs/PwxruzrztHogj6G3fSUnHX4QlK5UqXW3HKNe0Lac7Fesgl5FVUMtKydXNiB7vydZZCPTut8SFotDmM9h3bt4ek9Btjclejd9CltHgYAyBTKu27xsTkt2wIJb1MoEMmI0cX/MKeePGD0f2UhmVveNHq2ZyEpbBi8554owcynWvtn9I19ZxY3AAAvwwpex5QAAOxJzOLGoTdxFcToUgCAE4UVcnwskVKt/sUh4mVYQfvAbFPfVF3XxBW7iOC0Ovjt+BxPz9Cne4SL7u9MZf/qFPOElPmImP7EJ/Pei8QrdmHHsXZl+9j31iGoeecAukcWXKhsF/9cfEDOd49o5i8T4HYsa7+KLH4d9VZPeBNX8Q9zCgCguW/63E0v7vK+dQ/L2rm1nAsP/B55pdt6pz32Sn9ETP3RNhJaFbqG580JiabPGZFZTSLJsaa0A6x93Tka57/fnexJTFPXuOOOnZznX3eO5owvKZVquUKlUKrgcoSR3/bYKx1gelR+3YC+IUmuUCYUtD8lvRU8wKzoOXfTR4Mg9JwWJ0xcgRjjjZQpVBFZTdccIx95pTe9I+4NsfXOiMttBQC0D8z9/Z7fIm9HJJFftAqEPZ9d1XefkAgp9WVY4ZWnUU9ImY+IqXbeGfcJyT8+ps0ubwIAOBNL+MAcF/8cfFDuj7YRxrg9Uu4dW7AgJJm6MWgZDegUTwdrP/JKN3dPwLaQHF95yTbczif9sVe6rXeapWfKD49DJ+f5zX0zd9zisSGYV5+GY1m7Z3ThmmPkO2M04Vy7uHFIpVLLFUq5QoUgQCxV3HVPKNMu5iC+tw6G7qXy1tE7rvEC0f5L0j2yoG9M4a5s1nVN3XNniDHW0kun8Ua2Dcw6+bJcqNn/Csz5pyXN1jsDbjdwjHINykWPmpzn/82EBCMaI7IaLz6i2XpnPvZKt/XOsHqV8r1NGJzSoqytQZC00i4Dl2hzQmJRw9Bx1C0Uy267xZe3HAwYa+HMGuHo61v77ooJLk/f2BeuYC5Y+IWk16FfXXeOfqadhkezmuzffnsbeqaekrNc/HNwATn/sAh+5p+9d5feZu300i70kItWgTpMTACA4NRanPY8QMvag1N73si1TeG5G17lLSMAgG2BxAhHv/17op1P+iNi+hNSpvFzxgOPJPWJQ6Q+mDeyvGXEFB+LXfXUdE5csPCHnrGCusHrztFLvJ2Hnsn8LWFN57gFIXl9W2TmxugemT/uio29U1/e9f1XYB4uIPsZNds1KNfsRfJttwS4Uoas3TE0h+7/lJxFTqjc3BWvbghW1nd5m0LpMaYoAMDM0oaeoQ+7qu/wV4NTyzecYzLLe5bXd9e3RTY+GSbPj5hr+8SWu799Q7zopXfcGEDL2tghAcva7Kp+U9f4hdXttQ3ByvruyvquUCxHR1qVWlPdMXHvRdIz/2zZMYEEh1kbfUfBCVj7hnPM+CGLf1pJ9wPCW68Os7L3olWgWq3B2jogkos7f7ShIQAkF3XYeu1/pVCqPjL0wsaQrPB3g1Nrv7cKrmwfP65JWNZWqtR33eKTCjuKm4ZN8bEKpRq8zdpuwXkeEYWbO+LVjV34lKHBcWKeZ4ijpxR1LfF3N3bELlT2NcdI9BJqtaa2a9KckIwaKJ/4ZJpiWDsopeab3/ZZ28ydgW2hV0wZzj97c1e8ur67sr67tiGAnNjQM2WCj8Wu2H62D8N6I5d5O2GZDbtCKdAJyNo1HW95WaRypZk7I69uP4xardH84hgO48FrOyeMcHTssqy5b/rCff+tXXFz38wtt7gdwf5FL9mEnNAb2T2ycN05Oqe6f5m/y98W3nNPtPTcm2v/6hjpGrw/nRyYXP7JlgZDkmnp9Y+8Mza2RfCVXt0QiLRjxoEYki2BJKmw/ZINDbVLHIBIIr/tFl9Yf9Cp0zU8f905egUTYjQwufwPc+rUwjoA4IKFX1Dq/vwP2yOishodMXPt5r4ZA+fI4qbhlfVd/pbQCBdrf8xcOxXjb3snawel1OAPzbU5WpPa6oYAZe1dkdQEH5dV0buxLYLdf31bJD9N1ssHY+2Jef5Fq2DUeggAeBlWaOuTAVdDaxsCM/fEoJQa6Jbkb4vMXyZ4RRebv0ySHh8p8Sq6+BExFbuemuDy9G5613VNgKNY2z+p+oDJAgBw3HJMrdE88k43cKHzt/cjLvjbQt6mIKW48/7LfT/VI+/0Iy0kmRU9V+zC0IFKqdLcwNHj89sAAE29uli7f3zpsl3Y1IKuCPy+8cUfHgXzjlko6GbtJ6TMd7L2yPRBX1DnEPc7q8AxTGyJHSkTxti0DsxetAqewlghrIlp0OdW2z351X0/NCWkuX9G35iSVdFz4OQOvkwdcz0sawMAkos6fraPMHCOQpfJkLUhg8dkN997m1IhWJW9d93i0Y/P/NnQQoLF0NTy91bB0JnxklZw3XnPDKJUqi090y5aBx3H2hll3Ua46MPZbnPLm3+/S63p3BuQFla3vzQPxC5J1RpELJXrjpcAWtaubBt7+7YAFyr7GXV/Btc3vvitZeDwzAq89EXroNrO/bGQGFls9SoFADC9uP7lXd/mvhm0kZ/f8SfFlh93dSxrR7ObsSO0mTvjN48k+L8Rjn7HLQF1ykUwG647R8P+W946+otDuOAoU/WRkX+BKTUH5gEoNAhiTUzDTupFEoVareFtCn+ypeXXDaDbg9Jq77jFK1UacIi1DZwjsXPtx9poCHhp1HgCALjhHPNE26N1sPZ3lu9mbQfy/oxeB2trEMTOJ5Mc//7RkKdgbWJ0iTOGGgAAfeOLl21pkH0QBPGKLrnyJCK/bqB3bDEgpeYf5hTUpokgyBNSpr6JHxrX5Uxlnb8dhL3RB7C6sfulGaXg7SFXgyAGjlG4gGwAwNjc2vlb/i2c/XFimb/zow0NH5TbMcQdmFxOKGjPKOvRYS0a5/JMnicY/iuWntNS1THxOrrEEEfvGVnoG1u88MAvtaRrYHI5vbT7SzMqaiY2cI56oH2Jd4QSE3ycpWdKfc9U68DsY590Axc6zDOs7RzXN6Viefl1TOlnt8loDIlbSJ6BS0xp88jw9Ep562hQaq1QLBucWnYNym/um+kfX8IH5TwPyD0u77S5b0bf1G9kZs/E/5NtqK33/ntpTUzDTjMPYGxu7bJt6ODkQQ+wQqV2obINXKLLWka6RxaI0SUXLAKgaV6mUNmTmDdw9Iq20a7heUJE4XeWQXCStSOUXneJNnWNa+ydTi3psiamXbKLSi3pAgAEpNSEZtSPzfJKmoYMcTE1x4S1AQAQBLn/MjFC6wjlbQn0bnp9cdd3RztFzSjrNsbToWF9a1f8s33YU9/MtoG5wanllOLOpMIOAABnfOlriwBGfvvg1EpWZe/XD/yv2ocDAAYml11D8ht7pznjS7+H5D3zz4ZrtdGZ1a/MqX5JVeWto56RRSbPE647R8NL3HNPvO78lmNAKJYZ42Ifvkpp7pseml5hVvTG5rSoVGq1RuPom/Xj47CylpG8Oo6DL+vXZwwsazf3z9zExfWPLwKd2BFKf3WMLG0aObC9Z3ThgjmVzKjoHlkobhr6xSnanZaPTkTIjMqf7MJzazl944u09LovzajQzaNSaWy9M648iahoG82p4diTmNec43QETSuUqnM3vOH9r+2c+NoiIKuylzOxlFzY8YnJG3NtpM2vjpGf3/V/EVZQ3DicXNTxhRklVjvQypWqBx5Jd9wYtV0TQ9MrubWcCGYD9D9/edeXEFYIAEgp6fKJLR2cWqnvnrrlFq8jFau0efhjEx9qYlV995QXvdSLXgZd+uGZjRcf0bIqevrHl2JyWr6861vUuJe49DcTEpmx79C7Yhdm57PXIwrrBz+/S00v7a5oG1Wq1KXNI98+DCmoH+wbW2TktendeG1H2jMBXTCn/k7LBwCIpXI9IxIDk+j0dzMKJPTjkFne88U9v6zKvqr2MQRB+seXzt/y79WGja6s7+ob+xZpo8Ja+me+uu8XnFrbP77YO7YYllkPLYEnxClYm1nRC8MGUCysbXvRy1a1HkilSh2f3/bwVeoTMss1KG/07ciehu4pSyKzf3xv8ClvGXnklTlyfPTP8PSKa1DegahbAEB56wh0HC+v7zwipk2+PWOdXlwnRBQ+IbOfUtjP/LMPRxYfwI5AEpvbav4y8ZFXpjUxrbFnGvaIgvoBq1cpjtTsvNoBVmVvQHIN3P9NfFkYswE9fGV993V0ySPvTDsS0y+xGg3fGZxatiamrW3uz5SzKntdg/LQ/iZTKBn5bY+80u3JWXYkZnppt1qDCMWycGajHSnTgZJNjq8QH2/eGZvjWRPTUN/v6+jSWEzSMKuyzz/piCRDiGX+jldMyfzKEc4xkUQemlFvRUx7QmYRwgqxTjaBSBqcWmtNzHhCZnlEFmGdYKvru6+iSmx8mG4heYu87YT8NkjQnUNcfFCOEzXnkVd6daeulxJBkNCMemwefBSrCeuPauHM+ifXwK4LAFhc2/aKKXlCYj2lsB0orFZt/Flp87A1Mc2Rks2q6sur5UDtAaFYHpnVaOuT6UDJ9oktxcbnVrSNWXik2PgwYUR5QGotXKiGpNVRE6sONJK3KSQzKp+QWfZklj2JWdc1CR+mVK4My2x8SEyzJzMHJpdLmoawc7SBieXH3hlYZ+mREMsUb+LKekePIPfOIe5TcqYdifnIK5VV1Y/9SqVSJxV1WHomPyGz8QE5g5icDrFUEZxa+5CY8ZScNTKzWlDHySw/uADCnucpOauibQwAoEGQnGrOw1cpTyns4sah1JIudKblGVmUXtJZ0TZq5ZVp4ZGSV/NWBvy2QBKUWmNHYtqTWXakzJKmYRhe4hqUx6zoBQBMzPMJ4YX2ZJYdiZlZ3q3b+VbXPWlNTHvknUkIK0RzVTQIwqzohb/XmcruGt43rj7zz8ZOw6PYTejSTa5QxeW2mRNSyYwKhUqt1mjSS3ssPZOf+mZVtI4mFLSj8cTutPy00i54iB0ps657P9LBP6k6q7JXR4MlMmUUq+mBR2pgcg0AgLu6ZU1M467s9SCJVOFOy+8c5qL7dw7Pu1DZT8hZjtQcz8gi7lH98TicqUed4Qx/AejOXz1uTabWqRilAwiCnNw5dqgxupp6qkTc4zQMdF/iSBwYJBAE+SNEvk57TqVKrVvV60iciLWFYllmeU9mRW9meU9GWTf278CWzPIeZkVPVuURex7YObO858h9dJz88IHH7ZBV2XtcG47c/3CbsSc5cMXDP/nIyx3+eNS96s2q7GVibuzJG6/jZr7z3ur4VkcD3vkV3H7gdsEfeJKncKpfdFxjjntqx7U8q1XIAPcAACAASURBVLKXWdGDtlz3DdTxrNGfeWRT9/4v78ks79ERp3yGM5wEJ2LthdWtL8x8PzejfH6X/F/y98V/0489+/s3/ZlRvrzri02jP8MZ3gMnYm24XPqj/+C1/g0XOmFLAABqzZ/sl2oQjebf8Sz+un8aBNH8W17X9/77LxSbPsOHxZ/Irj0wubRwvHrGvxPcla28+qHK1tE/SBp0gssb5x4t3nSGM+hG/8SS7pjRvyJGZlZ1BCb8+aFBQPvgHFQa+DfgT8TaP1gHvwwr/E+3Aqzwd3+ypTn55XnRy5Z4f8hi1sIjBRtZfHLk1PY7+GYJj8+ZPIMXvSz4+HDSPwIyuTK5qNM3sZocX+FFLy9rGf1DZ9M/24c5U1nv3u+PQUZZzzP/7ON0lN4bOnrE2qbAmpjejEkE+RNCKld+ZOR1OAv/D8KfiLUvPQ5BVXj+g0gqbDfG0WHHe2dyxPvB6lWa2VF5Iu9EWmmX+cuEM3eWDuCDcnXrRXxw8LeEl2xCXPzZcbltbkF515zjXahs8Qm0N6fm+UmFHadlwGuOkdjM6X8z4vNaLT2TdQiBnQQiiTyxoB2r8KyjR6xsCIzxsTCx7k8LqVz5salPwn8ha1+2o3lGFr17vz8YIWl1R+ojf0BYE9NQYZMz/NXB2xQa4+jd2tjhjsE5fRNqU9+754b13ZPXnaNPW97IwDkKKmr9dbEtkBg4RrUP7mc1/9V7hFSu/NSUhFWb+kNxCtZOLOjoGV1o48y6BuXjg/KwyTyMvLYOzDNglvdAST8AQHxe29DUSn33JC4w72VY0fgcDwCQUd6NC8h9FVU2MrtvzLpiF0aMLuFMLrmHFrr45yQXdSgxZuXazon/G1ni6Jvly6hGsz+a+mbYlX1TC+tuIQXk+IpTmaErWkf/b0SJo2/W65hyqIWiQRBWZa/J8/if7SPICdWnylZqH5z7v5ElT8lZAck1UAVtmb8bltnwr8Ccp+SsoNTaNUxu+oF3tLl/mhhT7uibRYgowQb2Jxa0944tlLeOPvPPgxkEPSMLsTktqPz02Nzam7jKp+RMj4gSrLReft0APijfhZrDrOhVnjiyVSyVR2Y1zq9slTaPPPPPdQ8trGx/K8F6dX03ILnGyZflFlJYoi2mtS2URmY1zq9sRrOb/xVYiMrlvBNV7WNuIQUO1OzEwnZ0vqlUaZKLOnABuc5UdmRWI8poGzuiSGbjIm8nNKP+eVB+VftYDLsZqwvW2j8L66jl1XCKtflyS7ydqKzG1Q1BXG6rI4VNiivHJge1D8y+iipzorB9YkvDMhsjs5qEkvdZxEDWbtdm+iyubumbUCra9jKGCuoHCzDZHw09UylFnQgA7QNzT0hZ31gGvIoqoSZU6a57h4WBS7RrUG7f2CIhvOiZf27x29Xj2jizr+nljr5ZL8OL0WTUuq5JbJpfQ/dkTvV+tk5z33RZy8gJrTrtA3OM/DYYc72xIw5MqXH0ZRHCizknLoY3u7ThEVH0T4sAZyrLL6kOKnRbE9MtPJKHp1dfRZc6U7OzKnrRSHOJTBHBbBzXCi2UtYy4hhQ4+WWnFHceV2LiMBRKdTSrcWphvbR52IWa8zK8GB1lpXJlBLNxAuNnisttaRuYg5eOYjXNLm3k1nCcqNleMWVrGwK1RhPNbnamZr9hVKHVqaRy5ed33iQVdrT0z+CD8p4H5efXD2AbkFc74BqS70BhBaXVbWjLtEpliihW48zienJRp0tgQccg94Q/5xSs/e3DgJ/tI97EleXXDVITa/75wB8dLT8xeYNVObhiH2bjnQEAQBDkszu+xnh6SFpdYcOwLYl5xT6cwqh0pxUUNgw/IWd9bx2M5hMa4mIuPo7wjCzKqxuIzW397LZvSsme5lZOTf+NZzGZFX2FDYOkuKq7bvHwl/vEluob+hDCCsOYjYz8Nqyavm7E57ddtqMlFXUV1A9Sk6ovWgc19U0DABp7piw9041w9OTiri6MmqBu1HRO/PiYFpHVVFA/6EUvgyUOQlLrPCKLChoG8+sGzNwZrkG5CNjrGFjWLqgfvGQbGp3dWlA/GJbZeNE6KFebcva1hf+VJ+GkuHJGYXd56wgAIDSj7vxNb5FEBgDgTCzdeBYTntVU2DDIKOj82SECFgcoahy65RqXUzNQ2DCcUty5c+KKSmsbAj1DktWrlIDk6sKGYVJc5Zd3KWhK7jJ/x8ydQYqrKGwYyqrq/8UhHFZBnF3a0Df2tSamUROqGIVdOqTSsWjqmzbBx2ZV9hc0DCUVdsAkUo0GeRVVYvUqpaBhqKB+0NIzGV17jcys6ptQ7HzS/ZKqEgo7mvumv30YmK2lHo1Gc9mWFpBaAwAwcI620KodtQ3M6ZtQn/lnB6bUFDQM3XKNs/RMhbaL7pH5Cw8CYnJaC+oH7cnMcze9M8p7Tv7+YAFZu7F3CkEQhVLNquy9557I05YTuusWj4rYAAB+p+V/beEPABibXSNEFH9vHRLJakot6cJWd9INM/eE7x6F/x6Sn1s7QMtouGDuh6qXFDcN/2QTGsVqKagfDGc2XbQOgkKSOTWc76wCYUkmDYKY4On/nwkJekcQBPnFIYKkU2EDC1Jc+ed3yCq1RoMg7rT8fwXmFDYMZZb3VraOntCYv7YpCM9suGgdTIwsTi3tgXmPThTmhd9oLlQ2s7KPntN6wdwPplMCAHibQn1jXzjy1XVNmuBjWdUc+NqcvEq1UCw7d/P1PfcEX0ZlQcOwW1DB/9iEwII7m7sSfSMyU6ucgyDgI2MfmFrM2xTqGZIeEVNDM+oLGoaM8bF33BheMaXEyOL8+kHj5/F33OIVKjUAQCpXfmVOveoQSYotL2wYDkyt++z2G7TGRTiz4ZYbI7d2oLBhCBeQbU9mQk2FzR2xnqGPuXuCL6OSUdilQ379AE7B2pcehzz0TEGzsH51jEQlyf9pEYBNoTbExUDFEgRBLjzwd6Gy4UguEEm/MKPYaIUfV9d3r9iHo5P0XxwibrkxUHnSyKzGW27xarVGIlVcels15gYuBiq1+ydXf2RKxk7zT4Jl/u5X9/2wFak9I4usiGnQih2WWe8acoqKn0ql2hQfi5We2BZKEACw1ufukfl//uaPJqCjrC2VKX60oWGrrEYwG41wdDj3/Mk21BhHx9Y/i2Y3/d2MCvV67HzS3TGKoJ6RRVCOh5JQ6YYpiXByxxh/S3juxmusRI6dT7qHVnuBklB5DyNemlTU8YtDJIKARd62nqGPT9yxykRHIia7GSvoAxvZPjD33cNAtCsu8be/MqfCXj0+x9M3ehOQsv+Oob8XADA2x7tsR4OVfbDyXp1DXH0jMjoKjs6u6Rm96RrmAgBC0+tQKbSNHTG2YstpsbEjuu4cbfI83p7EvE9I/vQ2JalwX83u4atUbMWcV1ElP9nR4P9tnNk7bvGnHSpM8HQTfBz6dpkTksxfJgIApHLlT3Y0Wtq+Wik9u/m6c7RUphSKZT/YBMMetLC2/YNN8D/u+3UOzQEAlng71xwjT17e0D+5+hvLQARBZAoVtqDPqSAUy03xcb0YtQk7UuYPNjT00T8PyL1iHw7/h68lXEiFZtTbYxSaTv5uiyTyj019UNVDtVrz2W1yaEY9AGBLING/8TpHW+EIQcBX9/1o6XUAgPVt0bkbrwNT9tQsphf45276vNF2kL7xRbQmolSu/Ow2GReYg+ZGuocWQA6cX9362iKgTytEo1Kpv7MMhOINW7vi8ze98AG56lPGqp2CtS9aB1MwBRfMXiQ80ioW6WDtf5hTolj7rPS9dQhZW1NDrlA99Ewu0Srm/GRL84rZl4XrGuZeeOA3t7w5Oc+/YhsWm9PKquzLLO/Jr+V8YUaxIqYAAMjxFRetgk71gwEANZ0TpvjYXYzkcX335KemZBh3GJhSgztNSdOV9V1DHL0bozCAYlsgaeiZrukcj2I36RmRUGEWlLWHplZuOMdgi2GOzq59cusNnDVftAr0ZbxV4QKytlKllsgUpq7xXjFl2VV9meU9+XUD5oSkT01JAICGnskfbcP9kqpPpWwAtN0DKwYSn9v6s30EtDvZ+aS7+OfkVPdnlvfk1nDcQvL0TSgiiXyZv3PupnfLKV38vaMLPz4OexVVMsHdD2KLz201xMWwq/qY5T2syr7EgrbztwOzKvsAAGNza3qGPtiK19Ud499aBsB+TkmovK2NQMCydscg99xNb1QDZIm3c+6md23XBAAgNqcF7f8TXN7P9mGzGNGVU4G/JTTE0WOyWxp7pxp7pmKyW7+zCknXFirSwdq1nROm+NjTlpc1cH5L5PopiQlVwsfneNffLr09Oc//+Nab9oE5AIA9iQklnNhVfS/DChx9We6hBQCWVcPHyk88ckDWhhYSQljhFbuwnNoB0SktS/wtkTGOjn1nrIlp9wlJ6Ecfevn31sFwqgdfS2j16hjiXrIN86KXnTb2USiWfWTkzcIIiXz7MBAS0fbxrL3XI7T65jtCyUdG3tnaScDaxu4t17j+sSWgtWunlezrcefVDnxvHSKVK2s7J648CU8r6WZV9DLLe9hVffrGvlDlZmtXrH/zdcHbtpST4HSsTcJMqbDd4wBrG+FisawdlrlXCkit0XxvHUKKLYUf5QrVfUIiWyuIc8AbOTS98ult8ujs6jiX94NNiHtooU9sqVdMiVdMyZuEGmg3hKx9WrGFkuaRu27x2JoD7YNz+kZv4GTttKy9wNu+8SzmcGX35v4ZC49kt5BCSkKlA4V17qYXajtDWbtndNEIR1/GFACaWdrQMyRBc81Fq0DyMawtFMuMcPQn5Kw3cWVeMSVe9FKfuEpUsLhndAEflH/FLiwotfbkUzn4jsJyGxBppV0XHvhBje9HXukWnmnwcq9jSnxiK0Iz6pUq9eLa1rmb3o06ix4ciZGZ1d9pBZftwnzoZXDmSM9uuWIX7hVb5h1TCq9CTqyZXFgHAIzOruoZ+mCl2KVy5TXHyMyyHgCABSE5VdthDrP2mFbPlruyde6md333JACgd3Th41tv3EIK/JOqr+NinwfkvrdkB7SQ9GGKAhMiCv9x3w8umA6wNjG6+ABrb56mYCAAwMB5T/MS4gkp85ZrHABgYHLZ8FkM1nDPXd3SM/SB7pns6n5T1ziVSoMPys2p6W/snbb0TEEQhBBR6J90UCdLByBrK7RVxNLLuswJqabPGY09p5h0wzt2gLWxnp7X0aWXbEIOszYAYGByyTUk/7JdGJlReXJHLmTtDIzs+zeWgZA6D7A2AODC26yNXnpjR/Q3ExJqulnbEBjh6K2cOYB6I4v2vZHlraNfmFEFYllV+/hFq6BXUSVe9DJIX76JtXDBB1kba0U4IT4Ma39+lxz8trjtSVhbJlfeJySi1snLdjTP8H3WrumcuIGLEUsV41zeNcdIbG0zFGRGxUWroMOqx7rR3Dfzi2MkWuITAFDYMPiLQwTkjtOyNm9LeN05ugFTCA0AIBDLbrvFJ+Tv0ejI7IqeoQ/qUUHf0Qku76p9ODa/oHOYe+lxCFytHxZih6ytUKplCpUpPrai9aCwJxa9ows/2NDyTvxOHJhZAAD8k6vR0k22PhnR7KbDR80tb5y76d1wmk6Lxejs6lX7cHijGPntUB76yN30DH263l7QvI4ucQ3KG5td+9YyEPULvZO1YVMjmA1kRkVJ83A4s7Gu+z0bDwE5CGumC0iu/sSUBOsV3MPoUwMAPCOLLtmGwv+r28fvuDF2RO8omHAAx7H29OL6VftwrK2jd2zxx8d71tsl3s5V+/Dm/mk7Uvr43Bp/S3jdObp9YM78ZULzCcJdUGBZG0KuUEWxmn+2j+BtHq0FfxhrG0ITfFwHxox7ctaGGJpeuWxHS8HMbXVDB2tv7Ur0bvoUYiprf3HX9ySsvbq+a4SjQ78lZG2s9mxiQTtcPVR3jBvjY47kKMjaWFPtCfH+rG36PN7WZ89CbUfKfOy9VwChqGHoS/NgGDwHWTs0Y8/WptZoLloFo2YQyNpoNRkDl+jvH4VCbVWVWmP+MgEaLuVK1T33xNfRpfu/ViDZFUkBAGRGxXeWAadl7U2B5Kp9BCrtvSOS/uoYhdq8ApKrT8XaCAD3Ccm/eexVEF9c2+4dXeBvCa85RGIDafSMyeOYuTa0ESuUqrtujN9D9szTCpXawiPlCSkT2saOY204ifOJLb3rFo/q0Etkyo0dsQZBJhf4aKcywcemn/jNXt8Wnb/pbf4yCZYLWd3Y/cqcijJ1clHnFbswtBShQqWGDjTuyuZ7sPbU4joaN2LpmQy1QCe4/ItWwdjJPm9TuKeFfRRr944ufG8d4kRhYZdoOlh7bnnrnCEJNtU3oRIXkM2ZWBqeXhmZWUUrYyAIklPNwbbhnVjbEBg+o9d1TUrlSqlcucTfue0W/4SUCeu6haTXX7YLg0LhPaMLP9qG39BWam/pn/3Oaq/s4XE1qQ/DwDkKW23usXeGKT4eAKBQqc1fJqJBgSq1xpqY9sgrXVv+GDyjZlsT0x4R0+HyyzUoz9Qt/j4hUUdZksOArK1SawQi2ZxWhrRzmHvZjnbkvOpIbAskaH0DuMRBewSEZ2TRD4+OsJBMLa7D4ssAAHNCYkx2yxFnPwqHWfuChT9kbblCdcM5BpISgoDYnJa/3QmAtToPs/Z5Y58MreAtZG0YuyWVK/9uRjVwjILmuB2h5JJNCCw2vbEjvmofEY/RuF7fFsHqrP8O1v78LhnbPe65J1p6JsP/B6dWLtmGWhPToPkMF5QHa4QjCKJ/43VQ6p45X6XW/NPCH61GLJUpTXD0LO3YddE6yAgXh/PPxvnnmhOSrjlEDmsnoZ1DXAMXuo13WkhaHTG67BExdWx2DQDgGVX0xV3f91jbVnWMXXkaaU9i+qfU3nVjWBPTNrVFpMiMCrS2xQkxMLl81T7c1DXOPazIwDEqoaBdrdFQE6t+sqUFptZTEqte0ArO3fRGf85d9wQjHB3+3z0yf80p2pqYGpBS9/BV6m23eDSu8fPbvgeqRtHS6/RvvIaPfHVj1/xlwh23+MDUOr/kWguPlIrWUQRB/hWYY01Mi2Q123pnPKOyNw8JlB8H/pbwY1Mfe1KGnU+Ge2jxNcdIa2IaWpdAKlc6UdgGztHkhKqgtDpLz2Q4s5hb3tQ39as9ZRIEMbrY/GViJKvF0TfLjpSJegLjctv+x4bmHlpIS69z9M0ihBXCBdDQ9Mr5W/7YukUAAKVSbYij65v6QYMSBLZsRWv/rL6pH7qUWeLtnLvpA8MZu4bnf7QJsSeznKnsp5SsG89iKlpHAQBqtebCA//jyqwciR2h9MqT0PPGvp+YvPnElPyLYyQ+KBelsPVtoRGOboyL+VdAnguV7RVbcdeNAe3C/C3hrw5RRji6W3DeDMYerRs/2ARjPXKOvlloRZ6+8aVfHaOsiCkBKXVWr1JuucVhdb0ZeW0f34tA5wGJBe0fmYUfMMG9Ez5xpZ/eJgMAxrk80+fxHuHFwWkNpq5xyUUdJ88IRRAEH5jzvXXwU3IWfHPuujHQHgEAIMWWf2sZAH10axsCfRMKnAsTwgp/I6REslrsyUx7MnPtmEpPhyEQSfWM3iS/VZsmCLIqAKCqfezbh0GOVLatd4YXvczaOwMWp4WXRi0Y/C3huZteqG1gmb9z1T68pX8WACCRKfRvvH74KtWexHSjFRnh6GbujBXt+q+wYejq0ygXKpuWXucWlO9CZcOgqc0dsb6J75FFEHXjFKxd2zWBLU81OruKteXNLm0w8tuZFT1yhWqJv4PG7Va1j6FvpAZBWvpn0C6q1iCdQ9zV9b1bX9c1Ob+6xdsUppR0p5d2b75dPX1jR8Sq7I3Jbkkt7UH74ejs2nsnTc2vbiUXdcTltR8o+zS1sH7y4FMU6zuizPIeRkFH7+gC6keu756MzW2vah+TyhXN/TMoA3YOc7HLQ96mIK20Kza3rbB+ECscXNs1ic4TIaYX16s6xtF5mVKlLm8dic1tSyjsbOmfhWsOoURW1DgUm9vGruo71TSKvyXUu+lV3TE2OLWSUNhV0jR8WLW5uW+GUdARn99e1T4Oo2UlMkVpy6juUveHIVMoK1pHY3Pb0su6d982EYxzeaklXfScFmZFD1pWQiCWlbWM7Byqvjg8s1reOoptZ9vALOq03NqVlLaMogIAKpW6sXeatymUKVS33BhRrCZINAiCxGQ333WLh/P63rEFzsRJYyoAABoN0jE4V9AwnFvLyasbPByPsbkrTi3pTC3t5m8JxVJ55zAXJbiNbVFyUUdOTf9JcikhmvtmsO/n1AIfq7W/vi3MKOuOzW0rqB888PjEEnlJ0zA6J9jaFZc0DR1XC/s4THB56Ag9u7SeVNgRn9/eNjCr+6jDUChVRQ1DiQUdy+s7AICu4Xlsj1hY3WrlzMJ+JJMrS5tH4JsgkSlKm4djc9syyrp11MI+DJVKXdYysogx+veMLmC1gIamVuILOuDYMMHlwWJ7coUKvTQAQCZXNfROoX4IqVzZypndFkgBAGoNUtE2tiWQTC3wE4u782o5Bx7oIm87rbQ7Jrs5vbwHDRNQKFWlzSMnX6Og+BPlRp7hPwvepkDP0OdwldX/97AlkHx517eocf+XBqXUWBFTVKo/RCzsDGf4sDhj7TPsYX1b9OltclmLLg/n/xvQIEhwau1NfLxHRHFKUaetT6YpPq4bU87qDGf4M+OMtc+wB6VK3T0yf9pAtL8uZpY36romG3umWzkzZ4JcZ/gL4Yy1z3CGM/zX4S9dm+L9WTuK3ZSC8cn+B8HfEi7xdj7gYxCKZe6h+dCtpFSpO4a4b+IqXseUZZb3CETvnpTBausCsUwolsnkSrFULhDLhBK5XKFSqdTE6GJszMN/LRAE4a5sbe+eLjPwPwWJTDGzuK6jUq1ALJtd2njvVB0AALuqLzjtAyuD78JWfdDiHmRGRUnTKSIjdUMsVQjEMoFYBuMm4f8SmQKKunhEFLWf3tWpG7PLm/igXGf/vA/lwpleXHcPLVw7QUkEhVI1gwlefG+8P2v/6hiJTfo6EiqVenNXfKqqzO+Bp75ZaOL1BwFvU6hvQoXpUn3jiw+JqUGptWGZDQbOUQ8ISRvviqUbmFi28Eg2JySbvWBcsQszxsXeJySavUiKz2vVIIjeTZ8IZsOHaupfF2Kp/AszCoyZ/fOjvHVUz9BHh15HUlGH/s3XC/+LMhoOFNZ3D08tz6AbMdnN54293yNKQQc+u/3mQykqiyRyQljhPUKS+cvEa46R1xwjzV8m3SMk4wJypDKlQqnSM3oTn9v67hOdGAiCOFCY5i8T6rqnu4bnTx4mrwNNvdP6pv4nqcXTO7qgZ0iqf9+UNBTvz9rYdIbjsLC6+ZSUOf8H1xXrHOaeNl5YNzZ2xOduvIZhQGKpAg3i2RKIv7MMwoqxHAmBWDY5z59a4PdPLP3iEB6X2zK9uD4+x1vdEChV6s/vvInP+5Av4l8Uao2mpGl49C9Sd2plfbegfnD3+DzG2eXNgvrBU4VaHsDvtPxrjpHvffiRmFrgFzUOwYjGD4XDyV/vDaVKPbu8MTnPn15cd6Gy7XwypxbWJ+f504sbag0CSw2kftAFvViquO4c3fxBF7ttA3PnbnqPvx2keyS2BZKC+sGTSxUeh9OxtgZBJrg8mBN1zz0BzY2EmF/dGplZRdM6ZAplK2f2J1ta28Ds5o4YGz26xNsemVnFpsAqlGqYLMdd2YR1vyQyBdSGnl/ZworFzC1vHpmSAC0kGgSBniWFUjU2t4YmOqNQqtST8/zxOd7hGiI7IunIzNrGjnhXJNXTsvYBmL1IeIBJUNYNhVJ1zz2hCqNSLVeoPrv9JqWoAwAwtbg+d5RikUgiH5tbm15cP/lyW6XWzC1vDs+sHsg7UChVcMjZ3BGPzKweMO9I5cqx2bUp7YUUKvWOUIrOPtQajUgix05GxFIFumySypUTXN7kPF+OeawwhFYiU0xweacKp4WYX90amVk7HJR9HOQK1QSXP7WwrtQmx6pUGrFk/7Gq1BqhWAYXYUqVGt6K+dWthdUt+LNQJ+TUwjr2pUK0b5FAJJ3g8qRyBbr9uEsf2EEk3vv502+fGUIglo3Ors2vbokk8s0dEXwVUdYWS+QHlKMlMsVJ7qdMrhqf400vrh9Yd8JWyRRKWINmdUMwNrem0j7KRd7O1Dwfe4hCqYaZXJu74uHp1a23HdQHWBtBkJmljdHZtZMYD3WAwqg8MIUXyxR/M/GBkk9TC/zDk7/TXlquUI7MrF13ji5vGdnelaCMJJMrISccFliXypWT8/wJLv9wQP3apnBkZlUiU/aOLZ6QtQ9ArdZMLayPz62ddlg9BWtvCyQuVLapW+JvnmlkRsVNXJwTZS+zVixVeIQX/uaZaubOuEdIgTe6e3je7EXS53d977kzbEmsVs4MAECpUpMZlZae6XBPtNJaVkWvNTE1r27AFB9v4ZGsUqm96WWvoorTSrseEtMNXOIIYYXr26I3cRWWxHTDf8URwotQobLAlBonChO+mivrAsNn0bk1HHda/j1CsoFzTBJG0mWCy7P1zrhPSDF/mWT+MgmrFdk5xDXFx5q9SHj4Ki0gtebjW2+Km96SPoD41TECq7imG0Kx7K4bA5seLVeo/mFO8Ygs9mVUWnimGrjQqYmVWHZu7Jm6T0g0JyTd90ixJzGXDo06hzEwuWzrk/HwVdpd9wRTN0Z8XhvKHbm1nIeeqfl1A1avUu64J5rgY1HFyLG5NRvvDHNCsoVnWmxuC4IA/rbIGB+HZkwMTCzddU9AE6n6J5YeEVOhbHTv6IKlZ/IDQtIDQoo1MW1yng8A0CCIBSGRkd/mQy+9/XtK0rvqeiAIMH+ZkFrSCQBQKtWBKTXmhNR7L5KcqOyTLM5mlzbsycwHhBQLz7RwZgMcTqo7xo1wsTvCPVv54NSKgUsMJM2SpuH7hMTChsE7bgyzF4xtdTg6RAAAIABJREFUgUStQW65xmWW9wQkV1t4phni4h21NTkFIqkpns4s73EPyb/9Iq2mc2JmccPAJQbmR8wsbdiTjri0IY6OEtzDVynR7OaQtLrfPFMNXOjE6BJ0eCuoH7zjnnTPPdHMnXH1aYSlZzLUMEFZm1nRe5+QiOZq7Qql9uSs+reFbg5jcp5v55MJH2gUqwm+VCVNwyb4uF2hFAAQzWpyoLByavqtiGlG/4q39c7gbQqjWE0PiZnGeIYdKRMNH8qq7LUippQ2Dz/ySr/rlnAdF1uEmcFgWZu3KXzmn23hkXrvReK9F4loIZHJef4TEvNUBXxJseUHysaKpYrP75Jf08vexJVZeKYZuNCDU2vRd/u4S+vA2Ozab4SkL8yoJs8Z+KBcmHTTPjBn5s6wICTfc080xceVYiJfm/qmzdwTzAlJ914k3nKLxxYJya8bMMTR771ItPXJ8IktPW/kNXGC+t3cla3rLvSBySUAwOqGABeQ84CQak5IpiRUnqoQ3UlZG0EQO590U3zsEm9na1cSm9Py6d0AVMXGmcp+Ss7a3BVL5crm/pkr9uHD06tKlbqhZ+oXh8iGnqmVdQFs1quokvuExLVNgVSuHJhcvmofAVcrUaym87cCiNElozNrM0sbCIJYeKR8ZOSdXd2/LZR0Dc9fMPczxNETCtp3hNLO4fkvzPxQNnT0zUJ11OaWN/WNfR8R05v7psVSRVpJ12e3fWEu2eau+JpjVAy7Gfo9IllNd90SxBI5AGCJv/PtwyD/pGqxVDHB5T/zzz5vQinFuFwUStXc8mZYZsNV+4iTv4uHWVuhVF944Hf5SXhx45BIIq/vnvzstm+hNt1jcGr5W8vAyvYxqVwplMhcg3LxAbmad9WurO2ayKnhiCRyiUxZ3Dj0k23o9OJeHnNcXqu+qZ9fUvXEPG9LIHGgMG882xOywQflkuMr5EqVQCSb4PI0GkSjQcxfJgZo1YTDMuv/Zh4Zq7UqBqXW/uoYpdEgS7ztHx/Tsip7pXKlRKZ8E1f22CtdpVIjCPjSzPc7y8DChsH51e132lIRBHxsSgpIroY/wRQfu7YhgE6/d3oOAACvooo9IorkSpVQIp+Y58F5E7O855wRia+tSNDKmdMzocB6SemlXedvB76gFQxNrcwsbajUGrFUrn/j9XXnmJqOCZFEzplYvmgZCI1XO0LpuZte1xwiqzrG51e3hWJ5K2dWz4QCVSE9I4s8I4+6tCGJr5Uku2Dhd9mWVtI0LJLIO4e5fzejQu3WtQ3B99bBGWXdYql8dnnjonVIDLsZ8j7K2pzxpX9aBAxqbejVHeNfmFHeWf/bPbTAh14qV6oEYtnEPB+eM6mg49wNbziWvIos1jMiM/Lb1jaFU4sbP9jQrtiH0zLq+VvCyYX1Cxb+0exmeKrIrMbzpn7+SdVTC+siiZyaWH3ZLoyvXdejrC2TK83cGV70MqFELpUrc2s4Bs5R8Ln3jS9+dd//VOo0R7L2382oV+wjy5pHRBJ5ZdvYZ7ffQOEBHZfWAbVaw5lYNnCOyq8bWNsUqNSa0dnVCw/8GfltIolcIJIlFXZ8axkwOrsGAOifWPrKnJpa3CmSyHdF0rjc1u+sAmHPaumf/vQ2GWa0dg5xb7nF6d30gnMX3Rjj8s6bUGExmaCUWhcqWyJTiqWKCe4RS38dOClrL/J2frAJxgY/GOKioV7H7PLGJdtQbJbtL47hxOhiAMD0At/wWcy0doXI3xJetQ+v79qfNVgQkuxJTABANLvp09uUJf6+M+c3j6Q7mLLN9mTm1afh6EcXKjtG+5LhA3MMnKPg/9yVrXM3fVCiVCjVeje9oIxnTk3/jWd0dDECxZJqOycAAKzKvmuOkahvl7cpPHfTC2shyaroNXCJCUiuHjvNOujIufbnd96Ea0UQAQAXrYMIEXsvKzm+wtZ7v1ZAK2fmI2PvU9WJV6rUn98mo9Iu8Xltn5i+2dYqOFd1jOkZkmASszOV7RqUf8AIE81u+smWBjfiA3KNnzOsiClwcmPnkxmX1woAiGE333Pf90KPz/HOG/pAWZiv7vud3E+FFTKu65r80YY2e2ItDgAAIbzQkcI+kLSdXd1/3thnXSsFhVWPyijrPm9ImsLocoilir+ZkGB5DQhaep2FRzKCICKJ/CMjL6hpBdHcP41KdbuHFjhRWbov/bWFv1f0vli8gUs0VE8cnFz+zSMJPZYUW4Y2AGVtBEFMXeNeaetRuIcWQC1s3cAH5uACspWqt1qVVtL1icneC0CMLv7WMgC1hAQk13xiSkL3JMeXoaI3Uaymz+/4okb8HaH0F4wUGsra7QNzl21paxt7P1mt0fzDnAILOSmUqpX13VMFCBzB2jLFx6Y+sdnN6JavLfx9Ykt1X1o3NnfEJvhYtAhXYEoNVrUKAHCfkEiKK4M3xMLjLQXK227x/snVAACf2HKsUk1j7/QJLSQT83y9mz6wZo1fUtVvHqkS2akNieDkrN01PG+Cp2NVC8zcE6A3snOI+51l4FPfLJx/tguV/Twg5wvzgBdhBQCAiTneDecYNN9/bI73PzYhdj5MXECOC5XtGpT3tWUwLG0TxWr66j4V2xMsCMlY3U4nKssEv68v4xFeiArfHGJt7yZtiQ2JTPE3E1JaaRcAgJ7d/OPjUFxAzjNqNs4/+yk5S89ozwwSnFr3HKPzt7W7742EiGY3PSCc1JyN4jjWRoWwAQA/2YaiTOdOyzdwoT8PyHWhsvEBOZaeKeduemHrBhyHziGuF72MGF38Oy1fz4iUqZUli81p+cLMFx3GK9tHz914DYs/dA1zTZ7HPSRmZJb3oCPZ2NzaLw4RS7ydhbXt3zyS6romLtvRFta21zYFV56ED8+sAADI8RVXn0biA3Ke+WfjArIfe6XrGZKg8vXfzahHqrkeCSxriyTy30Pyr9iHk2LLsYJHOjA0tWz2IsnCIyW1uFOitTnqYO20kq5PTEgCTDYNZG209BQAoLB+8PO7vjtCqVSuPH/TOxcjxtbCmTl30xvOpwYn333pf1oEBKXsh/EZ4WKhOXFzR3zFLiy9rFsiU0wurF96HIpKvmG9kclFHcb4GKVSLVeofrAJLj1Bwmrv2MItt4TfPFPTS7vRGupY1n4VVXLFPgzdPzit9p8WAejHCGbjM2o2+v9X9yhoZ1RrNDecY9BqTShrFzYMfWsZ4EJlP6Oyn1Gzn1GzPzL1jTrxC3AAx7F2Rum+UN9F6+A3cWX/m0sfkPbGB+UGJtdgd8AHsn+2jwAAuFDZsNgNCkffrBvPYuBX2PpTnUPcU7E2FEGbXtx4SMy4454Yl9t6cl8OxClY2whHx65BzLTeyPZB7s/2EcVNw62cmaa+6cbeKc7kCvSTjs+t3XCOmdCuHUZn1362j2BV9rUNzMI9e8eW4EgQmdX0D3MKdplgQUhGNQUBAA4UljEuFv1ICCtEJbsOs3a9tmYu7JnpZd3wEvdeJLYNzLb0zzT1TTf3zQzPrIllCgBAUGotVp11Wyg5wNrlraPv4Tc/jrWxMSSXbELQWRU+KBcXkNs+ONfcP93YO9U2MDc6u6Z4V7neosYhE3xsUmFHK2e2tGXkI2MSqkgZm/P/s/fmf01de9vwf/KCtn16Wvu22n56SnvX1vapIyBaBkUUEUQR5aAUTRkMCSGBMEOAMCSMYZ4JYZ7neZ5nSAKBEEgImZO93h8WbLbMWD0993u8flEg2XtnZ61rr/Udrqvxc1MSmmMpbR7Wu/oa1dCRbirTSruuOEY+9smA8VyVWmPiHJNZ3l3aPAw1Px/gU9j1g9XtY1buCTBWQ4gueeDFaumfaeierO+ebOyZGppaVKm1Wp3uSzPK8YsasawN0Tow+4yS9bNd8DHr2eVKdXZVn5ET/QE+BQYBMsq6TxvhV8Vbe/nOofk3WXtn2wFQ1sb4m2RX9vxkGyxXqmUK1elrXlgxNixrAwBkCtWuU+9l7X3dnaRypZVboulLpiUuwfzPxNdRxSg5Yll7YWntq1t+3aMLVW1jlx1px9SWksoUmeU9V55FPSSmQiLYxdo/2QWjceGApKpzlr7oe0NTax/7bEkJbrH2drpSo9WZOEejFIaydm5V72XHyOqOcTih6rsn+ycWT0pAKA5ibWwNyV8/9S7WfhGQ6/tm7elzarb5yzgAgBM1e1f5/BNyhpVHAgDgKSUTuw9rH5x7C9YGAKjVGnbDkKlLnLkr80QGeMdl7fmlNQPrADQlotXpLjwMtyeyAACTC8Jf7MOGp/eJ9o5ML15xjJzmbe18l1YllxwiGnv2mZNvwdqE6OOyNlxr51T2GjtH7fvp0sq6fnkUhibuBycXTxmTsNlItUb7FuVTJ2VtH0bZY3La7qMcBRsvVkR6PXqdn173Rp2QDmdtCOH65g/3A+s6t76UgMTKFwE5xFgO5F//xMqXwfl/BOXCADQAgJ7deGe/KhqtDvmLrA3hEpjr5Je171v2xaZM+bNdKJRPyansPW1MQD29cip79Q2JcKu3L2t/YkIIwlyAG63wkU8qAGBDpjyctfeeOqui+zisXdU2ZuWWIFeqZvki4ZsVYLsq/1yD84gxHOeAHLfwN9R6jwQUd65sHQUnZG20uCAio/5zUx+0xIsrWPvBJrC5d4trUOps7pv57XG4aD8JBARBTtpwdCLWPuTUh2MXa1MTq27hErAvuOESE5vXDAAgM8rveiShv9dqdcbOdJg8x0cV33Xf+VNWRY++IfE42chdrI3ismPkiQocj8vaOgS5hWNefkofnRWMzy3jo9gGtjueGn8E5xk5xQxO8jc2Fbzl9fya/ln+KgBAsLrxlTk5KqthZGYJtfi7YB/WNTIv2VQsCSUFtf3Q4SWUVfsPEyKWtU1dYrEhJzti6iXMmHYJyoWhcwCAIyUD9Qad4Yn0jUmVbVsJZalMqXfNC5aRrG/ILjlEOPtnzy2ubmwqhqeX8mv64Bpzmiv80tzPI4LNW15v6Z+xck84dye4AOPnxq4fxIUVbJ4kYwAAkEjlxk5RWG05pUrzkRGejgnVfWtFxYVtDdbxueVzt31DU2sFqxKJVNE+OFvSNKw7avQ7U3PuuCUuCSX8FXFkZv0pE1/4lAIARGTUf2TkJdncWoOwGwb1jbz5K+JNhYqWUT86s7QpV3Eahy450NAEZkv/zDd3/M/bBMFsWM/IwrnbvucsfdG8BX9F/L11EDG6hL+8LpHKe8e4RXWDGq0OAeDT694he1j4ICAI+OwmyT+hAgCQU9VbUNsvlSln+asWOCY21rwvNuWqiMz6gYnFTbmypnPit8c0mCJeFm38YBPowyif5a+y6wcNnehnzCiDk3wAQHxBq96V19h5vilXfmlO+eddKovTPsMTFtYNnDYmZFX2AADWJDL9awTUtQQAUN8zqW9MmuIK1RotLaNuYIK/69TpZd16hl5oNvKMKRm7OfvtcTjM38wtrlm8YrwKLQxm1VATKmkZDbPb3gLOAdk/24Wgb2nsmTprQfnhfuBxst9iqYKWUT88tbgpV5a3DF9yoEESwX5qXGjhd/f8Udb2ZZZ/9rsPeoSg5GpUVj42t+ljU//HPhmdw/Pjc8t2xNRf7MNQwdtzFhSvqGIAgEajs3RLvOeZMjG/vLGpmOat5lb1wmk+MrNk6sLA+nweide0Ipc3XbY3FSq9q6/jMeHEs7eOPvXhWBJuXHaIQDdzE/MrMJbFXxHzV8QetCKD+0ELgnUAwPD00lkLSmhq7aJQzBWsvQot+MEmGAYGKtvG9K95MQtaloSSorqBK88izpiRYQ7zcIzMCE4Z+8CSIXpOY/vgnEyh6hiau/g4DHriHBMnqPxbWZM+D8g1co6+4RKbVtrJ4nTAsD0AQCSReceWmzyPfkhMtXJPdg0pgHl8BAGM/Jbf7MNvuMR2jSwAADblqsDkmuvO0Q+JqffwKc8oWbDMK76g9bJjBLb49ykl05m6U2P3OpLtFr7zKKYwytDQkhedA81/AQBcwbrB/WDUDkqt0Zq6MFBTuOHpJXtS2m1c/ENi2u8ucbSMejT+0NQzedMl9o476z4+pXVg1j2sELtGjsiov/g47PgiyBCbcuUjUipWAVyl1v5iH5aO2ZU7UjKxG7HazolbuPh7nikPiemmLnGov/ghmJxftvViWbmnPPZJz6rosXJPRF3HUjgdvz0Ol22XG3ePzF9+Grm4IpEr1YToYnNX5mNylrkrowHj4CdXqm/jEk1exMBUklypNnkRY+WWiDWd6hias/ZMsnJPeUhMv+kSm1jYptMhCEAuPqYdf8mAIOCyQwQM8XMahyxeMR+RMs1fJvgnVh55n5UqjV98uZlrnAM529Q1Dlv1xWkcuuoUZYZLdvbP7hpZcPLLgqyXW9X7s13orrj25ze9g5Kr3GmFZn8mXX0WhVYrijfkP1gHcRp3jI87hucN7gctCNbUaq0vs2zvqYsbhs7bBKPL/KvPoqKzd5xWcKEFryPZAIAprtDUNc4/qSqluD2J3eYSlP+7SxxPsA4A8I7lYDeXSrXmWyv/Gy4xx+nfkyvVpNhSc1fmY1KWuWsc2n2H/dTUhDcyb9E5jffxO6lvRn6LV9TWdKal152z9Mss777hEnv9OcPGi4VNFF93pqNTj7u87hpScMMl7iExzfwlkxhbCuvKu0YWzj8I2buoPAQhKTW7+tdkStVPtm9Y6NkT08K2N3MHnfpwrIo3bQksrClSXeeEqUvMHfckS7ekxz7p2CVzVfuYqUuslXvKLVyiIyVzcmHnJmSWdxk60e/i058H5HSNLDzzyxw8xsN1irdqcD94YIIPAAhPqzV3jXMgZ91wiTmpnc2JeyN5y+vozm6XHrFIIpviCgXbdVcoVsWbS6sSbAWbWCqf5q0urkrQJ79Gq9uVlFdrtBoMU2i1b4xerVan3T6gRqNFuz8QBKjUWuy5tLqdV0IsCiXTvNW1jd0KGGq1dm5xDbZUaLRvvEuHINqjKvD2hVqj3TXrVGoNdvOo0yG7ZCJ0CMIVrM8uio5vZgoAmOWLtp+UCJq71+qQXXdVq9Wh17OyLp3mre6lSARBsCIEWp1uX+LgrYhn+KvYBgeVWnOiu4R9vVKtneGLoKvZMbEq3pzmifbOValcyV0Ww5us0Wxd+95bsSlXfWTklVHeDT8Ltu8RimBgP7UOQVRqLfqLvafW6t4YwLtuBYIA+KU4+2djnZJkCuUv9uHQKxk7jAEAGq32V/twbNbrSAjXN6d5os03rmrnU2u1ujeP/8bXqtHq0HEYnlZ31oIMANiQKXfF0+BH21UcsrImneIKVzD1mjodclIdCy3mAjDn0r4xWTBj+6BTH4m9U1Kt0c4vrS3sF1lWqbVzi6J92yY2ZMr5pXV4qL3H3Be72EkslU9xheKTdyd90Pz7gP9SSGVKfUMCtgnr3wBiTMlPdsGtA7PLoo3RmaUgVp2REx0ade5CecvI15bU2f26Z983gpKrPzIi/JXu/A94r/jA2h/wXwqFSnMfn1LZ9i4VbI6ESCIjM8qsPZODU6qdqNm4sOKDFKlic5v+fDM7929Dfk3/Y5805R7/uQ/4D8EH1v6A/16oNdq/oq361lCpNWsS2eHhe8Xft9TV6nTvW6fzA/4KTsDawjXpXnWVvwVaHSJYlez1ov3fCI1WJ1jdeB+TZHJB2DPKlR+j7gVBwLJo413tiAWija4R7vH9sw/Hv/O7Fq5JT5RLeAtIpHK0nPy/BMI16VtIiR0TmwrViui/636CE7H25aeRAe9atf3tsCSUnL3lW91xhJ4OFkqVprCu/0RyNv8ejMwsnbvtf4hw89shKLn68rOYh8SM46jqyJRqg3v+2PLkt0bH0PzPdqEPiBmBSVVvl7/dhcUV8dlbvgcpWjR0T8bkNr0rTr/kQNvVDvfOQWGWX38eva+Dh0KpjsxsaB/6e+wrR+cEYWl1Ism7N6m4+izKP7Hy6Ne9FeILWn62DXm7vvD/vTgBa39tScVHsY9+3fsHb3ld38ib03QCX9qC2oGPTINNnKP/01bo/RP8U8Y+79ZqdlEo/t46sKRpWKFU77s94grWqtvHUdHETYVK/9rrI1X6jgNHSqaTX5ZMoRJL5e/Ep4IrWNM38i5tHt73rxRGmYF14LvaAp69RfGOLnknhzoIf4YWGFgH7MvaaxuyryzIR9aqvycU1PZ/akIanz9aPuGk+NbK34N2RKOQYFVS3T5+0spaAEB4et0/TIib73mH9J+GE7C2gXUgMeb9juljYnlNqncNf9BM3hfOATmOlKxvLP2gdMt/DgYm+fqGBKxm7Ds45gTfyClavHlgg29F68hNl1j1dq06bEJLZr8D+fm7Hol5mALbvw6BaEPvGh6rUY4FgiDv0Hnun3ep5LgjLC/+Ijwji7ENirvw93oZvqezf28dhKdzDn9N++CssRNdfPJueHp2w5dmlA+sfSAMrAP94stX1qT07KawtLoODNHUdU1i6/Bb+2fQVrrazoll0Ub36EJoWkPfGFej0Va0jsiV6pa+mcDk6tTSzl3qAVK5MruqLyCpKjavZZdpALthkJpQmVPVOz6/fOqq5/FZe4orvOIYOb8oeuaXdfgA0up0xQ1DAYlV0bnNC9tie2qNtrp9nJZeR02oLKgbQOO/Iomsqm1MpdZWtY35J1ahomj5tf1BydWlTTtEsyFTVrSOqtSajqG5wJSahKKO+aUtCeldrK1DkJLG4aCUGlpGw5GtZQ09k+HpdYHJ1cWNQ2hkfHxumcKs+MEmMCanqaJ1VLGnEX9ggu9GY/+PTVASuz27sndDplSqNZ+YENLLuqZ5wrC0OkZ+C2/ljQLVvnFeRGZDQFIVu37woPSdWCrPruj59RHNJSg3r7oP1vnyV8Sskq6ApCpGfisqbACxIFhLLu4ISKqKL2zbK6hdVD9ATajMreobmxOcuup5EGvP8Fabeqfhol6j1RXVD8KRw9uvlg4AMLWw0tI3rVJrcqr7qAmVhfVDqNASeJO1uYL1tLLugMRKWmbDrgYKrmCdWdDqn1hZWDeAXeb3T/AjsxoDkqrYDUPY6NCCYD0quyksrW50RoCnF/9kuz9r63RIY/cklPCWK9UVLaObciUcMCnFHauHdm93Ds9H5zRREypTOJ1olEOl1lS2jUk2FX3jvKCUmviC1kPK4YXr0tqOCdj9O80VtvRNy5XqzPLugKTqyrZR7AXXdIwHJVfTMurR/v4ZnrCucwItQxasblS0jKALZyxr85bFaaVdgUlVYWl1/ZN8+MuxWYF3bJmBdUBcbnNOZR8qtDs+txyT2xyQVJVb3a9Q7XxNwjVpXH5rMKu2d5xHz274yoJ8TNZGEKSidSSEVROcUlPZNgYrrHvHuNimm/bBueGpRbFUXtY8so6JFy0sidoGZuFb2gdnQ1Nrw9JqOQ2DRXWDbdsbZZ0OKW0eCUqpDk+vR2e0WqOtahtb35APTy8Gp9QyC9oW/3LK5wSs/Yt9mOG/4l4G55OZFc4BuWdMfWq3I8tnLXwpjB0RlstPIx/7pAMAEAT52pJ6H5/yMjj/ZTiHXT+wuCLWu4rHhRU4B+SQmZWXHSOfkDNQHlyTyBx80h39sklxpW4RxUZOdKh4p9UhFGb5hYdhJEa5s3+upXvCxyak40RsIaKzm+57JgEAkoraz9uGbB4cBaOl11m8YpAZ5YSYsoztDsaYnKbbuHgyo5wUV3blaeTrKDYcoK39M/pGBGIMBxda4B1XfsaMHJRc7Z9Q+dQv0yu65AtTH7SPa2xuWe8a3jOS/So4n8ystHBLuuhAg6MTy9oajZYQXXxr61zlFx1o5S37f0YdgoSm1lx0oJEY5aS4MkMn+lNKJiSgruH5h8SMc7f9ngfk0bMb9+r2VreP3/VM/cbSzzU4zzOSLVjdUKm1X1mQTV8ynak5ZGal+cuEmy6xqCcRu37w+vMYUlw5mVFu6sLwjuHsSzqi9U1SbOl3d4PMXZnEaM4sXzQys2ToRH8eVECKK3Xyz/3FPgzVf+gb5119FuUSXEiKK3Xyy/nFPrxtYGvoa7Q6UlzZBfswUly5EzXH0j3xYxNS1QH1edSEyrMWFPjECkqpvoVjkuLKvKJL0W7YXQhLrT1j7usXX+EanE+KK/vhQag7rRDtj0BZe2VNeh+f4hZZTGaUuYYUXLAL7dgONw/PLBk7RTsH5JLiyh7gUxK2y705jUPXn0eT4irIjHIzVwYxpgQedWxWcNkx0tEvm8ystCem/d/HUVefRex7A1Vqzacm3lB/mCtY17+Kdw3OfxGQS2ZWGjrF2BJYB2VKy1tHzV2ZZGYFKa7Uyj3Z2jMZZv9E4s3TRl7/omb/EZRHZlaauMTexsUfJLFU1jyid81rbnEVABCRUX/G3JcYw3EJzH0dxfn2jn/i9sdMLem84RJLZlaQGBVxec3weUlLr/vc1AelTnb9oN61HYVhlLVXxZu2Xqw/aWwyo8w1tPBnu+DWgVkAQFPvtC0x45ylr3NAzusoztSCEP7SxDmaEFtGiiu955nyIiAXCgFxBes3XsQ8IKSSmRUOPhmXn0YbWAcch7WVKg0+in31WRSZUe4dU3rRgQbjNjWd45+bknpGFwAAA5P83x6HD07yJVLFVxa+GZge5gf4FNhwn1DY9t3dAHi3PzEhXHwSCSepVqsjxZbewjHJjHJSXMVFBxqUAt/YVPzDhPiEkukanEdmVpq/jDd3ZfzF/MEJWPuCfdjFJ5Ho+vdVcP59fAocfudu+/kyd7RyrjyNfOyTAQBAEOQbS79LDhFwNAAAJuZX9I28SbGlkKmHpxb1ruFRsSdSbKnJixj0OG60wkc+6QCA5r7pT01I6NozvqBV39jnoPXXLiAIYuWWALV3l0QbBtYBB71RoVLfcIlBG9DR1evk/ArKfS39Mwb3/OFKuW1g9pQxmZ611bicXNyub0RCm9loGXWGz6LgUBubFegbeeOjOPA4GzLlRQca9PG0rvj6AAAgAElEQVQZnFzUNyRAy5i86r5/WvmjCXcWp+OKY+S+cum1XROf3fSBphgAaoPYBGZXbFFV3yjX2Il+iLdAZduouSsTjZBIZcrPb/rcx6fABd2aRPb5TW8olrIoFH9rRS1t3rpjfKHYwDrgkCj8PY/ErIqtrKahE/1FwI6yBJ7OMXWJU2u0Oh1yySECW4yMCyu4hWPClENjz9SnJqTu7e+aWdCqb+yDCsvsgn9i1bnbvjqdTqnWXHeio0Y8B9XkhKfX6Rt5o1oFdV0TBtYBqJIwytpSmQpreveIlOoanAe21XjQ5kaFUg2NcgQiybd3/EuatjZ/S6sbBtYB7QOzAABrz2RUbGtpdcPQKfqSw4Gs/Y+bJDiceMvr+tcIHjQ2XLFO84R6V1+zMRILWMwvraENycJ1qYF1ILRRFYk3T1197UzNgf2rS0LJaWMvVA9yF8qah/Wu4eHAjsys1zcklm3vZcNSa8+YkuGEtfZMZnG2tG3R7sqIjPozZmQMaw/oXcOj5n8oa2/KlVj5raeUTFRos2NozsQ5Gu2zlcqVP9uFok9EhVL9s10o3Mu6BudddoyAXZRiqdzKPflbK//jsHZGeffnpiS01XNoevGfVtSGnkkAwIuAnAf4FKVSbU9MQzXp3GmF9z2T4DclksjO24bUdk0AAG66xKJ5+6CUajgwAAAFtf3f3qVKtp3n0su6LztEqNQahUr98XXCY580+LxcXd/89Lr3caTAD8HJIiSk2J3wQnX72I8PgqF260EKZwiCfGVBxsqqjc8t6xsS2ra3JFKZUv8aHsr0qDXaO7h4CrNicJLfPbIwPLXoEcHWu/pahyBRmY1YZ2GRRHb8uHZr/8z31oHoBtPBJ90lMHffV2p1Ogef9Jsusb37VXQsrkjmFkXVHeP6hkQosADlm9HpPTS5qG9ERMtU2gfnzF2Zq2tSsK311Y4hO3w0B6qHD00t6hsSeka5AABcaMETcsbw9FL3yPzABD+luOPUDb99tcQozPKnlEzsb1xD8sxc4+D/OwZnDZ3ou6IcWJQ0Dd10iUVdE6FB3xtCxvf8CXQOAKC0afiSA621f7Z3lNszstAzytW/RqAm7V8SoNZorNwS4bc5Ob9yyYGGLdoZmlw8Y0YemlqcXxRdcqCNze18rp4x7hdm5MHJRQBAWGottud7Vbx5SFw7IKnqa0s/2E9sR2BZvGIOTB5WJhTCqjlrQUGVEhRK1RXHSMa2PtGuuLZcqZ7li7jLaw+JaVCNT7C6ccUxsqlnetdhy5qHLznQWvpm4F3qHePqX/MKTqnWaHXGznTsphAfVXz+gAiJSq357KYPVC/hCtax0pVqjfYTEyIj/7CpvrImneGtjs4KPr3hHZXVACBrX3udjxFB+9KMHHhAGVh5y4je1deQtcPT6r6yoKDJZHbDgP5VPCzlxNM5V57uPB0hIjPrscHl4oZB/f1YG0KhUs/yRbyVdUdK5s92W3rfTb1Txk50NDbSMTR3wT6somW0b4zXM8odnl76wowMl7oWr+KxkuixuU1fYJb5h8AlMBcqT6Gw9kxypGTAW2f4LMrKM83Wi4UKGzT0TJ21oMwvrQEA0ko6f3kUplJrNFrtHbf4+q4t8akkdpuDTzr8vzut8BEpfWiKDydvaknnqRvUiYUVrVb3kZFXWsnONX9tuTXMtFpd3xi3a3iha2RhaGrx+Nn7k7G2N4a1u0cXPjbxhiVrh7N2eHot+qfxuWX9a16ol8SaRIZKYsoUKjPXOBMX5hNyhj2R5eCTbu3FcvbPRhDEJ64Mh1maLQrFx2ftsLTab+8GJrHbktntaaWdT/0yDe75i9b3jxIurUpeR7GNnGOekDNQOuYK1nChBbaEdOeAnHseyfpGWyYAkLXRlVrfOE/fkIAG9DuH5wyd6PDZvlehMTil5rt7/gCA4ekd1v4jKO/ik6gn5Ax7UtojUqotIdXKI2Ff4V03WiH+zSFIoHPOWfrB/7cPzBo60Q/xnOQ0Dt10iUWXNtvZyHb0BagkZn5N/9eWfvB67Ilp9sQ0S/eUgxZ9KrXGyi0RejL0jvGuOkbNL+6oWCwsrekbedd1TYzNLe/Sap/mCvWNSJCkCNEl2GU4f2X9SNaGi3TeitgtvNDQKfaZX/YMb39bnBBWzTlLP7R4BkHAFcdI9HRY1i5uGLJyT3jql+MSlPuDbegNlxgAwPzS2hXHiN6x3Q/1/Jq+byz97Ilv3KWK1tE1iczQid6NyU8cko3cy9pV29s+mUL1qYl3wgHN91KZkppYdcct0dk/+7FP+unrJLiUg6yNJod1CPKVBTk0df/Sxr2sjWZE8mv6Tl19DS3Q1jdk/omV110Y9zwSe7Y9SHexNqdx6CDWLmkavuuRCO/qedswI6ctn5PGniljJzoadm/onvrGyt+WkObgk25PZD0ipd/xZGWWd2s02t9d4rAbr6is+mNmIx+T0nfJCD8kpqIKz3g655NbkYkY7TOFUm3oFAU3xM8omWghxh9BeT/ZhRbVD2ZX9Z2z8GVuV169DM7/v48isJP3jlv8olCiUms+MvJKfZO1IVtuKtRO1KyHxLSHpHQ8Rmn9SJyAtb+750/BKIjXdk5cdohYFcsAAGdMyYFJWOeOSKjVi+wZKJC10Wc1lrWVKo2Zaxx8kGq0OrVGiw7u4JQaGHKBEImPu9belKt+c6DZEdOo8RXE6BJSbCkprszgnn9u1WF1DjO8VdfQQmMn+ppEhiCIIyUDF1oAV+vD00v617zgqhlrlQIA6B3jYlm7Y2jO0IkOOReyNqRmCDy9GD7nByf5+oaEnjEuAMA5IAcODo1Wq9Zo94rpoCDGlOwyHXYLL0RdkY5k7eKGITPXONRH/BAh47zqvhsvYjZkCq1Op9Ee0TKHZe2RGcFFB9ooZqMwMrP0rZX/xPzy5ILwogMN61zeP8H71sof5jACk6tRoWdwvLU2drhPcYUvgvJvuMSu7Rc6DE6pPmexIyq9KVded47OKNva8KKs3TE8f/Exra5zAkpCOgfkXHaIAADwVsRXHCP3liEV1PSbvIjdkCl33aXlNamxM70W01iAjyo+bxtyTNZG6elw1g5KqbmDi59fFOkQZEOm+NzUGx4EsjaqJ3dS1kazTVjWhlgUSkixpb/ah0OZ2dDUmjNmZPRZWNk2qnf19V7W7hnlXnSgwQQ+AAAXmo8KLDd0T5k4R6P9Mo0905cdIxeFEp0Owd5PmUJl4crAJi2Ov9Z28ssmxb1hbPKQuBX4WhCsGTnRnwcW3HSJXcQsJnwYZfc8ExcEa99aUeHklcqVrsF5fgmVr8IK/ggpyK/ZEWH+IygPFkbvmrwbm4qPjN4ITGHXuPDTnbRH9wSs/bNdqMlzBipi+8wv0xIXD8efiXP0H0Fb8Z3+Cd7/eysABjSPw9r6V/FonMgjgm1HYGFPCr+wwrqBM+a+aEg9Jqfp1HUK3Hhqtbr67snFA4w+m/tmfrQJ5r1pvWhLYBlhDBaw50KFW2d4qz/cD5xfWlNrdFccI1HWqOuaOGXk3TE0D/ZnbSK6AMGy9vj8ir4RERVclsqVPzwIin0jrj0PAEhit192jNh4U0luX7ffwroBg3v+aJXLypr0xwehmdsB5SNZu6x55KLDjkPKXtb+510qvNoprvC8TVDtmwbhB3E3lrWlMuXVZ1EBmPYKQkyJyYsYrVYnlSsvPQ4PT9tRs3OjFZq7MmCcPb+2/wtzClpVEp3TdOo6+aBs5HaERKPGCOaNziz9cD9wX6P3iIz6/3PTr3rbubS6Y/yMmc/Ynrh2Wknnje38CoKAex6JVxwjAQAqjdbQiY76K2o02oWlNQRBZvirP9mG1HTsvksarc7IiY4KDi+tSi49jb7oQHsL1v7YhHgQa9sRUoOStoKQC4K1j42J0HZjL2t/YebzFqydV92nfxUPZTvRBfimXPU/NkEtfdMAgJzKni/NKJDWVWrNE0rmqf1YO7ui57rzTtbKzov166Nw+P+WvpkLD8PQCMnKmvTXx+FoggS92wAAG69k1AtQLJWbvWR8Y+kHWVssldd2TsgU+7f4xuU1X3gYhmrNT8yvfGNJhVbjT8gZHrRCnU5n7EzHLoamuMKrz6Kcqdn38Sx49iWhxNApqrl/WiJViMSbWKpNLe287BCBVY6Ef93L2ucs/LCRibfACVj7nKWvwf1gJ2o2LaPhZXD+V7coaOKusm3s3G0/UlwZNaHSkZxh4Zb8L/9sAACCIHrX8H4JO5c4PL10+gYVVSVf35DrG3qjfDHNE/5sF2pPSsut7i+oHXANyYfP1Y1NhQUu/qIDLZnTiadzHCmZFx7R8qv74AFPXadgd/coEAQ8wKdYvNptvFJYN/DRdSJUucViZGbJyj2ZkdfCrh+yI6a40wrVGh2CANfgvMsOEXnVA8nsdmdqzmkT36beKQBAY/f06RtU6KYIAOgYmjttsuMe0NI3c94mBIYIxueWTxnizVzjXINzY/NazVzjDJ3o8PnXM8Y9fdMfLt9kCrWFK8PkRUxaaRe7fggfVUxLr9+XtRVKtR0h9ZIDLaGojcXpNHam2xFTUdOG5t7p87Yhc0v70BbE+Nzyl2YU54CciIz65bUNpVqjb0yKzdlx2DlrQUF9AoNSqn98EBqWVstpGIrMbHgVWnCQGbZKrTF2oqPdOsUNQ/+8G0SILs6r6cdHsf9pFYC2OOZV9/3zbpB3DCevpt8jgv3dPX+0vEQslZu/ZF52jEjmdL6OYjtSMn9+SMM6VGBBjCk5beSFIMjI9JKVe2J8fktR/eADfMrrKLZas8/iJTKj/rPf/Wy8WHh6cWhqnYF1oEdEEUqhH18nwLqC4eklA+vA11HsovrBiIz67+75Qy9BAEBhbf8XZmTX4LzY3BaLV8ywtDpIwcEpNT8+CA1NreE0DEVmNbwKLYDVhwW1/WfMKK8j2XF5rY6UjAeE9OvO0fs+9pQqtb4hEbLq3KLo9A0qupuUK9V61/BRGDMNLOJymw2sg5LY7RllXYToklPGPtC9U7gmPW1CSd+OAusQ5BMTAoW5f0E6u37gtIkvXDtTEyr/n6ueWNY+ZUQSrktXxZvWnsnhaXUlTSPO/tlPyOnQNlOh1Ji8iDF1iY3OaXEJyrUnpv1gE4jupT676f0yOB8AMD63/L11kHtYIbt+KDKz/vv7gagLBG9F/I2l3yNSelhaLbyGJHb79/dDqQkVxfWDzII2l8BcGLGs65r40ozyIiA3kd3hRM22JaT++jgc7qtqOsfPWfge5AQm2VSYujJuvIhhlXQxC1p/c6C5hhRotLrUks5f7MNhJLOlf+YjY2809w4AeOaXdeo6JR3jj0FhlP/4IMSemGZHSL2HTyVuF1bIlepbOKaJMz21pJNdP0iIKQ5LqwMAbMqV+sY+2Ba2z019doU3T4oTsDYtva5tcLZtcPbPCI5HRFH/mym7qvYxl6D815FsrmC9e2Qe5tMRBASnVGNzF8J1KYVZMb+dydVqdXG5zdhAoWB1IzS11i2c7RHBicxsWN7eNEmkcnpWI47Gic5uVKo0+dV9MNO1JtkMT6/btyNcp0OSitr2SrPLFWq/hAqsqTx6MZVtY+60QrcITlxuM5ockMqVsTlNOBqHll43vyiKy22GRbVziyIKswLV9uUK1iPS69DKqoWltcTCNpjxG5tb1ruKb+qdYnE6XoUVh7BqVrcD64tCCYVZgfLgplyZUNjqFlHsFsH2i69ALWb2Qq5UJxa14cKL/gxnZ1Z0Yy1veCvi+IJW7GN/LzqG5lxD8vwTKiWbCkSH+CVU9GBuSEZZdxXGzKGmY8Ijko0LK/CMLK7pmDhISliHIOllXdgb2zU87xHBxoUXkRnlu6rvO4bm3MILceFFvszy+TdFnMUb8qjMBhyNE5PTpFRp8qp6hw4wCqnrmghPrwMAaDTa8pYRt/BCtwgOM7/loCsMYdV8e8dvhi8kM8r+CCnYFSgLT69D/QT6xnnutEK3iOK6rsn2wbkUzFqpc3jeLbzwVVgRi9OBLaSr6dy+S1HFtZ0T6EKsY2gOF17gEcHpHl3gCtbSS7v2jX1ptbrApGoYfBNLFRRmOUp8CADxBa3YsmIsdAiSV92HCysixZVNLggzyrrgIkCuUFGYZUMYa0AWpwPrgIHF+NwyhVkOUx1NfdMhrBq05HxhaT0ivU6yqdAhSHPf9OsotlsEJ4RVg1UX4S2vUxhlOBqHXT8oU6hSS3bKxiMy6tFNw8AE34NW5BFRUtM50TE0j11s9U/wXgXnk2JL0RV32+CcJ60IF1bgGcXhNA6hj+GhqcXXUWy3yJK6rgmReDOluB3WWaVyOi69udrdBbFUHpXVgAsv+jO8iLNtoJxQ2FqH0UtIL+0qrN2xHozLbda7uhOjh3Wc5c0jS6uSRaFkcHLxsuOOE4hMoUoqanOLKMaFF/luT16VWusbX44lqLTSrl2b15Pig+bfvwNjc8v6hsT/tLbM/0IEp9R8dcv3kITBB/wvxaZMaUdIya0+mSnMkcDTi229ktEf4wtavr8fjH2BlVti5Nva0r81PrD2vwOjs4JTRqQTWcN9wPtAYHLVF6Y+f6MI6ge8JwxM8mMwIb53Av6K+OwtX+yTYHRW8LNdyPOggrya/rTSzn8FFlrg4rmC3XY/7xsfWPvfgfUNeQqn40T2Wh/wPtA/wcuu6HknslYf8B8FpUrzDhVpIOaXRGmlXbtCLtzldVZJV1JRW0Jha37t4PtQSTwSH1j7Az7gAz7gfxNOxtpdIwshqfWhqbUi8aYOQdCW6OzKXpiDUqjUKZyOmROa3W3IlMnFHfyDe/kOwZJQklzc8RaOmcdEblVv5zsV5DsSIzNLGWVdmvdmJqJDkP+qEMHcoiiF03FSFdCJ+ZXUkg6l6ogb1TYwW1g3cPhr/v+NDZkyubidd0CZqVyheodL4JU1aUpxh0j8vpa3+TV9B6V83xXeyQ05AWsvCSXnbUJcQ4oiMxumuMLH5AzYYwoA+OQ6gUAvBgCsimWnrvtgVVeOg7lF0SkT39KT6GWjaOqZPmXii5bfvXN8bkpyO0od+C9Cp0Ow5X30rEa9q17iPRbyRx/keKMhtbTzgl3o0n9NuKawbuDUdfIhdZD7IrGoTd/IG+1OOAhO1Oxvrfz/wtW9MyAIokOQfetE/zpa+mYe+aQ7kDMe+aTbEVj2pDQHn4zHpIyqtjHhuvSUCYXTsM/kHZtbPv8gtK5rf0eLt0DrwOxpE7+9vanvCucsKCinvQ8MTvLPPwhFO8PfGidg7aL6wSuOkWiFWVhaLaqBgnb7iCQybGH/MbGwtIbtKTgRdrW6vHP8G1TF6VkNxZhBz8xv+eymt+TQur29iC9ozak81m2v7550oxVJNv8jzOT+DeA0Duldfb1wwpRRWmnXx9eJhyhwQeBCC9AGv78X6xsyn7jS9zQRprnCgtoBdv1gXF7zWQtKCKumuH4wv6Z/Yn75EAF03rIYF1Y0/O4MpDqH5/WvEfZ2WrwrnLcJ8oh4j0u0+cU1XFgRVkLr7XAC1k4sarP2TNLt13l5JGtL5cp9u+xhH+CKSHoi1sYeDbI21G6WypR7dx9qjXZDpjyonU+uVGMvTKZQabRvvNLAOhA2wirVmn3l9+C7DvrT5qGOefBqrT2TQzAda5C1YYRkYz9uVarUG5hPCv91JGd4xxyhPX8QpDLlkaGAk75+1xehVGl25QBl8je2imq1RipX7ju6jsS+d0mr08GC4sq2sb2srdZo93XAUWu0MJaSXdn7kZHXcVj7l0dbrI1tat133/MXF8LY2yVTqHaZMS4Kxb8+Dm/cU46t0+mgIMG+x5TJVSfarwtWN4yd6MOYGnCuYA2V7dyUHzjRIOQK1UkdDKQypWr7mJC1IetJZfuMFjjZDxL0kCvUaFAXACBXqneNyfM2QbAr/X1M9oMu6S0sHY7F2giCZJR1Gf0r9lsr/2d+2VBjJTytLja3Gb7gENZu7pt56pdt8YphS0hPLNppEJrlixwpmeauTCdqTmZF90fGhIO6lrEYn1t+Ssm0eBX/gJDK4nQgCGgfnDtlSCiuHyQzyi1w8bYEFir3sb4hD0yuekhKN3dl3PdKRSt4NBqtW1hBdcd4cnHHXc9kK/fkhp4phVJNiiu1ck+08UqrxezpfrAJ8owsYtcP3iekWuASvaKLsd/NklCCCyu4455o5Z6Ij2LDhLIOQTwi2JVtozG5TbfdU1GZi71Y35Dj6RyD+8GXHSOeBxXAbub4gtYvzSg1HeOuIfnmLxOc/bNRC4W5RZEXnXPfK8XclWlPymjongIAyOQqCrP8+wchvz0Ofx6Qd1DLMoqm3uk/gvIg0/GWxbjQglu4RBsvVlH9/ppQWPBXxLiwglu4xPt4VkHtlggDp2HodSQbLYLuGJx7EZAL208Kavr9Eyub+6bveiQ7+WUhAISm1qaXdeXV9N92ZwWnVMPbFZ5eZ0tIt3jFeEhMx4aJW/tn/wjKQ+lpYn7FiZoNRQIaeqZeR7G7RxecqTnmLxOcqFnYFvaW/pn7XqkWuHhCdHFkVsNHRl5Y1k5itz8kZli8YjzxzcbSXE3nhDWedQuX4BtfHphc/dlN7yNZ+8/QgosOES39M8/8ssxdmU/9cmBvRWPP1IuAXCkmmB6d1cg+9A4z8luwYj5xuc1QugiCmdcCG0QbuqeeB+TdxsVb4OJxoQVwbIzOCB4SU7+yoFji4p8HFqAqg5zGIQdylsUrxkNSJvp9AQDC0+pSituL6gdvu6dgNZaPxCxfZPgsqntbtgEAwFteP2XolVLcHpFRf8c96Z5nCrr8WlmTOvtnw244pUoTnlZ315Nl6ZYUllarUB6tlDS1IHTyy7LAxT8gpCax23U6pGeUe+oant0w6Mvcmuyo7rlkUxHCqoGT3dqLhYpk6BDEg1ZY2Taayumw8ki+455U2zmhUmspzPK7nsk2XmnYbrILdqG48AJO45ANkWXxKuF1FBu7IBCsbrjTCq3cE63cEz0ji9BGudeR7PLWUUZey2331IOEcCEWhRJn/9zxOQEAQKZQBSdX3/VIvuOeRM9uVKlPkMc67lp7hrfqEVFs+Cyqsm18eHoJAHDZMeL2tnDwQazd1Dt9wS40p6pvYJJf1zV5ySEC6q0I16SXHSOfUbL6x3l51f1mLozTxj5HuvfOL61dsAvFR7L7x3lV7ePUxEqpTNk7xj1tTDJxjkkr6eyf4D/xSbv8NAp2uDb1TnlEFHWOLPRP8JPY7edtgoYmFwEAKrXm4+vEK46RycXtfeM8XHjRN5Z+TtSssNS6/gm+Wzj73G1ftEHrNwfa11bB1MTK3jFeSdPwOQtfWsaWgMb6htzUJZYQUzIwwR+Y5D8kpr4KzYcLos9+J/1gE0xLr6vqmMSKRu2CSq1t7pv53SXuRUBuQ880bKBKLm7/+IbfA3xKccNQ58iCiXO0jVcybFTLrOimMMv7xnn9E3wKo/yKY6RwXarV6TqG5m/hEhzJGfXdU91HOeDEF7ToGxHhLXINznsVWjA4udgxNF/XNXl4+wmCgFehBX8E5w1MLnYOL9R2TsDXUxjlH18noBnO9NIufWMSLHMkxZWeuk7GhRYU1A1UtI4BAIyd6J+aEP0SKstbx5v7prU63avQfCMnen33VN84L4nd/u0df5TdUoo79I28sVJwp0x8h6b4AID4gtZTJr640IKC2oHOkYUbL2LueybBu9Q5PH/O0jeEVds/zmfkt/xkG/LZTRKqyhKeVnfdObqpb2Zgkp9c3HHJIRy2IDZ0T521oMTkNvdP8OnZjd/fD/nqFuVwBxkAADGm5OObfv+iZtd0jHcOz5u6Mu55JOoQZHxu+bObPmhf7vzi2icmRCxB7EViUdsv9mFwwS6Wyr8wJX9j6adUawAAkk3Fl2aUjPJuAACZUZpW2tU3zuscnrd4xYDCA2KpIqeq52e70IjM+vruKfgAy6/p+9U+vLx1bGCSz2ka+dU+vGW7Y8DMlXHaiECOKytrGUPlJY6DvazNXxGfvub1i314bG5z/wSfEF3y3R1/eEsnF5ZPmfhC3Yvk4vZbOGb3KLd/YrGsZeTI8gHeivhX+3B3WmH/OK+mcyIgsUoiVQxOLZ4y9jZ2imJxOvon+E5+WRcdIiB7tg7MutMKO4YX+if4LE7njzZBcDZpdchnN70vOtCSitr6xvmeUZxzt32dqNnBKdV947zXdM5Xt3xRc5mrz6LOWQX5xVf0jHJLW0a+tqSi7s+STYXFq/jXUWw42R+RUv8IyoXblK8syAbWgWFpdVUdk1Ao/yAMzyydNvFr6p0GAMTltVi6JfSM8fonFstbRjZOsk4/QYQko6zL2jMJ/fF3lzhU83pf1kYQ5CEx1ROTygtNrb3kEAEAyK7s/cE6GH2O9Y5y9QyJR0ZIojIbfnschm5q4C1rG5jVN/Su6dhaHc/wVvWNSLBtd9cm/cLDkLDUGgCASq05Y7YjBSBXqD43JaHq5vCJglqr/Pgg2J6Yhh6Ekdds4hwD/ZBYnA5U6REAMD63/LmZD3Ri+9rS9xEp/ZjpwaeUzGhMg0BCYetH173ROpyy5mF9QyLM0e/aI58x80HNblyD8wKO54TN4nR8YkKAHn23cEx0w3QkdDrkDi6evkcNIyi5+pylr3JbVyinsve0ER4+9qgJFf+4SR7DBPJ+d4m75BCBRieGp5e+svDFKo+T4kotcEyNRgcAyCjr/sjIC00JNvfN6F3zgkITycXtHxkT0I7/8tYRfUMiFAZwpxVabAsMAZhXvLYVIVldl/5kG4JlT5MXMVB/2MkvC6tcFpZW94kJ4ci1tget8KyFr2ib3IemFs/bhsDV5QN8yjO/LPh7Fqfzpkvs4dGDRaH43G0/+IW2Ds7+ZBf6o01w9ygXANA6MHPVKWrvxbDrB89ZUOCEX9+QXXeORp1DlCq1yYsYuHuDeBGQc88zEf7fyj3xJ9vgwzUP9sW+a15laOkAACAASURBVG29a15oV7dCqT519TXcVc/yV/WuecGngm98hT0x/fgnis1t+sU+DF2BwpHfPbpwysi7YnvMQydouNrbNdl/exwGjeG1OuTsLV+38C0WUmu0X5mTUTcGkXjzimNkc+/Ww+yCXegDrxT0IEnsdmOnKBjByKro/s1hZ7LP8FY/u+kDNeK/swqwJbCO0wQAtT9hjzSeznHaHh4nxQlYO5ndftc9ER15R7K2XKk2d2U+ImcGJlX5MStCWDWmLnEfGeERBAlIrHLd1ggEACyuiI8T134ZnE/aY8YK49ro7J1fXNO75oUGWyRSRWZ5d2xuU0xu0xlzP+/YUrAtroZuPzVa3bdW/qhavEyuvIVjljRuCfcYWAeSMfq0rQMzX5iRR2YEAAAKs9zQiR6UVEWNrwhIrMSFF3x0w7+xdxoA8JUFGV2SH4lHpHQaxpmbmd/y2U0SGu2qbhvTu4pHbTl5K2JWSScjrzk4pUbfiIgqabwIyPHFXOchgKwNiSaZ3W5gHegdU3bMlBGL02lgHUiMLcPaHRzC2mRGmcG9AOwRjJzoTzB+Dvk1/eauDDkmUFjZNnrqmhcMgxzC2olFbZ//TkRNuWo6xvWu4eEa046QijUQgGp2kLV7x7g/2Qbj6Rz/hEo/ZkVISvXnphQbr2QAwF2PRHRbDQDIquw9Zjbyt8fh6I8SqeJHmyAouZdd0XPRgQYp9aZL7C6Z0H1x3zOJmlgJAPCLr6AmVj4kpsJ3URMq7Ek7S4eukYX4wvaEwlYnatbpa3i4IVgUio0wbj5LQsllh4gXQfkBiVV+zIpQVu2Fh+HfWwfBv5q7MrGN2sfHAay9Y0elVGk+u0mKy20G26xd1zUJAOgeWbj0lP6EknHMpb17WOFei1cY14azD2zxBr5020JoQ6bMruyJzW2Ky2366jbVM7IIAKDVIV+aUdCmc50OMbAOQCW0FCr1HVw8GpT70SYIH71z0q7h+S/MyDD5SU2quvI0Kii5mhpfEZBY5U4rPH3THz4wzt32DWYdEZaEwOrst/TPXHwS5eSfs8ti4jh4j6wtlSlvusS6BOfHF7TE5jbF5DQmFLXDXLN3DOcN5fvlY7H2i6A8n9j9WRtNnc/yRXrXvKC23MT8irVnsnNADjO/NTqn8UsLKgzhYSUxAQAqjfZbK39UmHBTpjRzjcur3goCGlgHogqrAIDOkfmvLChw3JBiS2+4MJj5LXG5zbG5TXF5LVkVPWsSGYKAQ4SM92I/1t6pIalsHdW7usVHzX3T5q4MPJ3DzG8JTK46ZURAlW5OzNrbPV29Y1y3cPYFu7CIjPrjiPz2T/A9Ijg/2YWEp9XCiARkbXRZlF/dj2Xt7+75Y9eYxk7RjzHy2blVvRauDKzlbk3HuN41L6jBBllbuB1AbBuYw7L2Zze90dViVfuY3jU8fJe1Z0oyRnW2rHmHtXtGuT/ZBgckVTPym+GYZJV2D0zwtVrdLRwTm4/JLO85Jmuj2UgAwKZc9ZNtMGTt1XXp15Z+Fa2jKyLpr4/DR2f28STaBWZ+i7krU65SW3smdw3Ps+sHbb1YWq3OlsDKKu8GAOgQhJ7VaPGKEZ7ekFTU9tQvE/0qd7E2b1l86XE4nl7C3J59ScUdKGOauzJRNfYT4SDWRmtI5Er1P0yIzPwWsM3aqNAjb3k9mFX7i33Yv6jZR7YU/hla4BW1P2ujNSTYU09xhQ/wKc7UHEZeS3RO09nb/sToErDN2qgfgkarM7gXgD5B5Uq1xStm1rZ133mboNeRbPR0feO8rywoA5N8AIAvs8LkeRw62WNzm7MqeuGnOGfpG4BJSByCXe4oC0trAUk1F2xDXYPzTlTT9R5ZW63WWuISUjj7aKhGZjZYuDLQH6e5Qn3DI6J+AABCdMkTctquXx7C2sSYEqxN1//YBEFXreOwNqp3bmAdgA3yZFf0mDjT4UI4KKUaGzxBcbj8/F7YE9OxEZJ9WRvykY1XclDylpKySq09fe11zjbRPKfmnChCsiti29gz9Z2V/9Cxi7Sa+2cM7gX2T/AAANSEynO3/dAdKovTqX/19TFZu7576oJ9CFYenVHQYvIiBpYBpHI6T13DozHQmo4JPUMClMPel7XnF0UAgGfULI+InbmXW92ndw0PWXt8bvlX+/Bp7m6nG50OsSWwsHk5Zn7raaOjIyR/hhactwlCf5zhC3+xD0VTC7iwAk9aUUxu03Vn+uHHgZhcWLnkEFHaPHzXPUEilU9xhcZO9JLGIWMnOoyYTXGFv9qHo8HT0uZh/at4yB38FbGREx3Nzq1vyK8+izpIW+5vYW0IgWjjF/vQpP2klbEgM8r3Tq59WRumXsmM8kekHeO6C/Yh7jQ2OB5rozYLP9mGvArORw+SX9Nn7EyHgdzwtDqbA3Ynb83aEPwVyc92odh93pE4SeVfYZulWwI6A01cYm2244DnbvtBj3aRRKZ37TVaOMwsaDGwDkB33/NLa7Bqp6V/5rQRMau8R6fTcQXrD4mp/zClHsnalW2jn9704TQOq9Qa3vJ6emmXRKroHF7QMySgpUjT3FV9I284UPBR7HueyTDeVN89qXcNDwMsWFtVAIBKoz1324/M2FrFb8qUN11i0cjDL4/Czt0O4DQOKZRq/or4fx4E/bEdAR+ZXvrmtl96WRdcooql8v4JnkarQxDkCzOfYIxb5uGwI6Q+9kmXypRwfDDymv/PdSLK2mXNw/rXCFCh5p5nogeNDQDQaLQZZV2nrpMLttfaztQcK/cEeJDDm69SijtOG3uJpbKNTWV15wTMIrYPzl6wCz1EGBYAsCaRV3eMQ138ruH5C3ahUPK4tX/2CzNyVfu4UqVuG5i9YB921sIX2gyS4sq+vUvFsrahU9Qjn534pnhTccUx8s/wAlhNNTy9dO62X2TmVuh8bHb5rAUls7xbqVIPTy+ZvIj55AYR+uMkFLZ9YuKFsnZ564i+IQFSW0xO00dG+J5Rrk6n6x5ZuOwY8dlNEhSD1Wh19kTWfXwKfKNOpxueWYJy/gFJVZ/dJI1ML+l0uua+6Z/tQr+2pB7ZZeNFL/74hl8oq0YslUtlyhdBuedtQ9Cil+6RhZ/sgn+2Cz3IM34XNBqdHYFl6BSLavM7UjJ+fhj+jLIVAJ3mCb+/FwRnyvqG/F/UbL2rryFrizfk31sHxhe0bspVsHiRFFd22SEcLZ6ZXFiBCsMAADMXBhrjjsyo32XNdQhm+aIrjpFdmIw3b3ldz9CrbFuTWqZQfWSEZ+RtR0gMCXAyVneML61KAAASqfyKY+SRLR11XZOf3vApqhtUqjSLQkl6adeaRNY7ztM3JKIa0VzBur4REd2+33HbWlM2903/P1dfe9E5AACtDjljRg7djmBotLpv7lAJ22EQuVJt7spAGfOyY8RZy4CiugG5QiVYlVywC3Wibt358fnlb+5QU4rb4WSXSOV941x4urO3KNTjLZiw2p9VHWNwZbMq3rzkQNu3TekgnIC1Uzgdb7D282jbbdY+a0GhJlQAAETiTb1reNSqTq5Ue0SwLztGPA/McwnON3WJ5WwHoehZjT/YBD8mZ1m5J6SWdN7zSC4+wI0Qi7C0OgPrABuvNGMnuktQrlKt6Ric0zMkjs5urbUXhZIzZhQYbBmeWrz5gmGDZz0PyAlh1fz6iAapWaXW/MOEiCqEKdSaH2wCo3O2SHxTpjR1YRTVbV3Mjw+Cn5AzXobmW7mzLjmE2xJY2JmcXtr12+OwR6SMV6EFpq4MalIVrMk9Y+YTduyZUFQ/+INNoKlrfGRGPQCAmd/yqQlRup2va+6d/uwmCfJRZdvYr/bhT/1yXgTkhKbWfncvKG979Fe1j523Dfn9j/ig5OrDs6ApxR2njbxkCpVwffO+Z/I9j0Qcrfi6c3TWUcyyLNqwxqfc80iGr8d2wBJjSn6wCbzvlf6EnMEq6TR1jYOPGVJs6bdWVGzg5eqzKOxaGwDQOTRv4hJn/pL5PDDP0CnSh1GGNTSIyKg3sA6475Vu45WcXtZl5hoHF/gJhW2fXieiWc3W/pnPfidNzq8AADYVqlfB+Rcehj3xy7UnstJLO2+6xKIPpCmu8L5XqolzzMuQvEfkLGvP5In5FQCAWCp38sv61T7cgZLzhJKRyuk0dWUc4gcE8WdowU92of6Jldedo393iTNyisHqH2i1OkMn+hlT8pHsjyIyo+Gj3wNRKwNaet3pG/5p26r8Oh3iF1/x2+NwXFgxPpKNp3PO3fZFI0h+8RUG1gGmrgy4/FwVbz7zyzJ0inIJyncOyLVwZbT0z8JXmrrEomttQ6dIC1fGMau2Z/miy460PaxNqGjdYm21RmtwLzBuh7WJsLbSI6Lod5c4j4ji311iyXFlB5U8v3ErMusNrAPu41OvO0c/p+bIlSpoF4XuCFfWpF+YkWFce3RG8LsL855nirN/dgir5qIDjbDN2p+bkmjpW0kmlUb7k20w6mQrU6gsXjFQvrpgF2pPTMOFFtxxT77sEHHfMwU+aSCyK3ouOUQ8JKa+Ci0wc2X4xlfAnPlXt3yPuc0dnRXoGxK7hucBAK9C801dYj0iim+4xPgnVqJpoePgBKwtlsq5gnV0HTe3KOJtb2wnF1aEa1IAgFarG50V7Op6mJhfqWgdre6YgC4VKKa4K5XtE5CPeMvrkuNpiUxxhZXtEzDYBADYlKtGZwVoXb1Oh8wtitDFjkQqr2ofr+uaVGu0q+JN+HBDEDA+t4xG1nTIG2/RIcjC0jr64+TCyqZCJVeq67unWwdm9jZKCNeldV1T5S2jPWNcNI88Mb98ZNEYFgtLa9UdE7AEQiSRTcyvoCdSqTUz/FX0S10SSipax2HRBX9FjFXl56+IqzsmF5aOaAJc35CPzy3DkLRKrWnsnS5vHTt8lY1CpdY09U2XtYyiVsgoese4td1TIskmAGB+aU2t1QIAlkUbU28eeZYv2msXJ5Up67unKlrHIIHuwsiMoKZzCs6fhaU1uDlYk8jG55bR55Nao53hrWKHft84r6ZzCpaFzS+tYf+k0yFdwwulzcMNvdOrb/o+d48s1HROwbs6v7R2eNUHAIC/IoblPe2DczWd43s7Wu95Jp4o76fWaEdnBGiWdVOmHJ1Z2jWlByf5ZS1j07xVAMAsX6TBPOT6x3l1XRPYqTQ4uVjeMlrbNYmVCplfWkN/XBZtHKQisu/lzfJFcoyOjUarG53duWAAAFewBieXSq0ZnRWglmD9E/zS5tETqfpM84SV7RN941u1szKFanRWgN4NONlRttnYVFZ3jNd2jKs12jWJTLA12ZGJ+RV0MiIIwL5FhyALgjX0xymuUCpTKlWahp7plv6ZvWke4fpmffdUWfNI9+gCOjYmF1ZWD3AP3wWlSjM2K0DvXu/YQmnz6CGVwQfhg+bfB3zA+8KCYO0n25CStxLY+YAPOAgfWPsDPuB9Ibeq97Ijbf2EQmAf8AGH4wNrf8AHvC8sr0mPH9H+gA84Jj6w9gf8zXjnFiQf8AF/O97rqH5frJ1R1nUfn6JSaQAA/gmVOExPzTGBj+LAOvm3wOTCiulL5viejNk7REJhqz0x9ThtKSfC6yg2tqnn+JjmrTb1Tv/HemstizZGZ5dHZpbG55Zn+aujM4KRmaXRWYFCqW7smTJziTtR8vZvB39ZbOrKxBpvHwmdDmnpn4HF5kdiWbRh6srsHJ47+qX/Frz1sHxPoDDK3WmF7/CAr4Lzj1lzjYVIIoOjemxueZa/OjYrGJkRwHKMKe6K6Uvmvtn1v473xdrUhMpPTAiwU9naM+W3x7STHsHkRexNl9i3O3v36MJpE9+O9+lB4xlZ9IUpaZes61+HsTPdzDXuLd6Ijyr+7HfSWyhL7AsEQWb5ondodBmT22SOS7iNi7/oQPvSjGzmGncLl2CJS5jliziNQ6eMSLy3cjL6uzC5sHL6OuVIvTMsNBrtudt+xxTdn1sUnbpOKWseftsLfMd462H5nmCJS7jiGHn4a5QqzfjcsvR4qky/2tPu41OOft2byK3qNX/JvO2WaOhEP2PmY/Ii9hYuwewls7VvZmxWcNrEt+tQMam3xvti7RBWzbnbfrBIy8En47pz9EmPYIlLsHJPeLuz943z9A0J2A6udw5SXKnBvQCt7h2ztgUu/p5H4lu8cVm0MTG/8g63Zc7U7JRDZSdPBKlcKd6Qb8iUWRXdRk50rmB9Y1Mhlsq1OqSgtv/U1dfYwtj/fExzhfrbukjHx+TCyjE/5l/xCXkfeOth+Z5g68UyPWpJt7y6cesVc3DiWO2+u1p2jwmZQgVHdUPP5CUH2sAkf0OmFEvlao22b4yrb0g40W7s+DgZa0ukirquydLmEbTJCgAwOiMoaxkpaRrGtiQcwtoqtba1f4bTONSzh1UlUkVl21ht16RSrbH2TLJ0S9h7DWq1tneMW9o0XN0+vn5AiTdk7bFZgUC0UdI03D40p9LsLmIfnl4qbRqu7ZzE7s0Fqxsrog0AQNvAbEXrGFy6wiLl2s5JMaY42juW8/39QADAwAS/uGHw8GgMb1lc3jpa3T6O5qZUak33yEJJ41B1+zhWtXLX9FCqNG2DsyVNw60DsyrNG4LuMzwhAKB3jFfXNalUaRRK9YpoA0qnCoSSLfnK/tnKtjFYvatUaxp7p2s7Jvauxwcm+SVNw029M7CSVKnSDE3yTZyj8XTO4CR/fnGnAHx0RlDaNFzXNYkVlhSJZYsrYh2CNHRPtQ/OHq79X94yYuoahxUeyavuPX0VvyaRTfOEnMahvW4sE/PLpc0jNR0ThxgGTnOFey+MJ1iv7ZwobhgcxHTqK1Ua2NE+v7hW0jQ8Mr11urFZQVnzyNjszveo0WinF1YAAMJ1aVnLaHPfjGy70nYvayMI6BpZ4DQOtQ7MHlTlLRJvopXUao22pX+2uGFocGpx7x2DrN3UOy2WystaRrCnBgCIxLJ5jJi4VKac4a7CkwrXNxdXxBqtrq5rEnZz8ATrEqlCq0Pquyer2sdFeyJRS6uSyraxspaR+Tcr/cVSeWXbWG3npFKtsXJPuOt+IGsPTS0WNwy2DszKlTu9M/NLoorW0bKWkRkMV2xsKub4W4LgJY3Dc9t/6pvgl7eMYlsNZArV1te0JCppGu4aWcBGI3extkKpbh2Y5TQO9W6zpFgqL2sePm8TlF7aNTi5iH5qjVbXMTTPaRzqHF7A3nZjp+gn5Ax457EJZJ0O4QrWsV0R+2Jgkm/kFMld3rn+ntEFfUOvsVnBkmijpGkE2uruAhR/bumbOcjG4SCcgLWnucJbOOZdT9ZDYvotHLOhe1KHIL7x5VbuyXaEVGvP5EsOEdXbiqkHsbZIIntKybQlptsSWBa4JHw0B7W1nVsUmbsybrklPyRlOgfkXHKMRnVOUGxsKp2o2fDtlm4JN1xi96XL/gme/jUvPJ3jTM1+SEy/+CTqCTkDLc5XqbXesaW//8GwJbDueaZcdYqq79qafm7hReaujIjM+kekjOsuDJMXMf0TfFxowUNS5s0/mDdfxKJrJV9m+bf3gqkJlfbEtPv4lO9tQpMwikVY1HSMGz6LeuCV+oCQ+tArdX5RJJUpn1Gy7IgZtgSWpXuSmWvc1LYyBpa1Basb9/Ep1p4sW8L/x957/7V15VvD/8lr8EyeuUnmmRknnzg4kzi2rxOH7gK2MSDbFIMxuhgsW8HIgBBFNFEEojcBEr333nvvvTdRhBCoIens94eNNidCYJzJzOQ+4/WTAVmn7bP23t+yVpopOZlASUHdEF0ji5ctAmJzWy3epjx6m7a2uZdc1HH9WRi8RhIjz4ycGJHR+IyWYfQy/p5L7ND0GomR/8wny9gl4R4pHqmHy+UKv4RKs7dsK8+0Jx4cK480/p5IIBSTGHlfPAq8ace0982G/eUYhrEym0xfJ1p5pltRuWbkREQcUVnNtxwiWFlNJq/jn7qnCg/O2pOWNo/ccYnFt4EUNQz96Y6PR1SJLY3z1DP9CiEIr8mQXNgOFW+sqZw7LrHjmuLCJU0jt13irKkcG1pmUmE73HAU1A/dc4m1o2U88Ui75RAZzqmHvx+dXf/CzD8mt4VIz7Kmci499Muq6sut7X9ATnrskfrVowDU87nKE3xhRmdlNZFC8m2oGXrEGDPX5H2RDJxgbbH00C2iyIKSZuWZZkFJd/TN1GhrYkCMggpfIonMjXn0eTtv7vC0uqXW8sbuRT0PcmgBKSTfhsrFHxoAEJHReNMuHM0NhQ1DX5rRoWQKI63OgBgVmdlk+jrRlsrBMPDUI/W5T4ZvQqUNjXvbJf6eyy8aPpt6p01c4m2oXBtq+k+OrLLmo9Ly+dVt/Mv4w/MojZI7CiUWzqnXJ0Y98Ugzf8umRpdBAsqo7L1lH2FD5Vh5pP1gx4RyWgCAkqbhb5+GJuS32VLTLChpOoSg+u6p6OzmJx4cCze2DiEImVS0D85/ZR6YVNj23CfDmsr5bzsWiZGHuALP2tu7B8+9MyAnmP6cTIstlyuUozPr5m+TPzfxuUeKs/fNgbuWfZHEJSj3iQfHyjPt0Vv2G0Y+EoVHrO3OKn6Ek/ntH1/6ySHyvZ5hfeNL+o4sfBfhwOSytp6HK7MQnv93Txnh3AaUopQdKqgx5eaUVCvPNEt3zjMa94McB8/L2odyhZFTzAvfTPhURmbWBiZX5ApFecvopkphx51VYumWDM/sNNa2pXKe+2bAz2zy93+0jyisHwQAKDHMlBRv8TYZTtcVraP/90EAXp0SYltwUNY8ArlJdig3c02C4shqGJpe1TakPfFMg1J5g9Orl839ixuPJDuC2LU6lgFwZXEoVwSm1NywC4ezMdE/+4LuO9gWsS04uGkX/pW5P2x43drd/+ZJMOqDD0yp0TbyjchogOvT6Ozmq1aMjR31QPAKb/eSGR21y3cMzS+s7fD3ROUto1AkTyqTPyAn+Krk+hBrK5RKU1KClWcaDMxtCw7MyElO/tnw1rUNzl00pjvSs1Z4u7A5ODCl5nMTb3hnnvtkXNTzgG3Nm3zhNevQry0DoJXJxrZQhxCcWHBkKhSd03LdNgwuJTAM2FDToWuz7FDx1CM1MqtJrlDCDGd2dZ8OIRBKdgAAXjHynFQixSFpdReN6SGpdfw9kfBAojhzrX2StUuahrWN/NxZxXB/wOQ2/O0BHbbaVneMf2FGn1J1V1JjSp+4s9UywHK5wsw1OavyqB1/a3cfrqGa+2ZQA21Zy8hVKwZU5BiYXNE28n3LLIRR+yB27R+NaOTQAiicQo0p/dGeCcft0jpfy8DLyjMNNo7Or25/+4QBjZzmVrbxrE2NKTV2ikE7FVNSAmqhxuNri0BoYtDUO2Oo0iATiWUndz/LG7va+h4mpHjIF/hDAwD8Eqv+fI+GFmjcip4Leh68nT0AgF9CpbaRX2Rm065QDFne+GXspYd0KJfK3xNdtw0jhRwJJC2t83Usg5AHRX794I/2EbCt0ZQUT6CkwPtQ3jL6fx8E2HtrUMcuqB/89K4XXEjui6SNPdMS2WHLwOynd2hIVqiqffwLMzqUtcqtHbho7MfMaIDtiET/7M/u+Qan1u6LpHKF8rF7CpI4b+yd1jamuzGLVngCAED74NwXZnRkHIxn7aceqUioen1beNOeWdYyCgCYWdrUdWS1DszKFQrYQ/uKkWf+9kiTQ3ggMSBGsUuORKxQhKS+e+oKIQjxbzC7Vp/Iem/RwUnWHpxc0Tak2XlnwK1qXk3/n4xpSC4pKKXmJ4dI2FB6KFeYv006Z088xHlZe2xu/Zp16MisZi9RaODGKe/+o5EnFNDQyNorvN0btuG1HZP7Iil/TySRHt51iX3kmggAWFrnX7MNg7oqEA/ICWfEtWEogBSSj1c3RlDFtY+zkS/9s12CcgEAcrnCxCUObwWwLTjQIQRCuagXvpm3cNrnlMhiHctjB273qBIflcA3Lbb8srk//ktu2IaetJjKre03IEbhO4BPXoVTQDZKrSDWnlrgXbVm4I1Na7smv7YIgpNN68Cslr4nXg4CL3JtS+PoE49zNeTQgm+fMtCPb5mF/knVAAC5QmnumsxIrRVJZPw9kVh6GJRS89ldL0i7NtTUuPyju4Rh2HOfjHeRxWLp4a5QfCCWsUs6L+i6Q7pnpNb+2cTnnFKTJ1m7oH5QS+/dJv9owhuYXNE2oMHl58+hBU7+OSKJbFco3hdJS5pHtPSpag6QSiX22D3NwSfjtCoUpRKbXdnW1nOHMkZwbPSoMtUzS5taBtR21cDrG1++6xIL9yIwTIFPCVJjyqw80gAAC2s7iLUPxDIjpxh2ceeBalS/Cs775knQyTP59ikDCoEOT69dNvcvbT61ZxIeGhmJoUPDtVpgSs0XZnTE2llVfRcNPeENpMVVXDKji3CRCgNi1DPaMeE6+GSiwZZa0mXsHMvfE+0KxYJ98dzKlpY+tbpjYlcovv4sDMkHAgDuv4nXGNd+FZx3sjzMnVXy/JcxYku3ZFJIHgAgp6b/op4H2upVd4xrGVDRWie/bpCgkntr6p2+oO+JX+Rae6Z6Rh85mSDWXlrnX7MJaeiZFh5I+HsiiVRuQIyGecVVnsCAGNU7ehSG3d49uGUfUVA3eCCW8fdEUpncyjNN15EF/4pYWyZXfGfFgHrccrnCgBjFfp88IdDE2v0Ty1r6nkjoalsg0tLzhFJLUpncxCU+NrdFJJbBAeMeXXrpod/5bUXPy9qtA7NGTlEbO+q5lPXtPVpcxQt6rktQrtHL2M/u0OAsqpG1JxZ43zwJeuSaYu2Z/piSYkvlXHsW+So4DwDQN74Mk1Tomx+5Jmpk7bG5dVJIAZGe4xKc+51VmKGmPCd8M/GxJFpc+XdWIQCAvX2JsVM08r4BACgx7NJDOlRDf+GbaYDjO0pk0VWrEPSjX0IlsryhxZXrEAKR36hMrrhmHUo7If8dn9+Kd0hBGJ5efRWc9z8BuS7BuVeeq12b/AAAIABJREFUhN12joG/R6zdOjBnQIza3DkOsU3M87QNadC+CPoDTC0chwt+wdpUzm2XGPQnNQ1oWkw5fNPE0kMTUpzRy1gb6tHjMHwZq09kwU2AtWdajGpjq1Aqn3ik/USMtqGmP3VPtaGm33WJ+96KAYkymF37hRkdr4ZxBk6ydn7dgLbuOzS0esaWtPQ8oUIQkZ79w3OWLZUDD2r6OuFr8wDkookwNLVq5pp091ViUEotCkHKZPKkwvbnfllO/tmP3VO1DLzgSk1tbEzMr1/Q82gbPBLPHJlZ03dkwYAVpM5anBRlTE7L3+77YhhYXOcj1ubtCG/ZR9wjJahuY9qtFyxkzocHYm2FUhmf1/qDXZilWzJSy8NDw6Gzm/923xcKLp7J2uU6hEB8sbA+keWI80x57nO88Y3KatIhBNlQ06080p54sAkU9hfmQc19M5MLPEOnKLw4yQNygkbWfkZLRwKNCI70LKQnDPHCN/OabSiArG3gjvRvK9pGL+i5ow1cecvoPVI8jLA19U5f0PPAi9iQGPmIZBFrj8ys6VgGwiAtHMPf2zLh8F5a5+s7srpHjqbnhbWda7Zh98lJaLTffB6J5Cfx2chgds0DchIAYGx24wohGO9Hehrey9rr28ILuu6lTcMAAP6eyNAp6o7L8YDRI8bccYk92/8Pj/OydtvgnK4ja/WX5Vl7B5LHlFRKZMnY3Mbyxi6T2/CJsedZrD3P+8GOWd89tbTOn1/dnlvZ3tgRws8MTq3oO7Lmlo8v2/xt0sls5NTSppFTdHR2y8zy9sqm4LlPxg/2GmoK4Zs5PHO8UPWMLrGhpgMA9kVSY+fY8pbjV0VyKL9qFQJDby98M/VVIwMA4BZRhFdP9omrgAt2AIBXbCl+GS6SyHQdWell3WpnkpDfhqJGCONzG4bEqNjclpnlrWXerjU1HQ1HxNpdIwu6jiy80NLA5PJfTHxGZtbBL11dINRY29j5mLXfMPKv2R6zNjW67DUjHwAgkR3eI8XH5rau8Hbh41jmHclmYRhm7ZmG7H6USoxAYQem1K5uCo4+ubGLNHfUvGzOxmmsjV5dqKEMWdvBN9M9qhQddGmdLzglL6RUYrVdU4/ephAobPja0xMrzd8mtQ/NL63zm/pmLuh5QL8Vtfqi8bn1C3oerSpDxaGpVV0HFgyJQOrEpxzDuA2mpHgAwPzqcYRka3dfl8jKqe5f2Ti6jaubApFEw+4KsTbExraQldX03RNGSpH6au7koZkZDaakBLgN8kusuvTQF73kBfVDv2Bty0B8Qao+keWAU5nHhyuZ3AYLt5Sljd2FtZ25le351e2dPRGGgaGpVX2VojfEQ9dEjdnIZ7T0kBM2Lk6BOb6/NOh4Qc+C61/I2mitXd46ekHPfVU1yPFjo6l3+oKe+8La8Tk4B+Y4qQRsj1l7eu0Hu7Dmvlk8pcChuLC6bUCMQpuqhdWdWw4RZS2jyxtHn1zb2hPj4tqItQenVv92329xfccnrkJjNP8kTmNttDhY29q7oOsO0waCfbGRU0xaafeK6kxWeIID8ftFEBHOy9rLvN2vLQPwu0WJVN43vnzDNhytB5MK2y8aeJzB2vw90U8OkdBqWg3bgoOvLQNQGmpfJL1qxXzsnqL2sYyKHnzu2Ckg+4athgjJ4NSqlgGNW3Gsb6nryIKLAiWGPfZIheFFiM7heR3LQLgXO8na3/6StV+pjNP8Eir/cj8APafesaUvzegjs+plRjWdk1+bBy7jNvVSmTytpMuUlIB+89yHg/wnEWuvbe99ZxVShDMsD+XUGzvHwFv6waxtHYp+pEaXvQktAABgGHjuk0HB8QgChmGP3VPQWhsA4BpRhLeYwAN/aKhCfkZj2DlZG0ZIApJrPki8f21rT4cQODa7jmHA2Ckaaf/OLG9d0Pf8dawdgXOSM3kdB5tN5laOs5EyueKha6LGQLYa1FgbIiC56uQy9uSh77+Jp8YcNZ1FZjZdeuiH1tpuEcUXDY8MHN7L2s9oXMTaZS2jN+3CToa2tgUiHUIQcngRHki+swrTqFxIiSoxIx+P5MNDhVyhDOc2GBCj0BA4EMtu2DHht+VU952TtZv7Z7UMaEh1Wiw9vGYdmqayWEGsvS0Q/WgfXtqsQeR5aZ1/yz6if+JotXsgkho7x5wW7lCr/LOlpntGl5i8joNWAQqFcoW3e8Za+INYW6FUPnZPpSedy3lKIz6ghuQVI+/K45C82oHarimnwLyC+qHt3YPvrUNpceWTi7zqjok7LrEXdN+pVjpVfzSiQoohUFIRt8bmtn5tEZxV3TuxwOsZWwznNgyobispJP+yRXBZ82hN54RTYM6PjrEns5GdwwtfmvmnlnRNzPNyavq/ehSA3/sj9E8sXzSm33KIjM1taeqbcQnKvWwRiOo0arsm/2LiE86pH5perWgbu2Ef8Sb0KD9j5Zl2zeqY4F4xcr80o6Mf3SOLEXN5x5ZfvE23pXJyavor2sZvvYh86pF6eCJKIDyQGhKjjV1iq9rHCxuGHHwzh6ZWukeXLj3045b3jM9vZFX2/s3UBwXTDZ1i7rkctTP4J9d88zS0sGFwdHY9qajjz/e8s1V2E429M9pGfqO4ScI3vvITY09InRZuKfgtCNE/S4dwHGZ1DSv4H1UisWNo4W/3/YJTa0dm1kZn1+PyWstUAuhE/6ybduHlraPdIwsAgIn5jS/N6J7RJYNTq2NzG8lFHXm1AzDJgz80PaHqsnnAyfIyhML6wVsOkfglc3Z1n7YBDb26nSMLF438oHzl8gb/imUQKSS/b3xpfH6DW9HDLe9RUw+fX93+ObyooWd6anGTnlhl5poMX3t774z75MSh6bWOoXnX8MKLt+kw4NA7vnzRmN6lajscmVnVNvKFbp8AgP6J5e+tQmFh0gpv96KBxw3b8HBOfVPfjGd0yecmPgMTy+Coy8YPddmUNY/+xcQnLq91bHZ9cGolKqtZYyn3pQd+0ColvayLnlg1Mc9rG5wzeR2Hnx0hljb4Woa0761D8YdGlbKrmwIdQqBbRFFj70xQSo0+MUqHELTK2wVHzV/eeNa+Zhv6xOM4RvfUPe2m3dErI5EePiAnmJLim/tnJhd4ZS2jUVnNcLMFX8by1tHqjnH4MuKdYhD6xpf+YuJLDi1oHZiLzml2CcoVHkg2toVXrRhOAdldIwvtQ/MESorRyxj+nggAwC3v0TLwQt1bxY3D2kbeKBRTWD/0k2pstA7M/sHQ57ZzTFJhe2PvjJ0396p1GIqAPyAnoOg8K6tZhxCUW9s/scDrGlkI49QPT68BAEQS2d+fBL/0zylvHYPTcEZF7yUz/9TSrvH5jf6J5YiMRmQzfd02DN9lU9QwfFHfw5AYBdkso6L3v+7QphZObXTsHl28ZhU6u3LskdQztnTRmI4yT6ubAm1D7yKVh0l999Rf7/tGZDSOzq4Nz6zF5LTUdn5Ax9YHsLZcoWRmNt5xiX9ATqInVsIauNb+2Sce7Gc+2SFpdVVt404B2fCpZ1f32VI5MLEQzK51izwy8VIolXl1g5ZuyTbUdGtqBi2uAlVHHsoVkZlNJqQ4C7eUuq7J2s6Jk8YCSiWWW9v/kJz4jJaVVtbFKet2Z2lYKs4sbT4gJ/SOL7mGF5q/S7PzzlBzs63tnCBQ2FZUroVbcnpZD+KB0LQ6V1ynbGJBm2/8cag6taQT1TClFHe8Cs7uGlm0cEsxfZ3kl1h1INZc8bbJ33cNL3zommJJSY7Pa4WhyayqPjNy4jNaFqesO7Wk01PVu+8ZXYbsH+VyRVJhx31yghU1w5bKaeqdQd85PL12n5yITwNkVvba0o5ueBC7Fr+Cjs1pgf5wR2de1JGY345+bB+at/PmwrI558AcZKU6v7bjHJhjSk7hqiT5BydXYdmlDY3r4JOJ+r7wh+ZW9LzwzeTvnVrG1DE0/45VLMLtB5v7Z83ISSgevczbfebNRfrdE/Mbr4LzrDzTbWhcWxoHLYoRRGJZVFYzgXJUo4bYf2mdT2LkP/XMeMPIb+6bcQ7MhX7nM0tb98nJaAqfW9l+5s1FscvZ5S3X8KPykqV1PrTT802oMKdwrD3TUZB0bVNwn5w4hKvYq+mYgOWJNrSMn0MLFlY1BEMd6VmwDmRkZs0lONeGlvnEIy2xsP2kDgFvR2hGTmofmjt5aIjGnmnzt0kW7tyIjIaFtR2vmFL4HrFLOl/4ZuL3OuTQgjDO8Zo9rbQb5fQAAFu7B77xFY/d02yo6QQKO7u6H56M7FARkdFk+jrBwi2lvnuqtmMi/JTNRM/o4hMPtjkl3d6bW9U2Bo88ucBzCsgmuKcTKGl+CZVokm7smX5ETkSr+7bBuRe+mfs4awvP6BKJVA4AaOqd1tZ9V9c1+YqRZ05JI9KzZ5ePSTMgqRp5ASuUWHbNgCUl2YaabkXl+sZXoLx0c9+MhVvKfXJipyqzWto88tg91YbKtaFlurOK0WhxDS8ITa9H37+zJ7qg545uVF3X5FP3VDV7ADymFnk/hxbgW6imlzbvk5MRjx+IpY70rDbc6G3snbalcuB7R2LkTS+pu+KdgQ/ujVQolSc7Vs7jTHHyv2gUzTg8fH+3oUKplJxSlXESZ8RbRRLZ2bYv58R5iuRlcoVajlihxM5zFRiG/Yrb+6EQS2VSTVdx8tJgR88/+3xOnob4zJugUCo13iWRRPardXxgmKK+Zwqc7xEDAMTSw5Nvx+kf1vwKqEEqO/Vuf2h3xmk47e6d52WE0FglJZEeys79DWqA2Ug4m54zZSKSyDSW6J1sehJJZGf7XaxsCi5b+KPi8X8exNJD2fucN07io+bfR3yEZiys7mgb+ZT/bsRA/qNQ3z2lbeQzsXAusa3fHLS48h/smZLT58t/Lz6y9kd8hGbw90QUZsnJDvuP+BdgemnTjVnMO9G29i+AXK6IyGjMrPoA0/R/MT6y9kd8xEd8xDF+/4LvH8Dag5Mram1p/wJML20W1A839EyfvwT9NweGYX0TS/+4bOm+SNozunhan+RH/Nvx8QH9HiBXKFv6Z3NrBxdOz/6pYWmdD+tG/kPwAax92SLQ89faFPw6zC5vffuUYe+X68Eq2TqfC/I/AwqF8tO73uHc+n/wezqG5rX0j/pH/nnoGV967pv1286vvgmVTG7jb/iFv0/8ax7QR5wNZkbjFUIwKaSIW959zkWvZ1SpDiHoN7co+d3iw1gbVdv8g8AwLL9usGvkPa4FIWl1qBvlX+nSMru8lVbahfTUFQrlp3e9Tqt8Oj8gKZwUePtt0dAzdeNZBKps+03wjMbF9yX9P4Om3hnUxwF+0wfUO7aUW9N/fmWJfzvkckVmZS9e9+bfApFEdss+AvbHyRVKjcGK9qF5KIWG4MEq+bez9qFckVHRO/IvWfJ/AGvrEII0Cuz9OhAobNQwfRrco369Cdk/gqae6Z8cIpHiqEKh/NzEBwrK/CPoHF7Q0vM4pwfVR/wL4JdQSfQ/1ug4ekDvk+U8DxLyWi1+TzYC54GJSxzUUPs3YltwYEiMOnviDEuvs/llozk1uuQKIfi0z/9roFBgt51j8M3M/zx8EGsH+sSV948vuzKL34QW4ps+AACNPVPvosqI/tlB7DpUu87fEycWtJNDCxx9s0LS6te29gAAgn1xZGbTVetQ87dJjLT6wl9OmxBSmTy9tFuXGK1PjApm10Fxn5SijskFXnHT8KuQoprOSQAAhmFZlb3ksEKngGxGWj1qstrk78fntm7sCNNLu4kBuSFpdWLpoUR2GM5tfBmYG85pOMOXqGNo/oVv9leP/KkxZcHs2rVNAYaBP5t4szKbOocX3oQVuUYUdw7P4/9LZdv424gSIj07lNOwvXuqJ3fn8IKWnnv/xHJ2dd//BOTS4qrxS5vqjgn8CqJrZJFd0gmrSstbRuu6Jodn1t6EFcfltgIA0ku7RmfXOwbnSSGF5PCitoFZ9B+X1vlxua1Qb3NgYplb3r2xLQxm1xL9c6JzWvByB9WdE+TwYufA3NC0elZWM+dE2yFCUcNQpUrkKLWk87RDAwD2DiRMbiPRP+cdq7S5fwYAsL4tTMhvW9/eC02r/5lZArWfeDvC0PQGJ/9s14jimo4jjSQMwxq6p2hxlUR6liuzuAlXLbvCEwQk1zj6ZnnHV+C183tGF6kxFUR6ll9SzbRKaUguV6SXdTsF5pFCC+u6NbecKZRYdlWf8cu4H+yZQey6+LxWAEDP2KK2nnvXyEJGZS8xIIeeVLWK04EBAMwsbfon1xDpWZ4xFT2n+NthGChrHjFzTblqzfBPqo7MaBQeSbuArMpeUkiBk39ObF4rip5nVfZ2jy4MTq64Mot/Di+CDZBV7ePk8KJ3rLI+nAJaUeNQQ8/0wtoONabcKSA7Pr8VH4IfnFylxVUR6Vk+CdX4upfcmoHOkYWO4XmXkKLsqr6dPVFMTgsppMDRNysiown25vB29oPZtVcIQdaeaYy0hsq2MQBAS/8sXuh8eGo1Ib8Nluo3dE+VNY9OLW2Sw4pC0urgsJErlOll3a8Yec7BeUmF7WfXkvP3RKysJqfAnFeM/OSiDlgtPru89S6y5EszunNgXnR288kCEiWGFdYNmrxOvG4bFphSG53dDO01qNElV60Y86vb/inVxICc5KIOfPPB4jo/MKWO6J/9jlXWNjgLTkFjz3RqyXG/e2v/LJ6CO4cXqjsm4L2KymoiMfKI9KzIzCbY0cPbEfonV+sQgm2o6Yy0BqRSq/HQa5uChPy29W1hSFrdz8ySXxHM/ADWvmkXftU2khScxynvfccq/eqRP+rXyq0d0HdkJRR2cMp73oQVPXRNhN1QrKwmR3oWp7yHU97z6G2KnTdXLleIxLKkwvb/fhb+2D01Nr+9vEWDXqVcoSxqGDZ2iTN2jo3OaRmYXFZi2Gd3vIycot1ZpcystpqOCaUS84wu+8mBxS7p5pT32Ptk/OTIgu2C/RPL2kY+zoG5QSk1nPLey+aBz30zKZEl7qySlOLOr80DnQNzTssU908sk0IKdAhB/ik10TktG9tCJYZ9bR7433aR5NACTnnvK0bBlcdB6MVILuowcopJKenmlPe8oGfbUNPFmpSDAADdo4vaBlRTUoJfQiW3oteGmnHVioH0N6w8067bHjfTe8WWfnrHGzYpPHZP+bOJjyuziJHemFzYDgC49JBu6BTlHlXKKe91DS/WsQwaVE0AVe3j2kY+UJM6KrtZS5/6c3hRELsmqajzimWQl8qzNbu679J938TCzvSy7hu24ZfMAspaRk+7Jz/aR1iq9ED+9sDvtEML9sUECtvCLZlb3huR2fQmtGBfJO0ZW9I28nnum0mNLgvjNi2s7WxsCx+Qk9xYpZzynviCjht24VCSdHx+47F7anx+O6e8h55c/fcnwVDGQXggsaGmu0WWcMt7WFnNqPehvntK15HFym7llPd4x1UZO0VDko3NbX1ATuBW9KaW9qSWdGqkD6USK2keuU9O+skxIjqnJa20Cz76iwa0Oy6xtLgKbkWvkVMMgcJG89zo7JqhU1QAu45T3sPMaP7RnqkxnoBhWH3X5FNP7vVnYREZjYkF7VBG2TexEp4Vp7zHjJxIYR51C1+3DbtmHUpPrOSU9xIDc3UIQYzU2he+mZyKvpdB+V89CkAWM/fJiZfM/KgxpfH57TE5LX828QlSSeu1DczqOrCYmc2c8h56Uo0+MQp1e/7kEKljGUiJLA7jtuTVDoRx6l2Cc9PLe9LLuo2dY6GAqkAojspq/u4pw847Iza/o75rEgBADi249NAPDYno7OYLuu8EQhEAgMTI+8TY6+fwwiB2fXR2sxLDMAy4s4rN3yZxK3q5Fb33XOLwTcVqWN/eu/8mwYbKSS/rTizs0CdGEf2z5Qrl2qbAL7HqskWga3hRamkXXHmo3duq9nELStoP9syo7Jbkog7Ye0VPrPr8fpANlcPMaIzJbbts7o/imdNLm8ZOMd4JVZzyHlZWyw27cLwCLR7ZVX2XzQP4QhE80B2X2E9veyFrpFsOkbBV0j+p+hUjL728J72sx4AYRQ4rAADw90SRmU3fPg154ZsZm98B9QxOO3Tb4Jy2kc8L30xqdGkYt/lXBDM/gLWvWjEekJNQ3/ZNu3CoACnYF3/7lJFfe7y3umnHhLr7+Ps+Mb/xt/u+yIvElspJeZ9wLTW6DIr0AwAUCuWlh/T7bxKRhHxL/+znJj6jKvZUKJTGTrH+SVUAgKHpVS1Dr+Sio77t+u4pbUPv+Pw2+GN+3eAth0jh6XrQHYPzt51jULeYQqG8dN/X3icT9VN99cjfM6oUALC2Kbhs4Y9EJzAMu/I4qEDT7gEA0DWyiD8NqUz+k0Nkkkrq3sE304AYhT5MT6r6yjwAsvZzn4xP73ijXnMAwGUL/yceaahn7NsnDChwAQCo65q8oOcOh0J8Xpu2PhWJLXArurX03GG7uaNvFhInau2ftXBLPiMIa+wci8TPzjh0eln3F2b+fNVD5wtFCiXWPbqgbeiDbxf2iavAW8fG5LboE1lyhVIiPcTvge6/SXCPKgEAzK1s3bQLX/qlP5ZUJtcnslhZzcefJ8VDMQBbGjcy4zicdcZ1MVJrkfQugNOqIQ15Eo3OrmsZUOE+D8MwW2oa3qv3NSPf5nRBuNTiTiucE1Pv2NKXj/wR/67wdi+Z+UFTwZ9eRBo6RQlFEgCAXKG4Zh36gz0TEr1EenjLIaKg7mg4EShsHcsAtPzPrOq7aR8m2BcrlMrbzjF4WX0CJcUt4mhWuOsSp0MIQofGS8R0DM1/+ch/RfWF5m+TihqOZZjeRZZ89yQYsXZCftund7yg5YpbRNEnt2ldOAv5pt7pyxaB26qSgamlzUsP/U6zgPFPqvreOhTNptNLmzqWAVBHd1coNnKKGZo6y24xKqvpBU57FgDgE1fxyW1vFFcJTa///B4NLred/HPwun3U2HKNIroAgJ29g2+eBOfXDQAAVni7VwhBfzHxhe/O2qbgph2ze3RR7Qa29M9+ZR6woWpkf0BOLG857sk67dBdIwvaht7/SJ7sw+LaPrj50+R1/GOPNABAz+jiNavQlKLOwvqhvNqBsubRT+96o9OVyuRdI4vNfTOc8m4tAy+4a8YwYOWRhrcm0AgKs8hNtSQ5GVwO59SryUsFs2uhGv3w9KqWvieSiZhe5F3Q80DJz6Gp1dvOMSsbp5qCN3RPGzlFo6oVeOjo7GOCuP4sDIr/1XVOXrMJ41b0FNQN5tcNFjcOa+l74pVM8IBh06lFnGRwSD7StDuDta080u6R4vFfdemhHwOnkKlPZCEdejxrR2c3f3bHS6LSyK/uGL+g5w5f4FfBeeg9L28ZMXaKFp2uFYln7TMO/ZZZeFLTDl71uGrKUWKYlQfbOTCnpHE4r3agtGnkTWi+tpE30o6YWOA19k63Dsz+YB8Bb47sUAFFjhp7ZxAFzy5v3bRnsjKbCusH82oHyltGv3saqktkAQDi8tq+sQpNLu58r90fPbEKiX+iU0Vcs7YpuKDnWdk+BgDYO5AYO0XT4iqLG4fg4cxckz69QzstphSf1/rYPRX9MamgXdcxqqBuML92sKBukFvec/G2PzRTvmkXTmIcTwYmpDgbz2O6d/DJQNP8A3ICgXKsgjmztPXlo4D2wTmBUPyjfURoen1Rw9G5/fA88nuVyqM+kaUm1ngglnYML7T0z8bnt2kZeEFBY+iphHT+wJmsTQrJV9PajMxsMnKKKWoYzq8dLKwfZBd3XrwTmK9p+YJhwNozPQr3NgEAbjvHOAfmAgBWNwUGxCi0ztCIsPR6u18a61CjS755fKyPllba9UcjT6FIKpcrTUkJ7yJL4VMrax61oaZf0H2nUbwBAGBDTYfa3Hm1Ay7BuejH/LpBQycWikfti6TtQ/Mt/bMxOS1a+lSYCBFJDk1J8fmqKVYsPdR4aABA18jChX8sffJhrI20IgEA0M0PANA+OK9jGegcmPeWWUgOLSCHFrhGlkGfjuHpNWvPdAe/LPeo0uc+GVr61PbBOQCAUon9OtaOyDyeoPyTqvGvHACAldn4JyMvAMDIzNoZapzD06u6Dqyp0/1567umjJyikawVPDQTJ5t5zTYMLjAr28a+tgx4zchzDS8khxa8Cc13jSw/LZYKSQEv1PcusviWSrpMjbX9k3/B2iZqrG3mF5hSg378ySHSUfVmqrP2PZpQpc5T3jp6QfcdXLSySzq1dd39k6rD0ht0CEHBqeoqyXj8grVPPzSJkU+LUc9Xq121XKEkUNimPydTmEVwtPwcXkRPqhJJZAdiWUBy9QNyAiWy9B2r+CtLBpoPtncPApKrbjlEWlM5cLs2Mb9x1Yrxgp79lln4JjSfHFrgGlGGLB+LGoefenBu2oXhaegkNLI2qvzDG6VvCw50HVmPPThuzKI3ofnk8IKfmcWsLHVDAATI2miOictr/fZpCDm8gBxWAK/aLaIMHugHe6Yz7hzuucRa4ST6nvtkhKYfDTwzchI+w7m2tff5PZ+K1rEdgeiabdgzn0y3CHRuJSnFRzsGNdbuHJ4nUFKcAnPdo0psqJwLeh4w1gf1/85g7cSCX7C2modUaHr9Netw1/BCdIEUVqnGfnSlErOksNVMVm87x1i4pQAAVni7BsQovKfVSWhk7SuEYFRDklzU8V/G1AOxTCqT33aJI1DSKOiphReHptedVpCWWdF71yVWrlC+YuRyK3pquybNXZMxDHNjFtHijkKLbYNzBAr7ZVC+Z3SJlWf6BV13mFA5EMvwrC0USTUeGgDQMTR/Qc9jfP7X99z+BqzdO7b0o30E3tgYQnqoIFDY9MQq+OCXN/gX9NwhdULWTizUbI+LcJK18dTJympWM7vxia+Aw3poevWcGsoaUdsxeds5Bu30z2Dtuq4pXSLrbGEjhJNrbSI9y0tFc9ae6YZOONZOqvrSjH681sapioOnQGNdAAAgAElEQVR/jLVhztYtojgysympsCMwpUYtsXwS52RtSmQx0h9Xu2pEhdBgITZHXZsUAMCt6DEgRqKB9ICcSKCk4j+wLThwCc59RE5WKJVQPXl87tSCHIVCmVPdr2MZ2KvSJjwJv4SqV7gIyRmsvS+SGjnFwHX3eRCb04KPkCQWtJ9mp3c2a9t7c5Fi3wNyAt6aYHBq5YZt+PzKzo7g4JZ9BNJxVQNeX1sokpqQ4qJUYaXR2TUtfU84oYolsgfkhLy649XxG0Y+Xlw+qbDjv27TTltrM7mNVpo8mzTClspRs0k0IcXBfojzsHZIat3zX+4eNLL2vkgqlyvukeLzas9bGAN9EFsHZm2pnJGZtY0d4U8OkV3DCw/ICVCcfe9Acs8lNl5V/DYwuYw2Z/siqSkpvlhVSAotRzQeun1wHk2Wvw6/nrWNX8bC57QvlhoSowJwj0EokookMpHkUNeBhZY/+XUD2obe7YPzAAAMw8zfJnnHvUcX/GzW7hlbunSfjtK186vbX1kEcsq6gUble33P5r6jHO57Wbu1f07HMhAmNjEMO3noq9YhkLX5QvEP9sxYXAmj4EBymkRf18iCtqEPOawAJuJHZtY+u+tTrFLuj8xs/OZJEEyGjM9vXLeL+N469Jys/aN9+HlYu7RlBInQ21A5jLTa6aXNyQXe3Or22UI5Z7A2/tDZ1X1/uU+Hw1GJYT2ji/sHku7RRTwVwrP6wZ6JKgSUSgyGR8I49WbkJPhL3o7wCiEYLgu2dg94KlfJrKpeA2KU7FAhVygfU1KRcS0A4EAsEx5IDg8VC6oY7r5I8r01o1FlEXsS/olVD3Ci/mqsvbjGv6DvCVkbAODKLDQjJ6Jt8qFcwT+RLkNIKmy/5RAJ13QYhk3M83QIQfig586eCAZ21Vj7rkss3gjC3puLUgLWnmlfWIS2qIYxObTgR/sI2aFcqcRsqRxHehYKyIilh0gcFc/aOwLRDdvwytajK2IXd2oZ0MZm1+HlGDtF4yOQ6WVdX5gdRb3nV7dvvWBdMvM7jbX7J5e/tgyAnsIQ24KD03T1YnNbvnkShAL0hQ1DfzHxQZrm72XtCG6jscrYAa4I1Vg7sbD9E2NPqAfrE1952zkGVfHKFcodgei0rDuGYY70LGtqOoHChjUFLwOzTV8nmJLiYcaFtyO8ZhOCnOES8tu09Klw1y49lOsTo+Jw8QONhwYAtA/O4Vl7YmEjraTrg+QbP4C1P73r5ariUADAPZdYFNev7Zq8YR/x3DcjIqPRM7rMhpoOOTE4pfbbJ4zgtIaA5GpXZqGWvhda1oVxGi7d9yXSc2B0TyNIjDwn/6MBrVAoL+h5BKf+wo+OkVqnYxn4NqLYP7nmJ4dIUkgBHCi9Y0sXb/t3q2qzhqdXtQy8ULCsb3z56hMGfs2rBt7O/g27cGPn2DehBfNrOxiGXdBzxx/6mm0YoqrC+sFrzyKI/tmRmU1vI4qf+2ao5c0QWgdmLxr7Ef2zrDzTXCNKrloxXjHykU7jjkBkQIwyehn9JqzouU8GJbLUgBgFJ4D7bxKR2Q3ERQN3WtxxjkHXkWXtebQsrWwb0zb2g/c/NL3ugp47Yu2qjnEtfSqUCc6o6Pna0v+5b4a9N9eKyrn/JvGMdesN23Az1+T3HlosPST6Z10hBLtGlFhSUh67p+6LpV0jCxdv0/FS1MIDyWNKigExKpBdF8ZtfOyeAvPSw9Or//0snEjPCk1v8E+s+srcH4Zxq9rHdYmsgOTawJQ6Y+fYfJUXUt/40i0HlpVnGjOj0Tex+jEldXBq9UAsM3NNeumfE53dauGW7BZRdIaubE3nxBePAm1pGUEp1QCAzqF5/Kmu8na19KnIk3dpnW/sFH3/TXxoen1wWj2BwsazsBr6J5Z1CEEE9zRqbOmuUAQAYGU1/f1piCuzODKzyck/+01oAXRv+Noi0M7nOD2j68jCx7Ut3ZJRochj99RrNuGOvpkv6NnWnqnfPg2pU9kyDM+s3XKIIFDY4dxG/+QaAiUV7Sy/e8JAev9KDHOPKr1mHRrGbQpIqiYx8rT0qagSxium/EszOtE/J7d2AAAgksgekBNuvYj8mVli5811Z5X+aB++xd8HADj4ZuKtriGCU2u/fcqgsEoiMhod6VkUZtH+KYrz+yKZlWfaj/bh9KRqcnjBjWfMpMKjwoHlDf4169CWMyVS2wbnLlswbKhcv4RKeAhyaMHn97xRjiGttEtL9922QAQA4O3sm5IS7rnEMlLrQtLrCRR2fp3mYgGImJyWT+6He7COiiDi89v+aHr8oxLD3CKKrtuGhXObA5KrXwbmaOlTEf9SIosvmwcQ/XNgPQJvR6jx0C19s9q3j32v4vPbvrYMOFkwcwY+gLVLm0cGcbnd/onldtyUuMITJBa2h6bXx+a1DUwef6y2czKM25RT078vltZ2TiDhcAwDVe1jzIxm/IfVMDC5Aj1N4OcLG4ZOZqU7hucjs5ojMprxYrj8PVF2Tf9xMcOeqLxlFNUn8IWi2s6Js43a1rf3orKb2SWd+2IZAOqH7hxe6MX5o8+tbMfltoSm18fltY2dYmMPANjk7+fU9B3KFZXtY8zMlsrWMbU5f2v3ID6/NTq3bW5lWySRNfZOQ5/Alv7Zxp5feKMUNQ7jD9Q7toTqmda2BDnV/QcSGQBgYmGjsH4IOZuo7oNkhbd70y68rGVUiWFyhUIkkRFVHvYaUds5gfxwzzg0AEChUJY2j4RnNGdU9sDS9a3d/eyafsH+Lyp2lEplResoM6MpIrO5uHEYPYuFtZ3IjMbIzOaFtZ3JBR5cc2EY1j26GJHZFJnVgrelBwBsCw7Sy7pDOQ3RuW3tQ/Pwfq5uCpIK28O5zbk1/e/VTx+YXInIbIGluDuCg+ya/l1VkZJcoaxsG8Ob3oqlh7k1/WHchqic1pqOibPFoycXNiKymgsbBtGSc3h6LSanNTS9PrGgHRV1VLWP4y+quW8G7+DRPjiHBt4DcoKVRypvRxib1xqZ2Yj3dQQA7ApF3PKe0PSGqJzW1oE5tPCs7pjAJ/eUSqysZSSM21zUOLQvllZ3jOMjgSVNIxGZTWj+FuyLU4o7WDlt4/MbcrmioWcain13jy7i/eMR+iaWY3LbwjiNyUUdKzzByQ8gyBXK4qZhZkZTZGYTPsMkkclrOye2ToRb1TAyu87MbC5rHoGXOTCxXIYzvN/Y3qtoG0OztexQXtQwFJ7RGJnVUtk2drZat/BAmlXVh05pi7+fXd2Htx9RKLGSpuEwbnNp84hQJIWW9vBPh3JlYf0QM6MJPTKNh97k7+fU9CNrCDdmkZ03V/EhbbQfNf/+E9E1vPDZXdocTp3HkZ6FasU+4vcJU1ICPp7zEf8PYGpx08It5YzKCI34yNr/iTgQyxz8Mk1+Zgel1MTmtlrTMh66Js6dW2LtI/4tsHRLfkxR97/+iP/VaB2Y+yDHSIiPrP0fCgzDesaWKlrHKtvGW/pnf7e2HR+BMDS1OvRPlh77iH8xfp2W90fW/oiP+IiP+N+E35i1U4o6UDpYDTz+/tlJhrVNgXtU6WkFGGpftf3vk9v+t6B3bMkzuuTsDOqvhuxQQY0pU5PE+iAEs2vw6SA8VjcFgjN7FAcmlz1YJWcIDEBgGLa6Kdjbf8/H1CBXKGix5SiVurcvWeHt/g7NSgJTairbNOT3fj9oG5yjxZaf03j3t0Lv2BIppMgpMK/7FPGQc4JT3hObp6FF4L0QiqTLG7/BgJErlEsb/N/KcOM3Zu07zrH4Bj887rrEWuIKUU+if2L54p2AdtULdgaMnaJRMdN/CNjFXVoGtH/cT0cj9sVSLQMvjZ0v58Rn92ivGfknfy+RHn5lHoAv8z+JzMoebUOflc1TBQYgRBLZJTM/n4T31PirQSyVaelTmSrNB9+EyksP/ZCUzfmBYdi+SPpbvXWHcuXevgTfofcnY6ob83edDWZlNl3Q8zx7Av5tIZEdGhKjiAG5Jc2jZ1SanQePXBNv4KTZzg8mt+HTOzTezntqWt6LqaXNPxhR8+p+GyHc35i1LdxSTktzl7WMoI4YjYDiId2nCGDiUdo88itC+P+rkVHR+wcDj5MNqL8JRNLDT4w91ZqMPwhXCMEaHTOUSiyrqrfn9O5EANuvdN8h7cPToFAqMyt7T+sAPA3SQ/mnd2hIyb13bCmzsve07o+zQYkoLm4cfv/nzoGxuXUiPXsTxwWXLfx94k4Vyfs9AK9D8q/B5ALvum3Yym/hymRL5Rg7x/yK/zg0tcot7/nHdxh7+xJ2Sdf8b5TwPy9ri6Uy/KnL5cpDXLGqUomJpTIAgIVbirlrEgBgk78/t7J9trvECm93bmUbKblA1oadabPLW9uC88ZAtgUH00ubpzWqQTE5AMCBWDqzvIWqOAVC8dzK9smSW7lcMb+6vbC2o1bqu3cgmVvdRgKYCGLp4czSFl6I+VCuwHc6KRRKiVQOv+1QroAGmEsbu7BRCmJjWzizvHVS7YjH359d3sIwLK924OLprL0jOJhZ3lr8ZXAJwwDs78IwMLeyfVKtWCqTw/smVyr/ZEQ9ydqyQwV+dalQKPHXhWGYRHoIpTZ0CIG02HIAwApv9+wYl1KJLaztLK7vII0OyNqCfbH0UD6zvCU8Xfocf2gkh6v50g7lM8tb24IDJab87I6Xmv8GfsO7yd+fXtrEH1QuVyyt86eXNlGTiFyh3Nk9uO0SG5HRIDyQiKXHcSqhSDqzvKUmww0AWOUJZpY2NeZ4ZYfymo6Ja7ZhozNre/tiODC+MvcPSKoGAKzwBMuaeOq0YYn/AHxD9/YlM8tb+AeH/gShUGJiySF8N2WHcvhM+Xvi2eUt5M66yd9fWNvBHyohv+3TO1S5XCGSHE4vbWrcr/B2hDPLW/g3ERHF6qZg8xTDdSWGLa3zYY8C+qVUdljXOfmTQ+TY3Pq+SKKRSZQYHEt8/D3ZFYpmV7YXVn/xnp5k7W3BwczyltrmVYlhUJ1iVyheWucrT6Gv1U3BzPIWal6DEElkajxwGhRKJTyK7FCh8a1/L87L2slFHbZUDhruYen1+B1xELsGNnw/9Ui9R0qIz28jUNiGTrEvfDO3VC4BlIhitFPe25eQQvJNXyeavk60oXKgxOLIzJq2njsrq+lNaIHJ63hdx6jTNhQ/hxZA9UEMwzIreh+4Jt91iSNQ2KglB4+Gnmmzt8mVbWPPaFzjl3Gmr+Nml7cqWkct3dONXeLvkxOnl46LJQenVh+7p5q+TrhPTrahps+tbAEA5HJFZGYTwT3dhBR32yX+uQ8HEVPP6KKlW7LJ60Szt+zs6j54f6KzW577ZqB7lV83aEZOhAq3YZz6N4z8rKo+Y5dER98sAIBSifkmVD16m3rPJdbsLZtb3oNOJrW0y+hlrMnreKfAHLfI4s/ueZ9kbbH00Deh8rF7uolL/G2XeFJIPprttnYPTEhxBfWDbswi09eJusToJJzwy8QC76Fr4m2XOAtKaji34XMTH3aJunBuS/+siUs8eoIFdYPWHmnoncyp6XdlFkLy/d6aQfTPCePUW1DYusRod1YJogkrjzSkRru4zrelckxIiabkJJeg3GXeLgCgsGHok9teKcWdDr4Zd0lxRk7RbadEyQgUNuykFQglpqT4vNoBd1apKTlZlxidoBLGAwBML26av0266xJnQWGHcxv+YkpPKDj6K7eih0Bho5k7nNtg8jrpnkv8Q9fEspYRAEBjzzSBwn5ATrrnEn+PFA9jzbxtIZGedekB/Qd7pi0tK0YVSipuHDZ/yzZxiX9ITnGLKIKkI5LIaLHlD11TTF4nvgktOPnI6romjV0SPjfxNiMn2VC5Q9MrAIBvngQ7B+eFcerN37J1idHU2HIZbkOgcViqIb92wIaaXto0QnBLMXaJNyXFIwNceNVomdXQM33XJRZKWrKLOx18M0uaRgiUVAOnGFtq2tbufkpxpwWFY/Qy9pk3F60tkgrbPzf1y67ue+6bcc8lwdA5Dt9kqFRi9MQqc8rRME4vO2p45pT1PPfJKGwYMnaJJVDYJ6fksbl1AoV9n5xo+jrB5HVCUeOREUFD99TRXXJle0aXoL5whMV1/jMa14SUaPo6ySkwZ4W3K5crQtPrCe7p91zibrvEO9IzEYfiWRvDMP+Umkdv2fdcYk1eJ7oxixBvzq5smbjElbeO2lI5914nTS9t1nVNPiAn7KuSLgdi2VtmoZkr24QU/8A1GTXH9owuIR7IUfEAHlu7B8bOsa39swCA4elVU1JcResYkZ5173WCPpF1RpOtRpyXtZv6ZnQIwbAdSySRXTb319J9B0ekRCr/2jIAMoK9N/dT04Bgdu0Kb3d0dv1761BK5FG0zpAYfZ+cCABQYpgtlWNKip9d2d4RHBTUD0J96rHZNW1D6m3nmLruqR2BKDS97pIZfVaTZPhPLyLN3ZIAADPLW/qOrLbBOb5QNLXIO7kQBgDk1Q5cvO1PjS4bnl5d2dy76xJ3zTrclVk0PLO+uM6/9eJY/Ghxbed7awa7pGtXKOYLxa7MQlsqR65Q7O1LmNyG4Zl1vlC8sLZjSoqDc4ZcoXxMSWFlNgn2JaubgrHZdTjnkxh5X5jR0ZNjchu09N7tHYgBAC5BudqG3v7J1cPTa7AD7S2z8CE5cZknEOxLmvtnb9iGw3hCQf3gp3e8K9rGdwQHZS2j158x/2Lie5ICVjZ3mdzGmZUtvlA0uci75RCB+Gt1c0/LwOshORHKwrFLuj67R4NtePw90fVn4SRG3tbu/tjsulNgzkVjXyjh8osv5+1++4RRpRLiIFDYF+8GoryQGTkJqmsCAH60j/iKEJJc1LktOGgfnP/rfb9EVVL607veUE7+QCzTd2Q5+Wevbe1tbAu5FT0wWFnSNHLR2M+WyukZXdwWiF4F511/FqbRbOhPt6nwzm/vHmjpe5qS4uGlccq7P71D6xheAAAI9iU37SOcAnN4O8LxeR6JkXfR2CdZNW34J1X9H2MvyNrMjMavLQN6xpb4e6LGnun8ugEMwzIre4ubhncEB3yhODC5xpAYdSCWKpTKqUWeCSk+iF0zv7YD9ZSr28evEILbh+YF+5Lljd0H5ASo6JZT029Kil/fFvL3RMPTq/w99S3j3oEkr3bgph2zpX92bnUHLoqvPwv72jIktaRrW3DQ3Df7ZxMfpPRw2rBU+9qorGZtYz+f+IrBqZW1rb0n7mxjpxi5XImuGmmcZVb2ahtQ17eEAAC/xEptI59wbsPs8tbEAu+qVciP9kzvuIr51Z2R2fVLD/2QCgq7pPPiHfoL38yhqVX+nsgvservT449PSiRRfffJCyu8wX7ktbB+eu2Rw4AjNTai8b0d5HF/RPLo7PrarGpxXX+d08ZvvGVW7v7O4IDdknnV48CoEmQWHpYUD90wza8qW9mhberptInksgMiNFE/+zVzT3ezj63vGdwakUgFIdzG8fneXyhaG51x9g5NlglBoBnbUpk8U075uDUKn9PNDi1qk+MehtWCF/WwamVi8Z+Zq7JjT3TkwubUpk8Lq/1/1N5QSiUymfUtBe+mes7wl2huKhx+KZdGPRmIlDY0dnNKh5YO7kfWt3c0zb0geY4bYNzF2/TifTs5r4Z/p7IJ65CxzLoPIt0hPOytkR2+N2TYLjK6J9c0SdGfW/FyK3pBwD0TyzrOrKgu5glJdmQyEL/6y2zUIcQCP9tSkqAsjizK1s6hMD2EwIxIzNrWvpU5DvF3xNp6XtqdBhAcoMzS5vfPA4+W2smr25AW88Dtf9WtI5pGdJQgCmzspdAYcMFY1R2s4nLsSDq+PzGRUPqyKy6fWcwu+a7J8EAAIUSu+MSG4ITm4Zwiyi+as3Am4AgCScSI+9riyDUzLq2tfe9dSicgSFuO8dA2bznPhn4FvOUos7zxLWdAnOQztTa1t4FXfcMlYmUUon9wdADPsGKltHvnjLQqnzvQPIHQ81xbQKFDXU+d/ZED8gJN59F+CVWAQD4eyJDp6iW/qOH9c2T4Fe4s73tEvNYlXn+yjzAN6ESANDQM/3Nk2B8ozO8RQX1g9r6HgtrR0+kf2JZ28Bbo2sqEq7a3j3Q0nPHbw7+ZOwFU441nZPfPAlGalMiiewTYyqKkISk1V16SJcrlIdyhdHLaDWpVbUl0uzy1ifGNJQHQyt9AACGAQefTEpkCfowu6Tz0gNfDMOyqvtuvWCdHf/tn1g2IEbht+c6loF4P2UDYhRSIznnsIzKbv6v215oaVzeMqqlT4VcAK8a7TByawcu6rnDo9MTK/963xdZnURkNGjrvkPLfHpiFbK8SCxo/9NtL9728Y295RABGWBjW/i9dSjyBgEAmJDiiAHZAIDQtLrP7vku8zSnmuPyWn96EYlnZCuPNKQINjCxok+MXN/aO/kfm3pnrhCC8SHBk8tbWlw5kpNFrL29u//dk2Ak2QYAqO6YuEIIhuQ7PLOmZeBViDMei89rRdH8kZm1b58wphaO9YuuPA6Cr/9dl9gwTr3Ga4SALyOss2ofnNPSp/aMHmVoljcEWgZe9d2napydxAdkIz2iSpwCswEAjNTagORqWmw5lD8O5zagig4Lt5RH5GOrCEpk0XdWDPhvxNqtg3NGTtEng1wwro3STVu7+xd032mUekGsjWHAO77ie2uGW0Tx8CnuyHCMbvGPGKq6ffyCnvu6ao1Q0TpqQoqDKztabPlN+0hScJ5zYM6r4DwbKkfbkAZnF5FEllzU4RVX6RNfYeAUg6xF8+sGv7cOfUHPxssynMHazoE5t+yPdaD6J5avPA567pPlEpT70j/nDSP/rw/9oUKbuWtSVtWxa192Vd9prL0jOIjKbvaKq/CJr/zehnnb5WhNAQdKZevR5kt2KP/srjdk7bjcVlvqsa6mRHb4J2MNcW0AAKe8+45LPACgrGWU6J/NLu7UJ7IAALWdk7ccItGG9woh2CumHP0v09cJT1VDArF2enm3pVuy4oS0cX7dgLYuhbdz9HL2jC1q6XkOTmpoJ1Fj7aKGo7GhVCr/bOIDWTupsN3K47hU6VAu/+yulxprK5UYf09k5BTTNqAhFFPXPUWLr6bFVRADsrUMvODWRy5XWLolozX7oVxh8TbZ9HUiiZEHH9wdl/g/GVNFEtkmf9+ayvnpRWQEt/FkwB2ia2RBnxiFV7e4bOFPT6hCPxq/PBZZPGNY4sHKavrzPRoK95e1jFzQfQfJ6AzW9kuo/No8AOUYorKbPjfxQQQYk9PyjHY0eSTkt316hyZS8TuGYfdcYqFa4dDUyjdPgu19MtEw/tvDQCgIykit/cKMfvKhQ7xjFbtF/MJGwyum9AuzI12q7pFFXUeWxjRJRmWvuWuS/ERWWSiSxOe3ecVU+MRX3HoRdf1ZGPw9Yu2h6VV9R9bi2vF3LqzuXND3rGwfByqFZ3y9Cj4HW9c1+bVlADEgxyUw1zkw51Vw7ifGPu7RpQCAgvojHqju0FxwocbaF/Q8JlXi4wtrOxf0PD6ovOIDWLuqffymXTh/T+Tgm9HQM9U/sWziEi+WHjr4ZqAXXq2GBPIX/Ddi7ZaBWX1i1MkpVK2GZJO/f0H33dlrbYi+8eU3ofk37COyqzVI4OPHKACgsm3sgp47kgQqax657RwDi4XdWSUECruua7Kqfbyibay6Y6JnbEksPRTsix18M4n0rJLm0fquSVtaBt4QeoW3G85t/OF5JDWmDCZ2XMOL0FUDAOLyWvGs/YM98/jMJ5av24all/XUdExUto1XtI21Ds6vbe0pFMqH5EQkcgsAyKkZ0Mjaq5sCAoVNDisobx2r65q8S4pDO0H8QAEASGXyz+56xea2AABiclqsccJyUrniNNaeWd66ah0ys7QZkFzNymoSiqSGxKiVDQEjtQ7FvsCJGhITUjwSiUasnVbW/YiceHgi/atWQ9I9uqil56nRklGNtZH435FjRkYjACCxoP2peyqaMuVKpUbW3t49MCBGI9VTCAwDcbmtJqS41NLu2s6JmNwWpPcLWRt55h3KFWauSe9YpfXdU/DB1XdPD8+sQQ0ghVJZ3jJq4Zai78jSaDeukbXxNSRGL2Oe0Y6E/zUOy5NqwKysps/veaPIUmnzyAXdd9BJlpFad+khXapKjRY2DuNZ+7K5PwpcRGY2fnaPhha/UVnNVh5Hs68aawMAHpAToDr84NTqdduwNNwwbhmYh2wbzK69ZOZ3Wg2GO6vENbwA/xtabPk12yOqPYO1OeU9D8gJauqm24IDWyrHKTCntGW0vnuS4J6Kvgqx9vD0mq4Da37lOJQ6v7rzR2Mq3ChA1sb7OONZu7pj4rpteH7dYHXHeEXrWEXbWPvwwoZqYl7ZFIRxGn94HkmLLT9ZpHSStZFS4PzqzgU9DyTfeB58AGsL9iXGTtFpZZ2WlOQV3u6+WHrXJTapsN3IKRppXJ2HtacWed88CT6ZOfzVrA0RkdFo7Bx7clZ/L2vfdYmFvRvh3AaCJp2Hmo6JWw6RqMMlMKXmSzN1mcr+iWUdy6CJ+aNQ9XdWIehPXrHlp7H2wtrODbvw/gn1W4FhmC2V83Po8YAO4zRcNHDfOtFblF7WfQ+3fSb6Z+s6HtXLn8HaJU0jV60YAuFRoGaZt6ul54HcT9Rg5ZEWxql18M2AA+uxe2o4p978bVJp03FbzXlYu7pj8nvrUHynFaTW34q14Vq7om3s70+Ct1WBgvXtPS099/h89QiJVCY3dIpS6wjb2xcbEqPKW46sD2aXt7X0jgakXK6weJuSpoqQKJWYnTcXmpSeAYu3yV4nzH0AAJ3DC/rEKPwcfAZrnzYs1XAGa4ek1f3tvi96NVhZzVp672AN8ntZG8nwJhS0/dHQc1UV4OLvia4/C4NL1OWN3Rt2Yb1jGmp2z2bt6JwWpJQN8ZiSimyCz2Dt2q7Jq9YMZNgIAMAwrKRpWN+RhZYF1OjSb1SuDoi1N7aF1/2Iz4gAACAASURBVKxD8Tvj0paRm3bhcC9+NmsPTK7csA3XWOGD0De+rGMZdFKa9N/G2gAAUki+ztMwR3oWXMu8iyz+64NAvHmjGTkJr9//JjQfxbXvusSZv00GACgxzIQUZ+wSO7GwsbTOj8puLmseBQAMT69pG3p3qpJdvJ19LQPNdemGTtHQ5aRlYDarqm9fJOXviUiM3Jf+OSfLorKq+7T03NHSvrx1VMvQCy1zSpqGDYlRsHdgcX1HxzIgILl6iy8USw/H5jYqWscAAL1jS189CqjrnhJLZP2Tyz/aR3xlHgAAWNkUJBV1rm3tSaSHnLIuA2LUJl8IAOgcXvjzPZ/cmv4V3i6nvOe7pyHfPQmG+p9E38xr1sfV/hiGkcMKdInR4/MbYunh1u5+RdvY7MoWACChoE1L911l29jW7n5OTf9Va8ZX5gHrJ7psSptHLpsHDkyuiCSyloHZL838kSHO6qZAS9+rWJWUl0gPL+q7Q7++Fd7uXx/4kUMLeDvC4ek1Wyrnr2aM1BM1JBDR2c06T8PuuMTCYq/koo6/PQzQJbLw4qtfmQdQcE0iRk4xqKPqr/d9qLHlAAC+UHSFEOjgmzm3sjW9uBmS3gDzh7m1/Vp6nquqLpuO4XltQ2+NEZLPTbxhVH2Lv6+lT82pOdpaKRTKPxh6wAjj/8/ee761ceVhw3+KsbN7bbLJm413ryROduOQPC6hu+JgMMYUG4MVjIwhgBAIgUwTTUj0LtGr6L2D6L0LRBeIJoG6NDrvh4PGYzp2sk+yD/eVDzFIQjNz5p7f+ZX7XlkXXn7wxjk4f3VDNMJdeeaX+YV5KNpDEpxa+/e7ZJgrIMdVfH7Pv7V/hr8uyq7qTWVzRLuyO/h4IqNsRyxbFgh9YsovmVBg/lGj0Tx0T7L2Yc4srcMsbQ1n/PN7/oX1AztimViq4AzNtQ3MajQgu7q3pZ+rUKgW+FvGTjGHntWpBcEnt/3yavtnltZhkePyA4pvzNtZpJsOUTbee3HJocvyoIg+Lavpr8be6IhpceOQjgEJZkjGZ1e/MKWksDuWBcLC+kFdu4jLZm9g4EKOq/jClIKydmRm4yUjb5S1o7KaUYuGFDbn0u2gp+TMwamlBf4Wnpr/lUUgWj/wpLFvOtLHZvlSuXJDKK5sH4MK74HJNZ/e8zuKtXnLm1fMg/0TKtc2dzZFkoiMhi8eBI5odYA7h+au29PmD2sx2BJJvn0c8tQvc3Zpg7sgCGM29I4vdA7zvnwY1NLPlcoU3WPzutbh31nthYxPiOkG2nqbZxT72jPa6MzKrkQ2MLn09aO3U2CDU8sXjfy6MMK2cfltlwy9YTUS0WhsSSwz9+TZpXWZQslfF5W3jG4IJcsCYTK7k78hksmVrPJuAxxdsLX/PsXejG0DMzqG5FHtYc4sbugYkY+fZdmHs7F2Vdv4//czNZW9txBLm4e/MAthYXoPnvtn2WMs3eLy20xdEmBF1caHiQvMhT/nb4ieU3Ju2NNMnONsSRmwtDI+y7/8IAANsnbEshv2UWWHzUlbEtJg90LXyNwDt0RrUqYFgekUmLdyWOGipHn4X2YBaPtaLWfiuj1tSxuL1XDGrb2ZaBzd0sd94Jb40CP1KTnDxDkWGq2q1OowZv1PDoyn/jmByTWByTWmrkkAAMHWDi4o19Q14al/zgO3RKzTVVRWk65dxL3XKd7RpfXdU3ZkFjSpIdDYpq7vOEBuiiQ+sRWGOLotKdOCkOZIyYbLVKVSh7Pqr9vTzAkZbuFFzb3TtiTW0oGqjliq8Ikp13vBsCVnRmY0etLY6EN0dWPnsumbem2VAzp5o2mQjsFZE6dYU/c0M7ekGs44gV6CdmvtwwRv7YplhGv4Xo1odIb/1aPQfTM1PznQsQY37hFFeG17yXV7GmpHPTbDN3NPNnSKNXGKwQfnw1pZeevoP80CBNoLNL0g0LUJPzSx8MPTCFg/3BJJLv8cUKFN2Ws04J5LPJoG6RqZu4OPu/9rygO3xKqOMWJ0WZo2sxGT2/KjXSRs0pcplKS4Ml27sPtuKbAdBQDQ2DNt7BRtTcp2Cs5jlnbddHjr7NXQM6X3gmHwy9tzmFHRbewU88SbZUvKuu+SAG+81JLOW86xzym5Jk4xEayGQz0ZFEpVcGrtVZtQU5cE6B940z4KW9Z2oRa4YjprDy7Lg3LMycWc76xD0cxJ5/Ccrk34gjY6SWFzfrCLuOeW5hpe2NLHtSMx4bMngtVw0yEKDcMTC9vv4hPQFojk4g7Uw55V3q1rF5Zf22/iFG2CTzR1TcKq7W+JJL7xVYa4aFtypgWB+dw/CzZ0MbKbrz2LVKqOnNto6ePexceZuqVYENIsPFM5GFmFoallM/fko1y5x3mrD91T4FpyDs7jb4jUCBKcWvuTA/2pf05IWq1/QqW51srDOTgfrb0Jd6VejLKbjnRrn0wT57gIVgP60BqDFIRZe8zSrv9YhaLV2mWB0CW82Mgp+ik544F7imt44Y5YvrEtxgXlmbolPfXPMXNL6j1sEAx7M3aPzl9+EIB6aa1v7V57Ftl4tOPSQZx5NnJXIkMPUqPR7Ihl2OqtVK58Zy4D0aD/lMgU+waC51Y2ZzCdp2oE2ZXIse30MrnyUF9OiUwh0z69lSr15NzazNIGcoSsuEqN7ErkbxOdKkT27gDCvm+lUiMzSxtjs/x9SeRlgXCctwbfi30Lb3ljnLd2UCFkRSDiaVv9JTIF/AIyhfJQf7LVjZ3RWT5veXPf8fLXRdzFDXgXSWSKoyYs5le2JucF8L3od0MQza5Ejv1AuUKFjdHkCtXk/N50kkKpPsYDSSyVY8MlsVS+jzX2vUClUqMDJmKp/J2ZIwThLq7PY7aZKtU7FwgewqHXHf0ojQbsO7R931+hVE3OC7aEYoAZJIEvE79rsLKyLpyaF8gx4zC7Evn47BosJMoVKmzODc7UyOTYU6GYnBNMzQuwrYrCXenY7OpRjRMoFla3Fle34TUVS+XYga99qxQcvSyxh4z1jtFoNFK5ErtgBFs7M9rBN4lMAe8XuUIlxixIhVKF/RoKpQq9jgqlSiJTAgA2heLphfVD50vXNveWMXrSDp7wg1Cq1NML69ML6/suuhpBjlnz8AUzSxtz/HeC8aW17Ym5NXjF0XtBKt9/3y2tCcdmV/edzIMUpFQd8v1hW/MCfwu7aHnLG+O81aOUgrA3I2Qk7HHJFMqDldVjcK75d45znOMcfyacs/Y5znGOc/yZcM7a5zjHOc7xZ8L7s7YaQTZFkjOlY04EotFML6xP8FYPTWu+B3bEctFJws3/z2J7R3Jokv3DoVCqx2dXecsbf0Al63Oc4yio1cimSPJbkc/vh/dnbf6G6GuLkDMNYh4PlRpxCSs0eZVs7Z12aLvue+DX8KLHxONEvQ9idmm9tnOqrGWkrGWkvHWspZ/7v0o9t5xjT+w4Pg3UCMKq6G7RShHsSOTmHsn3f03FBeYc2tVzjj8vVGqEWd7dNjBz8kv/hBib5V95RB38MC1vFHKFqrJtjFneU9YycrBKOTy9zCrvYVX0jPNWz/rJZ2Bt3vIGZ3AWVS9cWtvWMfItbfltFIcBAD1jC1+aB/aNLQh3pSc6m5wSNj6smw60k1+HwStqwRXL0Gd+GU/JmbakTJ+YUuUBpZ7/DXxtHuwWXnTy606CUqX++lGQB21PRiOrsud7m/ClNeGmUPw7xfIAgJHpld/q7kIxu7TBGeL9uR7S69u7LX3c38nk6CAUKvVXFoFejJKTX/onxMDk0kVjv64P882BmJxfe+iRauIU40jJ/daKehsfh3XTjs1v+8aS6hpejKcWXnkUfFC47XicgbUzK3qwM1rLAuEFfWJl+9k0Bo9BQf3gzxgNk98E9n5Zxu8OX52IXwJz37xrmPLnuo1Pj++sqJ5Rv41/ilyhQnNlwak1LtSC3+Rjj4FvbNlvzh3ppV1W3mfbmf1fR//EohEu+r9pyIe91v9jGHpXCulDMM5bzanug+2wc8ubH5uQXgTkwF+NcFe+Mg+q1E4bMLKb//UwEKuqdiJOxdoajWZgYtGZWnDtWURh/WBF66hSpeZv7OgYEOu7Jqfm16JzW3Kq+/bJew9MLMYVtDFympv7po/6ZBRDU8uu4cXX7WkFdYOd2tmktoGZ2LzW6NwWVAgQRXMvNya3NSa3tbV//2Ztnr8VX9ieWNixtLaNC8g5K2s7BeZBffqD4AzNxua3MXJa6runUCZf39rtGJyRKZT5tQNpJV0n7hI6Bmdjcltj81rRwdnpeQHWwWd8drVPO7AzvSDIqOiJzGxklnevYXpL2wdnN7bFi6vbcQXtrPIeKAM7NL0cm9+WU92PNVfsHplfWtsW7kpTS7pi8lr7MNPz+1h7cm41md0ZldVUwxk/63NqYGKRt7yh0YCOQd4Tb5apa0JJ0zA0uDgUa1u79V1TaNP9xra4c5iHdnwLdyS94wuw5XZoejm1pDMiozG/bgCWKFRqpLVv5qF7iplbUknTSFMvF/22LX3c6NyW2Pw2VAAI0Wja+meEu9K+8cXYvHZ0IG0fNBpN/8Tiy+CCG/aRRQ1DVe1jaLu0Wo1Uto1FZTWlsDvR8QKJTNHcO61QqvrGF+jZzegsWH33VHROS2XbGNqNq1SpW/q4EpmCu7gek9eWVtq1T094eHo5vqCdnt2MnbOQyZXwXY0903EFHfx1kWhXWtw4HJXVFJvfiu6pZ5Y2QlLrvrGkppZ0ljaPQO7uGJzFqiP1jS+iF6J9kLexLR7mrsTmtaM7FYVSXdYySstqSivtmj+Fa2v/+AKUzFSrkdb+GbFUPjm3FpPbmlnZi86y7X2ySl3aPBKZ2ZRd3Qenz1c3dzqHeDKFKruqN72sWyJVAADEUkVx4zAtq4lV0cPHDKlPzq0xy7sjMhoyK3uxjyXhjjSnuj8yo7GkeRg7OTG3spFe2k3LaiprGcU27zf1culZzclszsIRAzsohqaXdfS9h7nLQ9PL9OzmrKo+OOUokSoae6awWmCbQkn36PzpPW6McNH3XfakPmhZTY8Jbw0Ut0SSfz0MPJM52Wlj7fza/tuvEr82D8ZTCwk09o5YJtjavWTobUFIcQrKJUaX33SMfkpmoTu13Jp+E6cYL0Y5gV6q94IB5S+OQWnz8N3XSV+aBzpTizLKu5VqdWBqzU2HKC9GmXsk+/ozGjG6DFYJlCq1f0LlTw50+Ksf7ML94ivQm2SEu3LTIer5m1wCo+wpOVP3GcPMLfn0pwMA8EtgLirLiwLRaCIyGq7b07wYZZ5RpTfso9wii+CgQXnLyN9u+fnHV9qSWI4Beagk7KGIzWu95RxLZJQRGWU37feELgcmlz439YfaCKubuwa4aKjQPzy9bOqW5BFVRqCzn/iw7uLjUDWVK5YhdiQmMbrMK7r8hiPDkpBW1DD4mJjuFV1u8EvsA7dEdDRA34H+wC2RHF9BoJc5BmR/etcPlSXDsnZj95SJU6xHVCmBzr7rkkCOrzjKyONQfGNJJcWUAwCSizuuP6dftQl1jWCXH631PjW/9k+zQFS9IK2k85M7b1A9lpjclp8c6GpEU981eRcf78UoI9DZ992S7UhMiUyhViOMnOb/84z+g12Eazibml6nViMajSac2XDXJZ7IKCPQy27YR0GZBLlS9Y8HlBcBOc4h+b+EsPNq+w/9PhqNJremzxifcOVREJ5a6MUo2RSKAQBSudItosiSyCTQ2W4RbIMXjKGpJQDA7NLGRX1v75hS19ACL0b5ZbMA/4TK+IK2x4RUz6iSLy2CUfmRTaH4b8Ykt/Ait8gir+hyc4/0q9ZhKHGzm4ZNnGIIjDICvdQAF40OkS7wty4Z+nhEFL+g5LykstmNQ/iQfOfQQgKd/TKkQNc2DGr+tfbPPCay/mFKcaBku0WwofzFv8wCAjFhhwGOAVUkNRrNlxaBT8ksl9CCX0LYcKR5VyLHh+TbkDIIdPbrMLaRU/TEAQ2NfbjyKAj6FonEsk9u+76iFuBD8onR5cYv4y08UtCIYVcidwrOu/c6gUAvdaTkEuglCKIpbhz6+10KJaHKlsRyDMhd29zZEont/TKfv8kl0NkvqUW38XFwALhnbP6+S4InvYxAZz8ipD9wS9wUSQAAwl3pC0r2c0quF6PMJbQADX16xuZv4+N+pZUS6Gxzj3TX0EJ4e6aUcO7g47wYZe5RJSnFHcfM7ACo1Grg88wv0yW0wItRZvIq0cQpRrgrlcqVV61DQzG04BNdZu6RfFAK7Sj8aBdpqxVxfOCWSMKoFyCIxpKQhl760+AMGZKMim5Lz7cZkhWBUMfA25GSDYfrpubXdPS9oHjm9ILgslkAKibZN774jWXIzLF0BgDIre4zc0+G/1/UMPixCQkVYRnhrvzLPAhWPnOqez+57YdGPf0Ti1+aB8GIG0E0t/Bxtlphqal5wX+sI+D0+enxilpgR86s5UxUtI1WtI3B8dYazvjfjH3R8GR6XvC1eTBkpcq2sUsmAW+SquEqOWZVcIZ4Xzx4g/o8lLeO/vA0Aopc+8ZWmDjFqFRq39gyG1I6/BD+hmh6cW/sVa1GbtjTUKXQrywCbznHwsmumcX1T2773sHHQ62VsVn+P80C0dzcT470b61C0OjMPYpt5r4nl4qy9qZQcsUyJKd6T9aDvyH6xirkTBWnrx8FofmKgKSqVydlSBBEY+6RjFr32vtlXjQJYGolO+xIGT4x5QAA3somqhizIhBesQxu0gakPjGl2AxJXefk5Z8DUAmq3Jq+mw5RUplCjSCf3vM3wEXPrWyBk5JdaSWdT951kY7Ja9G1jUDfRUmsgrocvOUNHQNfIqMUWg2UNA/rGJA8o0pghJ5Z2XPVOgzeF5tCsY4+EXrEAADkStUt51ioprK4uv1Ps8A6rQDFxNzaN5ZUuBtY4G/pGPhYa52DdsVy7Ij/i4AcXODedrt3bN7IKRob5H5h+oaCSfHddKQ/88+Cx/5Ps4Af7CLhLDU8qFBm/U2Ht9LBnjQ2VsL3UHxpHgiFO0Ri2SVDor1fJhQ1WxEI/2rig4oHxOe3Xv45AFXkGOfxNRpQ3DB4ySQgjFmP9mkQ6Oz7Lm81Hhwp2XCUf2ltG73HpXKlrk04FC7mDPH0HKLQyUw4uimVK689i6RnN8Ef7krlurYRUKLA1DWBrdXLlitUx+8hh6eXLxqRXUMLxRIFAECwtatrEw4fb+Gshjv4eBjCK5VqgxcMVJLsRAxNL39tHozqQ3121y8o5Z3d/MvgPL+zuIaegbXTSzstPFLQcU+Y167VBm5qBPnYxBeKEzHLuoxw0aPclbEZ/tgsv3tk/qKRX0bFCRn3rMqeB25J8HK6RRTtK5RZee/J87+iFnjR30loWngkvwzOhV/ppiMd61/lQMnGujScBr+GF11/TncJLcAH578MKciu7gMAkGLKnYJysS9zpGRDZYPy1tEL+sR9Y7WHIiSt1tw9ZXpeMDbDH5/l13AmLpkEwOTPrlR+3yXempRj6pqwz/JOIlUsC4Srmzu6duGod8xlszchmCf/d9ZhqEK/Uqm28ExFfWl/tItEpSQAAO0Ds98+DoFPDpS1G7qmrj2jdQ7Pjc/yx2b4k3OCS4be5Pi3etknAqv59yaxCuvncBTCWXt8sSkSW/swHSnZt/FxAIDtHclNB3or5pkh3JEuC4TcRcHHJiTU/cs7ugwrzewbW2btzeQurI9yVybn1thNw5dM9gQlPrlNhsvyRCQXdzwmpqM3NjRdItDY3IX1US5/en4tnNWgY+grkysX+Fs6+t5o28yKQHhB37tGa/ozPS+45RwLT/KmUHxR36uw7u3+l57dbOIUo9Fo2I1Deg6MwcnlsRn+2MzKwMSijqFvbH4rAGBxdfuCvnfFu0UjRKNZWRcJtnZfhRb858meLlLnMM8AF72Mcbj/p1lgQNLb1iBsrP0PU3+sXIxajVgS0sjxldPzglEun7sgeJNUdUGfKD62hoyNtT8yJOZUvVWBv/zzG/RPP6dkYb8GRF5N/0V9LzQNIpUr7+LjIjMap+bXRrn82cX1V6EFn9wmo3oJYqliWSBcWRd+bRlMZJQBABZXt76xpAan1mB9ZfsnFn+wi2jonprgrY5y+TOL65fNAqDqkVNQ7h18/Cl70mBeG1vldgsvgsI+k3Nr/zClwJR3a//M14+CTvSnhtiVyq/b01wxbPYP0zeB7+Zg8dR8/4SqA289Emdg7bSSTguPFPQpt68aKVMoUTPsxKKOry2oduRMOxLTlsSy8WHdfpWItbo4FJkVPQ/ckqDQjCMlZ1+a4jkl65o9DQDwzC8zKrMJ+ysbH6a+Ix0AMM5bNXjBmJp/azbx3P/M1UinwLzAA6vNmVpAefe0uoYWXrEMAZC19bwO6jodBCWx6jvriKdklh0pw47EtPJm3sEnDGtzjgmF7X/9ORrrLaBWI+mlXebuybjAvBcBOZ/eD0R5CsvaGo3mqk0o+iulSoXVFP3RLtIl7C1rj8+u/sXYF25NUNYubxn5l1mAjQ/LjpxhS2LZklh3XicfKlZ+FLCsTUmohGL5x2Noavm6PW19a7e8deQ5JWtiblXvBWN9W9zQPWX8MhZKXoilighWg7lHslNQ7jO/zI+Myehug8goQbtWAAAEeqmubaS9X6YtiWVHynjizbyFj+ctbyCI5pPbZKyr5DFIKuqwJKShlKFSI0+I6Qa/xD73z7IlsZ6SMx8R0i0JaTKFcn5lS0ffGy23LK5uX9DzqmxHJV7XDV4w4M0PWbug7m1mJquq95M7vgqlKqe670vzILgY4Gm//SoROlUu8Lcu6HvXYXTgGrqnbHyYjgF5eGr+97ZRaIDMGeIZ4KKxy+941o7EWK7IFaoHbklGL+PRA7QgpFn7MI/v/NnH2tlY1tZK6QIArH2YcXn786J5Nf2XDImoWu/2jtQIF333dRK8cE/JrIce6bjAXATRKFXqpKIOc49kXGCOIyX74zuUN1rXiKbeaTP3lJsO9MjMJpiSbeuf+dI88LF3+lPy3gK49zoFchF/Q+RBKzZ6Ge9IycYyw6GArI2VnKUkVn2rFQ608EiGB/4mqQordHoMYDfzXa1eJoSuTTg2JIKyzBFap7fT4AysncrutPRMRQ3rIGujumtY1o7Pb7PwTFUoVXKFUiZXHip7dhCQtaF4jXNwPjb1AwB4TsmG0S4uIOfNuwRqQ2K9Ci0AAPCWN/UcGP0Y5W4HvywjXPTpjxFA1j7QxeweWbxPvh1PzYca31gh4+NBjqvABeYgCCJXqPZ53u+I5WZuSc8D8o2dYrhaMbDcmj69F4yBySWZXKlQqq7b015po2bs7bGPtRVKlbl7CirE+INdhFvE22/ePjj7g10k1CxGWbusecTYKXZ9e1emUMrkSunZ2/Xeg7UVSpURLjqvtp+W2QiXrKlrQkXraBizAfVbCGPWP3BL5C4IFErVpkjyyW0SWiDxopd4YQzA3COLXUMLNRrNvnOLXZYnIrGww9qbiaY+EURjSUinZzcjiEYmV0rlSlRZaWZxXUffGw1EFvhbF/S80HuBu7Cu58CA8R1k7VKM5VVMXgvM2mVW9pi6Joil8oO3CWRtNHgf5q7csI9iNw2LpQo1gnjQir/TKkd3DPKMnKJXMK6Dn931C8EE1Ea46OfaDMk/TP2huSWEUql+4JacXNxx8ACPwT7Wxnp3YJelHSkjMmN/rhayNlrW2xHLTJxiihoGVWo1/AJoUJhe1mXsFDs6w5crVHKF6lurEG+MzKRGAxp7pn5yZJDjKwEA7YOzNx2i5lY25UqVTK6UyhX7UmHTCwKX0AJDXDRWkvsgIGtjq+hERina+5FQ0PaTI31ta/d7m3A2xqXsGHjQiu+7JO6TxfeMYjsHv924y+Sqa88i84+ouByKs2VIbmHc6Q+y9scme6YhncNz/7YKneC9U9ZQn1Td0rK2CgCQUNiuaxuBGlwtrm5deRQMYxlGTvP1ZzS0djy7tPGlRRDMGUnlyqs2oWhSb2Vd9L0dHS3dzq1sDhzwHzgIp8C8gzu7jIru76yo6KZMsLX7rRW1oG4AnIW12c3DurYR+2TG4Op6k1RtSUhVqVTWPsxHhD15SS96qZOW/uQK1RXLENRSbx9rf2cd6kE7nLX1XjD0folBoxsCvcT4ZQzs3EJZm7e8edU6dJ9WJAw5t3ckHUO8E2/m92BtAEBwSu1z/0wr7zSYZ6Om1dqRmHfxcTVa0Xor77QI7Z2/si76i4kvmkzEnhwAQHZV7w37qINzsGdi7eTijnv4eOxPKIlV5u7JWAaAdHAoa8MaMjjA2h8ZEvEh+agMnpFTNDxXQ9PL/7HaP9MBb5N9rJ1fN2CICT4cKdlXtcZ+3SPzurYRWGcoAxwD3Y9P8Fa/MAuBJ+ogawMACPRSG593Etkajeb47P9xrP1zALosSbEVei8YKq1G69rmjhrRFNQNYFlbo9HgAnL2rRb4x11CC1EjTbFU8cUDCgzjsM0hMbktUPdYsLV7/RmtoO6dNgw1gqjUCPoMXtvc+dYqZGDyOAYY5q7oGJLDmQ3wn7tS+X+ehCZoN2rr27vGTjFukUW38XH7+uUOAkE08QVtpi4JsDKBRWZVz+UHAWhnQXnLyGf3Kcd3MezDGVi7bWDm73co5LjK5GKOWCrnr4su3gpga0X35UrVBT0vWlYTAECjAa9CC354Gpla0lnXOcHIaSbFVhz89vuQyuYY4OgwShLuSG85x95zic+tHcis7NV7EfWckgWDkQ2h2BAX88AtMa9ugFXec9ORjgvMQa9lQkHbP+4HUNPrkoo7HCnZZh7pP7vvVSNNXZO+twk9VGESC1sSi8go3ffDHYnsgVuiiVNMdlVfdnWfsVOMtc+eKndh/cBFkzenyWsrlCqozp5Z2VPLmQhl1oWk1SKIprmX+51VKGz+G+etfmTkDTmX3TR8xTI0qaijpGmYmlZ3QY+Iru+LmtRoLAAAIABJREFU+kTfuL1NFoIgl83eoGUAuUJpjHvr0mKMi/7GKhwXmBuT10qOr/zsHgW14vzsrh/6gSFptd9ZR0TnttRyxlPYHHcaG7ZJVbSNfWkeuC/VfhCf3PZ7rdWD9qKX2B1wGjoULf3ci8aU723C4ZnkDPEuGvv924qK+i1EZTV9a0XNqe4vrB8gxZZdNPJHM9TJxR2f36NEZjbl1vSpEUQqVz5wS7yFj82t6a/pGA9OqY1gNQIAlCq1jqEvNCc7+fv0cf9+h0KOr0xhc6CLxdKa8Ae7CFsSq6RppLJtzCemlFnWDQCYXhBcuhWIKtnPLm1cNPJDe2Ym5wT/eRwKW2I2heKPb5NvOtLdwotSS7qfU7K+fhSE+ph40Ut07SKSitrrOifi8tuI0WXQVIW3vHHxViAaEk3OrcHnYg1nIr6g7d9WoagH3sq66J9mAS8CcmLzWuGdX9E6dvnngOC0ughWg4N/1t3XqShrX9DzCkh+Z586u7xx1TrMgZJV0jxc0TbmxSjJruo9nrU/NiFBPhXuyi4a+6dhLJA+ueOLOgzA7/yIkMIs73EJLXSkZKsRTXZVr46xP9bmeHBy6etHQa+o+eWto+Utox60YthGmVvdf+VxaCq7k900FJhco2NAgjswVnm3HTmjsm0su7r3Fj4WzQQmFXV88zgsnFVfy5nIqOhxCy+aW9lcWtt+4sNMLu6o65xyCsp9Qck+PvnTP7F06VbALedYAo2dVtr9wC1R35GObfgjx1VcNKaEHOgxO4iG7qlLJgFfmwebe6Tcd4m//zrJ2pvJhaUOkeTu6yQjXHRmZW90but1e1pmRc+JH4jF2SbaK9vHHQNyQ9JqFSr1rkTuSS9BmxM0Gg0jpxmtz6gRJLemH08txFMLXMIKm3qnj++5AQD0TSwmFrajDfybQkloet3LkALn4AJs7gwAINjaDU6thb86uLOo5UzgAnLw1ML+ycUJHh/11c6r7Y/Lbz3KeBRFTnUfrD7vg3BXSstsfBlS4EwtZJV3o1uH4ellzyi28HTDnDK5MoXNwVOL8NRCj6hiaMOWVdmLPcC8mn708V7eOvpLYI5LaEHP2EJB3QDqx0ZJqELrwIhGQ89ubtMa16rVSHIxB+34/tEu0j2yqG1gBh9a5BSch/WDp6bVYc2qK9vH8dR85+A81/Di0uYRWBZOKGj/yYF+YhN6UEpNmZazqjvGc2tOtd2TK1TBqXXx2qSHRKZ4k1iVVfn2VKhUamZZ18uQQi966dgsP7mYg7bnK5Sq9LIux4D89NIuyDK7Enl8fhueWoSnFhFobFiKVKsRUkw5tkB9DDQaTXnrqGNAbmh6PbqZW90QUdNq8dTCV2FFbxKreCubAID1rV1Peina5CDY2g1KqUG9sgSbu4ycZhj/bgrFl4x8CuoHsqt6X4ayiYwStIkI/sWihkE8tdA5OM8ltKCucxKuqy2RxJNegjWy6h1fcAkrdAljl7WMtg/OxmBSxj2j878E5rpHFqPZ7dLmEQdKjktY4czSeucwDy4bjQaQ4ysaD5SXlta2A5Or4QEGpdScOO4RlFxT0TYGAJApVF70EqwJQEJhG9bca25l0yemHBdSSEmsgg+qvvFFIqNk913F6pnFdXJcBT608HVYcURGA9p2UtQwhAvMcw0vGphcyq7qhQ9FweYOI6cJTy3ChxXvs0xp7uO6hBY4B+e5RBTn1fSrVGqVGqlsG3Om5uPD2CFpdSdO6i6tbRPo7MW17ejcFqeQ4sDk6rV33aOq2sd0jPz6TrFl7xtf/DWy5FVooSMlG/73S1A+ekFFYllUViMuOP8ltQB9Np8e55p//+PQtY3A9pCcCTti+WNC6qHWnec4JTaF4gv6XoVnmaE4xx8WiUXthrjoY/xD/js4Z+3/cVy1DnsZmHvy6w5Dz+hCdG7zb/t9/l/DxvaujoEP7DU+x58auxL5t0+ooeknp0d+b5yz9v848mr7T+y5PApSufLEGvI5jodUrkwobJ+cP2Hg8Bx/fKxt7iYUtJ04Fv9fwDlrn+Mc5zjHnwnvz9r1XZOnLPL8GTG9ICisH1D9nhqtEpmCVd4dkt6AFhI/EJtCcW5N34m9On8Q/F9PDv6XMTqzwm4aer+9yx/kXInEstzqvmPshv/L3+f0UCrV+bUDWK3U9wN/XZRb03/87OhZIZEp93jggBDeUXh/1r7pyDDzSHnvt//BEZvfqqPvvb3zOzIgNa3uyqOgUFZTbnXfb5KI6BlbuGTypmfsN9CZ/L3RP7F4zZ7e+1tIYh4DpUpd1zX13D/LhpTxlJzZ2vfOXbEhFPsnVNpTsu3IWRGseqzJ+u+BwOSavxiT3mOCqaWPe82eNjF3Zu3890Nr/wwuMAcXlIsLyHkRkIMLgP+f2z4wu8DfumRMOdQIZWhq+Zo9HStd+YeCaFeqY0BC22HfGxUtIxeN/NHeod8EIWl1Vx6FhLKa8qr7Tmy0g3h/1r6Dj7c5XVvunwKJRe0VGI26pOKOT26TsXOovy2UKrXxy1h0QuE3kfDun1jUMfDpP0Vb0u8EtRqhZTYe1M49iOkFgWNA7tTvnO1t6ePewidEZjQU1g/iAnP/ZuyLDsLIFMqf3ZPuuyTWdU6VNo/o2oS/et9Om1MijFl/+eeAU84JYzE4tewYkHsaDdXfBGOz/KzK3tyavjBm/ad3/UJSa/Nq+zMquqfnBXMrm1j1FSy4i+uOAbnjs/+lR8uJ6BtfCE2vk2vD/x2x7CNDb7S5+71R0zF+QY/I++CYHYVCpTLCRWdri9Wn5IEzs7ZCqYaB4V183D7WhrPaB9+iVKkVR8+27MtCyBWqo1qqD/2VWo3IFWe+Ew7iCTGdmv52bCypuONjExLc9B2jont6gd192N6R3nKOPVgnPOYDFUrVUZtQ+K6xWf6HsLZcoTqozqpUqY8ZjNz3bVVq9V18XPqBewPOK5/yOxz8oVKpfr/d95ZIgtUY+soi8LFW0q+gfkDXLgKdpWzunf7kjt/Q9Pv43qnUyMGvB+UcsD85lLXlCtUxWbjjj/rQc6VQqk6cIzsl5le2DF9EY2f2pubXdPS9ofz9iVdEpVK/992BYt8nHPVHlar9K6SoftAAR0eb7nfEskuG3nAqQqlSH8owCKI58U5v6pl+b9Y+lB63dyQmzrHNZ+wXOBtrx+a3Wnim2ZKz8+sH7uDj7UhvJVSYpV125Kyf3ZKcqYX92rFRmVwZxqx/4s16REh1CsxzDWcnszkAgLmVTQKNPTrDdw0rfOKTNcFbBQCMz666hBaauafYkrISi9qxj52hqWU8tcjMPcWWnJ2q1Q/SaDQZFT22pCwzj7TA1FqsFcCZINyV+MdXXnkcpveC8TqMHZffBgBIKeF8ds+vbWDWPYpt5p7qGl60LHhn+iC/tv/5m9yf3ZJ+CSo4a35/dmnjl8Dcy6ZvHrglExklMIxilnXZU7J/dkuy988uflflYG1zh8gosSSkW3imuoYXYkPU6QXBi4Dch+4pnnR2VmXPRQPv92Dtef6WS2iBuXuKHTkrq6oX3vbbO1JyfMUTb6a5Ryqemo+qpnEX1gk09vjsqn9C5UOPVAdKNtRtWNvccY8s/tIi5JZz7OswNhyWmedv+cZW2JBYD9ySnYLz+7QSMUtr279GsiEj9I8v+saUj83yPWlsM/dkp+A8VNRXLFWEptdZEpiWRGZqSeeJE1LH4/qzCJS1CTT2rxgZNrFUfv0ZDdWqPT0SCtutSZnmnqk+MeWLa9sAgNaBGZfw4keeKWYeKaTYMnQOcB9rtw7MvAwpMHNPtvbJiMhoQPXQJTKFF72kZ3Q+nFVvQcxs7Z/hr+/8Gl6EVZgrahh0eJP3s1sSLiivpX8v8hXuSgOSaiw8Ux97Z+RU93347m2Ct6bnwMD6SEwvCC7qEwvqBxg5zRaEdDtyFkerxrwsEP4azoazfzK5kp7VZElkPiKkJxZ1nPUpsrS27RFRPDrDD0mtfeiRigvIWVkXrm7suEYUmXukOAXnLWC2HVK5kppe98SbZeGZ6hZRBH1Ky5pH7r1O/qdZIC4wzyW0cG1rR65U/c2YFJvXyirvsiQyn3izsBtrNaJh5DRD+nIMyKt/NwU0MLlk759t7pHiH1+ZWNRxydDnrKyt0YDY/Fb082u0I7Uzixu4gNzLpm8eeqQSGSWn/9gzsHZQSs23j0PKWkYbe7guoYWfmgah4qURGY0mTnH13dOdw7zIrGZDXAxcZG8Sq763CW/tn+UM8W460K/Z0+Ai4AzzLt0KeExMTyhsYzeNrK6LJufXrtvTYvPaOofnGrqn9BwYLG3INjS1fM2elljE6Ryeq+2cvOlAh92vNZwJY6eY+u5pzvBcccPg6ubO4d/7JMgVyvruydv4uBeUnKqOCahMzSzr+uh2oCUhLa+mv6V/xhBHtyMx0exzcnGH3gtGVcdE5zAvsYhz0yEKlXw6DXbEstyaPl2bcEpidV3XhFgqD2PV/2AXUdI8yhnipbA7v34UhE5Lrm3umDjFOFKyOUNz7YM85+C86/Y0qBY0t7L5vU24S1ghZ4iXWNj+kwP9kgHpeKWFg+BviG460F9R8zlDvLLWUf+ESsG2WCJTmHukWBHT2gZmOUM8L3rpVetQeIytfTOXTAKeU7KTizmc4Tlrb6aRU7RILJMpVOWtIzfs6e6RxVUdE4NTSwCA1BIOOb6iY4jXOTznElZ0Fx8P08f9k0uXbgXAqC2/buCSSYBzSD6zvKt9kHfPJd7MPQXqzdOzmx95pnCG5zqG5kqbhiVnTy+gkEjlX5oHQd04RKO5YhkcynzbeIuoESsiM/wsumsAgICk6h/twsvbxjjDcyGptRVtY2o1QowuSy3p5AzxmnqnjZ1iyFrhASxrV3eMX7EMjs1v4wzxylpGf3Kgu4YXaacipToGPgYv6FFZTSUtY7ylzY7B2Ysmb9AheGZZ100HekXbeOcwL62067o9DU7cBSbX2JGYncNzrQOzFa2jp9GBOh4HWZu7INAx8L7pEBWT28IZnsNT87+3CYfRzND00qVbATB8SSrueOie1D7I4wzPlzYP75yxYDAwuXTJJOC5fxarvJszPGeAY5g4xTkH5ycUtrf0z9x0pJt7JMNzpVIjuIAcO3IGZ3iuc3gOH5JvR85UqdTTCwJSbMUPdhH5dQMVbaO7UrlUpvj0np+ubWRoen3H0NybpJp/mQXAQESlRlzDCw1x0TWdk5whHj27+UvzQDR3P8Jd+do8iBxfyRniRee2fG8T/hdjn31uRMcD0Wg8o9g/vWBUcyY5Q7zo3NavzPe0EHbEspzqXl2b8IDkmrquyRO1TVCclrU3hJKvzIPRaWOFUq1rFwHlCtc2d76xpGKD/Bv2kbTMJgDAE2I6OjPd2D1l672XUekenb9oRE7TquADANwji20x+RZmefe3ViHwKf2KWgBFyyCSijp0bcIBAGmlnaYYPfUPhCMlm5HzVoU5pZjzkZEvWgKqbBvVMSDBYV+RWKZrE16MmRi875JAoJ/Nw1AmV93FxzX3cgEAK+uiyz+/wcrChbMaTF7GwDs8vqDtW6tQdG+lRhADHIOe3QwAYOQ0f28TigrMl7WM6BiQBs7ogZtQ2H7V5p3PBwDk1/Z/ZRG0iUkv3HdJgMLtHYOzFw19UQmO6YU1HUMy2gbzyDMFK/GKjY5XN3b+fpcM/WuguBo0ImE3DukYkHq1RVTOEE/HkAz3E6+oBYSo38YcMiav5bo9DWpKIBrNp3fJERnv6CjhAnIC39WqPx78DdFX5sFY4yipQrlPeimnuvdr8yB4HSFrK5QqjQaYuiZgBZc5w7wrlsFwy7K9I/3IyAcrQtvcN31B3xtS865Yds0uMqfq7Rk290iGm4an5MzAI5zz3g+Hsfa6joEPq3wvnNrekeoYeOfX9QNtdg5WI73oJXjqyQLrR2F4ekXH0LdIq5bTN75w0cgf3QbVd00a4BiwUap9YPaKZQhqTrYrkX92z7+xZxoAUNU2ZuqSgBb3dsSyvxiTsH6wn93bsyYYmFj67K4f1ivSLbzI2jsNXkdSbDlWoD+N3XnWDMnoDP+ze5SOQR76E88otiUhDd5oMrnyDj5+X538RJyWtXvHFo1wMVhlu/uv4619mACAzmHed1ZhAUnVkRmN4ayG6JzmvxiTIc86UrJRBb4wZv1DtySYOe0cntPR90Y5UY0gVsQ0G1JGVFZTGLOekd1sS2LpGJK3diQAgEeeKc/IWeivrIhMHQMfiVzBXVy/6ciw8WE2dE99+H7Q3i8zAiMsmVTc8ffbvmiLT0P31AV9IndhHQAwNsPXtQn3jauMzGgIY9ZH57R88SDw3uv4wz/3CGwKJSZOsVC0oaF7ytgpZkv4tl+la2TukiFpfJYPAHANL0LtrCDw1HwDHAMA4BZehHUtGeGuvEde25PG9j6glkWOr8SqcgMAyPEVULGoY3D2gr43ureYX9m8oO9d1zkJDsgNQiwLhLm1A8yy7jBWvY6hL/Q/w7J2Yf3ART0C6sbSN76oo7+nTF/dMfG9bYRnVOkpVe2PAmeI9/EtEhpAIBrN3+/4YdXvNBrNc/+s06gCYT/TCBfNP0z5c3BqOaOyN6Oi2yk4/yNDb5i7g6yNIBrhjtTYKbal921NTyyVf/HgTUxeCwBgSyS5pO+dj5Gva+nnoqw9NbemaxvhE1OOrr0vLahGTtEAgML6wW+fhJPiKtCo/ANxaIZER9+7Q5sP3JXIPzIkQrcTyNqdwzwAQHPvtK4tzSW8GKuZfHrAtYEGH9yF9Qv63qgx1gh3xcQpBka7qSWdP9rRIjMbI1iNEawGalrdpVuBiUXtAICSpuG7+Hg0zIfVSKzaz1cWQX4JlQCArKoec/cUrH9xUf3AJUPitkgCAHhKzmTkvB0PbuyeOitrF9QNmLomYTPaZS0jlwy9YepsUyg2cYpBNYVOidOydvvArBEumo9Jrt112atGdgzyvrOiBqbUMnKaaZmNtMzGxOIuGDpFZTV9cofsHFyApxZcsQxBc0mQtdEFoVIjjwnptuTMmNyWqKwmWmYjI6c1t6ZfoVSr1YiZe/JT/+yY3Bb44dG5rfl1/bC8yd8QhabXXXtGsyNlrKwfp5x7Ig6yNraHpLZz4oI+EeZhh6aWrlqHkhOq0eNNKOo8a2oby9o1nAkT59htTJ913/iCjoHPCHcZAPDqgCGDS2jBdXsaAMApMA+rpDw4ufQerP1reJE3o2zfD31iyvd5Cb1JrP7XwwCgZe1xLTXMLq1f0PeGO8qDrN3UO23qkkBglMXktpDiynQMSFBT9wBre6F52+7ReR19H5Smx3l8n9jK76zCfGMrZO9V3RqaXr5hH4UVa9VoNLecY7FnVaVSP3RLQt2zToO2gVnDd+8IAIBGA6JzW+67JIakN8Tnt9mSM/9+2xdqb6GsvSmUGOFisU36Mrny83sUWmYj0LI2NsOOZe1x3qquTbhvbCW69uILOWhTx9DUsmdU2b+tqMGptUrVh/aSHsXa6J8T7kpRpVYsawMApucF5Pjqq9ahBBpbLD1bhgS7NgAAk3NrF/S90fT9CHflJwf61NwaACC5mPPjUxotq4me1UTLbIzMbEgp7eYtbwIA2I1DB1kb20PypXkQjHhY5d0WHqkqzOliNw1d0CPCcP4xIR1rqVHHmTgra+dU9z1wTcSWpqvaRi/oea9oxcV+R9aenBfo2kVgGcEAx4CsPTS1fP0Z7aDcuEyhsiWxKlpHazgTRQ2DWMFDyNqo+rhGA+xIGREYlw0UakTzmJAem3ecg9SmSGKIi6am1R7zmhPxlMzCZkiOYW3uwvp1+4gP7FrDsnbv+KKuTThWCq64aeiGfRR0XveNrXhKzsS+94lPOsyW+saWPfN/WxDuHp3XMSSdlbXJ8RX2fpn7fhjBakA9PCGcg/Pgtrf9WNZ+6JaEMo5SpTZzT6Zn7YUqWzvSC/peUDP69KwNMTqz8q0VteJo++CjsCIQGbxgwAozFpTEKivvNPSfy2vCT+9RzlTKH5pa1rWLmOC90+s2Obf2o10kWnQtahi8ZOiDZW01gsgUKiNcNFaWemF166pNaPvALNCyNjYqxLL2/MrWdXvayPQKOBpdI3NXHoWcpv/yeHwIa0NwF9evWoftk70+Ecez9vD0sp4DY3peAADIruq953L4HreoYdDUJQF9zB/D2pVtY9ftaUJMLwMjt+WuSzxMPDoF5qEy3wCK6et7n4m1azkT155FYkeTEgrbbznHwqaX35e1ZQrl9zbhT/0yFUq1QqlKZXO+MA+F1UiFUvXQPckpKFemfZ5Mza9tCsVyheq5f5ZPdFlt52R1x3h99/SS1t2uc3hOx8AHa2CaW9P3tXkQyjiCrd3peQHMerDKu69YBqMvFmztTi+sazSgc3huSdvX8cAtkZbRCADQaDRx+W37lF1PA1sSy4GSLZMroJxjUnHH30x8Udau6hjTMfCBrK1SI0/JmU+8mbtaQ3ru4jr/jJH+plBi/EtMVfsYAEAqV95yjn0ZnA8X2eLa9lWbMJ+YvaxF28Ds5/coKGHl1/Z/fo8C51MK6gcvGZDgXcRb3njolvQXY7+zsnZt5+THt/yq2sfVamR9W1xYP7i+tTvCXfnClIJKLddyJj67/6ahZwoA0DYwc8HAZ2xmjzi4CwIdAxJkbUSjuYOP94kukyuUUrlSqVTfcY6DztYqNZJW2nnR2P9trG1I6h6ZAwAU1PVf0PNCnQ87R+YuGviOcFc0GtDcz4XVy/Xt3R/tImEe5vRY3RQ9cEt+5p8BpZYXVrf5GyLo9lDbNfmRsS88qwqlyjOq5K5LwolKnljIFaof7CIdKdliqUKpUjf1crtG5ifn1q5YBsPOCpFY9iIg5yNDH3gIoel1/3jwBu6UyXEVP9hFQGFVqVyJC8o1xEXDX22JJDr671gNtPRzLxj4wMeDGkFwATnmnqlox9TM0sbqhkiuUDX3c2Gj29zK5vc2oZBAuYvr7tpenbNigrf2kwN9P2sb+KDPtu0diY4ehrUNSbCS39LPhYU1kVh23Z6GWpieEti1AQCYnFvTMSA19e390eHp5ZvP92LtlXXRd9ah9OxmmCNWqpCxWT7Uaq/hTPzTLHB2aQP64+xK5JcMiOmYQtrlB2+gVSO09A1IrlGoVACA0Vn+F6YUdGcWX9B2ydAbltZHZlaMcNF/M/E90/ncFEquPYskxVZAmp6cF1w2e4MGiJtCsREu+vdibQBA58jcT47Rpm5JZu4pvnFlvnGVaA/J8PSyqVvyvdfx7jS2PSXb2psJ9ykRrIZrzyLcaWy38CLHgDyDF4z+iSUAAGeYd9GQPMx9y9pKlZoYXXbdnoanFrpFsO/g49GNtkKpJtDZ155F4KmFbpHsO/g4WO8KTK42coomRpc/dE9yCs6Ddi1w8+uqVeg/PQrqB782D7r/OgU6PScUtl8yJMJoFwDQNjDzFxPStNZ3bnph3YKQfgsf6x7JdgzIM3dPxi7u02BLJDHExaBOgwOTSyb4+Lv4uNdhxUY4xitqAVbSmp7d9J0V1eFNrsObnJsOdPSZpFSpfWLKv7WiOgYVWhLS0ko6b+Hj2s/irQ4A0Gg0ocz6rx8FPfHJNHGKcaBkQ0OAtJLOf1tRn5IzcAF5N+2jkov3Gi5b+md0DMlojLm0tv03E1/UdSWxsP0r88D7r1NgXJNf23/VOgwfWuwaWhiYUvO5aQB85cDk0kUjcs/YPAAgr7b/gr43f2PvATw8vfxXE9+hqSW1GnGgZJm6JhJjKm/hY0NSa8/aQ5ZV3XvpVtBFPeIFPa8L+kQdA9Kn9/zRpmxaVtNV61B7SrapW4qZW/J7UFvv2PxPOIYhLuYRIc0QFwO774mMkmv2NE96OTG6zDWs6LIpBTJscGrtp/f84U55UySxIzFv2Ee5hBU9cEu08ExD9y6bQrGOvg9WZLypb1rH0Bfd2/GWNy0JaSbOse6R7F+C8s3cU0Zn+FK50so7zdwjmRhdbuIUTc9uhnXgkqZhHUPyoXMxJ2J8du36M9oI9+3CnpoXXMR8mkSm+PyeP7zQozP8i0bknvEFAIBTcN49l3hiTMUdfJxffKX0jJ0/2LUBABib4X9k5IP+c3By6cazqJnFvYtV0Tp60zH6iQ/LM6rEzD3ZNbQQ9uCvbe7ce5147VnkM7+s1Q2RTK68oEdML30ba/9gF0HStvfUd0/ddGBYeKbiw4r0XjDIcRVohV8sleND8nVtwh2DCm180lPYHGOnmLNWDlr6uD/hYszckl3CivReMHxiytGVvCkSG+Ciq9oPEfQ/Bmfr194UistaRmC4JNqV8TAWJzK5sqmPW1A3UM2ZgIn2vomFr8xDsBt/R0o2LI6LpfL+iUXZgemYcd5qSdMIu3lkcHJ/9Wl0hl/SNMJuHsZG6AOTS4UNw3Vdk+hZWNvcufaMdtagDIK7sF7WOgYLHYKt3cGpZbQGLVeoxmb52PWnUiNtAzOFDYNVHeP7WrlPAzWCTM0LsLOXOxJ5dcd4UcNw32Fz3tMLgpKmkdKW0YMNjv0TiyXNY1BjYWZx/f0ms8dm+ezmUc4wDzv0MbeyUdoyWtI8gtU525XI+ycWsT0nE7xV7IGMzqyUtYyiGY+ZxfWixmG4/ecursMoTCJT9E8swth2UyTpn1hEr6BSpR6b5UPhfJUaaenjFtQPcYbeR6plQyjum1jsHVvoHp2H/3WNzIswX3VqQcBuGqnhTB60Ljsltnckle1j5a0j61tvrwtniFfUODI1L1AjyARvDVa6VtZFw9PL2LJ5++Bs0burFwCgUiMDE0tbmCawHbEMe8IBAGo10jHEK2wYrOqYWNReGoVS1dgzXdgw3IuRNJDKlWMz/PdbEjKFaoK3hl3zMoWyf2IR3WICAKYXBLCFQypX9k8swjgXQTQdg7MF9UOnF9bAArs24D/HZvloI6NEppicW8P2NW4IxTWcicL6wfp1fMuhAAAX8ElEQVTuKeyRSmSKyrax9oFZlRpBEE3/xCJ25Iq3vIG9bde3dyvbx4obh0dnDsk+dQ7zSlvG4OunFwRnfQ4BADaF4qr28eLG4WHuO5+vRjT7eOA0+B01/+q6Jj+7RxmbXVUjCKLRLAlEt/BxsQdsm39DaDQaWmbjm6QzeNSf4xznOMefC78ja8sVKgK99N6vaeS4CkpClTkhwzOK/btq9ChV6hrOBLbL+BznOMc5/sfwu+trL6xuDU4uDU4uLf0B1MTPcY5znOPPjnNXhHOc4xzn+DPhf4S1N7bFHUO895DB/EAolCpr77Tys/cR8zdEnCHeh49CKJQqzvDc+hFC9R8CtRqx8UlnNw4BANa3d808UnrHzqae7BJWGHe6MgY5vjIwuRoAoNGA3vEFbJX7jwNaZqMnjX3Wd8ELdJSTwDnO8R74H2HtrMoeHQPS763XfBBSuUJH3xs2C54JjJzmC3rEpbM3n+wDb3lDx4D04cLBB6FSIxf0vMKY9QCAhdWtiyaUsuazNd5eeRTkSMk+zSsNcTF38QkAAKVS/fk9yr6xzPfGplCywN9CkN9AuxwAYO3D1LUJPeu75lY2dAxIWMmdD4RoVza3sqn6MPnDc/yp8T/C2htCcd/44n/fA0mmUH5ym4ydlj4l1jZ3BiaXVB8shaxQqvrGFzd/B9cxlRr5+10yfCAtrW1f0Ceetav0R7tIl9NZDZi6JT3y3PNFGppehuMnH46syh6nwLzf5KMAAI6UbIMXjJNf9y7gBdr47SrkNR0TtiTWh0v6nePPizOw9sq6SK5QKZXq9oHZ7pF52HgqEsvaBmb7xhf36TchiGZgcqm+a3Lk3f7ETZGYM8Sr65wce9f2QqlSd43MN3RPza/sCVSpEWRpdRvbproiEMLGRgTRLK/tSZW29s/siGUaDRDuSGEAItqVwen58dnVhu6ppdV3TEBkcmXH4GxzL3d2cX1uZXOev3Wo8hR3cb2+a7J3fAG1wxBL5L1jC3WdE3BQaO/TDrD2jljWMcRr6Jqawmi3KpRqWIydXlhv65+VyJQIggh3pFjjscm5tYbuqZ7RBWz3rliq6BjkNXRPHapSBADQaIBoV4aeJYlMwRmaa+iePqaFfHZ5o6F7qnd8Ae2XF0v3Dq0PM1d5PGuvbuw093Fb+mb28ZFwV9rYM90ztoAgyI1nka+O1n4Ty+QtfTOc4Tk1gph7JFto3ex2JXLYq4sgmmWBUKPRLAuEzX1ctDXoqD8tEsvbBmabeqfXtnYBAPx1kW9sxS3n2LFZ/sziuvqIiHtLJGntn2np46LyVQCAibm1hu6plj6uSPy25ekga49wVxq6p3rHFrGmH/x1kVSuEIllzb1c2EyNXiCFUgWXAX9D1NA9hY4y8JY3mnqmD+aFtnekbQOzjT3TcLUDAASbO1FZTTfso/rGF6fm1uBSWRYIEQRZFghb+2eW17aXBULsXSNXqJbXtj9QmvwcfyicgbXv4OO9GCWBydU2pIwfntE8aSUj3BU7coY1KfOGY4xLWKFS+/zflchdQgsfe7MsCWmmbqmk2DIYVDb1Tpu6JtqSMi0JaQa42MCUGkhbIrHMJazQgsC0IjJ/CdwzW9oUSr42D4ZKHQAAtRr54WlEUnE7AGB1Y+dbq5Do3Jbn/lkPfmV1Ds91j8x9ZR4IY7SEgjYjp5iEgvZHnikPPVJ/tAtv0Xb7T8ytGTlFP/bOeEJM/8aS+n+eRkVl7U9uaDSa5GKO3guGJZFp7pHmE1OqUiETc2sWnim25ExLQqrxy3jX8CJ4Y+xj7b7xhTv4uMfeLEtCupFTHDm+Ap4T7uLGFcvg+IJ2G5/0nz2YYzP8qvbx/1hRoaihGkFC0+seuKdYEtIeETOekllQuWZlXfjMP+sxkfXYJ8Mtomh9+5B4bXNbfOVRcEXbKDwtz/2zHnuzLL2ZruGFWBpCkVbaqfeCYUlMN/dI86KXKFXq6QXBI0KqLSnTkpBq8jL+FTUfDhEcw9rV7eO38XFPvJlPvFm38LFdmOHju/g4M4+0Jz6ZruGF39lEYjUcsFha2zb3SL7/OsWalOkSWnDDMQbV6TXCRcO0zK5ErmsTHpHR6BSYd/9XZmH9wP4/7RzbPTqnvbKrpm6JFoS0x96sx4T0gcklZmnX9efR/zQLtPZhOgXmHrodGZhcuouPsyCkWxKZj4npE7xVuULlGcW29M54TEw3c0+9jY9Dp16xrL0jkTsF55m5p1kS0kzdkh95psxqvQTN3JLdIovI8RX3f2VGZDTIFaorliFlLSMAgNEZ/hXLkGQ2BxeY+5jI/Mo8sKhhkN009MAt+REh/YplMFayo2980cwt2YaU8ZiYboSLhrWT/Np+g1/iv3jwxpKQ/pTMWlkXKpRqXZvwcFa9U2Duzx7M5KKOu/h4JkbAKyqr+bl/9m9lcHOOPwLOwNrfWFKvWodBfYC2gZlPbvuaOMXA8dbmPu4nd/y6R/aqVU6BuY8IqZDX1jZ3bjpEFTUMAQDaB2dRUZum3ulvH4fAweiCuoH7LgkwHNgQitGZVB1DEipZqVYjfzEmhbHqAQDLAqGOIekWPm5oelkklilV6tLmER1D0jx/b4z+opF/XF7rpkiiUiN4av4PdhHwseEUnGfvnwknHgOTq++6JBycz6zrnPybCam5bxoAINqVVXeM70jkY7OrNVqtgAne6n+sQuGAKJa1+RuiK5Yhoel18FE0NLX89aOgzMoe+JaLxv4WHimTc2s7YjmCaNJLOy/oecFoMbGwXdcmHO4PFErVY0K6f0IlACA6p9nGZ897RbC1e6gztACepdp+AEB8fpsVMU37+p3dA1prTT3TfzMmQTmRHbGshjMh3JVOzq1VdezRMXdx/TsrKvznUaw9Prv6r4eB9d1706f07KZ7LvFyhUqlRm460B0p2XKFSqFUpZd1/eUWhXBY+U6j0Zi5JZm5Je1I5IhGU9ww9On9QFTB6rIpBSrHCnelOvpeN+yjukfnRWKZWKoY573zp6Oymu67JEJjthv2NJewApgi6xyZG5xcQhANPbvZwjNFJJZJZcqDOyrhrvQ7KyoptgwuvLaBmfFZvlgqL6wfhFs6uUJl7c1010pdY1nbgZJt4hQDa4wbQrGVd5qNTzrc6t2wp31y27e0eUS4K92VyLdEEh1DH+jjMTC5dNGE4hZetLi6BQCgJFb97ZafS1ghNGch0Nk37KPgXSPY2rlqE45mw9lNQ1AcXI0g2VW9t/Bxqxs7UpkSLtFL+t43nkV1jcztSOQSmeJ1aCFqMqVGNDcd6CEfJqx2jj8azsDaVyyDCfS3N+G1Z5G4gBz4/2oEsfBIgUYBa5s715/RKlpH5QqVRKpQI4iZe/L9A/YFWzvSvxr7QH24Gs7EFcuQvnfNxQVbuxf0vIq05gNqNfLpPX9aViMAYEUgvKBPzMJIRJW1jFzQ84Ly32HM+s/vURTaTWJx45COPhEOHDtQsthac6/esQVzj+SDbScEOntfDe3gDX/FMhgqrGNZO7em76YjQyp/y63+CRW38XFgT3aHBCNiCGZZ119NfIS7UkSjMfdIDk2vU6nUEqlCrUZC0+s+vecHAMis6Ln2NGp64ThD6PWtXR19IpSQz6zo+eFp1NTcka46xOiyp+QTDJr/bUX1ja0Ah7E23PdEsBrM3VPkCpVYqpDJlQOTSzoGpJGZldmlje+sQ7EaeLrWYYfmtRf4W7o24R0Ybdv7LgloXvvKoyCoaCgSyy4ZEmMwXSjhrHrsn+6fXNIxIE3MrY3OrHxvE34ww5BU2I4V9tuHhu7JH+wijko9QfgnVEJVcYBh7bXNXV3biLqut6oJ3aNz/zILhIpaP9pFYjUUN4Xii/pe8LEKzxW6NeEuCHQMfdu0ujE9Y/N38HGCzV0AQGH9oN6L6I1tsUSmlMoUqxuiC3pe8GYpbRq+75KIrluRWHbJ0Ds6961cZevAzKf3KHvubhNL/7ai8t5LPeocf1icibVDUDslAMAN+yh88F6pB9FonhDToXH99ILgO6swc480O1KGjQ/L3i/zezvaM/8sAIBGoylqGMIF5uGp+c8pWTqG5LyafgCARKagJFbp2kXgAnLQNX0ia6OKReAAa182e4OydkH94CV9IhSS9U+ovOkQNTG3trC6bUlIsyNlqA/4274IyKEepo7f0D2FC8zBUwt+Ccr9+M4baISBZe2ozKZn70qephR3XNDzAgDMLK7r6Pughwa0rC0Sy1Rq5J5LvAk+/imZZePDeu6fZeQUe82epkY02ztSAr30pgPDNbRw7Aj3a8jaMHuwvSP1ii6/YU9zCS08VM3KKTgv6DC7k+Y+rlNQrnNwnlNw3if3AmCkfxRr+8VXXbWJeEpm2ZJYduQMC8/Uz+9TRmf4bf0zd/DxWEWFa88Or0Z2jy4Y4ujYkuMDt8RDWfsjQ2IexhmHHFfxzp/2SP38PmVslt/YM30XH4fNQUMkFLQ9JqYf1UOSVzvw4P9v7zyf2rrSMP6nBDzZndkdTzbJTpwyuxs2aycxBuEsWDYxxjbFJgQPWFFQKAFkiikGQ0SREIgiZNMEAkw3XRjRTBNGIIHoIFEkVFE9++HA9Y0ETvAmk0DO75MQGt2rMo/Ofc/7Pg8l3z6AdWFtO4becDeVF5rOO/tVJgxOAjjVnpxdOx+YjRkYAXjxdyEGLgic/DPCMl72wNip9ksDdJF07Q3naCzlRChZdbmTAzMzC3h973s98Kc+8qNy/Kgcn+jiv11Jgrk5NR1jHmQmNmO8o9Gfct1by0N2DUa3YHpe9TMAQBq7jRj6i+U9IX4nHE21qYwG7M9zAbS7+6pttli8I4uhffjMvOzTAFoDXyhelIuk61PS9cV1BbxaZ9X0/ZfEbHk2JV6QCyakp36cLiFekFPpDR/deNDU+wIAINtSveEcjbd5PO0eh1dt/NLVVrVxsarcttFTzlGw/pBV1u12N9cnhnOZUvh1Qhk+NhQjKLE8kdVic2d9j/BCUHZV2+j0vEwoWXnXM9l+rZ1T3gPDfTDyqp/BlZpkUe7gHINPTsBU22g2u5Pzsst7Zpc24Ns1u7ypUOmwBf6EePVuKtfJNx0v+hh41YYIJavfpld/7Jsm+LHZMQAgOKUyntlkc2fzsxcXgrK5baPT87KpufUzXsmvXmvH0BsC4krnljen52Ui6frMgly2pbJYrJ1DYkIwfRNXTD93O+PA3cgR0dKFoGz80vhKGAvbjbRRbbxnaVRO/QGHtlqbn00Rgun2sXtMLv9GdPGhqt064kFm2jgBrciVRHJeIqtlQrI6u7RBSuV+6P0A/gtT7el52WeBWdDwGjK/uvWXL/bM8Jz8M/CWk/aqPbzvDjY1t/aGczQWjzA+s3I+MFu8KAcAMKt6PcjM6XnZzIJMJF0XSdfXNlWwNs1rH7tEztPsWzhB1YaBMhixuY3upFyt3vB5YFZZ85EjjBG/c35J1Wbx+gAACpXufFA2XkcgViu4Gl4AHwMA2FZpT7lS8Y6UkLspXOi+r9jRvkmgYkst8YLc4QI1u7wLvJZqbyo1Viv4gpTbOSTW7xo3D9rZg8QxG4mhLPxpm0xm0gMulf7ytb/rubcgxat2S9/UP26k4Y22/aiciMxaAD2CD1JthUprtVpvxXJsMsbsuRpekFx4QHXSXrUh3pFF+JQ8SHJhK2yL3n9pVpPJQknn4YdHPriWHJ1TDw5X7cJawUUSw/5MxIvydzzvY+bLm0rt21eSKekHWObKttXvX0uuatu7itLqDB/7ZfpEl2AncJhqH3boydm1M15J+CEguIJmcvnXIovsHw/pF86/dzUJi8EDABiMpnr+pMudHKwkFkN/8sG1ZHgbU22lWnf2Nu1Rw8sTK2sZPhdAU6i04BdSbWilf6AVXE3H+EVSLtYTolTr7FVbsig/H5SZXd71WWAmzEzR6o3bv0J7KOI34QiqfdojIQIXvfrRjdSvE/ZCeM0WCzE0D/PzY1b1vueVUt0+Nre8KZxdy63qHRUtAwBC06oJwXSheHV8ZuU+q9nxYhKsTdMr+Uxu7+Ladt/YnOudbGwBHpFZ+8ktWtewuK5rwjeG8+HNTLjWXl5XOBLi63BDH7Wd446ucdBkNamg5c9u9zDVLmt57uhChWvtHx53ngugfZfOC8vgUTJqC2sE9h1Ro9PLpz0Swmk1g8IF9pN+8sPqHY0+p6z7P7cyB4ULU9L17IpuR9e4WGYjAEBvMDo4R8FkObV291JoHpHCEkxIp6TrcXlN73gmQuPHF9L1U4T7PTjjysJagcOF6E2lFgDAH5l9yyMhq7xLvCCXLG2wnwy0CkRWAFLZbY8bh5ZlivaB6c8Ds9oHDrCflW+pHV3jYKEpraSd0zC4LFN0Ds58HpiFryBBhJK1ty8nUTKqB4ULjxqHvkmtUqh0udxeJ39a/8S8aH6dweU7uMRiqu3g/D0MV1xc23YkxMNGiC2l9mwALTChdHR6Wbqy2dj7oqhWYDSbTWaLV0ThJ7cye0fn2gemgxLLnQIYh/WQBCdXfHA9rWNwhj8y+01q1dnAXKwWfNo97vusvd1IR5d7Jbj5FNtD8yeL6/pNZovJbPGOZJ/7KqtVIOoelpAf8mDHRV33xF/d43gdY/wRif1erm7X4E5iugQzOgZn2gdnSKlVfWNzIun63z0Ti+v651e3GviT//RJO+OVBB/vS2U7+T2Et7PLe854pdR0jksWN2q7xt8mJmTuT1q9fy0lOKkCO8qmQuPoGlvWNAQAGJ5aPOV2f2C/70UoWXEkxHfv21WPiJacfNKnF2QAAIPR5BlWSAxlCSakC2vbXcNiJrcXyq5gXPonNyq7rr/7uUSl0au1uw4u9+yz04JTKt90i4ffUgCAT0yJV0Qh6v87GRxBtX2iS2CSJoScVoWN5FmsViqjActbMZktpU3DnhSWT0zJzZjH4bQ6+IO/uqEkP6z2iuQEJZa3CkQhKdwWgQgA0D0s9qc+8qOWfhlWwGkYxGrNG9ua79J57t+ybkaxx2aW6RU9MA9hY1tNCGH04yoG/BEJIYS+odQAAB43Dl2LKMRanZ5PLXlHFsu31bpdIymFG5rOa+mban72ouLp6LnbNHwoHIZgXOoVUXgljO0dWQxXSWqNPp7ZTKQU+lE59XxhVHY93N83GE2XyMzarr0dzrWNHcoPPCKl8Ho0505SxdT+1tz86hYhJFeIs+5t7J30IDMxq+L2genrUezr0RxfamlgfBl07q/rGr8ZxfaLLSOG5kPFtEeh0hFCGNCPv75b6BNd4hdbRgxl1R4SIDIgnPeOLL4SxvaOLKpoGbZarRqdIbHgKZFS4EtlP+maiMqpz+f1AfhLTMmHPTyyLRUh5GWH3+zSBjmtyiuS7Ut9dDW8gNcxDqsQSrWOSm/0+JblFV7Q81xS3jyM3yXDo981phS1XSQxLlPym3onG3qEWAAmtkGi0e1+cZfx9Me/VTaHrumcgB1BKu0uldHoRsq7RM5PyG+G3R1avSGN3e4awqSk81QHmU1uKTXhtLqLpDxiaN6D4jZYY6l8OkIMzfOPLWdU8jkNg9gFZVJBCxY9bjZbCmoEHmTmzZjHV8MLqvcDxQEAX8WX4ttJlWodIYTeOTQDAJhZkBNCcmf2szVml+TekcVYy6B4UU56wF2V712ryRXqe7mNX4YX+VI5lyn5LF4f7JAxGE30Sr7LHXpgQun2jtZgNF0kMVrtwlAqn444ut3Htjpj6E/CaTVItU8Gv+5spEKltXcQx0+F4FGqdQcON9p3sL0evaOzb3ncx1vFfp9VF5xy6OzcjkZv0z2CDYC8Gq3eoHotl/0djc7+xSr2p4d+JgqV7iebc3c0eptqr0qrP1L+FgBAqzcoDrqEV+sMh4202KDRGV5vxu+wQ+t2jfbfN41u137P2ebZbFqJjEbzjvqnP0GjyaxU61795P8nuwbTgV8A3a7h1SY2j5uG/uWTdtTPFHEsOCET7T8H8aL8jFdKUlHH8IvFCfFq8ZOhf/tnNPKPNqWNQPz+MRjNnwZkxtntPCNOBn8g1QYA9E9II3Ma7zHqkwpawzLrW/tsK78IxAlgRa4kP6y2MZNAnBj+WKoNMZstaMAXcYL5VYs2iN+cP6JqIxAIxPEFqTYCgUAcJ5BqIxAIxHECqTYCgUAcJ5BqIxAIxHECqTYCgUAcJ5BqIxAIxHECqTYCgUAcJ/4HdONTNrsiDl8AAAAASUVORK5CYII=&quot; style=&quot;margin-left: auto; margin-right: auto;&quot; width=&quot;400&quot; /&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;tr-caption&quot; style=&quot;text-align: center;&quot;&gt;Merck Manual - Home Edition [2]&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;&lt;br /&gt;
&lt;br /&gt;
&lt;span style=&quot;background-color: transparent; color: black; font-family: Times New Roman; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline;&quot;&gt;This  to me this is a very imprecise, unscientific way of estimating calorie  content in food as it translates into energy or fat storage for the human  body. The body is not a bomb calorimeter and as such translating or  equating 1 gram of fat to 9 Calories of energy that will be stored as  fat is pretty naive (on the part of the authorities, scientific or  governmental). The support for my statement above is evidenced by more  than one study, but my favorite is in a study published in the Annals of Internal Medicine in 2010 where it was clearly seen  that successful weight loss can be achieved with either a low-fat &lt;/span&gt;&lt;span style=&quot;background-color: transparent; color: black; font-family: Times New Roman; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: bold; text-decoration: none; vertical-align: baseline;&quot;&gt;low-calorie&lt;/span&gt;&lt;span style=&quot;background-color: transparent; color: black; font-family: Times New Roman; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline;&quot;&gt; or low-carbohydrate &lt;/span&gt;&lt;span style=&quot;background-color: transparent; color: black; font-family: Times New Roman; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: bold; text-decoration: none; vertical-align: baseline;&quot;&gt;unlimited calorie &lt;/span&gt;&lt;span style=&quot;background-color: transparent; color: black; font-family: Times New Roman; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline;&quot;&gt;diet  when coupled with behavioral treatment.[3] Focus here on unlimited  calorie intake of fat and protein. Another study in support of my  statement included the Atkins diet where it was seen: women assigned to  follow the Atkins diet, which had the lowest carbohydrate intake, lost  more weight and experienced more favorable overall metabolic effects at  12 months than women assigned to follow the Zone, Ornish, or LEARN  diets.[4] Therefore a low-carbohydrate, high-protein, high-fat diet,  with good amounts of vegetables and fruit is in my opinion the best  recommendation for weight loss. That being said the fats must be hormone  free (rBST), and non synthetic. (&lt;/span&gt;&lt;span style=&quot;background-color: transparent; color: #ff9900; font-family: Times New Roman; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline;&quot;&gt;I  am not a full supporter of the Atkins diet because of its exclusion in  certain phases of all forms of carbohydrate including vegetables and  fruit, and the other part is not addressing the kind of fats allowed  that may or may not include synthetic fats and fats coming from animals  treated with rBST. To be fair though the latter happened more than 2  decades after his initial publication of the Atkins Diet Revolution. I  admire the gentleman immensely for breaking the ‘Fat Barrier’.&lt;/span&gt;&lt;span style=&quot;background-color: transparent; color: black; font-family: Times New Roman; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline;&quot;&gt;)&lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;background-color: transparent; color: black; font-family: Times New Roman; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline;&quot;&gt;My  direct message to Anonymous: Do not count calories to lose weight but  AVOID refined carbohydrates (refined sugars, flour, rice, potatoes,  etc.). Feel free to have unlimited amounts of healthy oils and a minimum  amount of protein (hormone free) of 80 grams per day. This can  translate into eating 1-2 pieces of fried chicken daily or equivalent  (as long as there are no mashed potatoes, breads, pasta, lasagna, etc.)  and this should be amply sufficient for absorption of your vitamin D  supplement. Additionally you may have unlimited amounts of vegetables  and use fruit as your dessert. Please continue the exercise and target  sleeping 7.5 to 8.5 hours per 24 hour cycle.&lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;background-color: transparent; color: black; font-family: Times New Roman; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline;&quot;&gt;I  do realize that the calorie count concept will be hard to get rid of  but the science just isn’t in favor of limiting fats and protein.&amp;nbsp;&lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;background-color: transparent; color: black; font-family: Times New Roman; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline;&quot;&gt;&amp;nbsp;Also  an opinion of mine not yet proven: I fear low fat is more in favor of  cancer evolution than not, unless the fat intake has come from animals  treated with rBST. I fear the last will contain said hormone (in meats)  or higher levels of insulin growth factors (in milk and its products)  both which will encourage increase in cell size and number artificially.  &lt;/span&gt;&lt;span id=&quot;internal-source-marker_0.41588019753344607&quot; style=&quot;background-color: transparent; color: black; font-family: Times New Roman; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline;&quot;&gt;This seems to me to be dangerous ground to tread.&lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;background-color: transparent; color: black; font-family: Times New Roman; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline;&quot;&gt;I hope this answers your questions. Stay the course of health, it is very very worth it.&lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;background-color: transparent; color: black; font-family: Times New Roman; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline;&quot;&gt;&lt;/span&gt;&lt;br /&gt;
&lt;hr /&gt;&lt;span style=&quot;background-color: transparent; color: black; font-family: Times New Roman; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline;&quot;&gt;&lt;/span&gt;&lt;span style=&quot;background-color: transparent; color: black; font-family: Times New Roman; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline;&quot;&gt;References:&lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;background-color: transparent; color: black; font-family: Times New Roman; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline;&quot;&gt;[1] &lt;/span&gt;&lt;a href=&quot;http://en.wikipedia.org/wiki/Food_energy&quot;&gt;&lt;span style=&quot;background-color: transparent; color: #000099; font-family: Times New Roman; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: underline; vertical-align: baseline;&quot;&gt;http://en.wikipedia.org/wiki/Food_energy&lt;/span&gt;&lt;/a&gt;&lt;span style=&quot;background-color: transparent; color: black; font-family: Times New Roman; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline;&quot;&gt;&lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;background-color: transparent; color: black; font-family: Times New Roman; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline;&quot;&gt;[2] &lt;/span&gt;&lt;a href=&quot;http://www.merckmanuals.com/home/disorders_of_nutrition/overview_of_nutrition/calories.html&quot;&gt;&lt;span style=&quot;background-color: transparent; color: #000099; font-family: Calibri; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: underline; vertical-align: baseline;&quot;&gt;http://www.merckmanuals.com/home/disorders_of_nutrition/overview_of_nutrition/calories.html&lt;/span&gt;&lt;/a&gt;&lt;span style=&quot;background-color: transparent; color: black; font-family: Calibri; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline;&quot;&gt; &lt;/span&gt;&lt;span style=&quot;background-color: transparent; color: black; font-family: Times New Roman; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline;&quot;&gt;&lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;background-color: transparent; color: black; font-family: Times New Roman; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline;&quot;&gt;[3]  GD Foster, HR Wyatt, JO Hill, AP Makris, DL Rosenbaum, C Brill et al  (2010) Weight and Metabolic Outcomes After 2 Years on a Low-Carbohydrate  Versus Low-Fat Diet. Annals of Internal Medicine 153: 147-157.  Doi:10.1059/0003-4819-153-3-201008030-00005.&lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;background-color: transparent; color: black; font-family: Times New Roman; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline;&quot;&gt;[4]  CD Gardner, A Kiazand, S Alhassan, S Kim, RS Stafford, RR Balise et al  (2007) Comparison of the Atkins, Zone, Ornish, and LEARN Diets for  Change in Weight and Related Risk Factors Among Overweight Premenopausal  Women: The A TO Z Weight Loss Study: A Randomized Trial. JAMA 297:  969-977. Doi:10.1001/jama.297.9.969.&lt;/span&gt;</content><link rel='replies' type='application/atom+xml' href='http://thepillarsofhealth.blogspot.com/feeds/36412489317949919/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://thepillarsofhealth.blogspot.com/2011/11/how-much-fat-to-eat-to-absorb-vitamin-d.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/36412489317949919'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/36412489317949919'/><link rel='alternate' type='text/html' href='http://thepillarsofhealth.blogspot.com/2011/11/how-much-fat-to-eat-to-absorb-vitamin-d.html' title='How much fat to eat to absorb vitamin D and how many total calories per day to lose weight. (To Anonymous)'/><author><name>Dr Dhia Aldoori</name><uri>http://www.blogger.com/profile/12785445082984259058</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='23' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgIcbY6lOf-A2OAQZ3CCF-V44BF68CUZ1wYcXS06NXVQS-lTFiik3VkOYsT0dmfX2RcYB8yuWeKbUAP5w5AeDWHc1bdI-0eQEt4lr6yM4tplO9dgbQ9nT74rRU6KPLeXw/s149/Cropped+PA307202'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-7196398195634872986.post-3065346679453030368</id><published>2011-07-03T11:01:00.000-04:00</published><updated>2011-07-03T11:01:42.231-04:00</updated><title type='text'>The Pillars of Health:The Prelude: Preview &quot;Fat Intake and Weight Gain&quot;</title><content type='html'>&lt;a href=&quot;http://thepillarsofhealth.blogspot.com/b/post-preview?token=7AE68jABAAA.y_AAz89KYTSXx5-jlUTsCw.7Rkdet2KqhsEF_RaB2Vyzg&amp;amp;postId=5264608656070303473&amp;amp;type=POST&quot;&gt;The Pillars of Health:The Prelude: Preview &quot;Fat Intake and Weight Gain&quot;&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='http://thepillarsofhealth.blogspot.com/feeds/3065346679453030368/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://thepillarsofhealth.blogspot.com/2011/07/pillars-of-healththe-prelude-preview.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/3065346679453030368'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/3065346679453030368'/><link rel='alternate' type='text/html' href='http://thepillarsofhealth.blogspot.com/2011/07/pillars-of-healththe-prelude-preview.html' title='The Pillars of Health:The Prelude: Preview &quot;Fat Intake and Weight Gain&quot;'/><author><name>Dr Dhia Aldoori</name><uri>http://www.blogger.com/profile/12785445082984259058</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='23' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgIcbY6lOf-A2OAQZ3CCF-V44BF68CUZ1wYcXS06NXVQS-lTFiik3VkOYsT0dmfX2RcYB8yuWeKbUAP5w5AeDWHc1bdI-0eQEt4lr6yM4tplO9dgbQ9nT74rRU6KPLeXw/s149/Cropped+PA307202'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-7196398195634872986.post-2592941485119214455</id><published>2010-04-04T19:29:00.003-04:00</published><updated>2010-04-04T19:44:07.586-04:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="diet"/><category scheme="http://www.blogger.com/atom/ns#" term="magnesium"/><category scheme="http://www.blogger.com/atom/ns#" term="potassium"/><title type='text'>Magnesium Low</title><content type='html'>Answering &lt;span style=&quot;color: rgb(51, 102, 255);&quot;&gt;Nazek&lt;/span&gt;:&lt;br /&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;Disorders of Magnesium Balance (1)&lt;/span&gt;&lt;br /&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;Introduction &lt;/span&gt;Magnesium is the most abundant intracellular divalent cation and, after calcium, the most common divalent cation in the body. The majority (99%) of magnesium residing inside cells. Consequently, plasma magnesium concentration does not reflect total body magnesium. Magnesium plays an important role in neuromuscular coupling, largely through its interaction with calcium. Disorders of magnesium primarily reflect hypomagnesemia, with cardiac arrhythmias and other features similar to those of low calcium. Among the causes of hypomagnesemia are malnutrition, chronic alcoholism, kidney abnormalities and malabsorption. [&lt;span style=&quot;color: rgb(255, 102, 102);&quot;&gt;Is she taking any laxatives?&lt;/span&gt;]&lt;br /&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;Magnesium Intake and Distribution&lt;/span&gt; Magnesium is found in many foods, including green vegetables and meat products, and the normal diet is usually more than ample. Approximately 5 mg/kg per day of magnesium is required for normal magnesium balance. Factors that control gastrointestinal magnesium absorption are unclear, but about one-third of ingested magnesium is absorbed.&lt;br /&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;Magnesium Excretion&lt;/span&gt; The distal nephron (part of the kidney), however, is the major site of fine regulation of magnesium excretion. Loop-acting diuretics predictably have a potent magnesium-wasting effect. [&lt;span style=&quot;color: rgb(255, 102, 102);&quot;&gt;Is she taking any ‘Water Pills?&lt;/span&gt;], [&lt;span style=&quot;color: rgb(255, 102, 102);&quot;&gt;One-Alpha should only be given to patients suffering from kidney disease. Is that the case here?&lt;/span&gt;]&lt;br /&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;Role of Magnesium&lt;/span&gt; The major role of magnesium is as a cofactor for hundreds of identified enzymes that produce or require ATP, such as kinases, ATPase, and adenylyl cyclase. Disorders of magnesium may lead to impaired energy production, substrate utilization, and synthetic processes.&lt;br /&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;Hypomagnesemia &lt;/span&gt;(Low magnesium) ESSENTIALS OF DIAGNOSIS&lt;br /&gt;• Plasma [Mg2+] &lt;1.7 style=&quot;color: rgb(255, 102, 102);&quot;&gt;The numbers given satisfy this criterion.] • Cardiac arrhythmias, refractory potassium deficiency. [&lt;span style=&quot;color: rgb(255, 102, 102);&quot;&gt;What was her potassium level?&lt;/span&gt;] • Features suggestive of hypocalcemia: tetany, weakness, increased deep tendon reflexes, altered mental status, and seizures. [&lt;span style=&quot;color: rgb(255, 102, 102);&quot;&gt;Are there any symptoms like these?&lt;/span&gt;]&lt;br /&gt;[&lt;span style=&quot;color: rgb(255, 102, 102);&quot;&gt;Please provide also the laboratory reference levels for any result mentioned as this varies between laboratories.&lt;/span&gt;]&lt;br /&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;References &lt;/span&gt;&lt;br /&gt;1. Bongard FS, STAT!Ref, Teton Data Systems. Current critical care diagnosis &amp;amp; treatment. 3rd ed. New York ;London: McGraw-Hill; 2008.&lt;br /&gt;&lt;br /&gt;[&lt;span style=&quot;color: rgb(255, 102, 102);&quot;&gt;Above doesn’t replace the input of a medical professional who interviews the patient and carries out a physical examination followed by a discussion of care – that is the premier method of obtaining medical advice at this time of medical science development&lt;/span&gt;].</content><link rel='replies' type='application/atom+xml' href='http://thepillarsofhealth.blogspot.com/feeds/2592941485119214455/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://thepillarsofhealth.blogspot.com/2010/04/magnesium-low.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/2592941485119214455'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/7196398195634872986/posts/default/2592941485119214455'/><link rel='alternate' type='text/html' href='http://thepillarsofhealth.blogspot.com/2010/04/magnesium-low.html' title='Magnesium Low'/><author><name>Dr Dhia Aldoori</name><uri>http://www.blogger.com/profile/12785445082984259058</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='23' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgIcbY6lOf-A2OAQZ3CCF-V44BF68CUZ1wYcXS06NXVQS-lTFiik3VkOYsT0dmfX2RcYB8yuWeKbUAP5w5AeDWHc1bdI-0eQEt4lr6yM4tplO9dgbQ9nT74rRU6KPLeXw/s149/Cropped+PA307202'/></author><thr:total>0</thr:total></entry></feed>